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 Introduction 
 Coronary artery disease (CAD) represents a wide 
 spectrum of underlying anatomical disease ranging 
from near normal, minor single-vessel disease (SVD), 
to extensive triple-vessel disease. Its presentation is 
similarly variable, from a single episode of chest pain to 
acute coronary syndrome (ACS) or even death. The 
aim of treatment in CAD is to relieve symptoms and 
improve quality of life, reduce cardiovascular (CV) 
events, and prolong survival. There have been vast 
improvements in management over the years, following 
a greater understanding of the underlying pathophysi-
ology, the identifi cation and appropriate management 
of risk factors, development of new medication, and 
advances in revascularization techniques, both percuta-
neous and surgical. These developments have resulted 
in a move towards an anatomic treatment for CAD even 
though it is the minor lesion, so-called vulnerable 
plaque, which is suggested as the most likely culprit for 
mortality. Nevertheless, in those patients presenting 
with ACS or ST-elevation myocardial infarction the 
long-term benefi ts of percutaneous coronary interven-
tion (PCI) have been confi rmed in multiple randomized 
trials ( 1 ) ; however, debate surrounds the ideal manage-
ment of the majority of patients who have angina, and 
who have not experienced any previous CV events or 
had an interventional procedure, so-called stable CAD. 
 Medical therapy versus mechanical 
revascularization 
 Medical therapy which encompasses lifestyle modifi ca-
tion, risk factor reduction, and pharmacological therapy 
(antiplatelet and antianginal) has a strong evidence base 
and clearly has a central role in the management of every 
patient with CAD. Intuitively it would seem apparent 
that PCI would be the ideal treatment for every patient, 
however the current evidence taken at face value would 
tend to suggest otherwise. The largest trial to date com-
paring PCI (and best medical therapy) with best medical 
therapy (BMT) was the COURAGE trial (Clinical 
Outcomes Utilizing Revascularization and Aggressive 
Drug Evaluation) whose publication has been well pub-
licised and debated amongst general  cardiologists, inter-
ventional cardiologists, and the general public. This trial, 
which recruited only 6.4% of the 35 539 patients who 
were assessed for entry, reported at median follow-up of 
4.6 years no signifi cant difference in the primary event 
rate (death or non fatal MI) with PCI compared with 
BMT (19.0% vs. 18.5%; 95% confi dence interval [CI], 
0.87–1.27; p = 0.62) ( 2 ) . This added to the evidence from 
earlier meta-analyses in 2000 (3) and 2005 (4) both of 
which concluded that PCI improved symptoms but did 
not reduce mortality or the incidence of CV events. 
There is no doubt that PCI helps relieve symptoms ( 2 , 3 , 5 ) 
but what is its true effect on mortality and morbidity, 
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and can these general conclusions be applied to all 
groups of patients? The importance of this issue cannot 
be overstated given the vast resources that are spent on 
managing these patients who comprise 85% of the PCI 
workload in the United States ( 2 ) . Most importantly a 
recent meta-analysis which included the COURAGE 
data and comprised 7915 patients found a 20% reduc-
tion in all cause death amongst the PCI-treated patients 
compared with BMT (271 deaths vs. 335 deaths; odds 
ratio [OR], 0.80; 95% CI, 0.64–0.99; p = 0.263) ( 6 ) . 
 It is essential to consider some of the limitations of 
the previous trials which have been performed compar-
ing the two groups. They have all suffered from the low 
risk ( 7 ) of the population being studied, and have been 
under-powered to detect a signifi cant mortality differ-
ence. In addition, mean follow-up time has been just 
under 4 years, which may be too short to detect mor-
bidity in the BMT group, whilst those in the PCI group 
may experience peri-procedural events which will be 
detected on short-term follow-up. Importantly in the 
COURAGE trial the rate of spontaneous MI (not peri-
procedural) in the BMT group was higher than in the 
PCI arm (119 vs. 108), but peri-procedural MIs were 
much higher in the PCI group (35 vs. 9). Peri-procedural 
MIs are not benign and do affect prognosis ( 8 ) , some of 
these may occur through trying to achieve the ‘perfect’ 
angiographic appearance, when simpler less compli-
cated procedures may produce the same symptomatic 
benefi t, at a lower risk. The advantages of PCI are 
 further reduced by high cross over rates, ranging from 
6–44%, from BMT to PCI although this is a reality of 
the chronic nature of CAD rather than a ‘fault’ of the 
trials. The benefi t of PCI has also been hampered by the 
trials being performed before the drug eluting stent 
(DES) era. It is well documented that restenosis, which 
is reduced signifi cantly by DES compared with bare 
metal stent (BMS) or balloon angioplasty (POBA), is not 
a benign phenomenon and can present as an acute MI 
in between 9.5–19.4% of cases ( 9 ) . 
 The presence of ischaemia affects clinical outcome 
but amongst the trials there is considerable variation in 
the objective evidence of ischaemia required for patient 
enrolment, with some simply relying on symptoms and 
angiographic evidence of stenosis. PCI is very effective 
at relieving the subjective symptoms of ischaemia. 
Evidence from the nuclear subset of the COURAGE 
trial which looked at 313 patients who had myocardial 
perfusion imaging before, and 6–18 months post rand-
omization, would suggest that it is also more effective 
than BMT at relieving objective ischaemia. In this sub-
set of patients those having PCI and BMT had a greater 
reduction in signifi cant myocardial ischaemia than 
BMT controls (p = 0.004), and this translated clinically 
into a signifi cantly lower rate of death and MI in these 
patients (13.4% vs. 24.7%, p = 0.037). Also of note were 
the zero rates of death and MI in those patients having 
no evidence of residual ischaemia at 6–18 months, 
compared with a rate of 39.3% in those with grater than 
10% residual ischaemia. In summary, PCI with BMT 
has been shown to be better than BMT at relieving sub-
jective and objective ischaemia, and this has translated 
into better clinical outcomes. The SWISS II study 
showed similar benefi ts in the presence of proven silent 
ischaemia ( 10 ) . Future trials need to ensure that the 
degree of myocardial ischaemia is accurately assessed to 
guarantee the validity of the conclusions reached. 
 In the ‘real world’ aggressive medical therapy is 
 frequently diffi cult to implement because real-world 
patients experience side effects from therapy, and may 
subsequently be non-compliant with medication, or 
lifestyle advice. The COURAGE trial has shown what 
can be achieved in the ideal world with reductions in 
blood pressure, LDL cholesterol, smoking rates, and 
improvements in diet, and exercise; however, these 
require additional resources and the manpower which 
most healthcare providers are simply unable to deliver. 
 In summary, medical therapy plays an important part 
in the management of patients with CAD, and the role 
of revascularization should be considered to be comple-
mentary to BMT which is central to management. PCI 
should be considered if BMT fails to control symptoms 
in those patients who are deemed to be at a low risk of 
CV events, whilst in those who are at higher risk, revas-
cularization with either PCI or coronary artery bypass 
grafting (CABG) and BMT must be considered early. 
 Risk stratifi cation 
 From the previous discussion it is apparent that risk 
stratifi cation plays a vital role in helping guide the man-
agement of patients with CAD. It also has an important 
role in providing patients, and their relatives, with 
answers to questions they may have about the likely 
course of their condition and their prognosis, and can 
also help inform other health professions planning 
other treatments and procedures. 
 Which patients are at high risk of events? The 
European Society of Cardiology defi nes those patients 
with an annual CV risk of >2% as high risk, <1% as low 
risk, and between 1–2% intermediate risk, and recom-
mends that risk stratifi cation takes into consideration: 
 1. Clinical evaluation of the patient 
 A clinical evaluation of the patient is essential in all cases 
and can provide information with regards prognosis, 
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and the following factors—although by no means 
exhaustive—are all associated with an increased risk of 
adverse prognosis in those with stable CAD: 
 ◆ History of diabetes mellitus, hypercholesterolaemia, 
hypertension, and renal impairment. 
 ◆ Severity of angina presentation. 
 ◆ Current smoking. 
 ◆ Examination fi ndings suggestive of peripheral vascular 
disease, or signs of left ventricular (LV) dysfunction. 
 ◆ An abnormal ECG (previous MI, left bundle branch 
block, left anterior hemiblock, LV hypertrophy, atrial 
fi brillation, and second- or third-degree heart block). 
 2. Response to stress testing 
 Stress testing provides additional information regard-
ing the patient’s risk, and currently numerous different 
non-invasive stress tests are available, which are able to 
provide prognostic information obtained not only from 
the presence or absence of ischaemia, but also from the 
degree and severity of ischaemia, the exercise capacity, 
and the ischaemic threshold. 
 There are no randomized trials comparing individual 
stress tests, and issues other than the patient’s physical 
and functional ability to exercise, or the presence of an 
abnormal ECG such as availability, local expertise, and 
preference of the referring physician do have an infl u-
ence on which test is ultimately used.  Table  14.1 lists 
the criteria on non-invasive stress testing which suggest 
a high risk of CV events and subsequently indicate the 
need for revascularization. Currently multisliced CT 
scanning provides an anatomical assessment of CAD, 
with limited data available on its correlation with induc-
ible ischaemia; however, with further evaluation in 
progress this may change. Whichever test is used, a nor-
mal result doesn’t exclude the presence of CAD or the 
risk of future events. 
 3. An assessment of left ventricular function 
 LV function is the most important marker of prognosis 
in those patients with CAD. Studies have shown that 
mortality is inversely proportional to LV function, and 
in those with an LV ejection fraction <35%, the annual 
risk of mortality is in excess of 3% ( 11 ) . 
 Table 14.1 Prognostic variables and criteria indicating a high risk of cardiovascular events amongst various 
non-invasive stress tests 
 Modality  Prognostic variables  Criteria for high risk of CV events  Annual mean CV 
event rate in normal 
test 
 Echocardiography  LVEF at rest 
 LVEF on exercise 
 LVEF <35% at rest 
 LVEF <35% on exercise 
 
 Stress 
echocardiography 
 Number of resting WMA 
 Number of inducible WMA with 
stress 
 WMA (involving >2 segments) developing at: 
 ◆  A low dose of dobutamine (≤10mg/kg/min) or 
 ◆ At a low heart rate (<120bpm) 
 Stress echocardiographic evidence of extensive 
ischaemia 
 <0.5% ( 11 ) 
 Exercise testing  Exercise-induced angina 
 Exercise capacity 
 BP response to exercise 
 Changes in ST segment 
 Exercise-induced ischaemia 
 High-risk Duke treadmill score (< −10) *  Low Duke score 
(>4) 0.25% (annual 
mortality) 
 Myocardial 
perfusion imaging 
 Large stress-induced perfusion 
defects 
 Defects in multiple coronary 
arteries 
 Transient post stress LV dilation 
 Lung uptake with Tl-201 
 Stress-induced: 
 ◆ Larger perfusion defect (particularly if anterior) 
 ◆ Multiple perfusion defects of moderate size 
 ◆ Moderate perfusion defect with LV dilation or 
increased lung uptake (Tl-201) 
 Large, fi xed perfusion defect with LV dilation or 
increased lung uptake (Tl-201) 
 0.7% ( 67 ) 
 * The Duke treadmill score equals the exercise time in minutes minus (5× the ST-segment deviation, during or after exercise, in millimetres) minus 
(4× the angina index, which has a value of ‘0’ if there is no angina, ‘1’ if angina occurs, and ‘2’ if angina is the reason for stopping the test) ( 68 ) . 
 BP, blood pressure; LVEF, left ventricular ejection fraction; Tl-201, thallium-201; WMA, wall motion abnormality. 
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 4. An assessment of the coronary anatomy 
 Coronary anatomy provides valuable information in 
assessing the patient’s risk of CV events, and in particu-
lar the extent, severity, and location of the disease are 
important factors which infl uence prognosis. A simple 
risk assessment can be based on the number of coro-
nary arteries involved, which is supported by data 
from the CASS medical registry which showed that 
12-year survival was 91%, 74%, 59%, and 50% in those 
with normal, single-, double-, or triple-vessel disease 
respectively ( 12 ) , furthermore survival rates were poorer 
in those with a combination of two- or three-vessel disease 
and a left main stem (LMS) lesion. Early data has shown 
the poor prognosis in LMS lesions treated medically ( 13 ) , 
and the improved survival with revascularization, which 
at the time of publication was predominantly CABG, in 
those with triple-vessel disease, two-vessel disease which 
includes the proximal left anterior descending artery 
(LAD), or two- or three-vessel disease and a positive 
exercise test ( 14 ) . 
 It has been argued that coronary angiography is inap-
propriate in those patients who are deemed low risk 
after non-invasive testing in view of the risk of the pro-
cedure, and the small chance that repeat revasculari-
zation is required. 
 Once the patient has been risk stratifi ed, and a deci-
sion reached to proceed with mechanical revasculariza-
tion, the patient must be evaluated with respect to their 
suitability for PCI or CABG. This decision is often com-
plex and requires a multidisciplinary team approach, 
with the cardiologist, interventional cardiologist, and 
cardiac surgeon all participating in the discussion. The 
last two decades have provided us with a large body of 
evidence to guide these complex decisions, and in the fol-
lowing section we will review the available data on stent-
ing in multivessel disease (MVD) and CABG, including 
the most recent evidence from the SYNTAX, FAME, 
and CARDIA trials. 
 Mechanical revascularization: PCI 
versus CABG 
 After its introduction in the 1960s, CABG become the 
accepted treatment for MVD ( 15 ) ; however, advances 
made in the percutaneous treatment of stable CAD 
from POBA to stenting with initially BMS ( 16 ) and now 
DES ( 17 – 19 ) , have made PCI a progressively more attrac-
tive alternative ( Fig.  14.1 ). All randomized clinical trials 
to date, whether performed in the early days with POBA 
or more recently with BMS or DES, show no mortality 
difference between PCI and CABG ( 20 – 22 ) . However the 
advantage of CABG over PCI in terms of restenosis rate 
and the need for re-intervention has progressively nar-
rowed, especially in some patient subsets. 
 Pre-DES era: balloon angioplasty and bare 
metal stenting versus CABG 
 The six randomized trials comparing POBA to CABG 
are summarized in  Table  14.2 , together with the results 
at the longest published follow-up. In 1995, prior to the 
publication of the BARI trial, a 3-year meta-analysis 
was published of the other fi ve trials which found no 
difference in the rates of death and non-fatal MI (CABG 
vs. POBA HR 1.03; 95% CI 0.81–1.32; p = 0.81) ( 20 ) . 
 In view of the superior results with stenting compared 
with POBA ( Fig.  14.2 ) ( 16 ) , fi ve subsequent randomized 
trials compared BMS to CABG in MVD. These fi ve tri-
als are summarized in  Table  14.3 together with results at 
the longest published follow-up. The ARTS-I study was 
the largest of these trials and enrolled 1205 patients with 
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 Fig. 14.1 Event-free survival at 1 year follow-up in the CABRI, 
ARTS-I, and ARTS-II studies showing a reduction in the difference in 
outcomes between CABG compared with balloon angioplasty, 
bare-metal stenting, and drug-eluting stents. Reproduced from 
Serruys, PW, ARTS I – the rapamycin eluting stent; ARTS II – the 
rosy prophecy.  Eur Heart J 2002;  23 :757–9 by permission of Oxford 
University Press. 
Redwood-Chap14.indd   224 4/6/2010   10:29:05 AM
Stable coronary artery disease: medical therapy versus percutaneous coronary intervention versus surgery 17
MVD that had an equivalent baseline chance for com-
plete revascularization. There was no difference between 
the two groups in either the prespecifi ed primary end-
point of major adverse cardiac and cerebrovascular 
events (MACCE) at 1 year, or mortality at 5 years (8% 
vs. 7.6%; p = 0.83). However, when compared with 
CABG the rates of repeat revascularization were higher in 
the stenting group both at 1-year (16.8% vs. 3.5%) and 
5-year (30.3% vs. 8.8%; p <0.001) follow-up ( 15 , 23 ) . 
 A meta-analysis of all fi ve trials showed similar MACCE 
rates and higher repeat revascularization rates in the PCI 
group at both 1- and 5-year follow-up ( 22 , 24 , 25 ) . The only 
study that has been at variance with these randomized 
trial results has been the New York Cardiac Registry ( 26 ) 
which looked retrospectively at risk-adjusted outcomes 
in 60 000 patients undergoing PCI or CABG. Risk 
adjusted survival was signifi cantly higher in the CABG 
group (HR 0.64; 95% CI 0.56–0.74) with the difference 
being most pronounced in patients with three-vessel 
disease and proximal LAD disease. The criticism of this 
registry is that risk adjustment is likely to be impossible 
and that clinical judgement could not be adjusted for in 
this complex cohort of patients (J. Daemen, N. Kukreja, 
and P.W.J.C. Serruys, personal correspondence). 
 The DES era—the game is getting closer 
 Randomized trials comparing DES and BMS have 
shown a reduction in the restenosis rates with DES. In 
addition, DES use has expanded to more complex 
patients and lesions including patients with MVD, which 
comprise close to 40% of PCI patients. The effectiveness 
of these devices has been shown in ‘real world’ registries 
such as RESEARCH and T-SEARCH ( 27 ) . ARTS-II was 
the fi rst CABG-PCI registry/trial to evaluate the per-
formance of DES specifi cally in MVD against CABG. It 
prospectively collected data on 607 patients with MVD 
treated with DES ( 28 ) who were then compared to his-
torical CABG control from ARTS-I. One-year follow-up 
showed that PCI with DES was non-inferior to CABG 
with respect to MACCE rates. The rates of repeat revas-
cularization, although lower than in the BMS arm of 
ARTS-I, were still signifi cantly higher than in the his-
torical CABG controls. These results were maintained at 
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 Fig. 14.2 The improved event-free survival in the Benestent I and 
II trials with the use of a bare-metal stent (Benestent I stent) or 
a heparin-coated stent (Benestent II) compared to only balloon 
angioplasty (Benestent balloon). The event-free survival, however, is 
much greater with a sirolimus-eluting stent. 
 Table 14.2 Results at longest reported follow-up in the six randomized trials of balloon angioplasty versus coronary 
artery bypass surgery 
 Study  Year  No. of 
patients 
 Longest reported 
follow-up (years) 
 Death  POBA vs. CABG  MI  POBA vs. CABG  Re-intervention 
 POBA vs. CABG 
 CABRI ( 69 )  1994  1054  1  3.9% vs. 2.7% 
 p = NS 
 p=NS  33.6% vs. 6.5% 
 p <0.001 
 ERACI ( 70 )  1993  127  3  4.7% vs. 9.5% 
 p = 0.5 
 7.8% vs. 7.8% 
 p = 0.8 
 37% vs. 6.3% 
 p <0.001 
 RITA (71 )  1993  1011  6.5  7.6% vs. 9.0% 
 p = 0.51 
 10.8% vs. 7.4% 
 p = 0.08 
 44.3% vs. 10.8% 
 EAST (72 )  1994  392  8  20.7% vs. 17.3% 
 p = 0.40 
 –  65.3% vs. 26.5% 
 p <0.001 
 BARI (73 )  1991  1829  10  71.0% vs. 73.5% 
 p = 0.18 
 16.4% vs. 16.6% 
 p = NS 
 76.8% vs. 20.3% 
 p <0.001 
 GABI (74 )  1994  359  13  25% vs. 21.9% 
 p = 0.64 
 4.3% vs. 5.6% 
 p = 0.6 
 82.9% vs. 58.8% 
 CABG, coronary artery bypass grafting; NS, not signifi cant; POBA, balloon angioplasty;  BARI, Bypass Angioplasty Revascularization Investigation; CABRI, 
Coronary Angioplasty versus Bypass Revascularization Investigation; EAST, Emory Angioplasty versus Surgery Trial; ERACI, Argentine Randomized Trial of 
Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease; GABI, German Angioplasty Bypass Surgery 
Investigation; RITA, Randomized Intervention Treatment of Angina. 
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 Table 14.3 Results at longest reported follow-up in fi ve randomized trials of bare metal stenting versus coronary 
artery bypass surgery 
 Study  Year  No. of 
patients 
 Longest reported 
follow-up (years) 
 Death  PCI vs. CABG  MI  PCI vs. CABG  Re-intervention 
 PCI vs. CABG 
 AWESOME (75 )  2000  142  3  24% vs. 27% 
 p = NS 
 –  – 
 ARTS-I ( 23 )  2001  1205  5  8.0% vs. 7.6% 
 p = 0.83 
 9.5% vs. 6.4%  30.3% vs. 8.3% 
 p <0.001 
 ERACI-II (76 )  2001  450  5  7.1% vs. 11.5% 
 p = 0.18 
 2.8% vs. 6.2% 
 p = 0.13 
 28.4% vs. 7.2% 
 p = 0.0002 
 MASS-II (77 )  2003  611  5  15.5% vs. 12.8% 
 p = NS 
 11.2% vs. 8.3%  32.2% vs. 3.5% 
 SOS (78 )  1999  988  6  10.9% vs. 6.8% 
 p = 0.022 
 –  – 
 CABG, coronary artery bypass grafting; NS, not signifi cant; PCI, percutaneous coronary intervention;  ARTS-I, Arterial Revascularization Therapy Study; 
AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; ERACI-II, Argentine Randomized Study: Coronary Angioplasty with Stenting 
versus Coronary Bypass Surgery in Multivessel Disease; MASS-II, Medicine, Angioplasty or Surgery Study for multivessel coronary artery disease; SOS, Stent 
or Surgery 
3-year follow-up with equivalent survival without 
MACCE (80.6% vs. 83.8%, p = 0.21) and lower freedom 
from repeat revascularization with PCI (85.5% vs. 
93.4%, p <0.001). In ERACI-III which prospectively 
added a 205 patient cohort to the ERACI-II population, 
PCI with DES had a lower MACE rate than an historical 
CABG group (freedom from MACE was 88% vs. 80.5%; 
p = 0.038) ( 29 ) . One observational study in 1680 patients 
confi rmed these fi ndings with equivalent MACCE rates 
in a non-diabetic population with two-vessel disease ( 30 ) . 
However, again the New York registry of 17 400 patients 
appeared to contradict these results showing lower mor-
tality rates for CABG at 18 months post procedure 
(adjusted survival of 96% vs. 94.6%; p = 0.003). Notably 
the difference was smaller than with a similar registry for 
BMS and the same concern regarding inability to adjust 
for all confounding risk factors remained. 
 SYNTAX, FAME, and CARDIA—results of the 
randomized trials: more answers but also 
more questions 
 Some of these earlier controversies in data interpreta-
tion are fi nally being partially resolved following the 
results of three major randomized trials presented 
in 2008 of DES versus CABG in patients with MVD. In 
addition, these trials also attempted to defi ne more 
clearly which specifi c patient populations benefi t from 
CABG or PCI. 
 Synergy between percutaneous coronary intervention 
with TAXus and cardiac surgery (SYNTAX) is a pro-
spective, multicentre, multinational, randomized trial 
of all-comers design. It recruited 1800 patients with the 
goal to assess the best revascularization treatment for 
patients with de novo triple-vessel or LMS disease by 
randomizing them to either stenting with a paclitaxel-
eluting Taxus® stent (Boston Scientifi c, Natick, USA) 
or CABG and also keeping a registry of those patients 
who were eligible for only PCI or only CABG ( 31 ) . The 
trial design was unique in that it employed the angio-
graphic scoring system of lesion severity called the 
‘SYNTAX score’ ( 32 ) . The patients recruited in SYNTAX 
are a unique study group in the PCI fi eld, given their 
exceptionally complex anatomy and advanced disease. 
The average SYNTAX patient received 4.6 stents com-
pared to the average 1.5 stents implanted in everyday 
practice. In addition, the patient profi le included 33% 
with >100mm stented length, 84% with bi/trifurca-
tions, 22% with chronic total occlusions, and 39% with 
LMS disease. Some of the sickest patients in the trial 
were not eligible for surgery and were treated with DES. 
The main results are summarized in  Table  14.4 . One of 
the most interesting results came from the SYNTAX 
score subgroup analysis which showed that PCI but not 
surgical outcomes were infl uenced by the angiographic 
SYNTAX score (lesion complexity). Analysis showed 
non-inferior results of PCI to CABG in patients with a 
SYNTAX score up to 32, whilst CABG was superior in 
those with a SYNTAX score above 32. Further analysis 
of the data will be required together with longer-term 
follow-up. The complexity of the patient population 
in this study certainly makes the data generalizable; 
however, one has to keep in mind that the surgery and 
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complex PCI in this study was performed in highly 
selected centers of excellence in Europe and the United 
States who were used to high volumes of complex 
patients and cases. 
 The CARDIA (Coronary Artery Revascularisation in 
Diabetes) study randomized 510 diabetic patients with 
MVD or complex SVD to treatment with either CABG 
(n = 254) or PCI (n = 256; 71% DES). The primary 
outcome—death, MI and stroke—was comparable 
between CABG and PCI at 1 year (10.2% vs. 11.6%; 
p = 0.63), whilst repeat revascularization was signifi -
cantly higher in the PCI group with a rate of 9.9% vs. 
2.0% for CABG (p = 0.001). Similar results were seen in 
the DES subgroup analysis with no difference in the 
primary endpoint (CABG vs. DES PCI, p = 0.98) and 
higher repeat revascularization with DES compared 
to CABG group. Stroke, however, was more prevalent 
in the CABG group ( 33 ) . The results of the Future 
Revascularization Evaluation in patients with Diabetes 
Mellitus; Optimal Management of Multivessel Disease 
(FREEDOM) trial which is enrolling at least 2000 dia-
betic patients with MVD randomized to CABG versus 
multivessel stenting with DES are eagerly awaited. 
 Lastly, the Fractional fl ow reserve versus Angiography 
for Multivessel Evaluation (FAME) trial offers another 
approach to MVD treatment. It incorporates the idea of 
revascularizing the territory which has evidence of 
reversible ischaemia and uses the fractional fl ow reserve 
(FFR) measurement as a gold standard for the haemo-
dynamic signifi cance of the lesion. The premise of the 
study is based on the result that deferral of PCI based 
on the FFR cut-off point of 0.75 has been associated 
with favorable outcomes in patients with MVD ( 34 ) and 
that only lesions with inducible ischaemia benefi t from 
invasive mechanical revascularization over medical 
therapy. FAME enrolled 1005 patients with at least two 
vessels with >50% lesions randomized to either angio-
graphic guided, or FFR-guided stenting using an FFR cut 
off value of 0.8. The main results are shown in  Fig.  14.3 
There was a 35% reduction in overall MACE which was 
achieved without prolonging the procedure, (p = 0.51) 
and approximately one-third of angiographically 
 signifi cant lesions were found not to be haemodynami-
cally signifi cant by FFR. In addition the FFR-guided 
stenting strategy lead to a signifi cant reduction in contrast 
use (272 ± 133mL vs. 302 ± 127; P <0.001) and a signifi -
cant cost saving ($5332 vs. $6007, p <0.001) compared to 
the angiographic-guided stenting ( 35 ) . 
 Lesion subsets 
 The previous section has been a general discussion com-
paring PCI and CABG. In the next section we have con-
centrated on six commonly encountered lesion subsets. 
 Single-vessel disease 
 Patients having revascularization have significantly 
lower 1-year mortality with SVD when compared with 
those having MVD; in fact the RITA trial showed this 
trend was maintained at 4.7 years follow-up (5.8% vs. 
3.9%). In addition, those with SVD having revasculari-
zation have lower rates of MI and cardiac death com-
pared to MVD, and also have better angina control at 
1 and 3 years, compared to those with MVD having the 
same type of revascularization ( 21 ) . 
 At present, approximately 4% of CABG is performed 
for SVD, however previously the rates were much 
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 Fig. 14.3 The adverse event rates at one year from the 1005 
patients in the FAME study showing improved outcomes with the 
use of an FFR-guided strategy ( 35 ) . 
 Table 14.4 12-month results from the SYNTAX study ( 31 ) 
 Events at 1 year  PCI 
 N = 903 (%) 
 CABG 
 N = 897 (%) 
 P-value 
 MACCE  160 (17.8)  109 (12.1)  0.002 
 Death/CVA/MI  69 (7.6)  69 (7.7)  0.98 
 All-cause death  39 (4.3)  31 (3.5)  0.37 
 MI  43 (4.8)  29 (3.2)  0.11 
 CVA  5 (0.6)  20 (2.2)  0.003 
 Repeat 
revascularization 
 124 (13.7)  53 (5.9)  <0.001 
 CVA, stoke; MACCE, major adverse cardiovascular and cerebrovascular 
events (all-cause death, CVA, MI, and repeat revascularization); 
MI, myocardial infarction. 
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higher, for example in the New York surgical registry of 
over 29 000 patients the rate of single-vessel CABG was 
8.7% ( 36 ) . These initial high rates of surgical revasculari-
zation are the result of the early trials which showed a 
distinct advantage for CABG compared with medical 
therapy in patients with specifi c SVD—namely a sig-
nifi cant proximal LAD lesion ( 37 ) ; in fact in the previ-
ously mentioned New York registry 74.3% (n = 1917) 
of patients having single-vessel CABG, had proximal 
LAD disease. It is not surprising therefore that most 
data on the outcomes of revascularization in patients 
with SVD has concentrated on those with a signifi cant 
proximal LAD lesion. 
 Two registries have concurred with the initial trials 
regarding surgical revascularization in those with sig-
nifi cant proximal LAD disease; the New York registry 
was by far the larger containing 3-year outcome data on 
23 808 patients (PCI = 21 231, CABG = 2577) with 
SVD. At follow-up those patients with SVD not includ-
ing an LAD lesion had a much better survival with PCI 
than CABG (95.3% vs. 92.4%, p = 0.003); however, if 
there was a >70% LAD lesion, CABG conferred a sig-
nifi cantly better prognosis. (96.6% vs. 95.2%, p = 0.01). 
Irrespective of the type of revascularization there was 
no signifi cant difference between outcomes in those 
with SVD in the non-proximal LAD. In fact any patient 
with a proximal LAD lesion, whether with single-, 
double-, or triple-vessel disease did better with CABG. 
The Duke registry was much smaller, containing 9263 
patients (medical therapy 2449; PCI 2924; CABG 3890), 
but concluded similar results at mean 5.3-year follow-up. 
Patients with SVD, including those with SVD and a 
mid/distal LAD lesion <75% severity, had better sur-
vival with PCI compared with CABG, whilst those with 
SVD due to a proximal LAD lesion >95% tended to do 
better with CABG. 
 It is, however, important to accept the limited clinical 
applicability of this data in the current era. Two main 
factors which may have infl uenced outcome were stent 
usage, which was only 11.8% in the New York registry, 
and usage of left internal mammary artery (LIMA) 
grafts. The Duke registry ran from 1984–1990 and the 
New York registry from 1993–1995, and although there 
is no comment on LIMA usage, in the 1980s studies 
reported rates of LIMA use of approximately 15% ( 37 ) , 
whilst in the late 1990s rates of over 90% have been 
reported ( 38 ) . The relevance of low or even moderate use 
of the LIMA graft is the fact that they have signifi cantly 
higher patency at follow-up, and confer a long term 
survival benefi t when compared with saphenous vein 
grafts ( 39 , 40 ) . 
 In recent years two meta-analyses have been pub-
lished examining outcomes in patients with proximal 
LAD disease randomized to either PCI or surgical revas-
cularization; Kapoor  et al . concentrating on any surgi-
cal technique ( 41 ) , whilst Aziz  et al . examined specifi cally 
those having the minimally invasive direct coronary 
artery bypass (MIDCAB) ( 42 ) . In both studies patients 
tended to be young with a total mean age of 58.9 years, 
and with well-preserved ejection fractions (mean of 
61.4%). The PCI technique varied in both, but of note 
the usage of DES was low, comprising of only 18.8% in 
Kapoor  et al .’s study. 
 Kapoor  et al . showed no differences in procedural 
stroke or MI, whilst Aziz  et al . showed no difference in 
MI, and stroke at maximum follow-up. In both studies 
angina relief was signifi cantly greater after CABG than 
after PCI, and following on from this, repeat revascu-
larization was signifi cantly less after CABG than after 
PCI; with results maintained to 5 years in Kapoor  et al .’s 
study (7.3% vs. 33.5%, p <0.0001). Results from both 
studies showed that no signifi cant difference in survival 
amongst patients assigned to either CABG or PCI, this 
extending out to 5 years in Kapoor  et al .’s study. The 
excellent long-term prognosis of both treatments is fur-
ther enhanced following the publication of Goy  et al .’s 
randomized study comparing bare-metal stenting with 
LIMA grafting for proximal LAD lesions, which showed 
no mortality difference at 10-year follow-up (PCI 8% 
vs. CABG 4%; p = 0.4) ( 43 ) . 
 So what can be concluded from the evidence pre-
sented? Many clinicians would have no hesitation for 
contemplating PCI for a single-vessel lesion (excluding 
proximal LAD) and registry data would support that 
in the current absence of randomized data—which is 
unlikely to ever be available. With regards proximal 
LAD lesions, data has shown no signifi cant difference in 
mortality between PCI and CABG (up to 10 years) and 
the fi nal decision should therefore be infl uenced by 
other factors such as patient preference, operator skill, 
and lesion characteristics. 
 Bifurcation lesions 
 Coronary artery bifurcations are at an increased risk for 
the development of coronary atherosclerosis because of 
turbulent fl ow and low shear stress, and have long 
posed a problem for interventional cardiologists. 
Despite advances in PCI they are associated with higher 
rates of MACE, restenosis, and a lower probability of 
success when compared to single-vessel intervention. 
Currently there is no randomized data comparing the 
treatment of patients with only bifurcation lesions 
between PCI and CABG; however, 1310 patients (657 
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CABG, 653 PCI), comprising 72.8% of the total cohort 
in the SYNTAX study had a bifurcation lesion. 
 Of the previous published studies most specifi ed the 
number of vessels diseased, as opposed to the precise 
lesion type, and therefore did not include a separate 
subset of patients with bifurcation lesions, or report the 
percentage of lesions which were bifurcation lesions. 
The ARTS-II study did have a bifurcation subset which 
comprised approximately 34% of the total cohort; how-
ever the study compared PCI in these patients with PCI 
in non-bifurcation lesions. The results showed no signifi -
cant difference in 1-year MACCE between PCI in the 
bifurcation and non-bifurcation lesions (13.3% vs. 11.0%, 
p = 0.46) ( 44 ) ; which is comparable with the MACCE in 
the surgical arm of ARTS-I (12.2%), which included 188 
(31%) patients who had bifurcation lesions ( 15 ) . 
 There is a lack of randomized data at present to point to 
whether PCI or CABG is appropriate for non-LMS bifur-
cation lesions; however interventionalists are moving 
away from mandatory complex bifurcation stenting tech-
niques towards the provisional T-stenting techniques ( 45 ) 
in view of recent studies showing similar outcomes 
between the two techniques, and only a low requirement 
of side-branch stenting in the single-stent strategy ( 46 ) . 
This is important as some would argue that bifurcation 
lesions should simply be regarded as high-risk single-
vessel lesions, and treated accordingly, whilst being 
aware of the extent of the myocardium at risk, i.e. how 
large and important is the side branch? The ARTS-II 
data show similar MACCE in dealing with bifurcation 
lesions compared to a surgical cohort, and therefore the 
decision with regards revascularization technique 
should be based on the same arguments as previously 
discussed with SVD, namely patient preference, opera-
tor skill, lesion characteristic, and extent of myocar-
dium at risk. 
 Chronic total occlusions 
 Chronic total occlusions remain the most challenging 
aspect of a complete revascularization strategy. They 
are present in up to 20% of patients but their proce-
dural success rate has been the lowest of all inter-
ventional procedures, 60–70% (with conventional 
techniques), and reaches 98% on the second attempt 
only in most experienced hands ( 47 ) . Use of novel tech-
niques such as retrograde technique ( 48 ) , dedicated wires 
(Miracle series and Confi enza), smaller balloons with 
very low crossing profi les (1mm in diameter) and other 
dedicated devices (Tornus, laser and blunt dissection 
devices) has improved acute procedural success, how-
ever, it has not reduced the likelihood of complications 
(such as perforation and dissection). 
 Multidetector CT has been very helpful in predicting 
interventional success as the assessment of lesion length 
and degree of calcifi cation is more accurate than with 
angiography ( 49 ) . Even with better acute outcomes, long-
term patency of chronic total occlusions remains low 
and has improved only somewhat with the use of 
DES ( 50 – 52 ) . In the PRISON II trial restenosis rates in 
chronic total occlusion lesions were 11% with sirolimus-
eluting stents and 41% with BMS (p = 0.001) ( 50 ) . The 
ability to achieve complete revascularization in patients 
with a combination of MVD and chronic total occlu-
sion whilst challenging is also of the utmost importance 
as it confers a long-term survival benefi t ( 53 – 55 ) . 
 Diabetes 
 Diabetic patients present a particular challenge for all 
revascularization strategies given the extent of their cor-
onary disease, its aggressive nature, and other comor-
bidities. The long-term survival in diabetics after both 
PCI and CABG is lower than in non-diabetics ( 56 , 57 ) . 
Until recently, based on BARI trial experience where 
mortality was 19% with CABG and 35% with PCI in 
diabetics (HR 1.87; p = 0.00249), CABG has usually 
been advocated as the preferred revascularization strat-
egy for diabetic patients. However, as BMS and DES 
were introduced the mortality difference between 
CABG and PCI has been eliminated, and now only the 
difference in the need for repeat revascularization has 
remained. In the ARTS-I trial amongst diabetics there 
was no mortality difference between PCI with BMS, 
and CABG (6.3 vs. 3.1%; p = 0.294); however, there was 
a 20% absolute difference in freedom from repeat revas-
cularization in favour of CABG. The 3-year follow-up 
of the ARTS-II trial looking at outcomes in diabetic 
patients showed that this difference in freedom from 
MACCE and target-vessel revascularization has nar-
rowed signifi cantly since the introduction of DES, such 
that there was no signifi cant difference between the 
MACCE in ARTS-II and the CABG arm of ARTS-I 
(p = 0.09). The incidence of death, CVA, and MI was 
signifi cantly lower in ARTS-II than in ARTS-I PCI 
(adjusted OR, 0.67; 95% CI, 0.27–1.65) and was similar 
to that of ARTS-I CABG ( 25 ) . The analysis of this and 
other similar trials has been limited by the post hoc 
nature of the substudy. 
 The first dedicated trial of CABG versus PCI in 
 diabetics using 70% DES was recently published ( 33 ) . As 
previously noted, there was no difference in the primary 
outcome of MACE at 1 year ( Fig.  14.4 ). Overall repeat 
revascularization was higher in the stenting group 
(9.9% vs. 2%) and also in the DES subgroup compared 
to the CABG group, but the absolute difference has 
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narrowed to only 7% in favour of CABG. With further 
improvements in DES technology, this difference is 
likely to become even smaller, and the higher incidence 
of stroke in diabetic patients undergoing CABG may 
offset its benefi t in terms of lower repeat revasculariza-
tion rates. 
 Chronic renal insuffi ciency 
 Chronic renal insuffi ciency often complicates diabetes 
and is also a risk factor for accelerated CAD. In addi-
tion, patients with moderate renal insuffi ciency are at 
risk for worsening of disease both after contrast admin-
istration during complex PCI and during CABG. To 
our knowledge the only study to date that looked spe-
cifi cally at long-term outcomes of patients with moder-
ate renal disease is ARTS-I ( 58 ) . At 5 years, there was no 
signifi cant difference between the two groups in terms 
of mortality (14.5% vs. 12.3%, p = 0.81), or combined 
endpoint of death, cerebrovascular accident, or MI 
(30.4% in the stent group vs. 23.3% in the CABG group, 
p = 0.35). The rate of repeat revascularization was 
18.8% in the stent group and 8.2% in the surgery group 
(p = 0.08). The event-free survival at 5 years was 50.7% 
in the stent group and 68.5% in the surgery group (p = 
0.04). Larger prospective analysis of these patients with 
and without concomitant diabetes will be helpful in 
determining the relative risks of the two revasculariza-
tion approaches. 
 Low and high body mass index (BMI) or the 
obesity paradox 
 Another group of patients that probably merits further 
investigation is the underweight and overweight group. 
In ARTS-I trial obese patients treated with bypass 
surgery had a significant advantage over low BMI 
patients in terms of freedom from MACE and repeat 
revascularization ( 59 ) . For patients who had been rand-
omized to undergo CABG, there was a significant 
decrease in repeat revascularization procedures in obese 
patients (p = 0.03). Major adverse cardiac or cerebrov-
ascular event rates were signifi cantly lower for patients 
who were obese (11%) or overweight (16%) compared 
with patients who had a normal BMI (24%; p = 0.008). 
No such effect of BMI was observed on outcomes of 
treatment with stents. In the ARTS-II trial, BMI had no 
effect on outcomes of stenting with sirolimus-eluting 
stents ( 60 ) . These results contrast with fi ndings of the 
BARI trial where obesity conferred signifi cant increased 
risk in the surgical group ( 61 , 62 ) . On the other hand 
another found a U-shaped relationship with a BMI of 
30 being optimal ( 63 ) . 
 Risk–benefi t and cost–benefi t analysis of 
choosing between PCI and CABG 
 Whilst clinical trial evidence shows that both CABG 
and PCI increase health-related quality of life (HRQL), 
in the long term CABG has a greater HRQL, and lower 
repeat revascularization rate, especially compared to 
bare-metal stenting ( 64 ) . This deferred benefi t, however, 
occurs at the expense of higher morbidity and delayed 
relief from pain in the time period immediately post 
procedure. Thus a decision regarding the procedure 
choice for a particular patient should be carefully 
weighed. Recently performed analysis based on ARTS 
study data using risk–benefit acceptability curve 
(RBAC), showed that the average patient has a risk of 
0.7 for an additional revascularization procedure  during 
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 Fig. 14.4 The combined rates 
of death, stroke, and MI, and 
MACCE (death, stroke, MI, 
and repeat revascularization 
with either PCI or CABG) at 1 
year amongst diabetic patients 
from ARTS-I, ARTS-II, CARDIA, 
and SYNTAX studies. From the 
limited data available there is 
an improvement in events with 
the use of drug-eluting stents, 
but repeat revascularization 
is still a prominent problem; 
however, matters appears to be 
improving. 
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the 3-year period after the index PCI procedure, in 
exchange for being pain free within 1 month of the ini-
tial treatment. Specifi cally, there is a risk of 0.96 clinical 
events at 3 years, including a risk of 0.57 for repeat PCIs 
and 0.33 for additional CABG events ( 65 ) . Similar analy-
sis further stratifi ed by other patient characteristics such 
as SYNTAX score will need to be performed in the cur-
rent DES era. The SYNTAX trial may raise a further 
issue of the increased risk of stroke in CABG patients in 
exchange for the higher risk of repeat revascularization 
events with PCI ( 31 ) . 
 Assuming the advantageous risk–benefi t ratio, the 
issue of cost-effectiveness of the PCI versus CABG is an 
important one from a societal standpoint. In the BARI 
trial initial PCI costs were lower than CABG costs, 
 however, at 5-year follow-up given the need for repeat 
procedures in the PCI group the cost difference has 
narrowed. At 10–12 years there was no economic advan-
tage of one procedure over the other ( 66 ) . In the ARTS-I 
trial at 1 year PCI was less expensive, however, at 3 years 
whilst a cost saving was still present, it was signifi cantly 
reduced in the stent arm due to repeat procedures ( 64 ) . 
Similar cost analysis will be needed in the SYNTAX and 
FREEDOM trials given the high costs of DES, and often 
wide spread use of glycoprotein IIb/IIIa inhibitors and 
novel antithrombin agents in the PCI arm. 
 Summary 
 A large proportion of patients with CAD have stable 
symptoms. Patients must undergo risk stratifi cation 
using available resources and expertise to determine 
who requires additional revascularization. In those 
deemed low risk, symptoms can be appropriately con-
trolled with medication with no detriment to long-term 
prognosis. Those patients who are high risk, or not con-
trolled with medical therapy, should undergo revascu-
larization, although the ideal form of revascularization 
is yet to be determined. 
 Whilst over the last decade we have accumulated a lot 
of evidence regarding outcomes of PCI versus CABG in 
the treatment of MVD, it is only recently that trials such 
as SYNTAX are starting to provide us with scores and 
tools in terms of anatomic and clinical patient charac-
teristics that will allow us to better individualize the 
treatment choice for each patient. The SYNTAX score is 
one such tool that may facilitate better decision making 
in complex cases. This tool, however, still requires both 
retrospective and prospective validation in larger cohorts 
of patients. 
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Objectives We aimed to assess the predictive value of the SYNTAX score (SXscore) for major adverse cardiac events in the
all-comers population of the LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
Background The SXscore has been shown to be an effective predictor of clinical outcomes in patients with multivessel dis-
ease undergoing percutaneous coronary intervention.
Methods The SXscore was prospectively collected in 1,397 of the 1,707 patients enrolled in the LEADERS trial (patients
after surgical revascularization were excluded). Post hoc analysis was performed by stratifying clinical outcomes
at 1-year follow-up, according to 1 of 3 SXscore tertiles.
Results The 1,397 patients were divided into tertiles based on the SXscore in the following fashion: SXscore 8 (SXlow)
(n  464), SXscore 8 and 16 (SXmid) (n  472), and SXscore 16 (SXhigh) (n  461). At 1-year follow-up,
there was a significantly lower number of patients with major cardiac event–free survival in the highest tertile of
SXscore (SXlow  92.2%, SXmid  91.1%, and SXhigh  84.6%; p  0.001). Death occurred in 1.5% of SXlow
patients, 2.1% of SXmid patients, and 5.6% of SXhigh patients (hazard ratio [HR]: 1.97, 95% confidence interval
[CI]: 1.29 to 3.01; p  0.002). The myocardial infarction rate tended to be higher in the SXhigh group. Target
vessel revascularization was 11.3% in the SXhigh group compared with 6.3% and 7.8% in the SXlow and SXmid
groups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p  0.006). Composite of cardiac death, myocardial infarc-
tion, and clinically indicated target vessel revascularization was 7.8%, 8.9%, and 15.4% in the SXlow, SXmid,
and SXhigh groups, respectively (HR: 1.47, 95% CI: 1.19 to 1.81; p  0.001).
Conclusions The SXscore, when applied to an all-comers patient population treated with drug-eluting stents, may allow pro-
spective risk stratification of patients undergoing percutaneous coronary intervention. (LEADERS Trial Limus
Eluted From A Durable Versus ERodable Stent Coating; NCT00389220). (J Am Coll Cardiol 2010;56:272–7)
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The SYNTAX score (SXscore) is a comprehensive angio-
graphic scoring system that is derived entirely from the
coronary anatomy and lesion characteristics (1–3). It was
initially designed to quantify lesion complexity; however, it
is also able to predict major adverse cardiac events (MACE)
after percutaneous revascularization in patients with mul-
tivessel coronary artery disease (4–6) and/or left main
disease (7). More recent data indicate its ability to predict
periprocedural myocardial infarction (MI) in patients
undergoing elective percutaneous coronary intervention
(8). In this substudy of the LEADERS (Limus Eluted
from A Durable versus ERodable Stent coating) trial, in
which the SXscore was collected prospectively in 1,397
all-comer patients, we assessed its prognostic value for
MACE at 1-year follow-up.
Methods
Study population. LEADERS was a multicenter Euro-
pean noninferiority trial comparing the safety and efficacy of
the BioMatrix Flex biolimus-eluting stent with a biodegrad-
able polymer (Biosensors, Morges, Switzerland) with the
Cypher Select sirolimus-eluting stent with a durable poly-
mer (Cordis, Bridgewater, New Jersey) in 1,707 all-comer
patients. Detailed study protocol can be found in the main
report (9). The study complied with the Declaration of
Helsinki and was approved by all institutional ethics com-
mittees. All patients provided written informed consent for
participation in the trial.
SXscore and angiographic analysis. From the baseline
diagnostic angiogram, each coronary lesion producing
50% diameter stenosis in vessels 1.5 mm was scored
separately and added together to provide the overall
SXscore, which was calculated prospectively using the
SXscore algorithm (described in full elsewhere) (1–3). All
angiographic variables pertinent to SXscore calculation were
computed by blinded core laboratory analysts (Cardialysis
B.V., Rotterdam, the Netherlands). The SXscore is not
currently validated in patients with acute MI or previous
percutaneous coronary intervention and coronary artery
bypass graft. Core laboratory analysts were blinded to all
clinical data, and therefore patients with occluded infarct–
related arteries were scored as occlusions of unknown
duration in a similar manner to any chronically occluded
artery. Those patients with in-stent restenosis lesions were
scored in the same manner as if the lesion was a de novo
lesion.
Study end points. Definitions of all end points are pro-
vided elsewhere (9). The primary end point of this substudy
was MACE, defined as the composite of cardiac death, MI,
and clinically indicated target vessel revascularization
(TVR) within 9 months. Secondary end points were any
target lesion revascularization (both clinically and nonclini-
cally indicated), any TVR, cardiac death, death from any
cause, MI, stent thrombosis (defined according to the
Academic Research Council
[10]), device success, and lesion
success.
The pre-specified principal
outcome of the angiographic
substudy was the in-stent per-
centage of diameter stenosis.
Secondary angiographic out-
comes were the in-segment per-
centage of diameter stenosis,
minimal lumen diameter, late lu-
men loss, and binary restenosis.
Statistical analysis. A stratified
post hoc analysis of clinical and
angiographic outcomes was per-
formed according to the tertiles
of the SXscore (4,5). Dedicated
software and visual coronary angiography served to deter-
mine the SXscore (1,2). All randomized patients without
previous surgical revascularization (1,397 of 1,707) were
included in the analysis. Angiographic outcomes were ana-
lyzed using SAS version 8 (SAS Institute, Cary, North
Carolina) Proc Mixed for continuous and Proc Genmod
for binominal outcomes, taking into account the within-
patient correlation structure of these data. The Cox
proportional hazards model was used to compare clinical
outcomes among the groups. All analyses were performed
using SAS version 8.02 by a dedicated statistician. All p
values and confidence intervals (CIs) were 2-sided. Mul-
tivariate model included SXscore, diabetes, beta-blocker
use, stent type, and the presence of acute coronary
syndrome as covariates. Testing for (linear) trend was
done by using generalized linear models with SYNTAX
class as a covariable for continuous variables and the
Cochran-Armitage test for trend in categorical data.
Results
SXscore and baseline characteristics. The SXscore was
collected prospectively in 1,397 of the 1,707 patients
(81.8%) enrolled in the LEADERS trial. The score ranged
from 0 to 49, with a mean SD of 13.5 8.7 and a median
of 12 (interquartile range 7 to 19). In this post hoc analysis,
the SXscore tertiles were defined as SXlow (SXscore 8)
(n  464), SXmid (SXscore 8 and 16) (n  472), and
SXhigh (SXscore 16) (n  461). Baseline clinical and
angiographic characteristics of the patients are listed in
Tables 1 and 2.
1-year outcomes. The SXscore significantly predicted the
rate of MACE at 360 days (Table 3, Figs. 1 to 4). There was
a lower number of patients with MACE-free survival in the
highest tertile of the SXscore (SXlow 92.2%, SXmid 91.1%,
and SXhigh  84.6%; p  0.001). Death occurred in 1.5%
of patients with SXlow, 2.1% of patients with SXmid, and
5.6% of patients with SXhigh (hazard ratio [HR]: 1.97, 95%
CI: 1.29 to 3.01; p  0.002). The rate of MI tended to be
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
SXhigh  SYNTAX
score >16
SXlow  SYNTAX score <8
SXmid  SYNTAX score >8
and <16
SXscore  SYNTAX score
TVR  target vessel
revascularization
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higher in patients with SXhigh (MI HR: 1.2, 95% CI: 0.9
to 1.61; p  0.22). TVR was 11.3% in the SXhigh group
compared with 6.3% and 7.8% in the SXlow and SXmid
groups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p 
0.006). Composite of cardiac death, MI, and clinically
indicated TVR was 7.8%, 8.9%, and 15.4% in the SXlow,
SXmid, and SXhigh groups, respectively (HR: 1.47, 95%
CI: 1.19 to 1.81; p  0.001).
Multivariate model. In a multivariate model, SXscore
remained a significant predictor of MACE and mortality.
Patients in the SXhigh group had a 50% greater chance of
the composite of cardiac death, MI, and clinically indicated
TVR than patients in the SXmid group (p  0.001), which
was comparable to the 51% higher composite event rate
among diabetic patients (p  0.022). Use of the biolimus-
eluting stent tended to reduce the composite event rate by
26% (p  0.07).
Stent thrombosis rates. The rates of definite stent throm-
bosis were 0.9%, 2.1%, and 3.5% in the SXlow, SXmid, and
SXhigh groups, respectively.
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Baseline Clinical Variables
SXlow
(n  464)
SXmid
(n  472)
SXhigh
(n  461)
p Value on Trend
(2-Sided)
Age 65 yrs 210 (45.3) 224 (47.5) 239 (51.8) 0.048
Male 346 (74.6) 344 (72.9) 340 (73.8) 0.79
Diabetes 93 (20.0) 117 (24.8) 111 (24.1) 0.15
Current smoking 134 (28.9) 121 (25.6) 126 (27.3) 0.61
Hypertension 353 (76.1) 353 (74.8) 324 (70.3) 0.048
Hypercholesterolemia 314 (67.7) 314 (66.5) 285 (61.8) 0.06
Family history of coronary artery disease 201 (43.3) 188 (39.8) 168 (36.4) 0.034
Renal insufficiency 17 (3.7) 21 (4.5%) 28 (6.1) 0.09
Previous MI 132 (28.5) 145 (30.7) 137 (29.7) 0.69
Previous PCI 179 (38.6) 165 (35.0) 147 (31.9) 0.036
PVD 26 (5.6) 36 (7.6) 31 (6.7) 0.51
Previous stroke 13 (2.8) 19 (4.0) 16 (3.5) 0.59
Clinical presentation
Stable 146 (31.5) 154 (32.6) 108 (23.4) 0.008
Unstable 127 (27.4) 89 (18.9) 88 (19.1) 0.002
STEMI 46 (9.9) 90 (19.1) 128 (27.8) 0.0001
Non-STEMI 90 (19.4) 90 (19.1) 97 (21.0) 0.54
Silent ischemia 55 (11.9) 49 (10.4) 40 (8.7) 0.12
Values shown are n (%).
MI  myocardial infarction; PCI  percutaneous coronary intervention; PVD  peripheral vascular disease; STEMI  ST-segment elevation
myocardial infarction; SXhigh  SYNTAX score 16; SXlow  SYNTAX score 8; SXmid  SYNTAX score 8 and 16.
Baseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characteristics
Angiographic Variables SXlow SXmid SXhigh p Value
No. of diseased lesions per patient (based on SYNTAX application) 1.47 0.66 2.37 1.00 3.45 1.44 0.001
No. of treated lesions per patient (as defined by the core laboratory) 1.2 0.46 1.47 0.7 1.69 0.86 0.001
Ratio of diseased to treated lesions 1.22 1.61 2.04 N/A
Coronary artery treated
LAD 162 (34.9) 242 (51.3) 296 (64.2) 0.001
LCX 140 (30.2) 144 (30.5) 164 (35.6) 0.079
RCA 216 (46.6) 209 (44.3) 174 (37.7) 0.007
2-vessel disease 49 (10.6) 102 (21.6) 138 (29.9) 0.001
3-vessel disease 3 (0.7) 13 (2.8) 23 (5.0) 0.001
Stent type
Biolimus-eluting 229 (49.3) 235 (49.8) 239 (51.8) 0.45
Sirolimus-eluting 235 (50.7) 237 (50.2) 222 (48.2) 0.45
No. of implanted stents 1.47 0.8 1.90 1.12 2.33 1.39 0.001
Total stent length/patient, mm 25.9 16.5 34.2 21.7 42.9 26.2 0.001
Chronic total occlusion 6 (1.3) 10 (2.1) 19 (4.1) 0.006
Moderate to severe calcification 23 (5.1) 96 (20.3) 184 (39.9) 0.001
Bifurcation lesion 57 (12.3) 161 (34.1) 184 (39.9) 0.001
Use of glycoprotein IIb/IIIa inhibitor 80 (17.2) 113 (23.9) 154 (33.4) 0.001
Values are mean  SD or n (%).
LAD  left anterior descending artery; LCX  left circumflex artery; N/A  not applicable; RCA  right coronary artery; other abbreviations as in Table 1.
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Discussion
Complexity of disease and lesion characteristics are well
recognized predictors of periprocedural complications (8)
and long-term mortality (11–13). The SXscore was devel-
oped to comprehensively assess lesion characteristics and is
based on the combination of classifications from the Amer-
ican Heart Association/American College of Cardiology,
modified BARI classification, chronic total occlusion and
bifurcation scores, and Leaman classification (1). It has
previously been applied in both the SYNTAX trial and
the ARTS II (Arterial Revascularization Therapies Study
II), both of which demonstrated the good predictive value
of the SXscore in patients with multivessel disease, with
the highest tertile patients having significantly more
MACE during short-term (4,5) and long-term (6)
follow-up.
This study is the first to report the utility of the SXscore
as a predictor of MACE, including cardiac death, in an
all-comers population including patients with acute coro-
nary syndromes. Overall, this patient population had much
lower SXscores than the SYNTAX trial population; how-
ever, despite this, the SXscore still appears to have good
discriminatory power for risk assessment.
Study limitations. The limitation of the SXscore is that it
does not incorporate clinical patient characteristics. Patients
who underwent previous coronary artery bypass graft sur-
gery have not been included because the SXscore algorithm
is only currently available for patients with de novo disease.
Modifications to the SXscore for risk stratification in
patients after coronary artery bypass graft surgery are cur-
rently being developed. The SXscore of patients who
presented with acute MI or had previous percutaneous
Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscoreTable 3 Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscore
Type of Event Risk Factors Used
SXlow
(%)
SXmid
(%)
SXhigh
(%)
p Value
SYNTAX
HR,
SYNTAX
Lower Limit HR,
SYNTAX
Upper Limit HR,
SXscore
Death SYNTAX class, DM, STEMI 1.5 2.1 5.6 0.002 1.97 1.29 3.01
Stent thrombosis SYNTAX class, DM, STEMI 1.1 3 6.1 0.001 2.13 1.4 3.24
MI SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.3 4.9 5.9 0.22 1.2 0.9 1.61
All TVR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
6.3 7.8 11.3 0.006 1.38 1.1 1.75
All TLR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.7 6.1 8.7 0.019 1.37 1.05 1.79
Composite of cardiac
death, MI, clinically
indicated TVR
SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
7.8 8.9 15.4 0.001 1.47 1.19 1.81
BES biolimus-eluting stent(s); DM diabetes mellitus; HR hazard ratio; PCI percutaneous coronary intervention; SES sirolimus-eluting stent(s); TLR target lesion revascularization; TVR target
vessel revascularization; other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Curves for MACE at 360 Days According to the SYNTAX Tertiles
Patients in the highest tertile of the SYNTAX score have an increased major adverse cardiac events (MACE) event rate (p  0.0002).
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coronary intervention were included in this analysis, despite
no previous validation in these patients. Scoring of the
infarct-related vessel as a chronic total occlusion may
confound the results and have complex effects on the
SXscore. There is the danger of overestimating the SXscore
if all ST-segment elevation MIs with an occluded infarct–
related vessel are taken as chronic total occlusions, particu-
larly because the lesion is likely to be easier to treat due to
the soft nature of plaque as opposed to an occlusion, which
has calcified organized old thrombus and plaque (chronic
occlusion). Alternatively, there is the danger of underesti-
mating the SXscore because the underlying lesion complex-
ity will not be accounted for because the vessel beyond the
occlusion is not seen due to the occlusion. This is the subject
of an ongoing study. This study may have limitations
inherent to subgroup analysis (chance findings and under-
powering) (14–16).
Conclusions
This study demonstrates that the prognostic value of the
SXscore is valid for all patients with de novo coronary
artery disease undergoing percutaneous revascularization.
Figure 2 Kaplan-Meier Curves for Cardiac Death at 360 Days According to the SYNTAX Score Tertiles
Patients in the highest tertile of the SYNTAX score have a higher cardiac death rate (p  0.0001).
Figure 3 Kaplan-Meier Curves for All Myocardial Infarctions at 360 Days According to the SYNTAX Score Tertiles
There is no difference in the rate of overall myocardial infarctions across the tertiles of SYNTAX score (p  0.548 [NS]).
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Figure 4 Kaplan-Meier Curves for Target Lesion Revascularization at 360 Days According to the SYNTAX Score Tertiles
Patients in the highest tertile of the SYNTAX score have an increased risk of target lesion revascularization (p  0.036).
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Background—The age, creatinine, and ejection fraction (ACEF) score (age/left ventricular ejection fraction1 if
creatinine 2.0 mg/dL) has been established as an effective predictor of clinical outcomes in patients undergoing
elective coronary artery bypass surgery; however, its utility in “all-comer” patients undergoing percutaneous coronary
intervention is yet unexplored.
Methods and Results—The ACEF score was calculated for 1208 of the 1707 patients enrolled in the LEADERS trial. Post
hoc analysis was performed by stratifying clinical outcomes at the 1-year follow-up according to ACEF score tertiles:
ACEFlow 1.0225, 1.0225 ACEFmid 1.277, and ACEFhigh 1.277. At 1-year follow-up, there was a significantly
lower number of patients with major adverse cardiac event–free survival in the highest tertile of the ACEF score
(ACEFlow92.1%, ACEFmid89.5%, and ACEFhigh86.1%; P0.0218). Cardiac death was less frequent in ACEFlow
than in ACEFmid and ACEFhigh (0.7% vs 2.2% vs 4.5%; hazard ratio2.22, P0.002) patients. Rates of myocardial
infarction were significantly higher in patients with a high ACEF score (6.7% for ACEFhigh vs 5.2% for ACEFmid and
2.5% for ACEFlow; hazard ratio1.6, P0.006). Clinically driven target-vessel revascularization also tended to be
higher in the ACEFhigh group, but the difference among the 3 groups did not reach statistical significance. The rate of
composite definite, possible, and probable stent thrombosis was also higher in the ACEFhigh group (ACEFlow1.2%,
ACEFmid3.5%, and ACEFhigh6.2%; hazard ratio2.04, P0.001).
Conclusions—ACEF score may be a simple way to stratify risk of events in patients treated with percutaneous coronary
intervention with respect to mortality and risk of myocardial infarction.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00389220.
(Circ Cardiovasc Interv. 2011;CV-4:00-00.)
Key Words: ACEF score  SYNTAX score  biolimus-eluting stent  sirolimus-eluting stent 
biodegradable polymer  cardiac death  major adverse cardiac event
Several validated risk assessment scores such as theEuroSCORE have been developed for mortality risk
assessment in cardiac surgery.1 More recently, these sim-
ple scores incorporating patient clinical characteristics
have also been applied to patients undergoing percutane-
ous coronary interventions (PCI).2–4 In a recent study,
Romagnoli et al3 reported an area under the receiver
operating characteristic (ROC) curve of 0.91 for in-
hospital mortality among 1173 patients treated with PCI,
indicating a good discriminatory power of the EuroSCORE
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in patients undergoing PCI. A novel and even simpler
score has been proposed and tested in patients undergoing
coronary artery bypass graft surgery incorporating age,
creatinine, and ejection fraction (ACEF score).5 The ad-
vantage of this simplified risk model is that it avoids the
problem of “overfitting” to many independent variables
when applied to populations with low numbers of events.
In patients undergoing isolated coronary artery bypass
graft surgery, the ACEF score calculated by age/ejection
fraction1 (if creatinine 2.0 mg/dL) had an area under
the ROC curve of 0.826, which was higher than that of
more complex risk scores. To our knowledge, the perfor-
mance of the ACEF score to predict event rates and cardiac
mortality has not been tested in patients undergoing PCI.
In this post hoc analysis of the “all-comers” LEADERS
trial,6 we assessed the value of the ACEF score in
predicting major adverse cardiac events (MACEs) at
1-year follow-up. In addition, we have compared its
predictive value for events with that of the SYNTAX
score7 and have assessed the additive value of both scores
(the so-called clinical SYNTAX score). Finally, we aimed
to test whether the ACEF and combined ACEF*SYNTAX
scores performed as well in this all-comers population
undergoing PCI as they did in the multivessel-disease
patient populations undergoing coronary artery bypass
graft surgery and/or PCI, for which they were initially
developed and applied (shrinkage phenomenon).8
Clinical Perspective on p ●●●
Methods
Study Population
LEADERS was a European multicenter, noninferiority trial com-
paring the safety and efficacy of the BioMatrix Flex biolimus-
eluting stent with a biodegradable polymer (Biosensors, Morges,
Switzerland) with the CypherSelect sirolimus-eluting stent with a
durable polymer (Cordis, NJ) in 1707 all-comer patients. Details
of the study protocol can be found in the main article.6 The study
complied with the Declaration of Helsinki and was approved by
all institutional ethics committees. All patients provided written,
informed consent for participation in the trial.
ACEF Score and Analysis
The ACEF score was calculated according to the following
formula: ACEFage/left ventricular ejection fraction1 (if cre-
atinine was 2.0 mg/dL).5 Patients were divided into tertiles
based on the ACEF score. A modified clinical SYNTAX score
was calculated by multiplying the ACEF score by the SYNTAX
score.
Study End Points
Definitions of all end points are provided elsewhere.6 The primary
end point of this substudy was MACEs, defined as the composite
of cardiac death, myocardial infarction (MI), and clinically
indicated target-vessel revascularization (TVR) within 12 months.
Secondary end points were any target lesion revascularization
(TLR) (both clinically and nonclinically indicated), any TVR,
cardiac death, death from any cause, MI, stent thrombosis
(defined according to the Academic Research Council9), device
success, and lesion success.
Statistical Analysis
A stratified post hoc analysis of clinical and angiographic
outcomes was performed according to tertiles of the ACEF score.
All randomized patients were included in the analysis. Angio-
graphic outcomes were analyzed by SAS v8 Proc Mixed for
continuous and Proc Genmod for binomial outcomes, taking into
account the within-patient correlation structure of these data. The
Cox proportional-hazards model was used to compare clinical
outcomes between the groups. All analyses were performed with
SAS 8.02 by a dedicated statistician. All probability values and
confidence intervals were 2-sided. The multivariate model in-
cluded ACEF score, diabetes, -blocker use, stent type, and
presence of acute coronary syndrome/ST-segment elevation MI as
covariates. Testing for (linear) trend was done by using general-
ized linear models with ACEF class as a covariable for continuous
variables and the Cochran-Armitage test for trend in categorical
data. C-statistics and ROC curves were constructed to assess the
ability of the ACEF score and ACEF*SYNTAX score (modified
clinical SYNTAX score) to predict events.10
Results
ACEF Score and Baseline Characteristics
The ACEF score could be calculated retrospectively for
1208 of the 1707 patients enrolled in the trial. We were
unable to calculate the score for 499 patients owing to the
unavailability of renal function assessment or ejection
fraction (mostly in patients presenting with ST-segment
elevation MI). The score ranged from 0.562 to 5.403, with
a meanSD of 1.2780.539 and a median of 1.131
(interquartile range of 0.964 to 1.398). In this post hoc
analysis, the ACEF score tertiles were defined as follows:
ACEFlow, 1.0225 (n404); 1.0225 ACEFmid 1.277
(n402), and ACEFhigh 1.277 (n402). Baseline clinical
and angiographic characteristics of the patients are listed
in Tables 1 through 4. In addition to differences in age and
the presence of renal insufficiency (creatinine 2.0 mg/
dL) among the 3 tertiles of ACEF score, patients with
higher ACEF scores were more likely to be female, have
diabetes, smoke, have hypertension, have a prior history of
MI, have concomitant peripheral vascular disease, and
present with an unstable coronary syndrome. Conversely,
patients with low ACEF scores were more likely to be
hypercholesterolemic, have a family history of heart dis-
ease, and were more likely to present with stable angina or
ST-segment elevation MI. The 3 groups did not differ
significantly with respect to angiographic characteristics
except for a slightly higher number of lesions, a trend for
a greater number of stents implanted, and a significantly
greater number of lesions with moderate to severe calcifi-
cation. All 51 patients with renal insufficiency were in the
high-ACEF-score group. Thus, the ACEF score calculation
for the low and mid ACEF tertiles was age/left ventricular
function.
One-Year Outcomes
The ACEF score significantly predicted the rate of MACEs
and cardiac death, as well as the rate of MI at 360 days
(Tables 5 and 6 and Figures 1 through 4). There was a
significantly lower number of patients with MACE-free
survival in the highest tertile of the ACEF score (ACE-
Flow92.1%, ACEFmid89.5%, and ACEFhigh86.1%;
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P0.0218). The composite end point of cardiac death, MI,
and TVR occurred in 7.9% of ACEFlow patients, 10.4% of
patients with ACEFmid scores, and 13.9% of ACEFhigh
patients (hazard ratio [HR]1.34, P0.007). Cardiac
death occurred in 0.7% of patients with low ACEF scores,
2.2% of patients with intermediate ACEF scores, and 4.5%
of patients with high ACEF scores (HR2.22, P0.002).
The rate of MI was significantly higher in patients with
Table 1. Baseline Clinical Characteristics According to ACEF Tertiles
Baseline Clinical Variables, No. (%)
ACEF 1.0225,
n404
ACEF 1.0225–1.277,
n402
ACEFF 1.277,
n402
P Value on Trend
(2-Sided)
Age 65 y 61 (15.1) 227 (56.5) 305 (75.9) 0.001
Mean age, y 56 66 71 0.001
Male 320 (79.2) 302 (75.1) 286 (71.1) 0.009
Diabetes 82 (20.3) 89 (22.1) 114 (28.4) 0.008
Current smoking 148 (36.6) 87 (21.6) 83 (20.7) 0.001
Hypertension 277 (68.6) 318 (79.1) 320 (79.6) 0.001
Hypercholesterolemia 281 (69.6) 277 (68.9) 248 (61.7) 0.019
Family history 173 (42.8) 166 (41.3) 137 (34.1) 0.012
Renal insufficiency (creatinine 2.0 mg/dL) 0 0 51 (12.7) 0.001
Mean ejection fraction, % 64 58 45 0.001
Previous MI 102 (25.5) 121 (30.1) 161 (40.1) 0.001
Previous PCI 138 (34.2) 158 (39.3) 157 (39.1) 0.16
PVD 18 (4.5) 32 (8.0) 45 (11.2) 0.001
Previous stroke 12 (3.0) 14 (3.5) 17 (4.2) 0.34
Clinical presentation
Stable 139 (34.4) 130 (32.3) 94 (23.4) 0.001
Unstable 100 (24.8) 94 (23.4) 71 (17.7) 0.015
STEMI 50 (12.4) 51 (12.7) 96 (23.9) 0.001
Non-STEMI 79 (19.6) 82 (20.4) 94 (23.4) 0.20
Silent Ischaemia 36 (8.9) 45 (11.1) 47 (11.7) 0.21
STEMI indicates ST-segment MI.
Table 2. Baseline Characteristics According to ACEF*SYNTAX Score Tertiles
Baseline Clinical Variables,
No. (%)
ACEF*SYNTAX
8.80, n356
ACEF*SYNTAX
8.80–18.74, n355
ACEF*SYNTAX
18.74, n356
P Value on Trend
(2-Sided)
Age 65 y 131 (36.8) 157 (44.2) 216 (60.7) 0.001
Mean age, y 56 66 71 0.001
Male 271 (76.1) 268 (75.5) 257 (72.2) 0.25
Diabetes 69 (19.4) 78 (22.0) 93 (26.1) 0.035
Current smoking 118 (33.2) 88 (24.8) 93 (26.1) 0.041
Hypertension 264 (74.2) 266 (75.0) 269 (75.6) 0.70
Hypercholesterolemia 243 (68.3) 245 (69.0) 215 (60.4) 0.030
Family history 145 (40.7) 142 (40.0) 122 (34.3) 0.08
Renal insufficiency 4 (1.1) 7 (2.0) 33 (9.3) 0.001
Mean ejection fraction, % 64 58 45 0.001
Previous MI 97 (27.3) 108 (30.4) 117 (32.9) 0.11
Previous PCI 132 (37.1) 131 (36.9) 119 (33.4) 0.33
PVD 16 (4.5) 23 (6.5) 30 (8.4) 0.039
Previous stroke 9 (2.5) 13 (3.7) 11 (3.1) 0.75
Clinical presentation
Stable 107 (30.1) 112 (31.6) 78 (21.9) 0.017
Unstable 95 (26.7) 70 (19.7) 68 (19.1) 0.016
STEMI 35 (9.8) 61 (17.2) 94 (26.4) 0.001
Non-STEMI 77 (21.6) 79 (22.3) 81 (22.8) 0.75
Silent ischemia 42 (11.8) 33 (9.3) 35 (9.8) 0.42
STEMI indicates ST-segment MI.
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high ACEF scores (6.7% for ACEFhigh vs 5.2% for
ACEFmid and 2.5% for ACEFlow; HR1.6, P0.006).
Clinically driven TVR also tended to be higher in the
ACEFhigh group, but the difference among the 3 groups did
not reach statistical significance (ACEFlow5.4%,
ACEFmid6.5%, and ACEFhigh8%; HR1.22, P0.16).
The rate of composite definite, possible, and probable stent
thrombosis was also higher in the high-ACEF group
(ACEFlow1.2%, ACEFmid3.5%, and ACEFhigh6.2%;
HR2.04, P0.001). Patients treated with biolimus- and
Table 3. Baseline Angiographic Characteristics According to ACEF Tertiles
Angiographic Variable
ACEF 1.0225,
n404
ACEF 1.0225–1.277,
n402
ACEFF 1.277,
n402 P Value
No. of diseased lesions per patient (based on SYNTAX application), meanSD 2.211.31 2.461.32 2.501.41 0.004
No. of treated lesions per patient (as defined by Corelab), meanSD 1.350.63 1.500.76 1.420.67 0.17
Ratio of diseased to treated lesions 1.63 1.64 1.76 NA
Coronary artery treated
LAD 188 (46.5) 199 (49.5) 195 (48.5) 0.57
LCX 131 (32.4) 137 (34.1) 112 (27.9) 0.16
RCA 160 (39.6) 162 (40.3) 153 (38.1) 0.67
Two-vessel disease 72 (17.9) 94 (23.9) 67 (17.4) 0.88
Three-vessel disease 5 (1.2) 8 (2.0) 11 (2.9) 0.11
Stent type
Biolimus 208 (51.5) 201 (50.0) 192 (47.8) 0.29
Sirolimus 196 (48.5) 201 (50.0) 210 (52.2) 0.29
No. of implanted stents, meanSD 1.781.13 1.901.17 1.931.17 0.07
Total stent length/patient, meanSD, mm 32.022.2 33.521.7 34.721.8 0.08
Chronic total occlusion 9 (2.2) 9 (2.2) 12 (3.0) 0.49
Moderate to severe calcification 47 (12.8) 86 (23.8) 98 (28.9) 0.001
Bifurcation lesion 107 (26.5) 127 (31.6) 117 (29.1) 0.41
Use of 2b3a 91 (22.5) 84 (20.9) 109 (27.1) 0.13
NA indicates not applicable; LAD, left anterior descending; LCX, left circumflex; and RCA, right coronary artery.
Table 4. Baseline Angiographic Characteristics According to ACEF*SYNTAX Score Tertiles
Angiographic Variable
ACEF*SYNTAX
8.80, n356
ACEF *SYNTAX
8.80–18.74, n355
ACEF*SYNTAX
18.74, n356 P Value
No. of diseased lesions per patient (based on SYNTAX application), meanSD 1.490.66 2.411.09 3.281.50 0.001
No. of treated lesions per patient (as defined by Corelab), meanSD 1.200.44 1.480.73 1.620.80 0.001
Ratio of diseased to treated lesions 1.24 1.63 2.03 NA
Coronary artery treated
LAD 119 (33.4) 184 (51.8) 231 (64.9) 0.001
LCX 104 (29.2) 115 (32.4) 114 (32.0) 0.42
RCA 167 (46.9) 154 (43.4) 127 (35.7) 0.002
Two-vessel disease 35 (9.8) 82 (23.1) 97 (27.3) 0.001
Three-vessel disease 0 (0) 10 (2.8) 14 (3.9) 0.001
Stent type
Biolimus 184 (51.7) 173 (48.7) 178 (50.0) 0.65
Sirolimus 172 (48.3) 182 (51.3) 178 (50.0) 0.65
No. of implanted stents, meanSD 1.450.77 1.951.19 2.251.32 0.001
Total stent length/patient, meanSD, mm 25.615.9 35.023.0 40.924.3 0.001
Chronic total occlusion 3 (0.8) 10 (2.8) 12 (3.4) 0.026
Moderate to severe calcification 18 (5.2) 66 (18.6) 146 (41.0) 0.001
Bifurcation lesion 51 (14.3) 117 (33.0) 136 (38.2) 0.001
Use of 2b3a 66 (18.5) 85 (23.9) 116 (32.6) 0.001
NA indicates not applicable; LAD, left anterior descending; LCX, left circumflex; and RCA, right coronary artery.
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sirolimus-eluting stents had equivalent event rates across
all 3 ACEF tertiles.
Multivariate Model
In a multivariate model, the ACEF score remained a
significant predictor of MACEs and mortality (Tables 5
and 6; note that the HRs are adjusted for the following
variables: ACEF score, diabetes, -blocker use, stent type,
and presence of ST-segment elevation MI/acute coronary
syndrome, the same variables used in the assessment of the
predictive value of the SYNTAX score in the LEADERS
trial).7 Patients in the ACEFhigh group had a 34% higher
risk of the composite end point of cardiac death, MI, and
clinically indicated TVR than did patients in the ACEFmid
group (P0.007), which was comparable to the 60%
higher composite event rate among diabetics (P0.012).
Use of a biolimus-eluting stent conferred a nonsignificant
12% reduction in events and with -blocker use, a 16%
reduction, but there was no difference in events due to
acute coronary syndrome presentation.
C-Statistics for ACEF Score and
ACEF*SYNTAX Score
The ACEF score c-statistic values for predicting cardiac
death and the occurrence of MI were 0.727 and 0.615,
respectively, in this all-comers patient population (Table 7).
This compares favorably with SYNTAX score c-statistics of
0.647 for cardiac death and 0.561 for MI in the same
population of the LEADERS trial. Conversely, the ACEF
score’s ability to assess the risk of overall MACEs and TVR
Table 5. Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of ACEF Score
Type of Event Low, n Low, % Middle, n Middle, % High, n High, %
P Value
ACEF HR (CI)
Patients, No. 404 . 402 . 402 . . .
Death 3 0.7 11 2.7 27 6.7 0.001 2.71 (1.69–4.35)
Cardiac death 3 0.7 9 2.2 18 4.5 0.002 2.22 (1.33–3.71)
MI 10 2.5 21 5.2 27 6.7 0.006 1.60 (1.14–2.24)
All TVR 34 8.4 39 9.7 42 10.4 0.27 1.14 (0.91–1.42)
Clinically justified TVR 22 5.4 26 6.5 32 8.0 0.16 1.22 (0.93–1.6)
All TLR 24 5.9 31 7.7 36 9.0 0.10 1.24 (0.96–1.6)
Clinically justified TLR 16 4.0 22 5.5 30 7.5 0.041 1.37 (1.01–1.85)
Composite of cardiac death/MI/TVR clinically indicated 32 7.9 42 10.4 56 13.9 0.007 1.34 (1.08–1.67)
Composite of cardiac death MI 12 3.0 25 6.2 40 10.0 0.001 1.79 (1.32–2.41)
Stent thrombosis 5 1.2 14 3.5 25 6.2 0.001 2.04 (1.35–3.07)
Definite stent thrombosis 3 0.7 10 2.5 15 3.7 0.012 1.92 (1.15–3.18)
Possible stent thrombosis 1 0.2 4 1.0 7 1.7 0.058 2.20 (0.98–4.96)
Probable stent thrombosis 2 0.5 1 0.2 4 1.0 0.27 1.72 (0.65–4.52)
Table 6. Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of ACEF*SYNTAX Score (Clinical Syntax Score)
Type of Event Low, n Low, % Middle, n Middle, % High, n %
P Value
ACEF*SYNTAX HR (CI)
Patients, No. 356 355 356
Death 6 1.7 7 2.0 22 6.2 0.002 2.06 (1.3–3.28)
Cardiac death 3 0.8 7 2.0 18 5.1 0.002 2.40 (1.38–4.16)
MI 13 3.7 17 4.8 23 6.5 0.07 1.37 (0.98–1.93)
All TVR 28 7.9 31 8.7 39 11 0.10 1.23 (0.96–1.57)
Clinically justified TVR 19 5.3 23 6.5 27 7.6 0.21 1.21 (0.9–1.62)
All TLR 23 6.5 23 6.5 33 9.3 0.12 1.24 (0.94–1.64)
Clinically justified TLR 17 4.8 18 5.1 24 6.7 0.25 1.21 (0.88–1.66)
Composite of cardiac death/MI/TVR clinically indicated 28 7.9 34 9.6 52 14.6 0.003 1.42 (1.12–1.79)
Composite of cardiac death, MI 14 3.9 19 5.4 37 10.4 0.001 1.70 (1.25–2.31)
Stent thrombosis 5 1.4 10 2.8 24 6.7 0.001 2.19 (1.4–3.43)
Definite stent thrombosis 4 1.1 7 2.0 14 3.9 0.028 1.81 (1.06–3.07)
Possible stent thrombosis 1 0.3 2 0.6 7 2.0 0.034 2.90 (1.09–7.77)
Probable stent thrombosis 0 0 3 0.8 4 1.1 0.08 2.83 (0.9–8.88)
T7
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was lower (0.577 and 0.527, respectively). The SYNTAX
score in the same population was a better predictor of MACEs
and TVR, with c-statistics of 0.61 and 0.58, respectively.
Combining the ACEF with the SYNTAX score in the
modified clinical SYNTAX score (ACEF*SYNTAX score)
resulted in improvement in area under the ROC curves for
MACEs (from 0.577 to 0.618) and TLR (0.527 to 0.575;
Table 7). However, the area under the ROC curves for cardiac
death and MI decreased after combining the SYNTAX score
with the ACEF score.
Discussion
With the rapidly expanding indications for PCI and the
concomitant increasing age and clinical complexity of pa-
tients undergoing these procedures, risk assessment with
respect to overall MACE rate and particularly mortality rate
has become a very important aspect of daily clinical decision
making. Multiple risk-assessment models have been devel-
oped for surgical patients and are starting to be used increas-
ingly in the assessment of patients undergoing PCIs, partic-
ularly when decisions are needed with respect to the
Figure 1. A, Kaplan-Meier curve for MACEs at 360 days according to ACEF score tertiles. B, Kaplan-Meier curve for MACEs at 360
days according to ACEF*SYNTAX score tertiles.
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appropriateness of surgical versus percutaneous revascular-
ization in patients with extensive coronary artery disease and
multiple comorbidities. Some of these risk scores, such as
SYNTAX, have excellent prognostic value7,11–13 but are
based solely on anatomic information and only indirectly
incorporate clinical characteristics, in so far as patients who
are older and have renal insufficiency tend to also have more
calcified vessels and more diffuse disease. Many of the
surgical risk models incorporate too many variables, which
results in inaccuracies and the overfitting associated with
them; in addition, some models incorporate several patient
characteristics that impart high risk to surgical patients only
but not necessarily to patients undergoing PCI. The ACEF
score, though only currently validated in a surgical patient
group, is simple and easy to calculate and combines 3 important
clinical characteristics, namely, age, creatinine (renal insuffi-
ciency), and left ventricular ejection fraction.5 As such, it is
extremely useful and applicable to patients undergoing PCI. In
this substudy of the all-comers LEADERS trial, which well
reflects the real-world population of patients being treated in
Figure 2. A, Kaplan-Meier score for cardiac death at 360 days according to ACEF score tertiles. B, Kaplan-Meier score for cardiac
death at 360 days according to ACEF*SYNTAX score tertiles.
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tertiary PCI centers, we tested for the first time the predictive
value of the ACEF score for MACEs. Indeed, the ACEF score
appears highly predictive of cardiac death and MI risk. It is
less robust in its ability to predict the overall composite
primary end point, which is largely due to the lower ability to
assess the risk of repeat revascularization.
We have recently performed an analysis on the ability of the
SYNTAX score to predict events in the LEADERS study.7
Compared with the ACEF score, the SYNTAX score was better
at predicting overall MACEs and the risk of repeat revascular-
ization. However, the ACEF score was a better model to predict
risk of cardiac death and MI. The use of the ACEF and
SYNTAX score in combination in this all-comers patient pop-
ulation with a median ACEF score of 1.131 and a median
SYNTAX score of 12 did not result in a better explanatory
model for risk assessment, which is likely to be the result of the
low number of events and the aforementioned overfitting. This
finding contrasts with our analysis performed in the higher-risk
multivessel-disease population enrolled in the ARTS-II study,
who had a median SYNTAX score of 19 and a modified ACEF
Figure 3. A, Kaplan-Meier curve for MI at 360 days according to ACEF tertiles. B, Kaplan-Meier curve for MI at 360 days according to
ACEF*SYNTAX score tertiles.
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score of 1.1, wherein the combination of the 2 scores in the
so-called clinical SYNTAX score resulted in higher c-statistics
and better predictive values for both mortality and overall
MACEs at 5 years of follow-up.14
In summary, this first assessment of the performance of the
ACEF score as a risk model to predict cardiac death and MI in
an all-comers population of patients undergoing PCI with
drug-eluting stents appears adequate. One may consider using
anatomically based scores, such as SYNTAX, to more accu-
rately assess the risk of repeat revascularization. The combina-
tion of these 2 scores may be needed in particularly challenging
and high-risk patient populations, such as those with multivessel
disease, to improve the accuracy of risk prediction. In
addition, the SYNTAX score is better validated in guiding
the treatment choice of coronary artery bypass graft versus
PCI.11,12 On the other hand, the ACEF score is composed
of objectively measured variables, whereas the SYNTAX
score assessment involves a subjective evaluation of an
angiogram, which may be prone to interobserver
variability.15,16
Figure 4. A, Kaplan-Meier curve for TLR at 360 days according to ACEF score tertiles. B, Kaplan-Meier curve for TLR at 360 days
according to ACEF*SYNTAX score tertiles.
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Limitations
We acknowledge that this substudy suffers from the limitations
of post hoc analysis. In addition, the ACEF score has not been
previously validated in patients undergoing PCI, and further
validation will be necessary in a larger cohort of patients from a
pooling of multiple PCI studies. Last, the follow-up in this
substudy of LEADERS and thus assessment of the predictive
value of the ACEF score are limited to 1 year. In one third of
patients, the ACEF score could not be calculated owing to
missing creatinine or ejection fraction values (mostly in patients
presenting with ST-segment elevation MI).
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CLINICAL PERSPECTIVE
Risk stratification is becoming an increasingly important part of the assessment of patients who are candidates for coronary
revascularization. We have recently reported that the SYNTAX score, which was initially developed for risk assessment in
patients with multivessel disease, is also predictive of major cardiovascular events in an all-comers patient population undergoing
percutaneous coronary intervention. The SYNTAX score, which is based entirely on the extent of coronary disease, has its
limitations and does not take into account important clinical variables that may also influence outcomes. The ACEF score,
defined as age/left ventricular ejection fraction1 (if creatinine 2.0 mg/dL), was initially validated in a cohort of patients
undergoing bypass surgery and incorporates important clinical factors. In the current study, we demonstrate that this simple score
is also a valid predictor of outcomes in an all-comers patient population undergoing percutaneous coronary intervention. The
combination of the 2 scores may be particularly useful in very clinically complex patients, enabling physicians to provide an
individualized assessment of risk, which is vital for appropriate informed consent.
Table 7. C-Statistics
Event ACEF Score c-Statistic
ACEF*SYNTAX
Score c-Statistic
MACEs 0.577 0.618
Cardiac death 0.727 0.71
MI 0.615 0.597
TLR 0.527 0.575
AQ: 6
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Background—Presently, no effective risk model exists to predict long-term mortality or other major adverse cardiovascular
and cerebrovascular events (MACCE) in those patients undergoing percutaneous coronary intervention (PCI). This
study aimed to assess whether the Clinical SYNTAX Score (CSS) calculated by multiplying the SYNTAX Score to a
modified ACEF score (age/ejection fraction 1 for each 10 mL the creatinine clearance 60 mL/min per 1.73 m2)
would improve the ability of either score to predict mortality and MACCE.
Methods and Results—The CSS was calculated in 512 patients enrolled in the ARTS-II study who had serum creatinine
levels, ejection fraction, and body weight recorded at baseline. Clinical outcomes in terms of MACCE and mortality at
1- and 5-year follow-up were stratified according to CSS tertiles: CSSLOW15.6 (n170), 15.6CSSMID27.5
(n171), and CSSHIGH27.5 (n171). At 1-year follow-up, rates of repeat revascularization and MACCE were
significantly higher in the highest tertile group. At 5-year follow-up, CSSHIGH had a comparable rate of myocardial
infarction, a trend toward a significantly higher rate of death, and significantly higher rates of repeat revascularization
and overall MACCE compared with patients in the lower 2 tertiles. The respective C-statistics for the CSS, SYNTAX
Score, and ACEF score for 5-year mortality were 0.69, 0.62, and 0.65 and for 5-year MACCE were 0.62, 0.59, and 0.57.
Conclusions—An improvement in the ability of the SYNTAX Score to predict MACCE and mortality can be achieved by
combining the SYNTAX Score with a simple clinical risk score incorporating age, ejection fraction, and creatinine
clearance to produce the Clinical SYNTAX score.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00235170.
(Circ Cardiovasc Interv. 2010;3:317-326.)
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Coronary artery bypass grafting (CABG) has historicallybeen the preferred method of revascularization in pa-
tients with complex coronary artery disease (CAD); however,
recent evidence indicates that in specific groups of patients,
percutaneous coronary intervention (PCI) can offer a safe and
suitable alternative.1–4 This expanding use of PCI5 has
consequently increased the importance of developing a sys-
tematic approach for risk stratifying these complex patients
so that they might receive the appropriate revascularization
option. The ability to objectively decide which patients with
complex CAD are suitable for PCI has gained new ground
recently after the introduction of the SYNTAX Score.6,7 Not
only can this lesion-based scoring system quantify coronary
anatomic complexity, but studies also demonstrate that it has
a role in the short- and long-term risk stratification of patients
undergoing PCI.1,4,8–11
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One of the limitations of using the SYNTAX Score in this
context is that lesion-based scoring systems have been shown
to have a lower ability to predict mortality when compared
with scoring systems using clinical characteristics.12 In pa-
tients undergoing PCI, there are currently only limited data
available on the use of risk scores that rely solely on clinical
characteristics, such as the euroSCORE.13–15 Moreover, it has
been suggested that the use of too many individual variables
may reduce the overall accuracy of data.16 The recently
introduced ACEF score, for example, uses just age, left
ventricular ejection fraction (LVEF), and serum creatinine
(SCr) and appears to be as good as more complex scores in
predicting mortality in patients undergoing elective CABG.17
An acceptable modification to the ACEF score is to use the
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derived creatinine clearance (CrCl) instead of SCr because
this not only represents a better estimate of underlying renal
function but has also been previously shown to improve the
predictive accuracy of cardiac risk models such as the
euroSCORE.18
The aim of this study was to investigate whether a Clinical
SYNTAX Score (CSS), representing a multiplication of the
SYNTAX score with a modified ACEF score (through the
incorporation of CrCl), would improve the individual ability
of either of these scores to predict mortality in patients with
complex CAD undergoing PCI, who were enrolled in the
Arterial Revascularization Therapies Study Part II (ARTS-II).
Methods
Study Population
The ARTS-II study has been published previously.19 In brief, the
study was a multicenter, nonrandomized, open-label trial designed to
compare the safety and efficacy of the sirolimus eluting stent (SES)
in 607 patients with de novo multivessel CAD, using the surgical
group of ARTS-I as historic controls.
Patient Selection
Patients with stable angina, unstable angina, or silent ischemia, who
had2 coronary lesions located in different major epicardial vessels
and/or their side branches (not including the left main stem [LMS])
that were potentially amenable to stent implantation, were eligible
for inclusion. All patients enrolled into the ARTS-II study were
required to have a lesion with a diameter stenosis 50% in the left
anterior descending artery and 1 other major epicardial coronary
artery.
The goal was to achieve complete anatomic revascularization.
Coronary lesions were required to be amenable to stenting using a
SES with a diameter of 2.5 to 3.5 mm and length of 13 to 33 mm;
there was no restriction on the total implanted stent length. Decisions
to place stents in lesions with bifurcations, fresh thrombus, calcifi-
cation, diffuse disease, complex anatomy, or stenting of side
branches were left to the discretion of the operators.
The major exclusion criteria were patients with previous PCI,
LMS disease, overt congestive heart failure, LVEF30%, history of
a cerebrovascular accident, transmural myocardial infarction (MI) in
the preceding week, severe hepatic or renal disease, neutropenia or
thrombocytopenia, an intolerance or contraindication to acetylsali-
cylic acid or thienopyridines, the need for concomitant major
surgery, and life-limiting major concomitant noncardiac diseases.
Written informed consent was obtained from each patient prior to
enrolment, and the study was approved by the ethics committee of
each participating site.
Clinical SYNTAX Score
The CSS was calculated retrospectively for each patient using the
formula CSS[SYNTAX Score][modified ACEF score].
The SYNTAX Score for each patient was calculated retrospec-
tively by scoring all coronary lesions with a diameter stenosis
50%, in vessels 1.5 mm, using the SYNTAX Score algorithm,
which is described in full elsewhere6,7 and is available on the
SYNTAX Score website (www.syntaxscore.com). All angiographic
variables pertinent to SYNTAX Score calculation were computed by
blinded core laboratory analysts (Cardialysis B.V., Rotterdam, The
Netherlands).
The modified ACEF score (ACEFCrCl) was calculated retrospec-
tively using the formula age/ejection fraction 1 point for every 10
mL/min reduction in CrCl below 60 mL/min per 1.73 m2 (up to a
maximum of 6 points). Therefore, a CrCl of between 50 to 59
mL/min per 1.73 m2, 40 to 49 mL/min per 1.73 m2 and 30 to 39
mL/min per 1.73 m2 would receive 1, 2, and 3 points, respectively.
The LVEF used was the value recorded before the index PCI, and in
the event of multiple available values was the lowest recorded figure.
Creatinine clearance was calculated using the Cockcroft-Gault equa-
tion,20 using the patient’s age, weight, and SCr recorded before the
index PCI.
Presently, the only published prospective validation of the SYN-
TAX score comes from the SYNTAX trial.1 This study only enrolled
patients with complex CAD (3-vessel disease [3VD] and/or LMS),
and, in view of this, analysis of the CSS in patients who only had
treatment for 3VD is shown in an online Data Supplement. For
comparison, additional analyses in patients with 3VD have also been
performed using the CSS calculated using the standard ACEF score
(ie, using SCr, [ACEFSCr]); the SYNTAX score combined by
multiplication with the additive euroSCORE (EUROADD) and logis-
tic euroSCORE (EUROLOG); and the Mayo Clinic Risk Score
(MCRS); these can all be found in the online Data Supplement.
End Points
The primary end point of this post hoc study was mortality at 1-year
follow-up. The secondary end points were major adverse cardiovas-
cular events (MACCE), defined as a composite of death, cerebro-
vascular accident, any revascularization (percutaneous or surgical),
and MI at 1- and 5-year follow-up.
Definitions
Deaths included mortality from any cause. Cerebrovascular accidents
included transient ischemic attacks, reversible neurological deficits,
intracranial hemorrhage, and ischemic stroke.21 MI was defined in
the first 7 days after the intervention, if there was documentation of
new abnormal Q waves and either a ratio of serum creatinine kinase
MB (CK-MB) isoenzyme to total creatinine kinase (CK) that was
0.1, or a CK-MB value that was 5 times the upper limit of normal.
Serum CK and CK-MB isoenzyme concentrations were measured 6,
12, and 18 hours after the intervention. Commencing 8 days after the
intervention (the length of the hospital stay after surgery), either
abnormal Q waves or enzymatic changes were sufficient for a
diagnosis of MI. An MI was only confirmed after the relevant ECGs
had been analyzed by the core laboratory and adjudicated by the
clinical events committee. This 2-part method of defining MI was
developed for ARTS-I to address the difficulty in diagnosing an MI
after cardiac surgery.21 These definitions have been adopted by the
ARC Consortium and are applied whenever a comparison between
PCI and coronary artery surgery is performed. In the final report, the
window of 7 days is not specifically mentioned, and this window has
been maintained for the sake of comparison with the historical data
from ARTS-I.
Statistical Methods
All variables were stratified according to CSS tertiles. Continuous
variables are expressed as mean SD and were compared using
1-way ANOVA. Categorical data are presented as frequency (per-
centages) and were compared using the Fisher exact test or the
Pearson 2 test. The distribution of the SYNTAX Score, ACEFSCr
score, and CSS were assessed before and after logarithmic transfor-
mation using the Kolmogorov-Smirnov test. Clinical outcomes are
presented as hierarchical and nonhierarchical outcomes, with the
hierarchical outcomes only reporting the worst outcome (following
the order death, stroke, MI [Q-wave, followed by non–Q-wave], and
repeat revascularization [CABG then PCI]) that the patient experi-
ences. Survival curves were constructed for time-to-event variables
using Kaplan-Meier estimates and compared by the log-rank test.
Patients lost to follow-up were considered at risk until the date of last
contact, at which point they were censored. Cox regression analysis
was used to find independent predictors of MACCE, with those
variables with a probability value of0.10 in the univariate analysis
being included in the backward stepwise multivariable model.
Receiver operator curves (ROC) were used to compare the performance
and predictive accuracy of the CSS, SYNTAX Score, ACEFSCr,
ACEFCrCl, EUROADD, EUROLOG, MCRS, and the SYNTAX score
combined with the euroSCORE (additive and logistic) for MACCE and
mortality at 5-year follow-up. A probability value of 0.05 was
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considered significant, and all tests were 2-tailed. Data were analyzed
with SPSS version 17.0 software (SPSS Inc, Chicago, Ill).
Results
The ARTS-II study recruited 607 patients, of whom 512
(84.3%) had 2- or 3-vessel intervention at the time of the
index PCI and had LVEF, SCr, and body weight recorded at
baseline. Median (interquartile range, IQR) follow-up was
1800 (IQR, 0) days. The results of analyses performed in the
239 (39.3%) patients in the ARTS-II study who had treatment
for only 3VD and had LVEF, SCr, and body weight recorded
at baseline are shown in the online Data Supplement.
SYNTAX, ACEFSCr, and CSS Scores
The SYNTAX Score ranged from 4 to 58, with a mean SD
of 20.89.6 and a median of 19 (IQR, 11.9). The ACEFSCr
score ranged from 0.5 to 2.3, with a mean SD of 1.070.27
and a median of 1.1 (IQR0.3). The CSS ranged from 4 to
209, with a mean SD of 27.223.8, and a median of 20.5
(IQR18.7). All 3 scores were initially nonparametric
(Kolmogorov-Smirnov test, P0.05) and became normally
distributed after logarithmic transformation (Supplementary
Figure 1).
In this post hoc analysis, the 512 patients (1645 treated
lesions) were divided according to their CSS into tertiles
defined as CSSLOW15.6 (n170), 15.6CSSMID27.5
(n171), and CSSHIGH27.5 (n171).
Baseline Angiographic and
Procedural Characteristics
Baseline angiographic and procedural characteristics of the
study population, stratified according to CSS tertiles, are
shown in Tables 1 and 2. Patient age and hypertension were
both significantly higher in the CSSHIGH tertile, whereas body
mass index, family history of CAD, current smoking, and
CrCl were all significantly lower in the CSSHIGH. Table 2
demonstrates that indicators of lesion complexity, such as
lesion length and lesion type, were significantly greater in the
CSSHIGH tertile, reflecting the higher calculated SYNTAX
Score for these lesions.
Outcomes at 12 Months
Hierarchical and nonhierarchical clinical outcomes at 12
months are shown in Table 3. Overall the primary end point
of mortality was comparable among each CSS tertile.
MACCE (18.7% CSSHIGH versus 7.6% CSSMID versus 6.5%
CSSLOW, P0.001) and repeat revascularization (15.8%
CSSHIGH versus 6.4% CSSMID versus 5.3% CSSLOW,
P0.002) were both significantly higher in the CSSHIGH
tertile, compared with the lower 2 groups.
Long-Term Outcomes
Figure 1 demonstrates the rates of death, MI, repeat revascu-
larization, and MACCE according to CSS tertiles during
Table 1. Baseline and Procedural Characteristics of Patients
Variable, n (%) Unless Stated
CSS 15.6
(n170)
15.6 CSS 27.5
(n171)
CSS 27.5
(n171) P Value
Baseline characteristics
Male sex 139 (81.8) 128 (74.9) 128 (74.9) 0.22
Age, y, SD 57.49.1 61.68.5 67.68.4 0.0001
Body mass index, SD 27.84.2 27.93.7 26.74.0 0.006
Risk factors
Previous MI 51 (30.0) 64 (37.4) 63 (36.8) 0.28
Diabetes 36 (21.2) 49 (28.7) 55 (32.2) 0.07
Hypertension 108 (63.5) 113 (66.1) 129 (75.4) 0.045
Hypercholesterolemia 127 (74.7) 122 (72.2) 127 (74.3) 0.85
Family history of ischemic heart disease 75 (44.1) 62 (36.5) 47 (27.8) 0.008
Current smoker 39 (22.9) 36 (21.1) 21 (12.3) 0.03
Peripheral vascular disease 9 (5.3) 7 (4.1) 15 (8.8) 0.17
Chronic obstructive airways disease 4 (2.4) 6 (3.5) 11 (6.4) 0.15
Previous cerebrovascular accident 2 (1.2) 0 (0.0) 2 (1.2) 0.37
Creatinine clearance, mL/1.73 m2SD 95.223.4 91.423.5 74.327.5 0.0001
Indication for treatment
Stable angina 86 (50.6) 96 (56.1) 81 (47.4) 0.26
Unstable angina 69 (40.6) 58 (33.9) 67 (39.2) 0.41
Silent ischemia 15 (8.8) 17 (9.9) 23 (13.5) 0.35
Medications at screening
Aspirin 147 (86.5) 145 (84.8) 150 (87.7) 0.73
-blockers 127 (74.7) 117 (68.4) 124 (72.5) 0.42
ACE inhibitors/angiotensin 2 blockers 88 (51.8) 76 (44.4) 88 (51.5) 0.31
Statins 117 (68.8) 122 (71.3) 123 (71.9) 0.80
ACE indicates angiotensin-converting enzyme.
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long-term follow-up. There were no significant differences in
events (death/MI/repeat revascularization/MACCE) between
patients in the low and mid CSS tertiles. Patients in the
CSSHIGH tertile had significantly higher rates of repeat
revascularization and MACCE when compared with the
lower 2 tertiles. In addition, mortality was significantly
higher with CSSHIGH compared CSSLOW, whereas the rate of
MI was comparable for all 3 groups.
Multivariable Analysis
The results of the Cox multivariable analysis are shown in
Table 4. The log CSS, log SYNTAX Score, and log ACEFSCr
score were all univariate predictors of long-term MACCE.
After multivariate adjustment, the independent predictors of
MACCE at 5-year follow-up were the log CSS and the
presence of incomplete revascularization, diabetes, or periph-
eral vascular disease.
CSS Versus SYNTAX Score Versus ACEFSCr
The ROC curves for mortality and MACCE at 5-year
follow-up are shown in Figure 2. The respective C-statistics
for the CSS, SYNTAX Score, and ACEFSCr score for 5-year
mortality were 0.69, 0.62, and 0.65 and for 5-year MACCE
were 0.62, 0.59, and 057 (P0.05 for all).
CSS Versus MCRS Versus EUROADD
Versus EUROLOG
The Kaplan-Meier curves for 5-year mortality and MACCE-
free survival stratified according to tertiles of the CSS,
MCRS, EUROADD, and EUROLOG are shown in Figure 3.
Overall, there were no significant differences between
corresponding tertiles for the CSS, MCRS, EUROADD, and
EUROLOG. For each score, patient mortality and MACCE
among those in the lowest tertile were significantly better
than those in the highest tertile and comparable with the
intermediate tertile. A significant difference in mortality was
observed between the intermediate and highest tertile with the
use of the MCRS and EUROADD but not the EUROLOG or
CSS. Conversely, the significant difference in MACCE be-
tween the intermediate and highest tertile observed with the
CSS was not observed with the other 3 scores.
The ROC curves for mortality and MACCE at 5-year
follow-up for the CSSCrCl, CSSSCr, ACEFCrCl, ACEFSCr,
SYNTAX score, MCRS, EUROADD, EUROLOG, and SYNTAX
score combined with the euroSCORE (additive and logistic)
are shown in Figure 4, and Table 5.
The results of these analyses performed specifically in
patients with 3VD can all be found in the online Data
Supplement.
Table 2. Angiographic and Procedural Characteristics of the Study Population
Variable, n (%) Unless Stated
CSS 15.6
(n170)
15.6 CSS 27.5
(n171)
CSS 27.5
(n171) P Value
Ejection fraction 64.110.0 60.211.5 56.311.3 0.0001
Lesion characteristics
Lesion length, visual, % of lesions
Discreet, 10 mm 323 (65.9) 328 (60.4) 327 (53.4) 0.0001
Tubular, 10 to 20 mm 127 (25.9) 121 (22.3) 169 (27.6)
Diffuse, 20 mm 36 (7.3) 67 (12.3) 86 (14.1)
Lesion classification, % of lesions 0.0001
Type A 39 (8.0) 34 (6.3) 42 (7.0)
Type B1 124 (25.4) 141 (26.2) 125 (20.7)
Type B2 287 (58.8) 280 (52.0) 338 (56.0)
Type C 38 (7.8) 83 (15.4) 99 (16.4)
Moderate/heavy calcification 156 (31.8) 150 (27.6) 223 (37.6) 0.0001
Thrombus-containing lesions 3 (0.6) 5 (0.9) 0 (0.0) 0.06
Eccentric lesion 403 (82.2) 452 (83.2) 499 (81.5) 0.001
TIMI flow 3 439 (89.6) 463 (85.3) 527 (86.1) 0.09
1.5 RVD 2.5 11 (2.2) 38 (7.0) 52 (8.5) 0.0001
Procedural characteristics
Bifurcation requiring double wiring 139 (28.4) 178 (32.8) 199 (32.5) 0.24
No. of stents implanted, SD 3.21.1 3.71.5 4.21.7 0.0001
Total stent length, mm 60.723.4 74.029.1 83.835.9 0.0001
Maximum dilatation pressure, atm, SD 16.22.7 16.22.7 16.82.9 0.07
Direct stenting, % of lesions 227 (46.3) 203 (37.4) 144 (23.5) 0.0001
Use of glycoprotein IIb/IIIa inhibitors 55 (32.4) 50 (29.2) 52 (30.4) 0.82
Completeness of revascularization 128 (75.3) 96 (56.1) 83 (48.5) 0.0001
Postprocedural hospital stay, days, SD 2.81.5 3.32.7 4.12.8 0.0001
RVD indicates reference vessel diameter; and atm, atmosphere.
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Discussion
To the best of our knowledge, this is the first description of
the CSS that represents a risk score combining both clinical
and angiographic variables. The main findings from this
study are that the CSS has an ability superior to either the
SYNTAX Score or ACEFSCr score alone in the prediction of
MACCE and mortality at 5-year follow-up in patients with
complex CAD undergoing PCI. Furthermore, the log CSS is
an independent predictor of long-term MACCE in this group
of patients.
Risk stratification and the assessment of risk-benefit are 2
important aspects of clinical medicine,22 and should form an
integral part of the patient informed consent process. Tech-
nological advances mean that the majority of coronary lesions
are amendable to PCI; however, this may not always be the
most appropriate treatment for an individual patient. The final
decision of whether to perform PCI or CABG in patients with
complex CAD is no longer simply based only on the views of
the interventional cardiologist and cardiac surgeon; patient
choice now plays an important part in the decision. Conse-
quently, to enable patients to make the most appropriate
informed decision for them as an individual, a suitable
method of quantifying risk is essential. The importance of
risk stratification in these patients is further emphasized when
considering the escalating complexity of CAD being treated
with PCI and the increasing age of patients undergoing PCI,23
both of which are associated with less favorable clinical
outcomes and greater procedural related morbidity.24 Unfor-
tunately, despite the unquestionable need, and in contrast to
patients having CABG, few risk models have become estab-
lished into regular clinical practice for patients undergoing
PCI. The recently introduced SYNTAX Score offers the
potential to meet this unmet clinical need.1,3
The SYNTAX Score is derived entirely from the coronary
anatomy and lesion characteristics and is calculated using
dedicated software, enabling complex coronary artery anato-
my to be quantified.6,7 The score, which was an integral part
of the SYNTAX trial design,25 was initially devised as a
method to ensure that both the cardiologist and cardiac
surgeon accurately reviewed the angiogram of patients with
complex CAD, enabling a consensus regarding the optimal
method and completeness of revascularization to be reached.
Importantly, the SYNTAX Score was calculated a priori,
before the outcome of revascularization was known. The
results of the SYNTAX trial have subsequently demonstrated
that the score has an important role in stratifying patients with
complex CAD to aid revascularization decisions.1,26 Further
evaluation of the score has also indicated its ability to predict
clinical outcomes. In patients with 3VD, the SYNTAX Score
has been shown to be an independent predictor of MACCE at
both 1-year8 and 5-year follow-up.10 Similarly, in patients
with LMS disease, Capodanno et al9 reported that the
SYNTAX Score was able to predict both cardiac death
(P0.001) and MACCE (P0.04) at short-term follow-up.
More recently, analysis of SYNTAX scores collected pro-
spectively in the LEADERS study and retrospectively in the
SIRTAX study indicates that risk stratification using the
SYNTAX Score can be expanded to include all patients with
CAD, irrespective of severity.11,27
The SYNTAX Score is independent of a patient’s clinical
characteristics, some of which, for example, patient age, have
been consistently shown to be an independent predictor of
mortality.28 Furthermore, previous studies have demonstrated
the superior performance of clinical based risk models, such
as the MCRS, in the prediction of morbidity and mortality
when compared with lesion-based scores such as the Amer-
Table 3. Clinical Outcomes at 1-Year Follow-Up
Variable, n (%) Unless Stated
CSS 15.6
(n170)
15.6 CSS 27.5
(n171)
CSS 27.5
(n171) P Value
Hierarchical
Death 1 (0.6) 0 (0.0) 4 (2.3) 0.09
Cerebrovascular accident 0 (0.0) 1 (0.6) 3 (1.8)
MI 2 (1.2) 1 (0.6) 4 (2.3)
Q wave 1 (0.6) 1 (0.6) 2 (1.2)
Non-Q wave 1 (0.6) 0 (0.0) 2 (1.2)
Repeat revascularization 8 (4.7) 11 (6.4) 21 (12.3)
CABG 2 (1.2) 2 (1.2) 5 (2.9)
PCI 6 (3.5) 9 (5.3) 16 (9.4)
MACCE 11 (6.5) 13 (7.6) 32 (18.7) 0.001
Nonhierarchical
Cerebrovascular accident 0 (0.0) 1 (0.6) 3 (1.8) 0.33
MI 2 (1.2) 1 (0.6) 6 (3.5) 0.14
Q wave 1 (0.6) 1 (0.6) 3 (1.8) 0.63
Non-Q wave 1 (0.6) 0 (0.0) 3 (1.8) 0.23
Repeat revascularization 9 (5.3) 11 (6.4) 27 (15.8) 0.002
PCI 7 (4.1) 9 (5.3) 21 (12.3) 0.009
CABG 2 (1.2) 3 (1.8) 6 (3.5) 0.41
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ican Heart Association lesion classification.12 Therefore, the
absence of any clinical characteristics in the calculation of the
SYNTAX Score is a potential limitation to its use in risk
stratification.
The CSS described in the present study for the first time
represents a modification of the SYNTAX Score to accom-
modate for these inherent limitations. The present study has
indicated that the inclusion of patient characteristics does
Table 4. Univariate and Multivariable Predictors of MACCE at 5-Year Follow-Up
Univariate Predictors
of MACCE at 5 Years
Multivariable Predictors
of MACCE at 5 Years
Variable 95% CI	 P Value 95% CI	 P Value
Age 1.02 1.00–1.04	 0.03
Diabetes 1.80 1.28–2.54	 0.001 1.55 1.09–2.19	 0.01
Peripheral vascular disease 2.01 1.18–3.44	 0.01 1.97 1.14–3.41	 0.02
Log SYNTAX score 5.62 2.32–13.62	 0.0001
Log ACEF 7.11 1.56–32.45	 0.01
Log clinical SYNTAX score 1.81 1.42–2.29	 0.0001 1.77 1.02–3.07	 0.04
No. of diseased lesions 1.43 1.17–1.73	 0.0001
Incomplete revascularization 1.56 1.12–2.17	 0.009 1.43 1.01–2.02	 0.045
CI indicates confidence interval.
Figure 1. Kaplan Meier curves for death (A), repeat revascularization (B), myocardial infarction (MI) (C), and major adverse cardiovascu-
lar and cerebrovascular events (MACCE) (D) at 1800-day follow-up stratified accord to CSS tertile.
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improve the ability of the score, as indicated by the ROC
curves, to predict MACCE and mortality compared with the
original score.
Intuitively, the use of multiple clinical variables should
improve the accuracy of a risk model; however, this accuracy
may ultimately be contaminated by the desire to create the
“perfect model.”16 In practice, Ranucci et al17 illustrated this
by demonstrating that a simple scoring method using just age,
LVEF, and SCr (ACEFSCr score) is as good as complex
scores such as the euroSCORE (17 clinical variables) and
Parsonnet score in predicting mortality in patients undergoing
elective CABG. These 3 variables are known to affect the risk
of both CABG17 and PCI,28–30 and therefore even though the
score has not previously been validated in patients undergo-
ing PCI, it was considered acceptable to use as a basis for the
development of the CSS. Retrospective justification for using
the ACEF score as an integral part of the CSS come in part
from the comparable C-statistics for MACCE and mortality
between the validated MCRS and the ACEFCrCl (Table 5,
Figure 4, and Supplementary Figure 2). Of note, the combi-
nation of the SYNTAX score with the euroSCORE only
offered an advantage over the CSS in the prediction of
mortality among those patients with 2- and 3VD (Table 5,
Figure 4, and Supplementary Figures 2 and 3).
Figure 2. ROC curve for the SYNTAX score, ACEFSCr, and CSS for mortality (A) and MACCE (B). The use of the CSS leads to an
improvement in the C-statistic for both outcomes.
Figure 3. Kaplan-Meier curve showing the 5-year mortality (A) and MACCE-free survival (B) stratified according to tertiles of the CSS,
Mayo Clinic Risk Score (MCRS), Additive euroSCORE (EUROADD) and Logistic euroSCORE (EUROLOG). No significant difference was
observed between outcomes in Tertiles 1 and 2 (probability values not shown). *P (log-rank) values.
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The modification to the ACEF score to incorporate CrCl
has also not previously been validated. Notably, in previous
PCI studies that have identified renal dysfunction as a marker
of adverse outcome either SCr or CrCl has been used, not
both.31,32 Conversely, CrCl has been shown to be a better
predictor when compared with SCr of risk in patients under-
going surgical revascularization.18,33 Incorporation of CrCl
into the ACEF score can therefore be justified prospectively
by extrapolation of these previous results and retrospectively
by the improvements in the C-statistic for MACCE (0.60
versus 0.62) and mortality (0.67 versus 0.69) observed in this
study when the CSS was calculated using the ACEFCrCl
instead of ACEFSCr (Figure 4 and Table 5).
This study demonstrates a superior ability of the CSS to
predict long-term MACCE and mortality when compared
with the individual SYNTAX and ACEF scores. Importantly,
after calculating the SYNTAX Score, which remains an
important aid to deciding the appropriate revascularization
strategy, the CSS can be derived quickly, using easily
available variables that are not subject to any interobserver
Table 5. Comparison of C-Statistics Between 3VD and 2VD/3VD Patient Cohorts
Mortality MACCE
Risk Score
2VD and 3VD
(512 Patients)
3VD
(239 Patients)
2VD and 3VD
(512 Patients)
3VD
(239 Patients)
ACEF, creatinine clearance 0.69 0.82 0.60 0.64
ACEF, serum creatinine 0.65 0.73 0.57 0.59
Clinical SYNTAX score, creatinine clearance 0.69 0.80 0.62 0.67
Clinical SYNTAX score, serum creatinine 0.67 0.75 0.60 0.65
euroSCORE, additive 0.71 0.79 0.57 0.61
euroSCORE, logistic 0.73 0.82 0.57 0.61
Mayo Clinic Risk Score 0.71 0.82 0.59 0.64
SYNTAX score 0.62 0.70 0.59 0.64
SYNTAX-euroSCORE, additive 0.71 0.81 0.60 0.66
SYNTAX-euroSCORE, logistic 0.73 0.81 0.61 0.65
Figure 4. ROC curve for mortality (A) and MACCE
(B) at 5-year follow-up for different risk scores.
*P0.001, †P0.05, ¶P0.01.
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variability. The current analysis also indicates that whereas
the CSS has a similar ability to predict mortality when
compared with the MCRS and euroSCORE, it offers an
additional advantage in the prediction of ischemic end points,
which, as suggested by the C-statistics, are a somewhat
harder end point to predict than mortality. Clearly, additional
research is required to evaluate the potential of this new score
in more diverse patient populations undergoing PCI.
Limitations
The current study is limited by its post hoc nature. In addition,
the ROC method of analysis, although well suited for diag-
nostic purposes, may not be appropriate for prognostic
models because these models must incorporate the dimension
of time, which adds a stochastic element.34 It has therefore
been suggested that ROC analysis methods are not well
validated for the assessment of time-censored data; however,
in the current study the same methods have been used to assess
both scoring systems, and these methods are consistent with
previous published studies evaluating these risk models.17
Other potential limitations include that lack of validation of
the ACEF score in patients having PCI and the lack of any
external validation in patients having either PCI or CABG.
We accept that the current population may be too small to
make definitive conclusions; however, at present, in view of
its recent introduction, only select patient populations with
complex disease have a SYNTAX score calculation and
adjudicated long-term outcomes. The small sample size may
account for the similar outcomes between low- and
intermediate-risk groups when using the CSS, MCRS, EU-
ROADD, EUROLOG, SYNTAX-euroSCORE (logistic), and
MCRS (Figures 1 and 3 and Supplementary Figures 3 and 4).
It must also be acknowledged that there is a reduction in the
predictive ability of the CSS when it is used in patients with
2VD and 3VD, as opposed to when it is used in only patients
with 3VD. Importantly, however, this same observation is
seen with both the established scores such as the MCRS and
euroSCORE and the newer scores tested in this analysis
(Table 5).
Conclusion
An improvement in the ability of the SYNTAX Score to
predict MACCE and mortality can be achieved by combining
the SYNTAX Score with a simple clinical risk score incor-
porating age, ejection fraction, and creatinine clearance to
produce the Clinical SYNTAX Score.
Disclosures
Dr Dawkins is a full-time employee and holds stock in
Boston Scientific.
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CLINICAL PERSPECTIVE
Risk stratification is becoming an increasingly important part of the assessment of patients who are candidates for coronary
revascularization. The recently published SYNTAX study indicates that percutaneous coronary intervention disease is only
appropriate in a subset of those with complex disease. Patient outcomes were assessed according to the SYNTAX score,
which is based on the extent of coronary disease. The absence of patient features has limited the score for risk assessment
in everyday practice because the complexity of coronary disease is not the only factor that affects patient risk. The Clinical
SYNTAX score combines the SYNTAX score with a simple patient score. The Clinical SYNTAX score improves the
predictive ability for the majority of patients undergoing percutaneous coronary intervention and enables a physician to
provide an individualized assessment of risk, which is vital for appropriate informed consent. Moreover, the Clinical
SYNTAX score can be used to adjust for the differences in case mix between hospitals and individual operators to allow
a meaningful comparison of performance.
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analyses in those patients who had treatment for three vessel disease.  
 
Contents 
 
1. Clinical SYNTAX score: calculated in patients with three vessel disease only 
a. Methods 
b. Results 
c. Summary 
 
2. Clinical SYNTAX score: calculated using original ACEF (serum creatinine) 
a. Methods 
b. Results 
c. Summary 
 
3. Clinical SYNTAX score compared to the SYNTAX-euroSCORE  
a. Methods 
b. Results 
c. Summary 
 
4. Clinical SYNTAX score compared to the Mayo Clinical Risk Score.  
a. Results 
b. Summary 
 
5. Supplementary Tables 
 
6. Supplementary Figure Legends 
 
7. Supplementary Figures 
 
8. Supplementary References 
A New Tool for the Risk Stratifi cation of Patients With Complex Coronary Artery Disease : The Clinical SYNTAX Score 61
Methods  
The main manuscript presents the results of the Clinical SYNTAX score (CSS) amongst the 
512 (84.3%) patients in the ARTS-II study who had treatment for two or triple vessel disease 
(3VD), and had a serum creatinine (SCr), left ventricular ejection fraction (LVEF) and body 
weight recorded prior to the index percutaneous coronary intervention (PCI). Currently 
however the only published prospective validation of the SYNTAX score comes from the 
SYNTAX trial1 which only enrolled those patients with 3VD and/or left main stem lesions. 
Therefore the results of the CSS applied to only those 239 (39.3%) patients who had 
treatment of 3VD and had their body weight, SCr and LVEF recorded at baseline are 
presented here.  
 
Results 
The mean± standard deviation of the SYNTAX score, ACEFSCr score and CSS for this 
population was 22.3±9.9, 1.1±0.3, and 30.7±27.9 respectively. Further analysis of the CSS 
was performed after dividing the 239 patients (939 treated lesions) into CSS tertiles defined 
as: CSSLOW ≤16.5 (n=80), 16.5<CSSMID≤31.2 (n=79) and CSSHIGH>31.2 (n=80). 
 
Baseline patient characteristics, together with lesion and procedural data stratified according 
to CSS tertile are shown in Supplementary Tables 1 and 2. Hierarchical and non-hierarchical 
outcomes at 1-year follow-up, which are shown in Supplementary Table 3, demonstrates 
poorer outcomes in those patients in the highest CSS tertile compared to the low- and mid- 
tertiles. 
 
 
1. Clinical SYNTAX score: only patients with triple vessel disease in ARTS-II. 
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Supplementary Figure 5 demonstrates the rates of death, myocardial infarction (MI), repeat 
revascularisation and major adverse cardio- and cerebro-vascular events (MACCE) according 
to CSS tertile at 5-years follow-up. Similar to the full patient cohort, there was no significant 
difference between outcomes between patients in the low and mid tertiles.  
 
The ROC curves for MACCE and mortality are shown in Supplementary Figure 6, and 
demonstrate the superiority of the CSS compared to the ACEFSCr, and SYNTAX score. Of 
note, and as shown in Table 5 (main manuscript), the C-statistics were greater in this cohort 
of patients with 3VD, when compared with the results from patients with 2- and 3-VD. 
 
The results of the Cox multi-variate analysis are shown in Supplementary Table 4 and 
demonstrate that the log CSS remains an independent predictor of MACCE at 5-years follow-
up in this more complex cohort of patients. 
 
Summary 
The results for the use of the CSS in this group of patients mirror the results from the larger 
cohort of patients.  Of note, is the improvement in the ability to predict mortality and 
MACCE with the CSS in this 3VD population compared to the larger cohort. 
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2. Clinical SYNTAX score: calculated using original ACEF in patients with triple 
vessel disease 
 
Methods 
The main manuscript, and section 1 of this appendix, presents the results of the CSS 
calculated combining the SYNTAX score with a modified ACEF score that uses the 
creatinine clearance (CrCl, ACEFCrCl) as opposed to the serum creatinine (SCr, ACEFSCr) as 
originally described by Ranucci et al.2 The CSS can be calculated using the original ACEF 
score (SYNTAX score x ACEF score) and the results of this analysis in the 251 (41.4%) 
patients who had three vessel intervention at the time of the index PCI, and had left 
ventricular ejection function (LVEF) and creatinine levels recorded at baseline are presented 
here. 
 
Results 
The SYNTAX score ranged from 4 to 56, with a mean ±standard deviation of 22.3±9.8, and a 
median of 21 (inter-quartile range: 13). The ACEFSCr score ranged from 0.6 to 2.3, with a 
mean ±standard deviation of 1.1±0.3, and a median of 1.0 (inter-quartile range: 0.4). The CSS
ranged from 4 to 111, with a mean + SD of 24.9+15.0, and a median of 21.7 (inter-quartile 
range of 17.8). The 251 patients (980 treated lesions) were divided according to their CSS 
into tertiles defined as: CSSLOW ≤16 (n=83), 16<CSSMID≤26 (n=84) and CSSHIGH>26 (n=84). 
 
Baseline patient characteristics, together with lesion and procedural data stratified according 
to CSS tertile are shown in Supplementary Tables 5 and 6. Hierarchical and non-hierarchical 
outcomes at 1-year follow-up are shown in Supplementary Table 7. Overall the primary end-
point of mortality at 1-year was comparable amongst each CSS tertile. MACCE (19.0% 
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CSSHIGH vs. 3.6% CSSMID vs. 6.0% CSSLOW, p=0.002) and repeat revascularisation (14.3% 
CSSHIGH vs. 1.2% CSSMID vs. 6.0% CSSLOW, p=0.004) were both significantly higher in the 
CSSHIGH tertile, compared to the lower two groups.   
 
Supplementary Figure 7 demonstrates the rates of death, MI, repeat revascularisation and 
MACCE according to CSS tertiles during long-term follow-up, whilst the ROC curves for 
mortality and MACCE at 5-year follow-up are shown in Supplementary Figure 8.  
 
Although the C-statistics for the CSS calculated using the ACEFSCr are inferior to the CSS 
calculated using the ACEFCrCl for both MACCE (0.59 vs. 0.64) and mortality (0.73 vs. 0.82), 
the CSS still performed better, in terms of area-under the curve, when compared with the 
SYNTAX score, and the ACEFSCr score (Supplementary Figure 2 and Table 5). 
 
The results of the Cox multi-variate analysis are shown in Supplementary Table 8. The log 
CSS, SYNTAX score and ACEFSCr score were all univariate predictors of long-term 
MACCE. After adjustment only the presence of diabetes and peripheral vascular disease, 
were independent predictors of MACCE at 5-years follow-up. 
 
Summary  
These results indicate that the CSS calculated using the original ACEF score is still superior 
to the SYNTAX score and ACEFSCr score in terms of its ability to predict MACCE and 
mortality, however its appears to be poorer than the CSS calculated using the modified ACEF 
score which utilizes the creatinine clearance, in patients with 3VD, or 2- and 3-VD as 
indicated in Supplementary Figure 2, together with Table 5, and Figure 4 of the main 
manuscript.
A New Tool for the Risk Stratifi cation of Patients With Complex Coronary Artery Disease : The Clinical SYNTAX Score 65
3. Clinical SYNTAX score compared to a SYNTAX-euroSCORE combination 
 
Methods 
The European System for Cardiac Operative Risk Evaluation (euroSCORE)3 relies on patient 
clinical characteristics, and has been used for many years to predict post-operative mortality 
in patients undergoing CABG. Recent data indicate that it may also have a role in the risk 
assessment of patients having PCI.4-6 As opposed to the ACEF score which uses just three 
variables, the additive euroSCORE (EUROADD) relies on 17 clinical parameters, 14 of which 
are relevant for PCI; importantly knowledge of the coronary anatomy is not required. Studies 
suggest that in those patients at highest risk, the EUROADD tends to under-estimate risk, and 
in these situations the logistic euroSCORE (EUROLOG), is advised.
7 Of note, the benefits of 
using the EUROADD and EUROLOG have already been examined in Table 5, Figure 3 and 
Figure 4 of the main manuscript, and are further examined in Supplementary Figure 2. 
 
The Clinical SYNTAX score has been calculated using a simple 3 variable patient based 
score, however to determine the effect of adding more clinical variables the SYNTAX score 
was combined with the EUROADD and EUROLOG using the formula: SYNTAX-euroSCORE= 
[SYNTAX score] x [EUROADD] or [SYNTAX score] x [EUROLOG]. The analysis was 
performed in same cohort of 239 patients described in this appendix.  
 
Results 
Supplementary Figures 3 shows the 5-year MACCE-free survival stratified according to 
tertiles of the CSS, SYNTAX-EUROADD, and the SYNTAX-EUROLOG. Overall there was no 
significant difference between corresponding tertiles for the CSS, SYNTAX-EUROADD and 
SYNTAX-EUROLOG.   
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Patients in the lowest SYNTAX-EUROADD tertile had significantly better outcomes than 
those in the mid (p[log-rank]=0.005) and highest (p[log-rank]<0.001) tertile, whilst no 
significant difference in outcomes existed between patients in the mid and high SYNTAX-
EUROADD tertile (p[log-rank]=0.34). Conversely the outcomes according to the SYNTAX-
EUROLOG mirrored those of the CSS, with no significant difference in events between the 
lower two SYNTAX-EUROLOG tertiles (p[log-rank]=0.41), and significantly more events in 
the highest SYNTAX-EUROLOG tertile when compared to the low (p[log-rank]=0.005) and 
mid (p[log-rank]=0.04) tertile.  
 
The ROC curves for MACCE and mortality at 5-year follow-up for the CSS, SYNTAX-
EUROADD, and SYNTAX-EUROLOG, which are shown in Supplementary Figure 2, 
demonstrate comparable C-statistics for all three scores.  
 
Summary 
These results indicate that there is no added advantage in patients with 3VD of combining the 
SYNTAX score with a detailed patient based score such as the euroSCORE (either additive 
or logistic), when compared to the combination of the SYNTAX score and a simple three 
variable patient based score, such as the ACEFCrCl score.  
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4. Clinical SYNTAX score compared to Mayo Clinic Risk Score. 
The Mayo Clinic Risk score (MCRS) is a validated patient based risk model, designed as a 
bed side tool, which uses a mixture of seven clinical variables (age, creatinine, LVEF, and 
presence of pre-procedural shock, MI within 24 hours, congestive cardiac failure and 
peripheral vascular disease) to predict in-hospital mortality after either PCI or CABG.8   
 
Results 
As mentioned in the main manuscript the ACEF is not currently validated for use in PCI, 
however as shown in Table 5, the C-statistic for the validated MCRS and the ACEFCrCl for 
both 5-year MACCE and mortality were similar providing some in-direct justification for the 
use of the ACEF score as an integral part of the CSS. 
 
Supplementary Figure 4 shows the 5-year MACCE-free survival stratified according to 
tertiles of the CSS, and the MCRS in patients with 3VD. Overall there were no significant 
differences in outcomes between corresponding tertiles for the CSS, and the MCRS. In 
addition, as with the CSS and SYNTAX-EUROLOG, there were no significant differences in 
event rates between patients in the lower and mid tertiles for the MCRS (MCRSLOW vs. 
MCRSMID, p[log rank]=0.77), whilst outcomes were significantly poorer in the highest tertile 
compared to the lower two tertiles (MCRSLOW vs. MCRSHIGH, p[log rank]=0.002 and 
MCRSMID vs. MCRSHIGH, p[log rank]=0.009). The ROC curves for MACCE and mortality at 
5-year follow-up for the CSS, and MCRS are shown in Supplementary Figure 2. Consistent 
with the other scores tested in this analysis, there was a reduction in C-statistics between the 
3VD patient cohort, and the 2- and 3-VD patient cohort (Table 5). 
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Summary 
These results indicate that PCI risk scores based purely on clinical characteristics (e.g.  the 
MCRS) are superior to those scores incorporating anatomical characteristics (e.g. SYNTAX 
score or CSS) for the prediction of mortality, but inferior for the prediction of MACCE.  
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Supplementary Table 1. Baseline and procedural characteristics of patients 
 
Variable (n,%) unless stated 
CSS≤16.5 
N=80 
16.5<CSS≤31.2 
N=79 
CSS>31.2 
N=80 
P Value 
     
Baseline Characteristics     
Male gender  65 (81.3%) 63 (79.7%) 57 (71.3%) 0.26 
Age (yearsrSD) 57.7r8.6 63.4r9.4 68.5r8.4 <0.0001 
Body Mass Index rSD  28.1r3.9 27.9r3.8 27.1r4.3 0.22 
     
Risk factors     
Previous Myocardial infarction  19 (23.8%) 30 (38.0%) 32 (40.0%) 0.06 
Diabetes   11 (13.8%) 20 (25.3%) 25 (31.3%) 0.03 
Hypertension   50 (62.5%) 57 (72.2%) 62 (77.5%) 0.11 
Hypercholesterolemia   65 (81.3%) 61 (77.2%) 60 (75.0%) 0.63 
Family history ischaemic heart disease  39 (48.8%) 24 (30.4%) 22 (27.8%) 0.01 
Current smoker  15 (18.8%) 16 (20.3%) 7 (8.8%) 0.10 
Peripheral vascular disease  6 (7.2%) 7 (8.3%) 6 (7.1%) 0.95 
Chronic obstructive airways disease  0 (0.0%) 3 (3.8%) 5 (6.3%) 0.09 
Previous cerebrovascular accident  2 (2.5%) 0 (0.0%) 2 (2.5%) 0.37 
Creatinine Clearance (ml/1.73m2±SD) 92.5r22.1 91.7r26.8 72.5r25.6 <0.0001 
     
Indication for Treatment     
Stable angina  47 (58.8%) 46 (58.2%) 37 (46.3%) 0.20 
Unstable angina  27 (33.8%) 26 (32.9%) 38 (47.5%) 0.10 
Silent ischemia  6 (7.5%) 7 (8.9%) 5 (6.3%) 0.82 
     
Medications at screening     
Aspirin 67 (83.8%) 67 (83.8%) 67 (83.8%) 0.98 
ß-blockers 55 (68.8%) 58 (73.4%) 55 (68.8%) 0.76 
ACE-inhibitors/Angiotension-2 blockers 47 (58.8%) 33 (41.8%) 42 (52.5%) 0.10 
Statins 54 (67.5%) 56 (70.9%) 54 (67.5%) 0.87 
     
SD for standard deviation;  
CSS, clinical SYNTAX Score;  
ACE, Angiotensin converting enzyme  
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Supplementary Table 2. Angiographic and procedural characteristics of study population 
Variable (n,%) unless stated 
CSS≤16.5 
N=80 
16.5<CSS≤31.2 
N=79 
CSS>31.2 
N=80 
P Value 
Ejection fraction  65.6r9.9 59.4r11.6 55.2r11.5 <0.0001 
Lesion Characteristics     
Mean No. of diseased lesions with stenosis 
> 50% 
3.7r0.8 4.4r1.1 4.8r1.2 <0.0001 
Mean No. of treated lesions 3.2r0.9 3.4r1.2 3.2r1.0 0.33 
Lesion Length (visual)(% of lesions) 
    Discreet (<10mm) 
    Tubular (10-20mm)  
    Diffuse (>20mm) 
 
182 (64.5%) 
76 (27.0%) 
23 (8.2%) 
 
191 (59.1%) 
80 (24.8%) 
37 (11.5%) 
 
179 (53.6%) 
87 (26.0%) 
49 (14.7%) 
 
0.02 
0.83 
0.04 
Lesion Classification  (% of lesions) 
    Type A  
    Type B1  
    Type B2  
    Type C  
 
20 (7.1%) 
61 (21.6%) 
177 (62.8%) 
24 (8.5%) 
 
19 (6.0%) 
88 (27.7%) 
165(51.9%) 
46 (14.5%) 
 
23 (7.0%) 
74 (22.4%) 
174 (52.7%) 
59 (17.9%) 
 
0.44 
0.29 
0.04 
0.001 
Moderate/Heavy calcification 91 (32.3%) 89 (27.6%) 124 (37.1%) 0.001 
Thrombus containing lesions 3 (1.1%) 1 (0.3%) 0 (0.0%) 0.01 
Eccentric lesion 245 (86.9%) 271 (83.9%) 267 (79.9%) 0.05 
TIMI flow 3 252 (89.4%) 283 (87.6%) 286 (85.6%) 0.38 
 1.5≤RVD<2.5  7 (2.5%) 25 (7.7%) 30 (9.0%) 0.003 
Procedural Characteristics     
Bifurcation requiring double wiring 81 (27.4%) 101 (29.4%) 121 (31.8%) 0.44 
Number of stents implanted ±SD 4.0±0.9 4.6±1.3 5.0±1.6 <0.0001 
Total stent length (mm) 76.1±21.6 87.5±26.6 100.0±36.7 <0.0001 
Maximum dilatation pressure (Atm±SD) 16.6±3.0 16.4±2.7 17.1±3.1 0.32 
Direct stenting (% of lesions) 129 (45.7%) 109 (33.7%) 68 (20.4%) <0.0001 
Use of glycoprotein IIb/IIIa inhibitors 27 (35.1%) 25 (32.5%) 25 (32.5%) 0.94 
Completeness of Revascularisation 61 (76.3%) 41 (51.9%) 40 (50.0%) 0.001 
Post procedural Hospital stay (days±SD) 2.8±1.6 3.4±1.8 4.2±3.0 0.001 
Atm, atmosphere; SD, standard deviation; CSS, clinical SYNTAX Score; No., number; RVD, reference vessel 
diameter 
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Supplementary Table 3. Clinical Outcomes at One Year Follow-up 
 
Variable (n,%) unless stated 
CSS≤16.5 
N=80 
16.5<CSS≤31.2 
N=79 
CSS>31.2 
N=80 
P Value 
Hierarchical Events     
Death 0 (0.0%) 0 (0.0%) 2 (2.5%) 0.34 
Cerebrovascular Accident 0 (0.0%) 1 (1.3%) 2 (2.5%)  
Myocardial Infarction 1(1.3%) 0 (0.0%) 1(1.3%)  
    Q wave 0 (0.0%) 0 (0.0%) 1(1.3%)  
    Non-Q wave 1(1.3%) 0 (0.0%) 0 (0.0%)  
Repeat Revascularization 4 (5.0%) 3 (3.8%) 11 (13.8%)  
    CABG 1 (1.3%) 0 (0.0%) 3 (3.8%)  
    PCI 3 (3.8%) 3 (3.8%) 8 (10.0%)  
Any MACCE 5 (6.3%) 4 (5.1%) 16 (20.0%) 0.008 
     
Non-Hierarchical     
Cerebrovascular Accident 0 (0.0%) 1 (1.3%) 2 (2.5%) 0.78 
Myocardial Infarction 1 (1.3%) 0 (0.0%) 2 (2.5%) 0.64 
    Q wave 0 (0.0%) 0 (0.0%) 1 (1.3%) 1.00 
    Non-Q wave 1 (1.3%) 0 (0.0%) 1 (1.3%) 0.78 
Repeat Revascularization 5 (6.3%) 3 (3.8%) 12 (15.0%) 0.03 
    PCI 4 (5.0%) 3 (3.8%) 9 (11.3%) 0.12 
    CABG 1 (1.3%) 0 (0.0%) 3 (3.8%) 0.32 
 
PCI, percutaneous coronary intervention 
CABG, coronary artery bypass grafting 
CSS, Clinical SYNTAX Score 
MACCE, major adverse cardiovascular and cerebrovascular events
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Supplementary Table 4. Univariate and multivariable predictors of MACCE at 5-years 
follow-up. 
Variable 
Univariate predictors of 
MACCE at 5 years 
Multivariable predictors of 
MACCE at 5 years 
 95% [CI] P value 95% [CI] P value 
Age 1.03 [1.00-1.06] 0.03   
Diabetes 2.27 [1.39-3.73] 0.001 1.77 [1.06-2.95] 0.03 
Current Smoking 0.50 [0.23-1.01] 0.08   
Peripheral vascular disease 2.55 [1.30-5.00] 0.007 2.22 [1.11-4.45] 0.02 
Log SYNTAX Score 3.27 [1.79-5.95] <0.0001   
Log ACEFSCr 2.99 [1.16-7.71] 0.02   
Log Clinical SYNTAX 
Score 
2.21 [1.58-3.08] <0.0001 2.11 [1.47-3.04] <0.0001 
Number of diseased lesions 1.43[1.17-1.73] <0.0001   
Incomplete revascularisation 1.93 [1.20-3.13] 0.007 1.84 [1.13-3.00] 0.01 
 
CI, confidence interval 
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Supplementary Table 5. Baseline and procedural characteristics of patients 
 
Variable (n,%) unless stated 
CSS≤16 
N=83 
16<CSS≤26 
N=84 
CSS>26 
N=84 
P Value 
     
Baseline Characteristics     
Male gender  65 (78.3%) 62 (73.8%) 67 (79.8%) 0.63 
Age (years r SD) 58.1r9.0 63.6r8.9 67.8r9.1 <0.0001 
Body Mass Index r SD  28.3r4.0 27.3r3.9 27.7r4.1 0.30 
     
Risk factors     
Previous Myocardial infarction  21 (25.3%) 31 (36.9%) 34 (40.5%) 0.10 
Diabetes   11 (19.3%) 23 (27.4%) 23 (27.4%) 0.04 
Hypertension   52 (62.7%) 60 (71.4%) 62 (73.8%) 0.26 
Hypercholesterolemia   66 (79.5%) 61 (72.6%) 64 (76.2%) 0.58 
Family history ischaemic heart disease  40 (48.2%) 25 (29.8%) 24 (28.9%) 0.01 
Current smoker  17 (20.5%) 14 (16.7%) 12 (14.3%) 0.56 
Peripheral vascular disease  6 (7.2%) 7 (8.3%) 6 (7.1%) 0.95 
Chronic obstructive airways disease  1 (1.2%) 3 (3.6%) 4 (4.8%) 0.41 
Previous cerebrovascular accident  2 (2.4%) 1 (1.2%) 1 (1.2%) 0.77 
     
Indication for Treatment     
Stable angina  48 (57.8%) 47 (56.0%) 43 (48.8%) 0.47 
Unstable angina  29 (34.9%) 32 (38.1%) 35 (41.7%) 0.67 
Silent ischemia  6 (7.2%) 5 (6.0%) 8 (9.5%) 0.68 
     
Medications at screening     
Aspirin 70 (84.3%) 70 (83.3%) 72 (85.7%) 0.91 
ß-blockers 58 (69.9%) 60 (71.4%) 60 (71.4%) 0.97 
ACE-inhibitors/Angiotension-2 blockers 49 (59.0%) 37 (44.0%) 42 (50.0%) 0.15 
Statins 56 (67.5%) 61 (72.6%) 57 (67.9%) 0.72 
     
SD for standard deviation;  
CSS, clinical SYNTAX score;  
ACE, Angiotensin converting enzyme  
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Supplementary Table 6. Angiographic and procedural characteristics of study population 
 
Variable (n,%) unless stated 
CSS≤16 
N=83 
16<CSS≤26 
N=84 
CSS>26 
N=84 
P Value 
Ejection fraction  65.9r9.8 61.5r11.9 53.3r10.1 <0.0001 
Lesion Characteristics     
Lesion Length (visual)(% of lesions) 
    Discreet (<10mm) 
    Tubular (10-20mm)  
    Diffuse (>20mm) 
 
184 (63.2%) 
84 (28.9%) 
20 (6.9%) 
 
200 (57.6%) 
84 (24.2%) 
44 (12.7%) 
 
185 (54.1%) 
90 (26.3%) 
50 (14.6%) 
 
0.002 
 
 
 
 
Lesion Classification  (% of lesions) 
    Type A  
    Type B1  
    Type B2  
    Type C  
 
22 (7.6%) 
62 (21.3%) 
186 (63.9%) 
21 (7.2%) 
 
21 (6.2%) 
94 (27.6%) 
170(49.9%) 
56 (16.4%) 
 
20 (5.9%) 
76 (22.5%) 
183 (54.1%) 
59 (17.5%) 
0.001 
 
 
 
Moderate/Heavy calcification 94 (32.3%) 91 (26.2%) 131 (38.3%) 0.001 
Thrombus containing lesions 3 (1.0%) 2 (0.6%) 0 (0.0%) 0.008 
Eccentric lesion 248 (85.2%) 285 (82.1%) 283 (82.7%) 0.046 
TIMI flow 3 258 (88.7%) 305 (87.9%) 291 (85.1%) 0.36 
 1.5≤RVD<2.5  9 (3.1%) 25 (7.2%) 32 (9.4%) 0.007 
Procedural Characteristics     
Bifurcation requiring double wiring 79 (27.4%) 93 (27.9%) 115 (33.0%) 0.03 
Number of stents implanted ±SD 3.9±0.9 4.7±1.5 5.0±1.5 <0.0001 
Total stent length (mm) 75.4±21.7 91.8±33.1 96.2±36.0 <0.0001 
Maximum dilatation pressure (Atm±SD) 16.7±3.0 16.5±2.9 17.0±2.9 0.53 
Direct stenting (% of lesions) 132 (45.4%) 121 (34.9%) 74 (21.6%) <0.0001 
Use of glycoprotein IIb/IIIa inhibitors 28 (33.7%) 25 (29.8%) 26 (31.0%) 0.85 
Completeness of Revascularisation 63 (75.9%) 55 (65.5%) 33 (39.3%) <0.0001 
Post procedural Hospital stay (days±SD) 2.8±1.6 3.2±1.6 4.4±3.0 <0.0001 
Atm, atmosphere; SD, standard deviation; CSS, clinical SYNTAX score; No., number; RVD, reference vessel 
diameter 
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Supplementary Table 7. Clinical Outcomes at One Year Follow-up 
 
Variable (n,%) unless stated 
CSS≤16 
N=83 
16<CSS≤26 
N=84 
CSS>26 
N=84 
P Value 
Hierarchical Events     
Death 0 (0.0%) 0 (0.0%) 2 (2.4) 0.33 
Cerebrovascular Accident 0 (0.0%) 1 (1.2%) 2 (2.4%)  
Myocardial Infarction 1(1.2%) 1(1.2%) 1(1.2%)  
    Q wave 0 (0.0%) 0 (0.0%) 1(1.2%)  
    Non-Q wave 1 (1.2%) 1(1.2%) 0 (0.0%)  
Repeat Revascularization 4 (4.8%) 1 (1.2%) 11 (13.1%)  
    CABG 1 (1.2%) 0 (0.0%) 3 (3.6%)  
    PCI 3 (3.6%) 1 (1.2%) 8 (9.5%)  
Any MACCE 5 (6.0%) 3 (3.6%) 16 (19.0%) 0.002 
     
Non-Hierarchical     
Cerebrovascular Accident 0 (0.0%) 1 (1.2%) 2 (2.4%) 0.78 
Myocardial Infarction 1 (1.2%) 1 (1.2%) 2 (2.4%) 1.00 
    Q wave 1 (1.2%) 1 (1.2%) 1 (1.2%) 1.00 
    Non-Q wave 0 (0.0%) 0 (0.0%) 1 (1.2%) 1.00 
Repeat Revascularization 5 (6.0%) 1 (1.2%) 12 (14.3%) 0.004 
    PCI 4 (4.8%) 1 (1.2%) 9 (10.7%) 0.004 
    CABG 1 (1.2%) 0 (0.0%) 3 (3.6%) 0.23 
 
PCI, percutaneous coronary intervention 
CABG, coronary artery bypass grafting 
CSS, Clinical SYNTAX score 
MACCE, major adverse cardiovascular and cerebrovascular events 
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Supplementary Table 8. Univariate and multivariable predictors of MACCE at 5-years 
follow-up. 
 
Variable 
Univariate predictors of MACCE 
at 5 years 
Multivariable predictors of 
MACCE at 5 years 
 95% [CI] P value 95% [CI] P value 
Age 1.03 [1.00-1.06] 0.03   
Diabetes 2.27 [1.39-3.73] 0.001 1.68 [1.00-2.82] 0.048 
Current Smoking 0.50 [0.23-1.01] 0.08   
Peripheral vascular disease 2.55 [1.30-5.00] 0.007 2.56 [1.24-5.28] 0.011 
Log SYNTAX score 15.3 [3.87-60.55] <0.0001   
Log ACEF 12.2 [1.40-10.99] 0.02   
Log Clinical SYNTAX score 8.82 [3.12 24.91] <0.0001   
Number of diseased lesions 1.43[1.17-1.73] <0.0001   
Incomplete revascularisation 1.93 [1.20-3.13] 0.007   
 
CI, confidence interval 
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Supplementary Figure Legends 
 
Supplementary Figure 1: Logarithmic distribution of the Clinical SYNTAX score (CSS). 
The CSS is normally distributed after logarithm transformation. 
 
Supplementary Figure 2: ROC curves for (A) mortality, (B) MACCE at 5-years follow-up 
for different risk scores amongst the 239 patients in the ARTS-II study who had treatment for 
triple vessel disease, and had serum creatinine, left ventricular function and body weight 
recorded at baseline.*p<0.001, †p<0.05, ¶ p<0.01. 
 
Supplementary Figure 3: Kaplan Meier curve showing the 5-year MACCE-free survival 
stratified according to tertiles of the CSS, and (A) the SYNTAX-EUROADD, and (B) the 
SYNTAX-EUROLOG.  
 
Supplementary Figure 4: Kaplan Meier curve showing the 5-year MACCE-free survival 
stratified according to tertiles of the CSS, and the MCRS. 
 
Supplementary Figure 5: Kaplan Meier curves for (A) death, (B) myocardial infarction, (C) 
repeat revascularisation and (D) MACCE at 5-years follow-up amongst 239 patients with 
three vessel disease in the ARTS-II study with a Clinical SYNTAX score. 
 
Supplementary Figure 6: ROC curves for (A) mortality, (B) MACCE at 5-years follow-up 
amongst the 239 patients with three vessel disease in the ARTS-II study with a Clinical 
SYNTAX score. 
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Supplementary Figure 7: Kaplan Meier curves for (A) death, (B) myocardial infarction, (C) 
repeat revascularisation and (D) MACCE at 5-years follow-up amongst all 251 patients in the 
ARTS-II study with a Clinical SYNTAX score calculated using the serum creatinine. 
 
Supplementary Figure 8: ROC curves for (A) mortality, (B) MACCE at 5-years follow-up 
amongst all 251 patients in the ARTS-II study with a Clinical SYNTAX score calculated 
using the serum creatinine 
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Supplementary Figure 3A         
         
CSS Low vs. Mid. vs. High p(log-rank) =<0.0001 
 
SYNTAX-Additive EuroSCORE Low vs. Mid vs. High p(log-rank)= 0.001 
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SYNTAX-Logistic EuroSCORE Low vs. Mid vs. High p(log-rank)= 0.005 
CSS Low vs. Mid. vs. High p(log-rank) =<0.0001 
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CSS Low vs. Mid. vs. High p(log-rank) =<0.0001 
Mayo Clinic Risk Score: Low vs. Mid vs. High p(log-rank)= 0.003 
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Clinical SYNTAX score
ACEFSCr
SYNTAX Score
Reference Line
Area under the curve
[95% CI]
P Value
SYNTAX score 0.70 [0.56-0.83] 0.01
ACEFSCr score 0.73 [0.61-0.88] 0.004
CSSSCr 0.76 [0.63-0.88] 0.001
Supplementary Figure 8A            
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ABSTRACT:
Background: The SYNTAX score (SXscore) has been shown to be an eff ective predictor of clini-
cal outcomes in patients undergoing percutaneous coronary intervention (PCI).
Methods: The SXscore was prospectively collected in 1,397 of the 1,707 in the “all-comers” 
LEADERS trial (patients after surgical revascularization were excluded). Post-hoc analysis was 
performed by stratifying clinical outcomes at 2 year follow-up, according to one of three 
SXscore tertiles.
Results: 1,397 patients were divided into tertiles based on the SXscore in the following fashion: 
SXlow ≤8 (n=464), 8 <SXmid ≤16 (n=472) and SXhigh >16 (n=461). At 2 year follow-up the rate 
of major adverse cardiovascular events was 18.4%, 12.0% and 9.4% in the SXhigh, SXmid, and 
SXlow tertile, respectively (HR 1.45; CI 1.21-1.74; p<0.01). There was a signifi cantly higher rate 
of cardiac death in patients in the highest SXscore tertile (7% SXhigh versus 2.4% SXmid versus 
1.8% SXlow; HR 2.22 (CI 1.5-3.27); p<0.001). Within the SXhigh tertile the rate of cardiac death 
was signifi cantly lower in patients treated with Biolimus Eluting Stent (4.7%) compared with 
Sirolimus Eluting Stent (9.6%) (HR 0.48; CI 0.23-0.99; p=0.046).
Conclusions: The SXscore when applied to an “all-comers” patient population allows for pro-
spective risk stratifi cation of patients undergoing PCI up to two years follow-up. In addition, the 
SXscore appears to separate the performance of devices in high risk patient groups.
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INTRODUCTION:
The SYNTAX score (SXscore) is a comprehensive angiographic scoring system derived from the 
coronary anatomy and lesion characteristics1-3 which was initially designed to quantify coronary 
lesion complexity. Additional analyses have subsequently demonstrated its ability to predict 
major adverse cardiac events (MACE) following percutaneous revascularization in patients with 
multivessel coronary artery disease at follow-up ranging from one- to fi ve-years.4-6 At one year 
follow up in the ARTS-II study, patients with a SXscore in the highest tertile had a signifi cantly 
higher rate of MACE compared with patients in the lower tertiles (HR 3.5; CI 1.7-7.4; p=0.0001); 
while a multivariate analysis demonstrated that the SXscore independently predicted a four-
fold increase in the risk of MACE. Furthermore, the SX score also showed a better discrimination 
ability than the AHA/ACC modifi ed lesion classifi cation (c-statistic 0.67 vs. 0.58, p<0.001).
The SXscore has not only been assessed in patients with complex coronary artery disease4-6 
and left main disease7-8 but it has also been evaluated as a predictor of peri-procedural myo-
cardial infarction in a 100 patients undergoing an elective procedures for long lesions and 
bifurcation stenting.9 Most recently our group has evaluated its value for risk assessment in the 
setting of a randomised trial with an ‘all-comers’ population. In the sub-study of the LEADERS 
trial (Limus Eluted from A Durable versus ERodable Stent coating), where the SXscore was col-
lected prospectively in 1,397 “all-comer” patients, we reported its prognostic value for MACE 
events at 1 year follow-up.10 In the current sub-study we assess the value of the SXscore at 
2 year follow-up and also assess its ability to discriminate between the performance of two 
stainless steel drug-eluting stents, one eluting biolimus from a biodegradable polymer and one 
sirolimus from a durable polymer, in the highest risk patient group.
METHODS:
Study population: LEADERS was a multicenter European non-inferiority trial comparing the 
safety and effi  cacy of the BioMatrix™ Flex biolimus-eluting stent (BES) (Biosensors, Morges, 
Switzerland) to the Cypher® sirolimus-eluting stent (SES) (Cordis, Warren, NJ, USA) in 1,707 ‘all-
comers’ patients. Patients over the age of 18 with chronic stable coronary artery disease or 
acute coronary syndromes including ST-elevation myocardial infarction were eligible if they 
had at least one lesion with ≥50% diameter stenosis and reference vessel diameter 2.25 to 3.5 
mm. The aim was for the patient population to refl ect real world clinical practice and thus no 
limits were set on the number or complexity of the lesions stented. The only exclusion criteria 
were: known allergy to acetylsalicylic acid, clopidogrel, heparin, stainless steel, sirolimus, bio-
limus or contrast material that cannot be pre-medicated; planned surgery within 6 months of 
percutaneous coronary intervention unless the dual anti-platelet therapy could be maintained 
throughout the peri-surgical period; pregnancy; participation in another trial before reaching 
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the primary end-point and lastly inability to give informed consent. The study complied with 
the Declaration of Helsinki and was approved by all institutional ethics committees. All patients 
provided written, informed consent for participation in the trial.
SXscore and angiographic analysis: From the baseline diagnostic angiogram, each coro-
nary lesion producing ≥50% diameter stenosis in vessels ≥1.5 mm was scored separately and 
added together to provide the overall SXscore, which was calculated prospectively using the 
SXscore algorithm that is described in full elsewhere.1-3 All angiographic variables pertinent 
to SXscore calculation were computed by independent core laboratory analysts (Cardialysis 
B.V., Rotterdam, The Netherlands). The SXscore is not currently validated in patients with acute 
myocardial infarction or previous PCI, and no scoring algorithm has been devised for these 
groups of patients at present. Core lab analysts were blinded to all clinical data and therefore 
patients with occluded infarct related arteries were scored as occlusions of unknown duration 
in the same manner as any chronically occluded artery. Those patients with in-stent restenosis 
lesions were scored in the same manner as if the lesion was a de novo lesion. 
Limitations: The methods employed for scoring acutely occluded arteries and in-stent reste-
nosed arteries has not been validated, and does not take into account some of the potentially 
diff erent lesion characteristics of an acutely occluded artery or a restenosed lesion compared 
to a de novo lesion. However these methods do allow the weighted score of the anatomical 
segment to be recorded, and do allow some of the lesion characteristics to be scored (eg lesion 
length, tortuosity, calcifi cation etc). 
Randomization and Procedures: Randomization was done centrally after diagnostic cardiac 
catheterization and before percutaneous coronary intervention (PCI) by use of a telephone 
allocation service (Limburgia telefonische Antwoord Service BV, 3068 NP Rotterdam, Nether-
lands). The allocation sequence was computer generated, stratifi ed according to center, and 
blocked with block sizes of 8 and 16, which varied randomly. Patients were randomly allocated 
on a 1:1 basis to treatment with BES or SES, and to active angiographic follow-up at 9 months 
or clinical follow-up only on a 1:3 basis with a factorial design.
BES were available in diameters of 2.25, 2.5, 3.0 and 3.5 mm and in lengths of 8, 11, 14, 18, 
24 and 28 mm. SES were available in diameters of 2.25, 2.5, 2.75, 3.0 and 3.5 mm and in lengths 
of 8, 13, 18, 23, 28 and 33 mm. Balloon angioplasty and stent implantation were performed 
according to standard technique and direct stenting was allowed. No mixture of drug eluting 
stents was permitted within a given patient, unless the operator was unable to insert the study 
stent, in which case crossover to another device of the operator’s choice was possible. Before or 
at the time of the procedure, patients were given at least 75 mg of acetylsalicylic acid, 300-600 
mg loading dose of clopidogrel, and unfractionated heparin at a dose at least 5,000 I or 70-100 
IU/kg. After the procedure, all patients were advised to take aspirin indefi nitely and clopidogrel 
for at least 12 months. In case of inter-current revascularization procedures requiring stent 
implantation, treating cardiologists were encouraged to use the study stent. For other details 
please refer to the primary endpoint manuscript.11
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Follow-up: Adverse events were assessed in the hospital and at 1, 6, 9, and 12 and 24 months. 
One in four patients was asked to return for angiographic follow-up at 9 months. 
Study endpoints: Defi nitions of all endpoints are provided elsewhere.11 The primary 
endpoint of this sub-study was MACE, defi ned as the composite of cardiac death, myocardial 
infarction (MI), and clinically-indicated target vessel revascularization (TVR) within 24-months. 
Secondary endpoints were any target lesion revascularization (TLR) (both clinically and non-
clinically indicated), which was defi ned as repeat revascularization due to a stenosis within the 
stent or within a 5 mm border proximal or distal to the stent; any TVR, cardiac death, death 
from any cause, myocardial infarction, stent thrombosis (defi ned according to the Academic 
Research Council12), device success (defi ned as achievement of a fi nal residual diameter steno-
sis of less than 50% during the initial procedure), and lesion success (achievement of less than 
50% stenosis with any approach for PCI).
The pre-specifi ed principal outcome of the angiographic sub-study was in-stent percent 
diameter stenosis. Secondary angiographic outcomes were in-segment percent diameter 
stenosis, minimal lumen diameter, late lumen loss, and binary restenosis. Angiographic mea-
surements were obtained within the stented segment (in-stent) and over the entire segment 
consisting of the stent and 5 mm proximal and distal margins (in segment). Percent diameter 
stenosis was defi ned as ([reference vessel diameter-minimal luminal diameter]/reference ves-
sel diameter) X 100%; late lumen loss was defi ned as the diff erence between minimal lumen 
diameter after the procedure and minimal lumen diameter at follow-up; and binary restenosis 
was defi ned as a percentage diameter stenosis of 50% or greater in the target lesion. 
A blinded independent clinical events committee adjudicated all endpoints, and indepen-
dent study monitors (D-Target, Montagny-pres-Yverdon, Switzerland) verifi ed all case reports 
from data on-site. Data were store in a database (KIKA Medical, Paris, France), which was main-
tained by a contract research organization (Cardialysis, Rotterdam, Netherlands) in collabora-
tion with an academic clinical trials unit (CTU Bern, Bern University Hospital, Switzerland). The 
operators were by necessity aware of the assigned study stent during PCI and angiographic 
follow-up, but patients and staff  involved in follow-up assessment were blinded to the allocated 
stent type. Angiographic fi lms were centrally assessed at one angiographic core laboratory 
(Cardialysis, Rotterdam, Netherlands) with assessors unaware of the allocated stent. 
Statistical analysis: A stratifi ed post-hoc analysis of clinical and angiographic outcomes, 
which was specifi ed after completion of patient recruitment, was performed according to the 
tertiles of SYNTAX score. The methodology used was similar to that used previously by Valgimigli 
et al in the ARTS-II study, and by Serruys et al. in the SYNTAX trial4-5 as well as by Wykrzykowska 
et al.10 Dedicated software and visual coronary angiography served to determine the SXscore 
as previously described.1-2 All randomized patients without prior surgical revascularisation, in 
whom the SXscore was collected prospectively (1397/1707), were included in the analysis of 
primary and secondary clinical endpoints according to tertiles of SYNTAX score. Analyses of 
the angiographic sub-study were restricted to lesions from patients who attended follow-up 
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angiography. Angiographic outcomes were analyzed using SAS v8 Proc Mixed for continuous 
and Proc Genmod for binominal outcomes, taking into account the within-patient correla-
tion structure of these data. We used a Cox proportional hazards model to compare clinical 
outcomes between the groups. All analyses were performed using SAS 8.02 by a dedicated 
statistician. All p-values and CIs were two-sided. 
RESULTS:
SXscore and baseline characteristics: The SXscore was collected prospectively in 1,397 of the 
1,707 patients (81.8%) enrolled in the LEADERS trial. The predominant reason for not calculat-
ing the score was a history of prior surgical revascularisation. In this post-hoc analysis, the 1,397 
patients were divided according to their SXscore into tertiles defi ned as: SXlow ≤8 (n=467), 
8<SXmid ≤16 (n=472) and SXhigh >16 (n=461). 
The baseline clinical and angiographic data according to the three SXscore tertiles has been 
previously reported and is included in Table 1 and 2.10 Briefl y, the SXscore ranged from 1 to 49, 
with a mean + SD of 13.5+8.7, and a median of 12 (inter-quartile range of 12; 7 to 19). Overall, at 
1-year patients in the highest SXscore tertile had a signifi cantly higher rate of death, TVR, MACE 
and a trend for high rates of MI.
Table 1. Baseline clinical characteristics based on SYNTAX tertiles
Baseline clinical 
variables, (%)
SX score <8
N 464
SX score 8-16
N 472
SX score >16
N 461
p-value on Trend
(2 id d )= = = -s e
Age >65 45 48 52 0.048
Male 75 73 74 0 79 .
Diabetes 20 25 24 0.15
Current smoking 29 26 27 0.61
Hypertension 76 75 70 0 048.
Hypercholesterolemia 68 67 62 0.06
Family history 43 40 36 0.034
4 5 6 0 09Renal insufficiency .
Previous MI 29 31 30 0.69
Previous PCI 39 35 32 0.036
Clinical presentation:
Stable 32 33 23 0.008
Unstable 27 33 19 0.002
STEMI 10 19 28 <0.0001
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Two-year clinical outcomes for the overall study population: 
At 2 year follow-up the MACE rate was 18.4% in the SXhigh tertile, 12.0% in the SXmid and 
9.4% in the SXlow tertile (HR 1.45; CI 1.21-1.74; p<0.01) (Figure 1A). In addition, there was a 
signifi cantly higher rate of cardiac death in patients in the highest SXscore tertile (SXhigh 7.0% 
versus SXmid 2.4% versus SXlow 1.8%; HR 2.22 [CI 1.5-3.27]; p<0.001) (Figure 1B). Myocardial 
infarction was higher in patients in the SXhigh and SXmid groups (6.2%) than in patients with 
SXlow group (4.3%) but this diff erence was not statistically signifi cant (HR 1.18; CI 0.89-1.56; 
p=0.24) (Figure 1C). Clinically driven TVR was 10.2% in the Sxhigh group versus 6.9% and 5.17% 
in the SXmid and SXlow groups (HR 1.45; CI 1.14-1.85; p=0.003).
 (Figure 1D). Secondary end-point of clinically driven TLR was 10.6% in the SXhigh group 
versus 7.5% and 5.7% in the SXmid and SXlow groups, respectively (HR 1.38; CI 1.09-1.76; 
p=0.007) (Figure 1 E).
Diff erential performance of the BES and SES in the SXhigh group: 
The analysis of outcomes in patients treated with BES versus SES has been performed in all 
three tertiles of the SXscore, however, diff erences between the two devices were only appar-
ent in the SXhigh group (highest risk) and are reported here (Figure 2). Baseline clinical and 
angiographic characteristics, and angiographic outcomes for the SXhigh group treated with 
BES versus SES are reported in Tables 3-5. There were no signifi cant diff erences between BES 
and SES treated group in terms of baseline characteristics and there was an equal distribution 
of the two devices between the SXscore tertiles (Table 2).
Table 2. Baseline angiographic characteristics by SYNTAX tertiles
Angiographic variable SX score <8 SX score 8-16 SX score >16 p-value
No of diseased lesions per patient.     
(based on SYNTAX application) 1.5 2.4 3.5 <0.001
No. of treated lesions per patient
(as defined by Corelab) 1.2 1.5 1.7 <0.001
Coronary artery treated
LAD
LCX
RCA
35%
30%
47%
51%
31%
44%
64%
36%
38%
<0.001
0.079
0 007.
2-vessel disease 11% 22% 30% <0.001
3-vessel disease 1% 3 % 5% <0.001
Stent type 
Biolimus
Sirolimus
49%
51%
50%
50%
52%
48%
NS
NS
Number of implanted stents 1.5 1.9 2.3 <0.001
Total stent length/patient (mm) 26 34 43 <0.001
Chronic total occlusion 1% 2% 4% 0.006
Moderate to severe calcification 5% 20% 40% <0.001
Bifurcation lesion 12% 34% 40% <0.001
Use of 2b3a 17% 24% 33% <0.001
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Overall MACE rate was 15.3% in SXhigh group treated with BES versus 21.8% in SXhigh 
group treated with SES (HR 0.68; CI 0.44-1.04; p=0.08) (Figure 2A). Within the SXhigh tertile the 
rate of cardiac death was signifi cantly lower in patients treated with BES (4.7%) than SES (9.6%) 
(HR 0.48; CI 0.23-0.99; p=0.046) (Figure 2B). TLR and TVR rates also tended to be lower in the BES 
treated group (8.7% versus 12.7% for clinically driven TVR; HR=0.65 CI = 0.36-1.15; p=0.14; 8.3% 
versus 13.1% for TLR; HR 0.59; CI 0.33-1.05; p=0.07) (Figure 2 C and D). The rate of myocardial 
infarction remained numerically higher with BES, which was driven by early events occurring 
within the fi rst 9-months of stent implantation. Of note, there were no additional myocardial 
infarctions with BES between 1- and 2-year follow-up compared with an increase in MI rate 
from 4.6% to 5.1% between year 1 and 2 in the SES treated group (Figure 2E). 
Stent thrombosis rates for the SXhigh group at two year follow-up: 
Defi nite stent thrombosis rates was 2.6% in the BES treated group and 5.1% in the SES treated 
group within the SXhigh tertile at two years (HR 0.5; CI 0.18-1.34; p=0.17) (Figure 3 A). Notably, 
there were no further defi nite stent thrombosis events in the BES treated group between year 
1 and 2. In contrast, the defi nite stent thrombosis rate increased from 4.6% to 5.1% in the SES 
treated group. Combined defi nite and probable stent thrombosis rates were 3.8% (n=9) for 
BES and 5.5% (n=12) for SES (HR 0.68; CI 0.29-1.62; p=0.39) (Figure 3 B and Figure 3B’). Most of 
the events occurred early after stent implantation (Figure 3B’). Possible stent thrombosis was 
2.6% in the BES group versus 4.8% in the SES group (HR 0.54; CI 0.2-1.49; p=0.23) (Figure 3 C). 
The rate of overall stent thrombosis in the SXhigh group was 6.0% (n=14) in patients treated 
with BES and 9.8% (n=21) in patients treated with SES (HR 0.6; CI 0.31-1.18; p=0.14) (Figure 3 D). 
The increase in stent thrombosis in SXhigh group between year 1 and 2 was 0.9% for patients 
treated with BES and 2.4% for patients treated with SES. When curves for cardiac death rate and 
overall stent thrombosis rate were superimposed, most of the cardiac death events could be 
accounted for by stent thrombosis events, implying that reduced thrombosis rate may be the 
mechanism responsible for the reduced cardiac mortality rate in patients treated with BES in 
the SXhigh tertile (Figure 3 E), although this remains speculative.
DISCUSSION:
The SXscore has previously been applied in both the SYNTAX trial and the ARTS-II study, both 
of which demonstrated the good predictive value of the SXscore in patients with multivessel 
disease, with those patients in the highest tertile group having signifi cantly more MACE events 
during short4-5 and long-term follow-up.6 More recently we reported the utility of the SXscore as 
a predictor of MACE, including cardiac death, in an “all-comers” population of the LEADERS trial 
at 1 year follow-up.10 Patients with a high SXscore (SXscore>16) had a 50% higher chance of a 
MACE event, and a 154% higher chance of cardiac death at one year. A high SX score conferred 
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Figure 2 A. MACE Rate in High SYNTAX Score (>16) 
patients treated with BES versus SES
Figure 2 B. Cardiac Death rate in High SYNTAX 
Score (>16) patients treated with BES versus SES
Figure 2 A. MACE* Rate 
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Figure 2 C. TLR rate in High SYNTAX Score (>16) 
patients treated with BES versus SES
Figure 2 D. TVR rate in High SYNTAX Score (>16) 
patients treated with BES versus SES
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Figure 2 E. MI rate in High SYNTAX Score (>16) 
patients treated with BES versus SES
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• BioMatrixFlex™ Cypher® Select™
239Patients 222Patients
Ageinyears 65.8 65.2
Malegender 73.2% 74.3%
Arterialhypertension 69.5% 72.2%
Diabetesmellitus 27.2% 20.7%
Ͳ insulinͲdependent 11.7% 9.5%
Hypercholesterolemia 58.2% 65.8%
Familyhistory 36.0% 36.9%
Smoking 25.5% 29.3%
PreviousMI 29.3% 30.2%
PreviousPCI 32.6% 31.1%
Ͳ with drugͲeluting stent 10% 9 9%  .
PreviousCABG 1.8% 1.7%
Chronicstableangina 21.8% 25.2%
• BioMatrixFlex™ Cypher®Select™
239Patients 222Patients
Acutecoronarysyndrome 66.1% 69.8%
Ͳ Unstableangina 20.1% 18%
Ͳ NonͲSTͲelevationMI 20.9% 21.2%
Ͳ STͲelevationMI 25.1% 30.6%
Leftventricularejectionfraction
54.5%52.8%
Numberoflesionstreatedwithstentperpatient
1.92.0
Number of study stent implanted per patient     
2.32.4
Diameterofstudystent(mm)
3 0 2 9.  .
g p
Biolimus Stent          
75 lesions
Sirolimus Stent 
73 lesions P
MLD
in-stent (mm) 2.19 s 0.61 2.12s 0.68 0.53*
i t ( ) 1 97 s 0 57 1 88 s 0 63 0 34*n-segmen  mm . . .  . .
Diameter stenosis
in stent (%) 21 7 s 16 7 22 4 s 19 2 0 82*-  .  . .  . .
in-segment (%) 27.8 s 16.1 29.2 s 17.3 0.60*
Late lumen loss  
in-stent (mm) 0.08 s 0.36 0.13 s 0.50 0.51*
in-segment (mm) 0.08 s 0.35 0.09 s 0.45 0.84*
Binary restenosis
in-stent (%) 4 s 5.3 4 s 5.5 1.00**
in-segment (%) 5 s 6.7 4 s 5.5 1.00**
*two sided t-test, equal variance, ** Fisher exact test used for p-value,95% CI. Based on t-test 
Table 3. Baseline Clinical SXhigh Patient Characteristics
Table 4. Baseline SXhigh Clinical and Angiographic Patient Characteristics
Table 5. Angiographic Follow-up Results of SXhigh patients
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a 2.5 fold increase in cardiac death, which remained true even after adjustment for other risk 
factors for cardiac death such as diabetes, presentation with acute coronary syndrome, beta-
blocker use and stent type. Here we report that the predictive value of SXscore remains robust 
at 2 year follow-up in this all-comers patient population.
The major fi nding of our study is that the SXscore may be an appropriate tool to stratify risk 
in all patients undergoing PCI out to medium-term follow-up. The second fi nding in this study is 
that SXscore appears to be able to discriminate between the performances of diff erent types of 
stents in high risk lesions. Patients with high SXscores treated with BES had a lower risk of MACE 
and cardiac death at two year follow-up compared with patients treated with SES. These results 
Figure 3 A. Defi nite Stent Thrombosis in High 
SYNTAX Score (>16) patients treated with BES 
versus SES
Figure 3 B. Defi nite and Probable Stent 
Thrombosis in High SYNTAX Score (>16) patients 
treated with BES versus SES
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Figure 3 B’. Defi nite and Probable Stent 
Thrombosis in High SYNTAX Score (>16) patients 
treated with BES versus SES (with event type 
superimposed).
Figure 3 C. Possible Stent Thrombosis in High 
SYNTAX Score (>16) patients treated with BES 
versus SES
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Figure 3 C. Possible Stent Thrombosis 
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suggest that the SXscore may be useful tool in the future clinical trials of new stent devices, 
particularly those with an “all-comers” design.
The mechanism of this superior performance with BES compared to SES in the high risk 
lesions and patient populations remains to be established. It remains a possibility that the 
diff erences in outcome may be a play of chance considering the small number of patients in 
the high SXscore tertile. Speculatively, the stent thrombosis data presented here, and the previ-
ously reported optical coherence tomography data13 (Figure 4), suggest that the reduction in 
Figure 3 D. All Stent Thrombosis in High SYNTAX 
Score (>16) patients treated with BES versus SES
Figure 3 E. Stent Thrombosis/ Cardiac Death in 
High SYNTAX Score (>16) patients treated with BES 
versus SES
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mortality rate by treatment with BES may be explained by the better stent strut coverage, and 
less acquired malapposition seen in patients treated with BES compared with SES. 
Overall the superior performance of BES compared to SES in these complex patients 
provides additional data to support the concepts behind the newer generation drug-eluting 
stents, which were primarily designed to improve overall safety following the concerns raised 
with fi rst generation devices.14 In comparison to the permanent polymer present on SES which 
remains exposed to the coronary artery environment long after its useful function has been 
served, the polymer on the biolimus-eluting stent completely biodegrades within 6-9months 
of stent implantation, leaving a bare stainless steel stent. Although the lower stent thrombosis 
rates, and cardiac mortality observed in this study are encouraging, additional, larger powered 
studies are required before defi nitive conclusions can be reached.
LIMITATIONS:
This analysis is subject to inherent limitations of all subgroup analyses such as statistical under-
powering. As such it can only be viewed as hypothesis-generating. Patients with prior coronary 
artery bypass surgery have not been included in the current analysis as the SXscore is algorithm 
is only currently available for patients with de novo disease. Modifi cations to the SXscore that 
will allow for risk stratifi cation in patients post-CABG are being developed by our group. While 
the SXscore was collected prospectively, the analysis of outcomes was performed post-hoc. In 
addition, while SXscore has not been validated in patients post-PCI and with acute myocardial 
infarction, these patients have been included in this analysis. 
CONCLUSION:
This study demonstrates that the prognostic value of the SYNTAX score is valid for all patients 
with de novo coronary artery disease undergoing percutaneous revascularisation out to 
two-years of follow-up. A potential new application of the SYNTAX score is discriminating the 
performance of novel versus fi rst-generationstents in high risk lesions in future clinical trials.
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ABSTRACT 
Background: The SYNTAX score (SXscore) can identify patients treated with percutaneous 
coronary intervention (PCI) who are at highest risk of adverse events. 
Objectives: This study assessed the ability of the SXscore to stratify risk in patients treated with 
PCI and treated with zotarolimus-eluting or everolimus-eluting stents. 
Methods: The SXscore was calculated prospectively in 2,033 of the 2,292 patients enrolled in 
the RESOLUTE All-Comers study. Clinical outcomes in terms of a patient orientated composite 
endpoint (POCE) of all-cause death, MI and repeat revascularization; the individual components, 
of POCE; target lesion failure (TLF, a composite of cardiac death, target-vessel MI and 
clinically-driven target lesion revascularisation), and stent thrombosis were subsequently 
stratified according to SXscore tertiles: SXscoreLOW9(n=698), 9<SXscoreMID17 (n=676); 
SXscoreHIGH>17 (n=659).  
Results: At 12-month follow-up, rates of POCE, MI, repeat revascularization, TLF and the 
composite of death/MI, were all significantly higher in patients in the highest SXscore tercile. 
Rates of stent thrombosis were all highest in the SXscoreHIGH tertile (p>0.05). After multivariate 
adjustment, the SXscore was identified as an independent predictor of POCE, MI, repeat 
revascularisation and TLF (p<0.05 for all). At 12-months follow-up the SXscore, ACEF score 
and Clinical SXscore had respective C-statistics of 0.57, 0.78, 0.67 for mortality and 0.62, 0.56, 
0.63 for POCE. No significant between-stent differences were observed for TLF or POCE in any 
of the SXscore tertiles. 
Conclusions: The SYNTAX score is able to stratify risk amongst an all-comers population 
treated with PCI using second generation DES; however improvements can be made with the 
inclusion of clinical variables.  
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CONDENSED ABSTRACT  
We assessed the ability of the SYNTAX Score (SXscore) to stratify risk in patients enrolled in 
the randomized RESOLUTE All-Comers trial treated with zotarolimus-eluting or everolimus-
eluting stents. Clinical outcomes were stratified according to SXscore tertiles, and at 1 year 
follow-up, rates of all clinical outcomes were higher in patients in the highest tertile. After 
multivariate analysis, the SXscore was also identified as an independent predictor of adverse 
outcomes.This study confirms the ability of the SXscore to stratify risk amongst an all-comers 
population using second generation drug-eluting stents.  
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ABBREVIATIONS AND ACRONYMS  
ARC = Academic Research Consortium 
CAD = coronary artery disease 
CSS=Clinical SYNTAX score 
DES = drug-eluting stent 
LVEF=left ventricular ejection fraction 
MI = myocardial infarction 
PCI = percutaneous coronary intervention 
POCE=patient orientated composite endpoint 
SXscore = SYNTAX Score 
TLF = target lesion failure 
TLR = target lesion revascularization 
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INTRODUCTION 
The SYNTAX score (SXscore) is a comprehensive scoring system made up of angiographic 
variables (1-2). It was originally developed to quantify the complexity of coronary artery disease 
(CAD), however subsequent studies have demonstrated its ability to identify patients treated by 
percutaneous coronary intervention (PCI) who are at highest risk of adverse events (3-8). 
 
Currently, prospective studies assessing its use in patients treated with PCI are limited to the 
SYNTAX study (4), which only enrolled patients with complex CAD (three vessel and/or left 
main disease), and the LEADERS study (3), which was more reflective of everyday clinical 
practice through its all-comers design.  Of note, other than the 703 patients treated with the 
biolimus-eluting stent with a biodegradable polymer in the LEADERS SXscore sub-study(3), all 
other studies evaluating the SXscore have assessed outcomes in patients treated with first 
generation drug-eluting stents (DES) (4-9). Second generation DES were developed on the 
background of safety concerns with these first generation devices, and early data suggest 
significantly improved outcomes (10-12), however the effect of this on the benefits of using the 
SXscore to stratify risk remains to be established.  
 
The RESOLUTE All Comers study(13) randomized 2292 patients to treatment with the Resolute 
zotarolimus-eluting stent (R-ZES, Medtronic CardioVascular, Santa Rosa, California) or the 
Xience V everolimus-eluting stent (EES, Abbott Vascular, Santa Clara, California). Results 
demonstrated that R-ZES was non-inferior to EES with respect to the 12-month primary clinical 
endpoint of target lesion failure (TLF, R-ZES 8.2% vs. EES 8.3%, Pnon-inferiority<0.001), a 
composite of cardiac death, target-vessel myocardial infarction (MI) and clinically-driven target 
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lesion revascularization (TLR), and the 13-month secondary angiographic endpoint of in-stent 
diameter stenosis (R-ZES 21.65±14.42% vs. EES 19.76±14.64%, Pnon-inferiority=0.035). In this 
sub-study of the RESOLUTE All Comers trial the prognostic value of the SXscore was assessed 
in isolation, and in comparison with the ACEF score(14-15) and the Clinical SYNTAX score 
(CSS),(16) in an all-comers population treated with second generation DES.  
 
METHODS 
Study population 
The methods of the RESOLUTE All Comers study have been published previously (13). In brief, 
the studied applied an all-comers approach to recruit 2292 patients with chronic stable CAD or 
acute coronary syndromes (ACS) including ST-elevation myocardial infarction (STEMI), who 
were eligible for enrolment if they had at 1 lesion with diameter stenosis (DS) 50% and a 
reference vessel diameter (RVD) between 2.25 and 4.0mm. No restriction was placed on the 
number of lesions or vessels treated or the number of stents implanted. Principal exclusion 
criteria were: allergy to study medication, metal alloys or contrast media; planned surgery within 
6 months of PCI unless the dual anti-platelet therapy could be maintained throughout the peri-
operative period, pregnancy, participation in another trial before reaching the primary endpoint 
and lastly inability to give informed consent. The study complied with the Declaration of 
Helsinki and was approved by all institutional ethics committees. All patients provided written, 
informed consent for participation in the trial.  
 
Randomization and Procedures 
Patients were randomly allocated on a 1:1 basis to treatment with R-ZES or EES, and to 12-
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month clinical follow-up only, or in addition active angiographic follow-up at 13-months, on a 
1:4 basis with a factorial design. A blinded independent clinical events committee (CEC) 
adjudicated all endpoints, and independent study monitors verified all case reports from data on-
site.  The operators were by necessity aware of the assigned study stent during PCI and 
angiographic follow-up, but patients and staff involved in follow-up assessment were blinded to 
the allocated stent type. 
 
R-ZES were available in diameters of 2.25-4.0 mm and in lengths of 8-30 mm, whilst EES were 
available in diameters of 2.25-4.0 mm and in lengths of 8-28 mm. Balloon angioplasty and stent 
implantation were performed according to standard technique, and direct stenting was allowed. 
The aim was to obtain full lesion coverage with one or several stents. No mixture of DES was 
permitted within a given patient, unless the operator was unable to insert the study stent, in 
which case crossover to another non-study device of the operator’s choice was possible. 
 
Procedural anticoagulation was achieved with unfractionated heparin 5000IU or 70-100IU/kg, 
whilst the use of glycoprotein IIb/IIIa inhibitors was left to the operator’s discretion. Pre-
procedure all patients enrolled into the study received 75 mg of acetylsalicylic acid, whilst the 
300-600 mg loading dose of clopidogrel was only given if no clopidogrel had been administrated 
in the previous seven days. All patients were discharged on 75 mg of acetylsalicylic acid 
indefinitely, and clopidogrel 75mg for >6 months following the index procedure. In the case of 
inter-current revascularization procedures needing stent implantation, treating cardiologists were 
encouraged to use study stents. 
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Follow up  
Adverse events were assessed in hospital, and clinical follow up was performed at 1, 6, and 12 
months. Additional clinical follow-up is planned at yearly intervals to 5 years. One in five 
patients was asked to return for angiographic follow-up at 13-months. 
 
SYNTAX Score 
The SXscore for each patient was calculated prospectively by scoring all coronary lesions with a 
DS50%, in vessels 1.5 mm, using the SXscore algorithm which is described in full elsewhere 
(1-2), and available at www.syntaxscore.com.(17)  All angiographic variables pertinent to 
SXscore calculation were computed by two core laboratory analysts (Cardialysis B.V., 
Rotterdam, The Netherlands), who were blinded to all clinical data, presentation and outcomes. 
In the event of disagreement, the opinion of a third analyst was sought, and the final decision 
was established by consensus. Patients with occluded infarct related arteries were scored as 
occlusions of unknown duration in a similar manner as any chronically occluded artery. In 
addition those patients with lesions due to restenosis or in-stent restenosis, were scored in the 
same manner as if the lesion were a de novo lesion. Although this methodology was not 
described in the original description of the SXscore, it has previously been applied to other all-
comers (3,6), and STEMI populations.(9)  
 
ACEF Score and CSS 
The ACEF score was calculated using the combination of the patient’s age, left ventricular 
ejection fraction (LVEF) and serum creatinine as described elsewhere.(14) Similarly, the CSS 
was calculated using the combination of the SXscore and the patient’s age, LVEF and creatinine 
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clearance as described in the primary manuscript.(16) 
 
Study Endpoints 
The primary endpoint of this analysis was a patient oriented composite endpoint (POCE) of all 
cause death, any MI, and any repeat revascularization. Secondary endpoints included the 
individual components of the patient oriented composite endpoint, together with 1-year rates of 
cardiac death, target vessel MI, clinically-indicated TLR, a safety composite of death/MI, TLF (a 
composite of cardiac death, target-vessel MI, and TLR) and definite, definite/probable and any 
stent thrombosis (ST).  
 
Definitions 
Definitions of all endpoints are provided in the primary manuscript (13). All deaths were 
considered cardiac unless an undisputed non-cardiac cause was present. MI was defined 
according to an extended historical protocol definition and according to Academic Research 
Consortium (ARC) definitions (18-19). A Q-wave MI required, in the absence of cardiac enzyme 
data, a history of chest pain or other acute symptoms consistent with myocardial ischemia 
together with new pathological Q waves in 2 contiguous ECG leads as assessed by the core lab 
or CEC. In the presence of elevated cardiac enzymes, new pathological Q waves in 2 
contiguous ECG leads as assessed by the core lab or CEC were sufficient to diagnose a Q-wave 
MI. In the absence of an ECG, a Q-wave MI could be adjudicated on the basis of the clinical 
scenario and appropriate cardiac enzyme data.  
 
A TLR was considered clinically indicated if angiography during follow-up showed a DS50% 
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(core laboratory quantitative coronary angiography [QCA] assessment) and if one of the 
following occurred: (1) a positive history of recurrent angina pectoris, presumably related to the 
target vessel; (2) objective signs of ischemia at rest (ECG changes) or during exercise test (or 
equivalent), presumably related to the target vessel; (3) abnormal results of any invasive 
functional diagnostic test (e.g. fractional flow reserve); (4) a TLR with a DS70% even in the 
absence of the above mentioned ischemic signs or symptoms.  ST was defined according to the 
ARC definitions (18).  
 
Statistical Methods 
All patients with a calculated SXscore were included in the analysis. All variables were stratified 
according to SXscore tertiles. Discrete data were summarized as frequencies (%), whereas 
continuous data were expressed as mean±standard deviation (SD). Testing for (linear) trends was 
done by using generalized linear models with SYNTAX tertiles as a co-variable for continuous 
variables, and the Cochran-Armitage test for trend in categorical data. The Fisher’s exact test 
was used to analyze differences in outcome between stents. Survival curves were constructed for 
time-to-event variables using Kaplan-Meier estimates, and compared by the log-rank test. 
Patients lost to follow-up were considered at risk until the date of last contact, at which point 
they were censored.  A Cox multi-variate model was performed using the co-variates gender, age 
>65, presence of diabetes, presentation with acute MI, stent type and SXscore. C-statistics from 
receiver operator characteristic curves were used to compare the discrimination of the SXscore, 
ACEF score, and CSS score. A p value of <0.05 was considered significant, and all tests were 
two-tailed. Data were analyzed using SAS version 9.2 software (SAS, Carey, North Carolina) by 
a dedicated statistician.  
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RESULTS  
The SXscore was available for 2,033 (88.7%) of 2,292 patients enrolled in the study, with the 
presence of coronary artery bypass grafts (224 patients) the major reason for inability to calculate 
the score. The SXscore ranged from 0 to 54.5, with a mean±SD of 14.6±9.2, and a median of 
13.0 (inter-quartile range 7 to 20). In this analysis patients were categorized according to tertiles 
of the SXscore defined as: SXscoreLOW9 (n=698), 9<SXscoreMID17 (n=676); SXscoreHIGH>17 
(n=659). 
 
Baseline Clinical Characteristics 
Baseline clinical parameters stratified according to SXscore tertiles are presented in Table 1. 
Advanced patient age, male gender, the presence of diabetes mellitus and multivessel disease, 
and presentation with an acute MI were all significantly more common in the SXscoreHIGH 
tertile. Conversely hypercholesterolaemia and presentation with stable angina were significantly 
more frequent in the SXscoreLOW tertile. 
 
Baseline Angiographic Characteristics 
Baseline lesion and procedural characteristics are shown in Table 2. In line with its method of 
derivation, the frequency of triple vessel disease and all markers of increased lesion complexity 
such as the presence of bifurcation lesions and total occlusions were all significantly higher in 
the SXscoreHIGH tertile. Correspondingly the number of treated lesions, stents implanted and 
mean stent length were also higher in the SXscoreHIGH tertile.  
 
Clinical Outcomes 
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Clinical outcomes at 1 year are shown in Table 3, whilst cumulative survival curves are 
displayed in Figure 1. Overall the POCE, the safety endpoint of death/MI, and the rates of MI 
and repeat revascularization were all significantly higher in the SXscoreHIGH tertile.  No trends 
were noted between rates of death, and definite, definite/probable or any ST and the patient’s 
SXscore tertile. 
 
Multivariate analysis  
The results of the Cox multivariable analysis are shown in Table 4. Following adjustment of 
confounding factors the SXscore remained an independent predictor of clinical outcomes such as 
MI, repeat revascularisation, TLF, and POCE.  
 
SXscore vs. ACEF score vs. CSS 
Table 5 reports the respective C-statistics for the SXscore, ACEF score and CSS for a range of 
clinical outcomes at 12-months follow-up. The SXscore’s discriminatory ability was best for 
repeat revascularization, poorest for the assessment of mortality, and comparable to the CSS for 
the composite endpoints of TLF and POCE.  
 
Zotarolimus vs. Everolimus  
For illustrative purposes a comparison of outcomes amongst patients in each SXscore tertile 
stratified according to stent type was performed. Overall rates of TLF, the device oriented 
primary endpoint of the Resolute All Comers study, and the POCE were comparable between R-
ZES and EES in all three SXscore groups (p>0.05). Notably, in 659 patients with the most 
complex CAD, mortality was significantly higher in patients treated with EES (R-ZES 1.3% vs. 
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EES 4.1%, p=0.03), whilst rates of clinically-indicated TLR (7.2% vs. 3.5%, p=0.04) and 
definite ST (2.2% vs. 0.0%, p=0.006) were significantly higher in those treated with R-ZES.  
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DISCUSSION 
This study, which represents the largest assessment of the SXscore in patients treated with PCI 
and is the first to assess its ability to stratify risk in patients treated entirely with second 
generation DES, demonstrates a consistent ability of the SXscore to identify patients at highest 
risk of adverse events following PCI. 
 
A key to optimizing outcomes in patients undergoing PCI is the ability to reliably identify those 
patients at highest risk of undesired events. With respect to this, the SXscore has been 
consistently shown to be an important tool for risk stratification, however prior assessments of 
the score in PCI populations have been limited by being retrospective (5-9,20) and largely 
including only those patients with the most complex CAD (4,7-8,20). In addition, other than the 
LEADERS study,(3) all other studies have enrolled patients treated with first generation DES.(4-
9) The current prospective study had an all-comers design, such that any patient with 
symptomatic CAD suitable for PCI, who consented to enrolment, could be included, thereby 
ensuring the patient cohort provided a good reflection of those patients routinely seen in ‘real-
world’ contemporary practice. Furthermore all patients received second generation DES, which 
have been shown to have superior safety and efficacy, compared to earlier devices (10-12). The 
confirmation of the ability of the SXscore to independently predict adverse clinical outcomes in 
any patient presenting for PCI treated with second generation DES is therefore important 
evidence to support the routine use of the SXscore in everyday practice. This ability to identify 
those patients at greatest risk of adverse events facilitates appropriate informed consent and 
counseling, whilst also prompting increased surveillance, and aggressive secondary preventative 
therapy and life style modifications in those at highest risk.  
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Analysis of the SXscore distribution in the current study clearly indicates the patients with very 
complex CAD are being treated with PCI; a consequence of the increasing age and co-
morbidities of patients presenting for revascularization (21), and the advancements in PCI 
technology. Objective evidence of this increase is reflected in the mean SXscores of the SIRTAX 
and LEADERS studies, which were 11.7±7.3 and 13.5±8.7 (3,6), respectively, compared to 
14.6±9.2 in the current study. Moreover the percentage of patients with SXscores>32, a group 
with the most complex CAD and previously identified in the SYNTAX trial as the threshold 
above which surgical revascularization provided the optimal outcome, is also increasing with 
respective rates of 1.0% and 2.9% in the SIRTAX and LEADERS studies, compared to 4.4% in 
the present analysis. The current study lacked a surgical control arm, and it is therefore not 
possible to state whether PCI was appropriate for those patients in the highest SXscore tertile. 
Moreover, at present no data are available comparing outcomes in patients randomized to 
treatment with PCI using second generation DES or CABG, however the utility of using EES 
compared to CABG in patients with complex CAD is currently being assessed in the ongoing 
EXCEL study.    
 
Despite the more complex patient population in the current study it is reassuring that no 
significant differences in mortality were noted across SXscore tertiles, a finding at variance with 
the LEADERS study, which did identify the SXscore as an independent predictor of mortality 
(3). Furthermore, whilst both studies indicated significantly higher rates of their respective 
primary study endpoints and repeat revascularization in patients in the highest SXscore tertile, 
the same was not true for MI in the LEADERS study or ST in the current study. This variation in 
the ability of the SXscore to predict ‘hard’ clinical endpoints is not clearly explained. Without 
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doubt it could be the consequence of underpowered sub-group analyses (22-23); however it may 
also reflect the limitations of using a risk model assessing only one type of variable. Consistent 
with previous studies (15-16), there were variations in the discriminatory ability of the SXscore, 
ACEF score and CSS, which respectively represent an anatomical, clinical and combination 
clinical/anatomical risk model, depending on the outcome measure being assessed. The C-
statistic for mortality was highest for the ACEF score, reflecting the heavy influence of pre-
morbid characteristics on this outcome. Similarly, the C-statistic for repeat revascularization was 
highest for the SXscore. One of the previous valid concerns with using the SXscore is the 
absence of clinical variables in its calculation, a deficiency which can be corrected through its 
combination with a clinical based score as reported previously (16,24), and highlighted in the 
present study through the improved C-statistics for all outcomes, apart from repeat 
revascularization, when using the CSS compared to the SXscore.  
 
The rates of definite ST in the current study were lower than those seen in corresponding tertiles 
of the SXscore in LEADERS, differences which may partly explain the lack of association 
between ST and SXscore tertile in the present study.  It must be acknowledged that the current 
study is underpowered to assess for this outcome, however the numerically different rates of ST 
according to SXscore teriles despite comparable duration of DAPT, suggest that there may be an 
additional role for the SXscore in helping tailor anti-platelet therapy on an individual level. 
Confirmation of this hypothesis however requires adequately powered randomized trials.  
 
The 12-months outcomes from the RESOLUTE All Comers study demonstrated that R-ZES was 
non-inferior to EES with respect to the primary clinical endpoint of TLF. Reassuringly the 
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present study indicates that comparable outcomes with respect to TLF were also maintained 
between both stents irrespective of the severity of underlying CAD. Of note, whilst the between-
stent differences in mortality and definite ST amongst patients in the highest SXscore tertile 
followed the trends seen in the full patient cohort, the same was not true for the differences seen 
in clinically indicated TLR. Similarly, in the LEADERS study a significant between-stent 
difference in cardiac death was observed amongst patients in the highest SXscore tertile which 
was not seen in the full patient cohort (25). Whilst these observations may suggest potential 
differences in stent performance with different severities of CAD, they should be regarded in the 
first instance as being underpowered, hypothesis generating analyses, and should ultimately be 
used as a stimulus for further more directed and adequately powered studies. Nevertheless, these 
observations do serve to highlight a new potential application of the SXscore as a means to 
further assess and compare the performance of new coronary devices.   
  
Limitations 
The SXscore has several limitations including intra- and inter-observer variability (2,26), which 
is inherent to its subjective derivation using coronary angiography; and the absence of specific 
algorithms for patients with prior percutaneous or surgical revascularization. Specifically, the 
current analysis may have limitations, such as underpowered results and chance findings, which 
are inherent to the use of sub-group analysis (22-23).  Missing quantitative values for the ejection 
fraction and serum creatinine also lead to the ACEF score and CSS being available in only 
approximately half of the study population. 
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The SYNTAX score is able to stratify risk amongst an all-comers population treated with PCI 
using second generation DES; however improvements can be made with the inclusion of clinical 
variables.  
CONCLUSION 
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Table 1. Baseline clinical characteristics  
 
Variable %, (n) SXscore 9 (N=698) 
9<SXscore17 
(N=676) 
SXscore>17 
(N=659) P Value 
     
Baseline Characteristics     
   Male gender  71.2% (497) 76.9% (520) 78.8% (519) 0.001 
   Age, years (±SD) 63.0±10.9 63.0±10.8 65.5±11.0 <0.001 
Risk factors     
   Previous MI  26.5% (182) 24.8% (164) 28.7% (185) 0.37 
   Diabetes  mellitus  19.3% (135) 23.2% (157) 24.7% (163) 0.02 
   Arterial hypertension   70.6% (493) 71.3% (482) 68.3% (450) 0.35 
   Hypercholesterolemia   65.6% (458) 64.1% (433) 59.8% (394) 0.03 
   Premature CAD in first degree relative 36.0% (214) 37.7% (218) 30.7% (169) 0.07 
   Current smoker  25.5% (178) 29.3% (198) 29.1% (192) 0.13 
   Previous PCI 31.2% (218) 26.6% (180) 29.9% (197) 0.57 
   Creatinine clearance, ml/1.73m2 (±SD) 96.2±34.4 96.6±34.7 90.9±34.3 0.006 
   Left ventricular ejection fraction <30% 2.0% (8) 2.4% (8) 1.6% (6) 0.69 
   Multi-vessel disease 32.4% (226) 57.0% (385) 78.8% (519) <0.0001 
   SYNTAX score (±SD)  5.7±2.4 13.3±2.3 25.5±6.7 N/A 
Indication for Treatment    
   Revascularization for angina or MI 86.8% (606) 88.9% (601) 89.4% (589) 0.14 
   Stable angina  37.5% (262) 31.8% (215) 30.2% (199) 0.004 
   Unstable angina  21.6% (151) 19.7% (133) 14.9% (98) 0.002 
   Acute MI  27.7% (193) 37.4% (253) 44.3% (292) <0.0001 
 
SXscore, SYNTAX score; SD, standard deviation; MI, myocardial infarction; CAD, coronary 
artery disease; PCI, percutaneous coronary intervention; N/A, not applicable 
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Table 2. Baseline lesion and procedural characteristics  
 
Variable %, (n) SXscore 9 (N=698) 
9<SXscore17 
(N=676) 
SXscore>17 
(N=659) P Value 
     
Extent of Disease     
  Number of disease lesions (±SD) 1.5±0.7 2.5±1.1 4.0±1.6 <0.0001 
  One vessel disease 67.6% (472) 26.9% (182) 7.4% (49) 0.005 
  Two vessel disease 29.1% (203) 54.3% (367) 36.1% (238) <0.0001 
  Three vessel disease 2.1% (15) 18.8% (127) 56.4% (372) <0.0001 
Lesion Location     
  Left main stem 0.0% (0) 0.6% (4) 5.8% (38) <0.0001 
  Right coronary artery 46.8% (327) 60.7% (410) 75.9% (500) <0.0001 
  Circumflex artery 34.1% (238) 53.3% (360) 74.5% (491) <0.0001 
  LAD artery  51.3% (358) 77.4% (523) 95.1% (627) <0.0001 
  Proximal LAD involvement 8.7% (61) 21.0% (142) 44.9% (296) <0.0001 
  All de novo lesions 89.3% (620) 92.5% (620) 90.6% (591) 0.39 
Lesion Characteristics     
  1  Bifurcation lesion 25.9% (181) 56.2% (380) 75.6% (498) <0.0001 
  1  Trifurcation lesion 0.6% (4) 3.6% (24) 6.4% (42) <0.0001 
  1  Ostial lesion 1.6% (11) 3.0% (20) 4.9% (32) 0.0005 
  1  Occlusion 3.6% (25) 25.3% (171) 49.3% (325) <0.0001 
  1  Tortuous lesion 24.8% (171) 45.0% (304) 62.7% (413) <0.0001 
  1  Lesion  20mm 8.0% (55) 29.6% (200) 53.0% (349) <0.0001 
   1 Calcified lesion 3.0% (21) 10.4% (70) 21.5% (142) <0.0001 
   1 Lesion with thrombus 5.8% (40) 6.5% (44) 10.9% (72) 0.0004 
   1 In-stent restenosis lesion 9.1% (63) 5.5% (37) 7.7% (50) 0.30 
  Off-label indication* 49.9% (348) 67.2% (454) 80.9% (533) <0.0001 
Procedural Characteristics     
Number of treated lesions (±SD) 1.2±0.4 1.5±0.6 1.9±1.0 <0.0001 
Number of stents implanted (±SD) 1.5±0.8 1.9±1.1 2.6±1.6 <0.0001 
Total stent length, mm (±SD) 25.7±16.3 35.3±22.9 48.1±30.3 <0.0001 
Mean duration of DAPT, days (±SD) 315±97  319±90 308±102  0.20 
 
SXscore, SYNTAX score; LAD, left anterior descending artery; DAPT, dual anti-platelet 
therapy 
 
 
*Off-label use included patients with at least one of the following clinical and lesion characteristics; renal 
insufficiency ( 140 μmol/L), ejection fraction < 30%, acute myocardial infarction (72 h),  > 1 lesion 
per vessel,  2 vessels stented; lesions > 27 mm, bifurcations, bypass grafts, in-stent restenosis, 
unprotected left main, lesions with thrombus, or total occlusion. 
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Table 3: Clinical Outcomes at 12-Months on an intention-to-treat basis 
 
Variable %, (n) SXscore 9 (N=698) 
9<SXscore17 
(N=676) 
SXscore>17 
(N=659) P Value 
     
Death  1.9% (13) 1.0% (7) 2.7% (18) 0.25 
Cardiac death 1.0% (7) 0.4% (3) 2.1% (14) 0.06 
Any MI* 8.0% (56) 12.1% (82) 18.2% (120) <0.0001 
Any MI† 3.2% (22) 3.8% (26) 5.3% (39) 0.01 
     Target vessel MI† 2.7% (19) 3.6% (24) 5.6% (37) 0.006 
Any repeat revascularization 5.0% (35) 7.7% (52) 13.7% (90) <0.0001 
      Clinically indicated TLR  2.0% (14) 2.7% (18) 5.3% (35) 0.0007 
Death or MI 4.7% (33) 4.7% (32) 8.2% (54) 0.01 
Target lesion failure‡ 5.2% (36) 5.9% (40) 11.7% (77) <0.0001 
Patient Orientated Composite Endpoint§ 8.5% (59) 11.2% (76) 20.0% (132) <0.0001 
ARC definite stent thrombosis                      0.4% (3) 0.6% (4) 1.1% (7) 0.16 
ARC definite/probable stent thrombosis 0.9% (6) 0.7% (5) 1.7% (11) 0.15 
ARC any stent thrombosis 1.4% (10) 0.9% (6) 2.6% (17) 0.10 
 
SXscore, SYNTAX score; TLR, target lesion revascularization; ARC, Academic Research Consortium; 
MI, myocardial infarction 
 
* Defined according to the ARC(18)  
† Extended historical definition(19)  
‡ Target Lesion Failure: cardiac death, MI† (not clearly attributable to a non-target vessel) and clinically 
indicated TLR   
§ Patient Orientated Composite Endpoint: a composite of all-cause mortality, MI (Q- and non-Q wave) or 
any revascularization. 
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Table 4. Cox Multi-variate Analysis 
 
Clinical Outcome Hazard Ratio for SYNTAX score* [95% Confidence Interval] 
P 
Value 
Death 1.19 [0.80-1.76] 0.40 
MI† 1.52 [1.17-1.99] 0.002 
Any repeat revascularisation 1.75 [1.44-2.13] <0.001 
Target lesion failure‡ 1.68 [1.36-2.06] <0.001 
Patient Orientated Composite Endpoint§ 1.68 [1.43-1.96] <0.001 
Any stent thrombosis 1.39 [0.89-2.15] 0.15 
 
*After adjustment of confounding factors: age greater than 65, gender, presentation with an acute MI, 
presence of diabetes, and stent type. 
 
†, ‡, § defined as in Table 2.  
 
MI, myocardial infarction  
 
Table 5: Comparison of Discriminatory Ability of SYNTAX score, ACEF score and Clinical SYNTAX 
score. 
 
 
SXscore, SYNTAX score; CSS, Clinical SYNTAX score; TLR, target lesion revascularization 
 
 †, ‡, § defined as in Table 2.  
Variable %, (n) 
C-statistic 
SXscore 
(2033 patients) 
C-statistic 
ACEF score 
(1218 patients) 
C-statistic 
CSS 
(1098 patients) 
Death  0.57 0.78 0.67 
Cardiac death 0.61 0.84 0.71 
Any myocardial infarction† 0.60 0.58 0.65 
Any repeat revascularization 0.63 0.50 0.59 
Target lesion failure‡ 0.62 0.59 0.63 
Patient Orientated Composite Endpoint§ 0.62 0.56 0.63 
ARC any stent thrombosis 0.60 0.72 0.68 
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Figure 1. Kaplan Meier curves 
Kaplan Meier survival curves for (A) the patient oriented composite endpoint (a composite of 
all-cause death, any myocardial infarction and any repeat revascularization; (B) Any death; (C) 
Any myocardial infarction; (D) Any repeat revascularization out to 12-months follow-up.  
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Objectives We assessed the impact of vessel size on outcomes of stenting with biolimus-eluting
degradable polymer stent (BES) and sirolimus-eluting permanent polymer stent (SES) within a ran-
domized multicenter trial (LEADERS).
Background Stenting of small vessels might be associated with higher rates of adverse events.
Methods “All-comer” patients (n  1,707) were randomized to BES and SES. Post-hoc–stratified
analysis of angiographic and clinical outcomes at 9 months and 1 year, respectively, was performed
for vessels with reference diameter 2.75 mm versus 2.75 mm.
Results Of 1,707 patients, 429 patients in the BES group with 576 lesions and 434 patients in the SES
group with 557 lesions had only small vessels treated (50.6% of the patient cohort). In patients with
small vessels there was no significant difference in overall major adverse cardiac events (MACE) rate
(12.1% vs. 11.8%; p  0.89) or target lesion revascularization (TLR) rate (9.6% vs. 7.4%; p  0.26) be-
tween BES and SES. The MACE and TLR rates in the small-vessel patient population were higher than in
the large-vessel population. The TLR rate was 9.6% versus 2.6%, and MACE rate was 12.1% versus 7.1%
for small versus large vessels in the BES arm (TLR: hazard ratio [HR]  3.724, p  0.0013; MACE: HR 
1.720, p  0.0412). In the SES arm, TLR was 7.4% versus 5.1%, and MACE was 11.8% versus 10.3% in
small versus large vessels (TLR: HR  1.435, p  0.2594; MACE: HR  1.149, p  0.5546).
Conclusions Prevalence of small vessel disease is high in an “all-comer” population with higher TLR
and MACE rates. The BES and SES seem equivalent in treatment outcomes of small vessels in this
“all-comer” patient population. (J Am Coll Cardiol Intv 2009;2:861–70) © 2009 by the American
College of Cardiology Foundation
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The recently published “all-comers” European LEADERS
(Biolimus-eluting stent with biodegradable polymer versus
sirolimus-eluting stent with durable polymer for coronary
revascularization) trial showed that the biolimus-eluting
biodegradable polymer stent (BES) represents a safe and
noninferior alternative to sirolimus-eluting durable polymer
stent (SES) in the treatment of coronary artery disease (1).
Biolimus is a highly lipophilic sirolimus analogue (2). It
inhibits the mammalian target of rapamycin and cell-cycle
transition in smooth muscle cells with similar potency as
sirolimus. It is eluted from a polylactic acid biodegradable
polymer solely applied on the abluminal surface. Unlike
paclitaxel-eluting stents (PES), BES has similar potency as
SES in the suppression of neoinitmal hyperplasia and
therefore late luminal loss (0.13 vs. 0.19 mm; p  0.34 at 9
months). The amount of late luminal loss is usually inde-
pendent of vessel size (3–8), and therefore a greater degree
of restenosis is observed in
smaller vessels owing to a re-
duced ability to accommodate
neointimal growth without caus-
ing hemodynamically significant
flow compromise (9,10). In the
RAVEL (Randomized Study
With the Sirolimus-Eluting Bx
Velocity Balloon-Expandable
Stent) study it was first demon-
strated that SES perform well in
small vessels with low restenosis
rates (11). At 6-month follow-
up, the restenosis rate in the
SES group was 0% versus 20%
to 35% in the different vessel-
size strata of the bare-metal
stents group. We hypothesized
that, given the non-inferior rate
of late loss in the BES arm of
the LEADERS trial, BES will perform equivalently in
small vessels to SES, unlike PES.
Methods
Device description. The BES, as used in this study and
already described in the preceding text, elutes a highly
lipophilic sirolimus analogue (2) (Fig. 1), which inhibits the
mammalian target of rapamycin and cell-cycle transition in
smooth muscle cells with similar potency as sirolimus. It is
eluted from a polylactic acid biodegradable polymer applied
to the abluminal surface (Fig. 1). This fully biodegradable
polymer polylactic acid is metabolized to water and carbon
dioxide and promises to cause less long-term inflammatory
reaction. Full resorption occurs within 6 months. In the
LEADERS trial the BES was found noninferior to the SES
in terms of major adverse cardiac events (MACE) at 9
months as well as in-stent percent diameter stenosis (p 
NS) (1).
Study population. The LEADERS trial was a multicenter
European non-inferiority trial comparing the safety and
efficacy of BES with SES in 1,707 “all-comers” patients.
Patients over the age of 18 with chronic stable coronary
artery disease or acute coronary syndromes including ST-
segment elevation myocardial infarction (MI) were eligible
if they had at least 1 lesion with 50% diameter stenosis
and reference vessel diameter 2.25 to 3.5 mm. The aim was
for the patient population to reflect real world clinical
practice, and thus no limits were set on the number or
complexity of the lesions stented. The only exclusion criteria
were: known allergy to acetylsalicylic acid, clopidogrel,
heparin, stainless steel, sirolimus, biolimus, or contrast material
that cannot be pre-medicated; planned surgery within 6
months of percutaneous coronary intervention unless the dual
anti-platelet therapy could be maintained throughout the
perisurgical period; pregnancy or participation in another trial
before reaching the primary end point; and lastly, inability to
give informed consent. The study complied with the Declara-
tion of Helsinki and was approved by all institutional ethics
committees. All patients provided written informed consent
for participation in the trial.
Randomization and procedures. Randomization was done
centrally after diagnostic cardiac catheterization and before
percutaneous coronary intervention (PCI) by use of a
telephone allocation service (Limburgia telefonische Ant-
woord Service, Rotterdam, the Netherlands). The allocation
sequence was computer-generated, stratified according to
center, and blocked with block sizes of 8 and 16, which
varied randomly. We randomly allocated patients on a 1:1
basis to treatment with a BES (Biomatrix Flex, Biosensors,
Inc., Newport Beach, California) or an SES (Cypher Select,
Cordis, Miami Lakes, Florida) and to active angiographic
follow-up at 9 months or clinical follow-up only on a 1:3
basis with a factorial design.
The BES were available in diameters of 2.25, 2.5, 3.0,
and 3.5 mm and in lengths of 8, 11, 14, 18, 24, and 28 mm.
The SES were available in diameters of 2.25, 2.5, 2.75, 3.0,
and 3.5 mm and in lengths of 8, 13, 18, 23, 28, and 33 mm.
We performed balloon angioplasty and stent implantation
according to standard technique, and direct stenting was
allowed. No mixture of drug-eluting stents was permitted
within a given patient, unless the operator was unable to
insert the study stent, in which case crossover to another
device of the operator’s choice was possible. Before or at the
time of the procedure, patients were given at least 75 mg of
acetylsalicylic acid, 300 to 600 mg loading dose of clopi-
dogrel, and unfractionated heparin at a dose at least 70
IU/kg. After the procedure, all patients were advised to take
aspirin indefinitely and clopidogrel for at least 12 months.
In case of intercurrent revascularization procedures requir-
ing stent implantation, treating cardiologists were encour-
Abbreviations and
Acronyms
BES  biolimus-eluting
stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
SES  sirolimus eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularization
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aged to use the study stent. For other details we refer to the
primary end point article (1).
Study end points. Adverse events were assessed in the
hospital and at 1, 6, 9, and 12 months. An independent
clinical events committee unaware of the patient’s treatment
assignments adjudicated all end points. One in four patients
was asked to return for angiographic follow-up at 9 months.
Definitions of all end points are provided elsewhere (1).
Briefly, the pre-specified primary end point was the com-
posite of cardiac death, MI, and clinically indicated target
vessel revascularization (TVR) within 9 months. Secondary
end points were any target lesion revascularization (TLR)
(both clinically and nonclinically indicated), which was
defined as repeat revascularization due to a stenosis within
the stent or within a 5-mm border proximal or distal to the
stent; any TVR, cardiac death, death from any cause, MI,
stent thrombosis (defined according to the Academic Re-
search Consortium) (12); device success (defined as achieve-
ment of a final residual diameter stenosis of 50% during
the initial procedure); and lesion success (achievement of
50% stenosis with any approach for PCI).
The pre-specified principal outcome of the angiographic
substudy was in-stent percent diameter stenosis. Secondary
angiographic outcomes were in-segment percent diameter
stenosis, minimal lumen diameter (MLD), late lumen loss,
and binary restenosis. We obtained angiographic measure-
ments within the stented segment (in-stent) and over the
entire segment consisting of the stent and 5-mm proximal
and distal margins (in-segment). We defined percent diam-
eter stenosis as: ([reference vessel diameter 
 MLD]/
reference vessel diameter)  100%; late lumen loss as the
difference between MLD after the procedure and MLD at
follow-up; and binary restenosis as percentage diameter
stenosis of 50% or greater in the target lesion.
Independent study monitors (D-Target, Montagny-pres-
Yverdon, Switzerland) verified all case reports from data
on-site. Data were stored in a database (KIKA Medical,
Paris, France), which was maintained by a contract research
organization (Cardialysis, Rotterdam, the Netherlands) in
collaboration with an academic clinical trials unit (CTU
Bern, Bern University Hospital, Bern, Switzerland). Clini-
cal follow-up was done at 1, 6, 9, and 12 months. The
operators were by necessity aware of the assigned study stent
during PCI and angiographic follow-up, but patients and
staff involved in follow-up assessment were blinded to the
allocated stent type. Angiographies were centrally assessed
at 1 angiographic core laboratory (Cardialysis) with asses-
sors unaware of the allocated stent.
Statistical analysis. A stratified post-hoc analysis of clinical
and angiographic outcomes, which was specified after com-
pletion of patient recruitment, was performed according to
vessel size. Methodology similar to the previously published
SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting
Stents for Coronary Revascularization) trial was used (9).
Quantitative coronary angiography served to determine the
reference vessel diameter (RVD). Patients who underwent
stent implantation in lesions with an RVD 2.75 mm were
categorized as having undergone treatment of small vessels.
Conversely, patients who underwent stent implantation in
lesions with RVD 2.75 mm were classified as having had
treatment of large vessels. Patients with stent implantations
in both small and large vessels were classified as “mixed”. All
Figure 1. Structure of Biolimus and Scanning Electron Micrograph of the Biolimus Biodegradable Polymer Stent
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randomized patients were included in the analysis of pri-
mary and secondary clinical end points in the groups that
they were originally assigned to (intention-to-treat analysis).
Analyses of the angiographic substudy were restricted to
lesions from patients who attended follow-up angiography.
Angiographic outcomes were analyzed with SAS version 8
Proc Mixed (SAS Institute, Cary, North Carolina) for
continuous and Proc Genmod for binominal outcomes,
taking into account the within-patient correlation structure
of these data. We used a Cox proportional hazards model to
compare clinical outcomes between the groups. All analyses
were performed with SAS version 8.02 by a dedicated
statistician. All p values and confidence intervals were
2-sided.
Results
Baseline clinical, angiographic, and procedural data. A total
of 1,707 patients with 2,467 lesions were randomly assigned
to treatment with either BES (857 patients, 1,254 lesions)
or SES (850 patients, 1,213 lesions). Four hundred twenty-
nine patients in the BES group with 576 lesions and 434
patients in the SES group with 557 lesions had only small
vessels treated (863 of 1,707 [50.6%] of the entire patient
population); 267 patients in the BES arm with 309
lesions and 272 patients in the SES arm with 311 lesions
had only large vessels treated (RVD 2.75); and 154
patients in the BES group with 362 lesions and 133
patients with 334 lesions in the SES group had “mixed”
disease (Fig. 2).
Baseline clinical and angiographic characteristics are
summarized in Tables 1 and 2. There were no significant
differences in the numbers of patients with diabetes, hyper-
tension, hypercholesterolemia, smoking history, prior his-
tory of MI, stroke, or peripheral vascular disease between
the SES and BES groups. These patient characteristics
differed, however, when compared for vessel size. There was
a higher proportion of women with small vessels (29% vs.
25% overall; p 0.001), whereas no significant difference in
the numbers of diabetic patients across vessel sizes was
found. Smokers were more frequently found in the large
vessel group (p  0.001), whereas patients with small vessel
disease had a higher frequency of previous MIs (p  0.007)
and past history of PCI (p  0.001). A high proportion of
patients in the entire cohort had presented with acute
coronary syndromes (between 51% and 61%) and 13% to
21% of the cases were ST-segment elevation MIs. Lastly,
patients with mixed vessel disease had a higher proportion
of multivessel disease (p  0.001).
Mean reference vessel diameters in the BES and SES
group were 2.21  0.34 mm and 2.24  0.33 mm for small
vessels, respectively, 3.21  0.47 mm and 3.18  0.37 mm
for large vessels, and 2.69  0.57 mm and 2.66  0.59 mm
for mixed lesions (Table 1). The lesion length did not differ
between the 2 treatment groups but differed slightly over the
range of 12 to 16 mm between vessel sizes. Percent diameter
stenosis was 63  18% in small vessels in both treatment
arms, 66  18% in large vessels treated with BES, 69 
18% in large vessels treated with SES, 62  18% in the
mixed vessels treated with BES, and 61 18% in the mixed
vessels treated with SES. The MLD amounted to 0.80 and
0.84 mm in small vessels treated with BES and SES and
1.01 and 1.07 mm in large vessels treated with BES and
SES, respectively.
Procedural results are shown in Table 2. Post-stenting
MLD in small vessels treated with BES and SES was 2.09 
0.35 mm and 2.13 0.35 mm, respectively (pNS); it was
2.76  0.41 mm and 2.67  0.38 mm in large vessels
treated with BES and SES, respectively. There were no
significant differences in acute gain after stenting with BES
or SES, the acute gain being 1.29  0.45 mm for small
vessels, 1.74  0.62 mm for large vessels treated with BES,
and 1.59  0.59 mm for large vessels treated with SES.
This translated also in equivalent diameter stenosis after
PCI in both stent groups.
Angiographic results. Angiographic follow-up at 9 months
were obtained in 168 patient in the BES group and 167
patients in the SES group (Table 2). One hundred nine
small vessel lesions, 62 large vessel lesions, and 82 mixed
vessel lesions were evaluated angiographically at 9 months in
the group treated with BES. One hundred fourteen small
vessel lesions, 58 large vessel lesions, and 59 mixed lesions
were evaluated angiographically in the SES group. In small,
large, and mixed vessels there was no significant difference
Figure 2. Study Flow Chart
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in late luminal loss, MLD, percent diameter stenosis, or
binary restenosis between BES and SES groups. In small
vessels late loss was 0.17  0.47 mm in the BES group and
0.22  0.51 mm in the SES group (p  NS). Correspond-
ing percent diameter stenosis was 24.9 20.7% and 23.8
21.3% in the BES and SES stent groups, respectively. In the
large lesion population, in-stent late luminal loss was 0.14
0.51 in the BES arm and 0.05  0.37 in the SES group
(p  NS). The percent diameter stenosis in the large vessel
group was 18.2  14.6% in the BES group and 19.2 
14.5% in the SES group (p  NS). Late loss, percent
diameter stenosis, and binary in-stent restenosis were lower
in the “mixed” lesion group treated with BES compared
with SES.
Clinical outcomes. Clinical events at 1-year follow-up strat-
ified by vessel size are listed in Table 3 and summarized in
Figures 3 and 4. Vessel size seemed to influence the TLR
rates in both SES and BES groups. Within the BES
treatment arm TLR rate was 9.6% in the small vessel group
(41 events) versus 2.6% in the large vessel group (7 events).
Within the SES treatment arm TLR rate was 7.4% in the
small vessel group (32 events) versus 5.1% in the large vessel
group (14 events). There were no differences in the overall
rate of MACE or TLR/TVR in patients with small vessels
and large vessels treated with BES versus SES stents. There
was no significant difference in overall MACE rate between
BES- and SES-treated patients with “mixed” vessel disease,
although rates of overall percutaneous TLR (7 [4.5%]
patients vs. 15 [11.3%] patients; p  0.037) were lower.
Tests for interaction between treatment and vessel size
reached statistical significance for TLR and TVR rates in
the mixed disease group.
There were 13 definite stent thrombosis events in small
vessels in the BES arm (3.0%) and 9 definite stent throm-
bosis events in the SES arm (2.1%) (p  0.38).
Discussion
We present here a novel stent technology now commercially
available in Europe that combines the biodegradable poly-
mer technology with solely abluminal elution of biolimus
and performs well in complex lesions such as small vessels in
an “all-comer” patient population. The main finding of this
substudy of the LEADERS multicenter randomized trial
focusing on the effect of vessel size on angiographic and
clinical outcomes is that BES seems noninferior to the
Table 1. Baseline Clinical and Angiographic Characteristics for Small, Large, and “Mixed” Vessel Groups
BES, Small SES, Small BES, Large SES, Large BES, Mixed SES, Mixed p Value*
Patient demographic data
Number of patients 429 434 267 272 154 133 †
Age 65 yrs 225 (52) 209 (48) 125 (47) 134 (49) 78 (51) 73 (55) 0.44
Male 295 (69) 314 (72) 217 (81) 207 (76) 125 (81) 105 (79) 0.001
Diabetes 104 (24) 105 (24) 63 (24) 56 (21) 51 (33) 29 (22) 0.18
Hypertension 315 (73) 319 (74) 193 (72) 205 (75) 117 (76) 88 (66) 0.74
Hyperlipidemia 291 (68) 299 (69) 170 (64) 177 (65) 95 (62) 101 (76) 0.27
Current smoking 85 (20) 96 (22) 76 (29) 82 (30) 41 (27) 33 (25) 0.002
Previous MI 151 (35) 146 (34) 64 (24) 84 (31) 59 (38) 46 (35) 0.007
Previous PCI 184 (43) 180 (42) 77 (29) 88 (32) 48 (31) 44 (33) 0.001
Previous stroke 24 (6) 16 (4) 7 (3) 6 (2) 9 (6) 6 (4.5) 0.06
Previous PVD 39 (9) 35 (8) 13 (5) 19 (7) 18 (12) 9 (7) 0.12
Multivessel disease 83 (19) 58 (13) 22 (8) 22 (8) 103 (67) 96 (72) 0.001
Clinical presentation
Stable angina 160 (37) 156 (36) 79 (30) 78 (29) 55 (36) 53 (40) 0.03
Acute coronary syndromes 224 (52) 233 (54) 156 (58) 166 (61) 87 (56.5) 68 (51) 0.042
Unstable angina 99 (23) 92 (21) 58 (22) 61 (22) 33 (21) 27 (20)
STEMI 54 (13) 61 (14) 56 (21) 56 (21) 22 (14) 18 (13.5)
Non-STEMI 71 (17) 80 (18) 42 (16) 49 (18) 32 (21) 23 (17)
Angiographic parameters
Number of lesions 576 557 309 311 363 334 ‡
Lesion length 15  13 14  11 17  11 16  12 14  10 13  9 0.001
Reference vessel diameter 2.21  0.34 2.24  0.33 3.21  0.47 3.18  0.37 2.69  0.57 2.66  0.59 0.001
MLD 0.80  0.40 0.84  0.43 1.01  0.63 1.08  0.58 1.02  0.48 1.05  0.53 0.001
% diameter stenosis 63  18 63  18 69  18 66  18 62  17 61  17 0.001
Values are n, n (%), and mean SD. *The p value is given for the difference among the 3 groups (small, large, and mixed) rather than biolimus-eluting degradable polymer stent (BES) versus sirolimus-eluting
permanent polymer stent (SES). †Tested: equal distribution in the 3 groups. ‡Tested: equal mean in the 3 groups.
MImyocardial infarction; MLDminimal lumen diameter; PCI percutaneous coronary intervention; PVD peripheral vascular disease; STEMI ST-segment elevation myocardial infarction.
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“gold standard” SES in small vessels. To our knowledge this
is the first report of another drug-eluting stent being
noninferior to SES in the setting of small vessel disease.
Angiographic outcomes at 9-month follow-up in a subset of
patients show equivalent late luminal loss, percent diameter
stenosis, and binary restenosis rates, which translate into
similar rates of MACE and TLR at 1 year in both stent
treatment groups in small vessel disease. This equivalent
performance is achieved in a complex “all-comer” patient
population that reflects “real world” clinical practice. These
results in small vessel disease are unlike those reported in
trials to date comparing SES and PES, where SES has
shown a consistent advantage over PES in both angio-
graphic and clinical outcomes (13–16).
Another important finding of our study is that the
prevalence of small vessel lesions (defined as reference
diameter 2.75 mm) is high (50.6%) in real world clinical
practice, and the overall rate of MACE and TLR in small
vessel lesions across stent types are higher than for large
vessel lesions (Online Figures). This latter finding is at
variance with recent findings of the BASKET (Basel Stent
Cost-Effectiveness Trial) 3-year follow-up, where within
the drug-eluting stent-treated group there seemed to be no
difference in the MACE and TLR rates between small and
large vessels (17). The increased event rate in the large stent
group seemed to be a late rather than early phenomenon,
with the curve diverging after 6 to 9 months, a phenomenon
that might have been missed in the present study with only
1-year clinical follow-up. Conversely, failure to detect ear-
lier higher event rates in the small vessel group in the
BASKET study might have been due to the lower
number of patients (187 patients with small vessels
treated with DES compared with 863 patients in the
present study).
The SES (Cypher Select) uses a poly-n-butyl metha-
crylate durable polymer technology for drug elution that has
been shown to cause inflammation and fibrin deposi-
tion as well as endothelial dysfunction and delayed endo-
thelialization (18). Poly-n-butyl methacrylate is hydro-
phobic and causes monocytes to adhere to its surface and
Table 2. Baseline Angiographic Characteristics, Procedural Outcomes, and Angiographic Follow-Up Results at 9 Months
BES, Small SES, Small BES, Large SES, Large BES, Mixed SES, Mixed
p Value
Interaction
Number at initial procedure
(at 9-month follow-up)
561 (105) 539 (114) 308 (62) 309 (58) 360 (82) 326 (59)
In-stent
Reference vessel diameter
After procedure 2.46 (0.36) 2.48 (0.35) 3.24 (0.42) 3.16 (0.40) 2.79 (0.52) 2.79 (0.52) 0.0192
9-month follow-up 2.55 (0.37) 2.45 (0.39) 3.25 (0.33) 3.21 (0.44) 2.84 (0.49) 2.81 (0.51) 0.7792
MLD
After procedure 2.09 (0.35) 2.13 (0.35) 2.76 (0.41) 2.67 (0.38) 2.36 (0.51) 2.38 (0.50 0.0033
9-month follow-up 1.91 (0.59) 1.87 (0.62) 2.65 (0.53) 2.60 (0.59) 2.08 (0.51) 1.83 (0.62) 0.209
Acute gain 1.29 (0.46) 1.30 (0.45) 1,74 (0.62) 1.60 (0.59) 1.34 (0.55) 1.32 (0.53) 0.0169
Late loss 0.17 (0.47) 0.22 (0.51) 0.14 (0.51) 0.05 (0.37) 0.06 (0.40) 0.25 (0.56) 0.047
% diameter stenosis
After procedure 14.8 (8.4) 14.1 (7.6) 14.6 (7.5) 15.2 (7.0) 15.0 (9.7) 14.7 (9.1) 0.3955
9-month follow-up 24.9 (20.7) 23.8 (21.3) 18.2 (14.6) 19.2 (14.5) 17.8 (13.7) 26.4 (20.0) 0.0236
Binary restenosis rate (%) 10.1 7.9 3.2 3.4 1.2 15.3 0.0144
In-segment
Reference vessel diameter
After procedure 2.37 (0.38) 2.39 (0.38) 3.14 (0.45) 3.06 (0.46) 2.69 (0.55) 2.71 (0.56) 0.0723
9-month follow-up 2.50 (0.38) 2.37 (0.40) 3.16 (0.36) 3.13 (0.46) 2.78 (0.52) 2.76 (0.52) 0.4379
MLD
After procedure 1.78 (0.36) 1.84 (0.37) 2.48 (0.46) 2.44 (0.43) 2.07 (0.52) 2.07 (0.52) 0.0845
9-month follow-up 1.73 (0.55) 1.65 (0.56) 2.42 (0.50) 2.35 (0.56) 2.08 (0.51) 1.83 (0.62) 0.1293
Acute gain 0.99 (0.48) 1.00 (0.47) 1.45 (0.66) 1.36 (0.63) 1.04 (0.56) 1.02 (0.53) 0.2238
Late loss 0.09 (0.44) 0.19 (0.48) 0.10 (0.49) 0.04 (0.33) 0.04 (0.42) 0.19 (0.51) 0.079
% diameter stenosis
After procedure 24.4 (10.1) 23.3 (9.3) 21.0 (8.6) 20.2 (8.8) 22.8 (10.6) 23.3 (10.5) 0.236
9-month follow-up 30.6 (19.2) 30.6 (19.7) 23.3 (14.0) 24.8 (14.7) 25.2 (12.7) 33.3 (18.7) 0.1105
Binary restenosis rate (%) 12.8 9.7 3.2 5.2 1.2 18.6 0.0052
Values are mean (SD), unless otherwise indicated.
Abbreviations as in Table 1.
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produce cytokines such as monocyte chemotactic protein-1,
plasminogen activator inhibitor-1, and tissue factor (19).
Persistence of this pro-inflammatory polymer is hypothe-
sized to be a potential major contributor to late stent
thrombosis events. The BES in the present study uses,
unlike SES, a biodegradable polymer made of polylactic
acid, which completely disintegrates to water and carbon
dioxide within 6 months. Therefore, it holds promise of a
lower rate of late stent thrombosis or need for dual anti-
platelet inhibition in the long term as well as equivalent
performance in terms of efficacy in the short term. The drug
is eluted on the abluminal surface and therefore might be
hypothetically less likely to cause delayed endothelialization,
while still preventing in-stent restenosis.
We noted a higher number of stent thrombosis cases than
in on-label clinical trials, particularly in small vessels in both
BES- and SES-treated groups of patients. Yet, the rate of
stent thrombosis corresponds well to other all-comer trials
such as SYNTAX (Synergy Between PCI With Taxus and
Cardiac Surgery) (20). It might also be explained by a
relatively high percentage of patients with acute coronary
syndromes, including up to 21% with ST-segment elevation
MI, because similar rates of stent thrombosis have been
reported in TRITON–TIMI 38 (A Comparison of CS-747
and Clopidogrel in Acute Coronary Syndrome Subjects who
are to Undergo Percutaneous Coronary Intervention–
Thrombolysis In Myocardial Infarction 38) and HORIZON-
AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trials (21,22). There
seems to be overall similar rates of definite stent thrombosis
in small, large, and “mixed” vessel groups. Longer-term
follow-up will determine whether the biodegradable poly-
mer adds any advantage over a durable polymer in terms of
very late events.
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Figure 3. Kaplan-Meier Curves for Overall MACE Rate at 1 Year
Kaplan-Meier curves for overall major adverse cardiac events (MACE) rate at 1 year. (A) Small vessels; (B) large vessels; (C) mixed vessels; (D) all vessels.
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Lastly, there seems to be an advantage of treatment with
BES in patients with “mixed” lesions and multivessel
disease. This difference in angiographic outcomes (late loss)
and trend to a significant difference in TLR and TVR in
patients with “mixed” disease must be explored further.
Although late loss has been established as a discriminating
factor in stent performance (3–5), it remains uncertain
whether this translates into differences in long-term clinical
outcomes. The interpretation of this result in this complex
group with “mixed” lesions is difficult; nevertheless, given
the prevalence of “mixed” lesion populations in our clinical
practice, it is noteworthy.
Study limitations. The study suffers from the usual limita-
tions of post hoc analyses and, for some subgroup analyses,
might lack sufficient power to detect superiority of 1
treatment over the other. Some of the key differences in
outcomes such as late stent thrombosis in a degradable
versus permanent polymer stent might emerge at long-term
follow-up.
Conclusions
Vessel size has been an important predictor of in-stent
restenosis and clinical events. The SES have been thus far
superior to PES and bare-metal stents in treatment of small
vessels. We demonstrate for the first time the non-
inferiority of BES to SES in angiographic late loss and
percutaneous TLR rates.
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Figure 4. Kaplan-Meier Curves for TLR Rates at 1 Year
Kaplan-Meier curves for target lesion revascularization (TLR) rates at 1 year. (A) Small vessels; (B) large vessels; (C) mixed vessels (p  0.05); (D) all vessels.
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Abstract
Aims: Lesion length remains a predictor of target lesion revascularisation and results of long lesion stenting
remain poor. Sirolimus-eluting stents have been shown to perform better than paclitaxel eluting stents in
long lesions. In this substudy of the LEADERS trial, we compared the performance of biolimus
biodegradable polymer (BES) and sirolimus permanent polymer stents (SES) in long lesions.
Methods and results: A total of 1,707 ‘all-comer’ patients were randomly allocated to treatment with BES and
SES. A stratified analysis of angiographic and clinical outcomes at nine months and one year, respectively was
performed for vessels with lesion length <20 mm versus >20 mm (as measured by quantitative angiography).
Of 1,707 patients, 592 BES patients with 831 lesions and 619 SES patients with 876 lesions had only short
lesions treated. One hundred and fifty-three BES patients with 166 lesions and 151 SES patients with 162
lesions had long lesions. There were no significant differences in baseline clinical characteristics, except for
higher number of patients with long lesions presenting with acute myocardial infarction in both stent
groups. Long lesions tended to have lower MLD and greater percent diameter stenosis at baseline than
short lesions. Late loss was greater for long lesions than short lesions. There was no statistically significant
difference in late loss between BES and SES stents (0.32±0.69 vs 0.24±0.57, p=0.59). Binary in-segment
restenosis was present in 23.2% versus 13.1% of long lesions treated with BES and SES, respectively
(p=0.042). In patients with long lesions, the overall MACE rate was similar for BES and SES (17% vs
14.6%; p=0.62). There was a trend towards higher overall TLR rate with BES (12.4 % vs 6.0%; HR=2.06;
p=0.07) and clinically driven TLR (10.5% vs 5.3%: HR 1.94; p=0.13). Rates of definite stent thrombosis
were 3.3% in the long lesion group and 1.3-1.7 % in the short lesion group.
Conclusions: BES and SES appear similar with respect to MACE in long lesions in this “all-comer” patient
population. However, long lesions tended to have a higher rate of binary in-segment restenosis and TLR following
BES than SES treatment.
KEYWORDS
Biolimus-eluting stent
(BES), sirolimus-
eluting stent (SES),
biodegradable
polymer, target vessel
revascularisation, long
lesions
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Introduction
Drug eluting stents have considerably reduced restenosis and the
need of repeat revascularisation compared to bare metal stents.1,2
The ADVANCE study was the first to demonstrate that stenting in
long lesions (> 40 mm) was associated with higher MACE rates.3
Sirolimus eluting stents (SES) have been shown to yield superior
results to paclitaxel eluting stents in most, but not all studies,1,4,5
particularly in complex lesions and patient populations.6,7 Patients
with long lesions remain at increased risk for impaired long-term
clinical outcome mainly related to repeat revascularisation
procedures. In a study of 500 patients with long lesions, SES
showed superior angiographic outcome in terms of late loss (0.09 vs
0.45 mm; p<0.001), percent diameter stenosis and binary
restenosis (3.3% vs 14.6%; RR=0.23; p<0.001), as well as TLR
rates (2.4% vs 7.2%; p=0.012) but not overall MACE rates.5
Biolimus is a highly lipophilic sirolimus analogue.8 It inhibits the
mammalian target of rapamycin (mTOR) and cell-cycle transition in
smooth muscle cells with similar potency to sirolimus. In the
LEADERS multicentre randomised study of biolimus-eluting
biodegradable polymer stent (BES) versus sirolimus-eluting
permanent polymer stent (SES), we noted that late loss in the overall
patient population was similar for BES than SES (0.13 versus
0.19 mm; p=0.34 at 9 months).9 In the present stratified analysis of
lesion length, we investigated the outcome of patients with short
and long lesions following treatment with BES and SES. We
hypothesised that since late loss and TLR rates were non-inferior for
the BES in the overall population in LEADERS, that this stent will
also perform equivalently to SES in the long lesion subset.
Methods
Study population
LEADERS was a multicentre European non-inferiority trial comparing
safety and efficacy of BES to SES in 1,707 ‘all comer’ patients. Patients
over the age of 18 with chronic stable coronary artery disease or acute
coronary syndromes including ST-elevation myocardial infarction were
eligible if they had at least one lesion with > 50% diameter stenosis
and reference vessel diameter 2.25 to 3.5 mm. The aim was for the
patient population to reflect real clinical practice, and thus no limits
were set on the number or complexity of the lesions stented. The only
exclusion criteria were: known allergy to acetylsalicylic acid,
clopidogrel, heparin, stainless steel, sirolimus, biolimus or contrast
material that cannot be pre-medicated, planned surgery within six
months of percutaneous coronary intervention – unless the dual anti-
platelet therapy could be maintained throughout the peri-surgical
period, pregnancy or participation in another trial before reaching the
primary end-point and lastly, inability to give informed consent. The
study complied with the Declaration of Helsinki and was approved by
all institutional ethics committees. All patients provided written,
informed consent for participation in the trial.
Randomisation and procedures
Randomisation was done centrally after diagnostic cardiac
catheterisation and before PCI by use of a telephone allocation
service (Limburgia Telefonische Antwoord Service BV, 3068 NP
Rotterdam, The Netherlands). The allocation sequence was
computer generated, stratified according to centre, and blocked
with block sizes of eight and 16 which varied randomly.
Randomisation was performed on a 1:1 basis to treatment with a
stent eluting biolimus-A9 with a biodegradable polylactic acid
polymer (Biomatrix Flex, Biosensors Inc., Newport Beach, CA,
USA) (Figures 1a, b and c) or a sirolimus-eluting stent with a
durable polymer (Cypher SELECT, Cordis, Miami Lakes, FL, USA)
Figure 1. A9™ Eluting Stent: Structure of biolimus and scanning
electron micrograph of the biolimus biodegradable polymer stent.
1a. Biolimus is a semi-synthetic sirolimus with 10x higher lipophilicity
and similar potency as sirolimus. 1b. Biolimus is immersed at a
concentration of 15.6 μg/mm into a biodegradable polymer, polylactic
acid and applied solely to the abluminal stent surface by a fully
automated process. Polylactic acid is co-released with biolimus and
completely dissolves into carbon dioxide and water during a 6-
9 months period. 1c. The stainless steel stent platform has a strut
thickness of 112 μm with a quadrature link design.
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and to active angiographic follow-up at nine months, or clinical
follow-up only on a 1:3 basis with a factorial design.
BES were available in diameters of 2.25, 2.5, 3.0 and 3.5 mm and in
lengths of 8, 11, 14, 18, 24 and 28 mm. SES were available in
diameters of 2.25, 2.5, 2.75, 3.0 and 3.5 mm and in lengths of 8,
13, 18, 23, 28 and 33 mm. Balloon angioplasty and stent
implantation was performed according to standard technique and
direct stenting was allowed. No mixture of drug eluting stents was
allowed within a given patient, unless the operator was unable to
insert the study stent, in which case crossover to another device of
the operator's choice was permitted. The length of the stent was left
at the discretion of the operators who followed good clinical practice
guidelines which include using one stent to cover the lesion when
possible. Before, or at the time of the procedure, patients were given
at least 75 mg of acetylsalicylic acid, 300-600 mg loading dose of
clopidogrel and unfractionated heparin in a dose at least 5,000 IU or
70-100 IU/kg. After the procedure, all patients were advised to take
aspirin indefinitely and clopidogrel for at least 12 months. In case of
inter-current revascularisation procedures needing stent
implantation, treating cardiologists were encouraged to use the study
stent. For other details please see the main manuscript.9
Study endpoints
Adverse events were assessed in the hospital and at nine and
12 months. An independent clinical events committee unaware of
the patient's treatment assignments adjudicated all endpoints. One
in four patients was asked to return for angiographic follow-up at
nine months. Definitions of all endpoints are explained in the main
manuscript.9 Briefly, the pre-specified primary endpoint was the
composite of cardiac death, myocardial infarction and clinically-
indicated target vessel revascularisation (TVR) within nine and
12 months. Secondary endpoints were: any target lesion
revascularisation (TLR) – both clinically and non-clinically indicated –
which we defined as repeat revascularisation due to a stenosis within
the stent or within a 5 mm border proximal or distal to the stent; any
TVR, cardiac death, death from any cause, myocardial infarction,
stent thrombosis (defined according to the ARC)10, device success
(defined as achievement of a final residual diameter stenosis of less
than 50% during the initial procedure), and lesion success
(achievement of less than 50% stenosis with any approach for PCI).
The pre-specified principal outcome for angiographic substudy was
in-stent percentage diameter stenosis. Secondary angiographic
outcomes were: in-segment percentage diameter stenosis, minimal
lumen diameter, late lumen loss and binary restenosis. We obtained
angiographic measurements within the stented segment (in-stent)
and over the entire segment consisting of the stent and 5 mm
proximal and distal margins (in-segment). We defined percentage
diameter stenosis as ([reference vessel diameter-minimal luminal
diameter]/reference vessel diameter) X 100%; late lumen loss as
the difference between minimal lumen diameter after the procedure
and minimal lumen diameter at follow-up; and binary restenosis as
percentage diameter stenosis of 50% or greater in the target lesion.
Independent study monitors (D-Target, Montagny-pres-Yverdon,
Switzerland) verified all case reports from data on-site. Data were
stored in a database (KIKA Medical, Paris, France), which was
maintained by a contract research organisation (Cardialysis,
Rotterdam, The Netherlands) in collaboration with an academic
clinical trials unit (CTU Bern, Bern University Hospital, Bern,
Switzerland). Clinical follow up was done at 1, 6, 9 and 12 months.
The operators were, by necessity, aware of the assigned study stent
during PCI and angiographic follow-up, but patients and staff
involved in follow-up assessment were blinded to the allocated stent
type. Angiographies were centrally assessed at one angiographic
core laboratory (Cardialysis, Rotterdam, The Netherlands) with
assessors unaware of the allocated stent.
Statistical analysis
A stratified analysis of clinical and angiographic outcomes, which
was specified after completion of patient recruitment, was
performed according to lesion length. Methodology similar to the
previously published SIRTAX trial was used.11 Patients, who
underwent stent implantation in lesions with an lesion length
≤20 mm (as measured by quantitative angiography at index
procedure), were categorised as having undergone treatment of
short lesion. Conversely, patients who underwent stent
implantation in lesions with length >20 mm were classified as
having had treatment of long lesion. Patients with stent
implantations in both short and long lesions were classified as
mixed. All randomised patients were included in the analysis of
primary and secondary clinical endpoints in the groups that they
were originally assigned (intention-to-treat analysis). Analyses of
the angiographic substudy were restricted to lesions from patients
who attended follow-up angiography. Angiographic outcomes were
analysed using SAS v8 Proc Mixed for continuous, and Proc
Genmod for binominal outcomes, taking into account the within-
patient correlation structure of these data. We used a Cox
proportional hazards model to compare clinical outcomes between
the groups. All analyses were performed using SAS 8.02 by
a dedicated statistician. All p-values and CIs were two-sided.
Results
Baseline clinical, angiographic, and procedural data
Of 1,707 patients, 592 patients in the BES group with 832 lesions
and 619 patients in the SES group with 876 lesions had only short
lesions treated. One hundred and fifty-three patients in the BES
group with 166 lesions and 151 patients with 162 lesions in the SES
group had long lesions. (Figure 2) 105 patients with 250 lesions in
the biolimus group and 69 patients with 164 lesions in the sirolimus
group had both short and long lesions.
Baseline clinical and angiographic characteristics are summarised
in Table 1. More patients with long lesions tended to present with
ST-elevation MI (26-29% vs 12%) in both stent groups. Patients
with long lesions treated with BES tended to have less hypertension
(67% vs 77% for short lesions, p=0.027). Patients with long lesions
treated with either stent had a greater number of current smokers
(29%-31% vs 22%-24%; p=0.011). Patients with short lesions
tended to have been previously treated with percutaneous
revascularisation more often, had more strokes and more
multivessel disease.
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maximum lesion length of 101.47 mm, 90% of the long lesions
were 20-50 mm. Reference vessel diameters did not differ
significantly between lesion or stent types. Long lesions tended to
have much lower MLD (0.48-0.58 mm vs 1.01-1.05 mm) than
short lesions and correspondingly greater percent diameter stenosis
(78-82% vs 59-61%; p<0.001). The lower MLD in the long lesion
group was significantly correlated with acute myocardial infarction
at presentation (data not shown).
Procedural characteristics and results
Procedural results are shown in Table 2. Average numbers of stents
per lesion were 1.14-1.15 in the short lesions and 1.99-2.0 in the
long lesions. Mean stent diameters per lesion were similar between
lesion types and groups. Total stent length per lesion was 20±9 mm
in the short lesions and 43±22 mm in the long lesions.
Percent diameter stenosis was 14.1±8.9% and 13.9±7.9% in the
short lesions treated with BES and SES, respectively, 17.2±7.4% in
the long lesions treated with BES and 17.3±7.8% in the long lesions
treated with SES. The differences were not statistically significant.
Long lesions had significantly greater absolute gain as the lesions
treated had lower initial MLDs (p=0.05). This effect was consistent
across stent groups.
Angiographic results
Angiographic follow-up at nine months was obtained in 313 short
lesions and 69 long lesions. There was no statistically significant
Mean lesion length for short lesions was 10.5±4.4 mm in the BES
group and 10.2±4.4 mm in the SES group. Long lesions measured
on average 32.6±14.8 mm in the BES group and 32.2±12.5 mm in
the SES group. (Table 1) The distribution for long lesions was
skewed to the right with minimum lesion length of 20.03 mm and
Figure 2. Flow chart.
N=2467 lesions for 1707 patients
Treatment Cypher Select Treatment Biomatrix III
1213 Lesions for 850 patients
Lesions 1213
Short (≤20 mm) 961 lesions
Long (>20 mm) 236 lesions
Unknown 16 lesions
Patient groups 850
Short lesions only 619
Long lesions only 151
Mixed 69
No info available 11
Lesions 1213, per patient group:
Short lesions only 876
Long lesions only 162
Mixed 164
No info available 11
1254 Lesions for 857 patients
Lesions 1254
Short (≤20 mm) 970 lesions
Long (>20 mm) 276 lesions
Unknown 8 lesions
Patient groups 857
Short lesions only 592
Long lesions only 153
Mixed 105
No info available 7
Lesions 1254, per patients group:
Short lesions only 831
Long lesions only 166
Mixed 250
No info available 7
Table 1. Baseline clinical and angiographic characteristics for short and long lesions.
Biolimus, Sirolimus, Biolimus, Sirolimus, p-value p-value short, p-value long, 
short short long long short vs. Biolimus vs. Biolimus vs. 
mean (SD) mean (SD) mean (SD) mean (SD) long Sirolimus Sirolimus
Patient demographics
Number of patients 592 619 153 151
Age>65 305(51) 315(51) 71(46) 72(48) 0.19 0.83 0.82
Male 433(73) 458(74) 122(80) 115(76) 0.12 0.74 0.45
Diabetes 156(26) 140(23) 38(25) 36(24) 0.97 0.13 0.84
Hypertension 454(77) 458(74) 102(67) 108(71) 0.027 0.28 0.36
Hyperlipidaemia 395(67) 427(69) 89(58) 104(69) 0.15 0.4 0.053
Current smoking 131(22) 147(24) 47(31) 44(29) 0.011 0.5 0.76
Previous MI 185(31) 210(34) 47(31) 44(29) 0.37 0.32 0.76
Previous PCI 231(39) 257(41) 49(32) 41(27) <0.001 0.38 0.35
Previous stroke 26(4.4) 17(2.7) 9(5.9) 10(6.6) 0.034 0.12 0.82
Previous PVD 44(7.4) 49(7.9) 13(8.5) 10(6.6) 0.95 0.75 0.54
Multivessel disease 123(21) 119(19) 9(6) 8(5) <0.001 0.5 1
Clinical presentation
Stable angina 200(34) 218(35) 55(36) 45(30) 0.59 0.6 0.25
Acute coronary syndromes 327(55) 332(54) 85(56) 94(62) 0.16 0.58 0.24
Unstable angina 142(24) 151(24) 28(18) 19(13) 0.001 0.87 0.17
STEMI 76(13) 77(12) 40(26) 43(29) <0.001 0.83 0.65
Non-STEMI 109(18) 104(17) 17(11) 32(21) 0.54 0.46 0.017
Angiographic parameters
Number of lesions treated 831 876 166 162
Lesion length 10.5±4.4 10.2±4.4 32.6±14.8* 32.2±12.5* <0.001 0.41 0.98
Reference vessel diameter 2.62±0.61 2.61±0.57 2.60±0.57 2.64±0.60 0.83 0.75 0.44
Minimal luminal diameter 1.01±0.44 1.05±0.46 0.48±0.51 0.58±0.57 <0.001 0.08 0.25
%diameter stenosis 61±15 59±15 82±19 78±20 <0.001 0.1 0.21
* lesion length distribution was skewed to the right and in both stent groups the minimum lesion length was 20.03 and maximum 101.47 mm with 90% of lesions falling between 20 and
50 mm
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difference in late loss, minimal luminal diameter, percent diameter
stenosis or binary restenosis in small or large vessels between BES
and SES groups, although this could have been due to the relatively
low number of lesions, particularly in the long lesion subgroup
(Table 2). Late loss increased more with lesion length in the case of
BES stents that in the case of SES stents (Figure 4). Corresponding
MLDs and percent diameter stenoses were not significantly different
(Table 2). Binary in-stent restenosis was present in 3.5% versus
8.2% of short lesions treated with BES and SES respectively, and in
16.7% versus 10.3% of long lesions treated with BES and SES
(p=0.12). A similar pattern was observed for in-segment restenosis
(23.2% vs 13.1% for long lesions; p=0.042). The proportion of
patients and lesions treated with overlapping stents in long lesions
did not differ between BES and SES.
Clinical outcomes
Clinical events at one year follow-up, stratified by lesion length, are
listed in Table 3 and summarised in Figures 3a and 3b as Kaplan
Meier curves. There were no significant differences in the rate of
MACE through stent groups or lesion types. The overall rates of
MACE were: 8.4% versus 10.2% in the short lesions treated with
BES and SES, respectively (p=0.32). In patients with long lesions,
MACE rate was 17% vs 14.6% in the BES and SES groups
(p=0.62).
TVR rates were 6.9% versus 9.9% in the short lesions in favour of
BES (p=0.07), 14.4% versus 7.3% in the long lesions in favour of
SES (HR=1.98; p=0.07). TLR rates shown in Kaplan Meier curves
demonstrated similar pattern of SES tending to perform better in
long lesions. In addition, TLR increased proportionally to the stent
length (divided by tertiles). For stent length of less than 12.9 mm,
TLR rate was 4.1%, for stent length 12.9-19.5 mm 5.6% and for
stent length >19.5 mm, TLR was 7.4% (p=0.0334).
The rates of definite stent thrombosis in the long lesion group were
3.3% in the long lesion group versus 1.3-1.7% in the short lesion
group. For the long lesions group total stent thrombosis rates were
0.7% for acute, 3.0% for subacute and 1.3% for late stent
thrombosis (at one year). These rates were comparable for short
lesions in acute and late stent thrombosis rates. The rate of sub-
acute stent thrombosis for short lesions was 0.8% (versus 3.0% for
long lesions).
Discussion
We present here a novel stent technology now commercially
available in Europe, which combines the biodegradable polymer
technology with solely abluminal elution of biolimus. Use of drug
eluting stents has improved outcomes in patients with coronary
artery disease treated with PCI,12 including complex lesions.13,14
However, lesion length has remained a strong predictor of in-stent
Table 2. Procedural outcomes and angiographic follow-up results at nine months for short and long lesions.
Biolimus, Sirolimus, Biolimus, Sirolimus, p-value BES vs. p-value BES vs. 
short short long long SES in the short SES in the long 
lesion groups lesion groups
In-stent
Reference vessel diameter
Post-procedure 2.78(0.54) 2.76(0.49) 2.74(0.51) 2.73(0.53) 0.46 0.8
*9 month follow-up 2.84(0.50) 2.78(0.53) 2.79(0.47) 2.61(0.49) 0.34 0.18
MLD
Post-procedure 2.38(0.50) 2.37(0.46) 2.26(0.45) 2.24(0.43) 0.71 0.74
*9 month follow-up 2.33(0.61) 2.18(0.69) 1.89(0.88) 1.86(0.68) 0.07 0.91
Acute gain 1.37(0.51) 1.33(0.48) 1.80(0.64) 1.66(0.64) 0.1 0.03
Late loss 0.11(0.44) 0.18(0.49) 0.32(0.69) 0.24(0.57) 0.37 0.59
%DS
Post-procedure 14.1(8.9) 13.9(7.9) 17.2(7.4) 17.3(7.8) 0.66 0.88
*9 month follow-up 18.3(15.1) 21.7(18.9) 32.5(28.7) 28.8(21.9) 0.19 0.48
Binary restenosis rate(%) 3.5 8.2 16.7 10.4 0.08 0.12
In-segment
Reference vessel diameter
Post-procedure 2.69(0.54) 2.68(0.52) 2.64(0.56) 2.63(0.58) 0.61 0.9
*9 month follow-up 2.79(0.51) 2.70(0.55) 2.73(0.47) 2.56(0.50) 0.17 0.25
MLD
Post-procedure 2.07(0.52) 2.09(0.50) 2.03(0.49) 1.98(0.48) 0.4 0.38
*9 month follow-up 2.09(0.56) 1.93(0.62) 1.73(0.84) 1.67(0.65) 0.051 0.7
Acute gain 1.05(0.53) 1.04(0.51) 1.56(0.66) 1.40(0.65) 0.73 0.013
Late loss 0.06(0.44) 0.15(0.43) 0.27(0.62) 0.22(0.56) 0.14 0.64
%DS
Post-procedure 22.9(10.3) 21.9(9.8) 23.1(8.6) 24.8(8.7) 0.019 0.12
*9 month follow-up 25.2(14.1) 28.5(18.1) 36.5(28.4) 35.0(20.4) 0.31 0.57
Binary restenosis rate(%) 4.2 10.6 23.2 13.1 0.036 0.042
* 9 months angiographic follow-up was done in 69 patients with long lesions (30 treated with BES and 39 treated with SES)
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restenosis.15,16 Although the pattern of restenosis after drug eluting
stents is more focal rather than diffuse, as with bare metal stents,
and therefore more easily treated, it still remains increased for long
lesions.5,7 Paclitaxel eluting stents have been shown to be inferior to
sirolimus eluting stents with TVR rates of 7.6% versus 3.2%
(p=0.03) in recent studies involving long lesions.5 Our study is the
first to compare the performance of a biolimus biodegradable
polymer stent (BES) with a sirolimus permanent polymer stent
(SES) in long lesions. The population studied was an ‘all comers’
population within the LEADERS trial, with a considerable number of
Figure 4. Late loss versus, A) lesion length and B) stent length for BES versus SES.
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Figure 3a. Kaplan Meier curves for MACE rate at one year follow-up. 3b. Kaplan Meier curves for TLR rates at one year follow-up.
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high risk lesions, average lesion length in the long lesion group of
32 mm and high proportion of ST elevation myocardial infarctions
(28% in the long lesion group). The TVR rate in the long lesions was
14.4% in the BES group and 7.3% in the SES group with a hazard
ratio of 1.98 and a trend towards statistical significance. This is
compared to 6.9% and 9.9% TVR rates in short lesions, in BES and
SES groups respectively. Therefore, SES tended to perform better
than BES in long lesions, although the result did not reach statistical
significance. Interestingly, in patients with multivessel disease and
mixed lesions, the reverse was observed with statistically significant
difference in favour of BES (2.9% versus 14.5%, HR=0.18;
p<0.001; data not shown). This latter effect did not appear to be
explainable by the interaction of stent type with patient diabetic
status. In addition, it paralleled the results (presented elsewhere) of
stenting by reference vessel diameter, where patients with mixed,
small and large diameter reference vessel lesions derived benefit
from stenting with BES.
No differences were observed between BES and SES in the rate of
MACE, or rate of stent thrombosis in the long lesions although the
incidence was rather high in this subgroup.
The angiographic follow-up was limited to one quarter of the patients,
and although corresponding differences in late loss and percent
diameter stenosis were found between BES and SES stented lesions
in the long lesion group, given low patient and lesion numbers the
results did not reach statistical significance. Further validation of the
results will be needed in larger registries of equally complex patients.
Limitations
This substudy is limited by post hoc nature of the analysis, and limited
number of long-lesions with angiographic follow-up. The study may
be under-powered to detect differences in the angiographic
outcomes. Longer term follow-up will be necessary to fully assess the
performance of biolimus stent, especially with respect to stent
thrombosis, since polymer fully degrades at six months.
Conclusions
Biolimus and sirolimus eluting stents appear equivalent with respect
to MACE rate in long lesions in this “all-comer” patient population,
however, biolimus treated long-lesion group appears to have higher
TLR rates. There were no statistically significant differences in the
late loss, percent diameter stenosis or binary restenosis rates for
short of long lesions treated with either stent, although the study
may have been underpowered to detect these differences in
angiographic outcomes.
Acknowledgements
We would like to thank Dr. Pedro Eerdmans, MD, PhD for his
assistance with manuscript preparation and data analysis.
References
1. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C,
Guagliumi G, Sousa E, Stoll HP; REALITY Trial Investigators.  Sirolimus- vs
paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY
trial: a randomized controlled trial. Jama 2006;295(8):895-904.
Table 3. Clinical outcomes of the short and long lesions stratified with stent type.
Biolimus, Sirolimus, Hazard ratio p-value Biolimus, Sirolimus, Hazard ratio p-value 
short short (95% confidence long long (95% confidence 
(n=592) (n=619) interval) (n=153) (n=151) interval)
Death 15 (2.5) 12 (1.9) 1.31 (0.62-2.81) 0.48 7 (4.6) 10 (6.6) 0.67 (0.26-1.77) 0.42
Cardiac death 9 (1.5) 9 (1.5) 1.05 (0.42-2.65) 0.91 5 (3.3) 9 (6.0) 0.53 (0.18-1.59) 0.26
MI 26 (4.4) 23 (3.7) 1.19 (0.68-2.08) 0.55 14 (9.2) 10 (6.6) 1.36 (0.60-3.06) 0.46
All TLR 34 (5.7) 44 (7.1) 0.81 (0.52-1.26) 0.35 19 (12.4) 9 (6.0) 2.06 (0.93-4.56) 0.07
TLR percutaneous 32 (5.4) 41 (6.6) 0.82 (0.52-1.30) 0.4 17 (11.1) 9 (6.0) 1.85 (0.82-4.14) 0.14
TLR surgical 6 (1.0) 7 (1.1) 0.9 (0.30-2.67) 0.85 2 (1.3) 0 (0.0) >100 (0-*) 1
Clinically justified TLR 26 (4.4) 34 (5.5) 0.8 (0.48-1.33) 0.39 16 (10.5) 8 (5.3) 1.94 (0.83-4.52) 0.13
Clinically justified TLR percutaneous 25 (4.2) 32 (5.2) 0.82 (0.49-1.38) 0.46 15 (9.8) 8 (5.3) 1.81 (0.77-4.28) 0.17
Clinically justified TLR surgical 4 (0.7) 4 (0.6) 1.05 (0.26-4.20) 0.95 1 (0.7) 0 (0.0) >100 (0-*) 1
All TVR 41 (6.9) 61 (9.9) 0.7 (0.47-1.03) 0.07 22 (14.4) 11 (7.3) 1.98 (0.96-4.07) 0.07
TVR percutaneous 37 (6.3) 53 (8.6) 0.73 (0.48-1.11) 0.14 19 (12.4) 11 (7.3) 1.7 (0.81-3.56) 0.16
TVR surgical 8 (1.4) 12 (1.9) 0.7 (0.28-1.70) 0.43 3 (2.0) 0 (0.0) >100 (0-*) 1
Clinically justified TVR 29 (4.9) 42 (6.8) 0.72 (0.45-1.15) 0.17 18 (11.8) 9 (6.0) 1.95 (0.88-4.34) 0.1
Clinically justified TVR percutaneous 28 (4.7) 39 (6.3) 0.75 (0.46-1.22) 0.25 16 (10.5) 9 (6.0) 1.72 (0.76-3.90) 0.19
Clinically justified TVR surgical 4 (0.7) 6 (1.0) 0.7 (0.20-2.47) 0.58 2 (1.3) 0 (0.0) >100 (0-*) 1
Stent thrombosis 18 (3.0) 12 (1.9) 1.58 (0.76-3.28) 0.22 7 (4.6) 8 (5.3) 0.84 (0.31-2.33) 0.74
Definite stent thrombosis 10 (1.7) 8 (1.3) 1.31 (0.52-3.32) 0.57 5 (3.3) 5 (3.3) 0.97 (0.28-3.34) 0.96
Possible stent thrombosis 5 (0.8) 5 (0.8) 1.05 (0.31-3.64) 0.93 1 (0.7) 2 (1.3) 0.48 (0.04-5.27) 0.55
Probable stent thrombosis 4 (0.7) 0 (0.0) >100 (0-*) 0.99 1 (0.7) 2 (1.3) 0.48 (0.04-5.31) 0.55
MACE 50 (8.4) 63 (10.2) 0.83 (0.57-1.20) 0.32 26 (17.0) 22 (14.6) 1.15 (0.65-2.04) 0.62
Target vessel failure 58 (9.8) 75 (12.1) 0.8 (0.57-1.13) 0.21 26 (17.0) 21 (13.9) 1.22 (0.69-2.17) 0.5
Values are n(%), otherwise stated; *Upper limit not defined
SYNTAX in RESOLUTE 161
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R;
RAVEL Study Group. A randomized comparison of a sirolimus-eluting
stent with a standard stent for coronary revascularization. N Engl J Med
2002;346(23):1773-80.
3. Serruys PW, Foley DP, Suttorp MJ, Rensing BJ, Suryapranata H,
Materne P, van den Bos A, Benit E, Anzuini A, Rutsch W, Legrand V,
Dawkins K, Cobaugh M, Bressers M, Backx B, Wijns W, Colombo A. A
randomized comparison of the value of additional stenting after optimal
balloon angioplasty for long coronary lesions: final results of the additional
value of NIR stents for treatment of long coronary lesions (ADVANCE)
study. J Am Coll Cardiol 2002;39(3):393-9.
4. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J,
Schühlen H, Schmitt C, Dirschinger J, Schömig A; ISAR-DESIRE Study
Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon
angioplasty for prevention of recurrences in patients with coronary in-stent
restenosis: a randomized controlled trial. Jama 2005;293(2):165-71.
5. Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y, Lee MM,
Koo BK, Oh DJ, Seung KB, Tahk SJ, Yoon J, Park SJ. Comparison of
sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the
treatment of long coronary lesions. Catheter Cardiovasc Interv
2006;67(2):181-7.
6. Jang JS, Hong MK, Lee CW, Park DW, Lee BK, Kim YH, Han KH,
Kim JJ, Park SW, Park SJ. Comparison between sirolimus- and paclitaxel-
eluting stents for the treatment of chronic total occlusions. J Invasive
Cardiol 2006;18(5):205-8.
7. Degertekin M, Arampatzis CA, Lemos PA, Saia F, Hoye A, Daemen J,
Tanabe K, Lee CH, Hofma SJ, Sianos G, McFadden E, van der Giessen W,
Smits PC, de Feyter PJ, van Domburg RT, Serruys PW. Very long
sirolimus-eluting stent implantation for de novo coronary lesions. Am J
Cardiol 2004;93(7):826-9.
8. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary
stent: a next-generation drug-eluting stent for coronary artery disease.
Expert Rev Med Devices 2006;3(6):731-41.
9. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A,
Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di
Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P.
Biolimus-eluting stent with biodegradable polymer versus sirolimus-elut-
ing stent with durable polymer for coronary revascularisation (LEADERS):
a randomised non-inferiority trial. Lancet 2008;372(9644):1163-73.
10. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE.
Stent thrombosis in randomized clinical trials of drug-eluting stents. N
Engl J Med 2007;356(10):1020-9.
11. Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S,
Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lüscher TF,
Garachemani A, Hess OM, Wandel S, Meier B, Jüni P, Windecker S..
Impact of vessel size on outcome after implantation of sirolimus-eluting
and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am
Coll Cardiol 2007;50(12):1123-31.
12. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P,
Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W,
Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-
eluting stents for coronary revascularization. N Engl J Med 2005;
353(7):653-62.
13. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA,
Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G,
Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted uti-
lization of sirolimus-eluting stents compared with conventional bare stent
implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation
2004;109(2):190-5.
14. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K,
Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de
Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Coronary
restenosis after sirolimus-eluting stent implantation: morphological
description and mechanistic analysis from a consecutive series of cases.
Circulation 2003;108(3):257-60.
15. Lee CW, Park DW, Lee BK, Kim YH, Hong MK, Kim JJ, Park SW,
Park SJ. Predictors of restenosis after placement of drug-eluting stents in
one or more coronary arteries. Am J Cardiol 2006;97(4):506-11.
16. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J,
Dirschinger J, Schömig A. Predictive factors of restenosis after coronary
implantation of sirolimus- or paclitaxel-eluting stents. Circulation
2006;113(19):2293-300.
Excerpt from the Reviewers
Since this is a sub-study, the authors should clearly define what presentation of these results add
over and above the results of the main analysis. Slicing and dicing the data has led to some
particularly small group comparisons, particularly when it comes to the angiographic follow-up data.
The study is under-powered, and therefore some of the results could be explained by play of chance.

Cha pter 9
The outcome of bifurcation lesion 
stenting using a biolimus-eluting stent 
with a bio-degradable polymer compared 
to a sirolimus-eluting stent with a 
durable polymer.
Running Title: Outcomes in Bifurcations lesion stenting
Scot Garg1MB ChB, MRCP; Joanna Wykrzykowska1 
MD; Patrick W. Serruys1* MD, PhD; Ton de Vries2 MSc; 
Pawel Buszman3 MD, PhD; Stanislaw Trznadel3 MD; Axel 
Linke4MD, PhD; Karsten Lenk4 MD; Thomas Ischinger5 
MD, PhD; Volker Klauss6 MD, PhD; Franz Eberli7 MD; 
Roberto Corti8 MD; William Wijns9 MD, PhD; Marie-
Claude Morice10 MD; Carlo di Mario11 MD, PhD; Pawel 
Tyczynski11 MD; Robert Jan van Geuns1 MD, PhD; Pedro 
Eerdmans12 MD, PhD; Gerrit-Anne van Es2 PhD; Bernhard 
Meier13 MD; Peter Jüni14,15 MD; Stephan Windecker 
MD,PhD.13,14
1 Department of Interventional Cardiology, Erasmus MC, 
Rotterdam, The Netherlands
2Cardialysis B.V, Rotterdam, The Netherlands
3 Medical University of Silesia, Katowice, Poland
4 Herzzentrum Leipzig, Leipzig, Germany
5Department of Cardiology, Hospital Bogenhausen, 
Munich, Germany
6Department of Cardiology, University Hospital Munich 
(Innenstadt), Munich, Germany
7Currently working at department of Cardiology, Triemli 
Spital, Zurich, Switzerland
8Department of Cardiology, University Hospital Zurich, 
Zurich, Switzerland
9 Department of Cardiology, Onze Lieve Vrouw 
Ziekenhuis, Aalst, Belgium
10Institut Jacques Cartier Massy, France
11Department of Cardiology, Royal Brompton Hospital, 
London, UK
12Biosensors Europe SA, Morges, Switzerland
13Department of Cardiology, Bern University Hospital, 
Bern, Switzerland
14CTU Bern, Bern University Hospital, Bern, Switzerland
15Institute of Social and Preventive Medicine, University 
of Bern, Bern, Switzerland

Bifurcations in LEADERS 165
FUNDING SOURCE
The LEADERS trial was funded by Biosensors, Europe SA, Switzerland
DISCLOSURES
Windecker is a consultant for and receives fees from ABBOTT Vascular, Boston Scientifi c, Cordis, 
Medtronic and Biosensors. Eberli is a speaker for Biosensors, and consultant for
Cordis. Eerdmans is an employee of Biosensors Europe. The remaining authors declare they 
have no confl icts of interest.
Corresponding Author
1Professor Patrick W. Serruys MD, PhD
Ba583a, Thoraxcentre, Erasmus MC,'s-Gravendijkwal 230
3015 CE Rotterdam, The Netherlands
Tel: +31-10 463 5260 Fax: +31-10 436 9154
p.w.j.c.serruys@erasmusmc.nl
Word count: 5,000
Ch
ap
te
r 9
166
 
Abstract 
 
Aims: This study investigated the differences in clinical outcomes between patients with 
bifurcation lesions (BLs) treated with a biolimus eluting stent (BES) with a biodegradable 
polymer, and a sirolimus eluting stent (SES) with a durable polymer. 
 
Methods & Results: The clinical outcomes were assessed in the 497 patients (BES 258, SES 
239) enrolled in the multicenter, randomised LEADERS trial who underwent treatment of ≥1 
BL (total=534 BLs).  At 12-months follow-up there was no significant difference in the 
primary end-point of MACE, a composite of cardiac death, myocardial infarction and 
clinically indicated target vessel revascularisation (BES 12.8% vs. SES 16.3%, p=0.31). 
Patients treated with BES had comparable rates of cardiac death (BES 2.7% vs. SES 2.9%, 
p=1.00), numerically higher rates of myocardial infarction (BES 8.9% vs. SES 5.4%, p=0.17), 
and significantly lower rates of clinically indicated target vessel revascularisation (4.3% vs. 
11.3%, p=0.004) when compared to those treated with SES. The rate of stent thrombosis at 
12-months was 4.3% and 3.8% for BES and SES respectively (p=0.82).    
 
Conclusions: In the treatment of BLs the use of BES lead to superior efficacy and 
comparable safety compared to SES.   
 
Keywords: Biolimus eluting stent, Sirolimus eluting stent, Bifurcation lesions, Biodegradable 
polymer.   
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Condensed Abstract 
This study reports on the outcomes of 497 patients with bifurcation lesions randomised to 
treatment with either a biolimus eluting stent with a biodegradable polymer (258 patients) or a 
sirolimus eluting stent with a durable polymer (239 patients). At 12-months follow-up the 
primary endpoint, a composite of cardiac death, myocardial infarction, and clinically-
indicated target vessel revascularisation, and the rates of stent thrombosis were all comparable 
between both stents. 
Ch
ap
te
r 9
168
Abbreviations 
 
ACS: Acute coronary syndrome  
BES: Biolimus eluting stent 
BL: Bifurcation lesion 
CABG: Coronary artery bypass graft surgery 
DES: Drug eluting stent 
MACE: Major adverse cardiovascular events 
MB: Main branch 
MI: Myocardial infarction 
MLD: Minimum luminal diameter  
NSTEMI: Non-ST-elevation myocardial infarction 
PCI: Percutaneous coronary intervention 
RVD: Reference vessel diameter  
SB: Side branch 
SES: Sirolimus eluting stent 
ST: Stent thrombosis 
TIMI: Thrombolysis in Myocardial Infarction  
TLR: Target lesion revascularisation 
TVR: Target vessel revascularisation 
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Introduction 
Bifurcation lesions (BL) account for up to one third of coronary lesions and are associated 
with lower procedural success, and poorer clinical outcomes.1 The previously high rates of 
target lesion revascularisation (TLR) and major adverse cardiovascular events (MACE) 
observed after the treatment of BLs with the use of bare metal stents1, 2 have improved 
significantly following the introduction of drug eluting stents (DES),3, 4 however safety 
concerns with respect to stent thrombosis (ST) have emerged.5 One of the potential causes of 
ST is delayed re-endothelialisation which may occur as a consequence of a hypersensitivity 
reaction induced by the presence of a permanent polymer.6, 7 The concerns of ST have been 
greater with first generation DES with durable polymers, and recent studies have 
demonstrated numerically lower rates of ST with newer generation DESs that have polymers 
which are more biocompatible,8, 9 or completely biodegradable.10 
 
The Biomatrix™ Flex biolimus eluting stent (BES) (Biosensors, Morges, Switzerland) elutes 
biolimus from a polylactic acid (PLA) biodegradable polymer applied to the stent’s abluminal 
surface. The polymer is fully metabolized to water and carbon dioxide within 6-9 months, and 
therefore has the potential to cause less long-term inflammatory sequelae. In the randomised 
LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial, BES was 
found to be non-inferior to the Cypher® sirolimus eluting stent (SES) (Cordis, NJ, USA) in 
terms of MACE at 9 months follow-up (9% vs. 11%, p for non-inferiority=0·003, p for 
superiority=0·39).11   
 
The objective of the present study was to investigate whether there were any differences in 
clinical outcomes between patients with BLs treated with a DES with a biodegradable 
polymer (BES) compared to a DES with a durable polymer (SES). 
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Method 
Study population: The methods of the LEADERS trial have been published previously.11 
The study applied an all-comers approach recruiting 1,707 patients with chronic stable 
coronary artery disease or acute coronary syndromes (ACS) including ST-elevation 
myocardial infarction (STEMI), who were eligible for enrolment if they had at ≥1 lesion with 
diameter stenosis (DS) ≥50% and a reference vessel diameter (RVD) 2.25-3.5 mm. The 
principle exclusion criteria are described elsewhere.11 The study complied with the 
Declaration of Helsinki and was approved by all institutional ethics committees. All patients 
provided written, informed consent for participation in the trial. 
 
In this analysis, patients with  ≥1 BL were identified using the electronic clinical record form 
(eCRF), and results from the core laboratory angiographic analysis which identified and 
classified all BLs according to the SYNTAX bifurcation score.12 The angiograms of 497 
patients (258 BES, 239 SES) who had a total of 534 BLs (282 BES, 252 SES) identified using 
either source were reviewed by two investigators (SG and JW), who were blinded to 
outcomes and stent type. During review of the digital angiogram films, the presence of a BL 
was confirmed if a lesion of ≥50% DS on visual estimation was present in a main branch 
(MB) and/or a contiguous side branch (SB) of ≥1.5 mm in diameter. Other information 
pertinent to the BL recorded during angiographic review was the number of guide-wires used; 
stenting technique; use and site (MB, SB or both) of pre- and post-stenting dilatation; pre- and 
post-stenting TIMI flow and total number of stents used. Clinical outcomes were compared 
according to stent type, whilst procedural technique was compared between stents after 
dividing BLs into ‘True’ or ‘Partial’ BLs. Those BLs with a Medina classification13 of 1,1,1; 
1,0,1; 0,1,1 (i.e. those with lesions involving both the MB and SB) were defined as “true” 
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BLs, whilst those with a Medina classification  of 1,0,0; 0,1,0; 1,1,0; 0,0,1 (i.e. those where 
either the MB or SB was involved) were defined as “partial” BLs.  
 
Randomization and Procedures: Patients were randomly allocated on a 1:1 basis to 
treatment with either a BES or SES, and to active angiographic follow-up at 9 months or 
clinical follow-up only on a 1:3 basis with a factorial design.  Percutaneous coronary 
intervention (PCI) was performed according to standard technique, and direct stenting was 
allowed. The choice of bifurcation stenting strategy and use of post stenting dilatation was left 
to the operator’s discretion. No mixture of DES was permitted within a given patient, unless 
the operator was unable to insert the study stent, in which case crossover to another device of 
the operator’s choice was possible. Procedural anticoagulation was achieved with 
unfractionated heparin 5000IU or 70-100IU/kg, whilst the use of glycoprotein IIb/IIIa 
inhibitors was left to the operator’s discretion. Pre-procedure all patients enrolled into the 
study received ≥75 mg of acetylsalicylic acid, and ≥300 mg of clopidogrel. All patients were 
discharged on ≥75 mg of acetylsalicylic acid indefinitely, and clopidogrel 75mg for ≥12 
months following the index procedure. 
 
Follow up: Adverse events were assessed in hospital, and clinical follow up was performed at 
1, 6, 9, and 12 months. One in four patients was asked to return for angiographic follow-up at 
9 months.  
 
Study endpoints:  
The primary endpoint of this sub-study was MACE, defined as the composite of cardiac 
death, myocardial infarction (MI), and clinically-indicated target vessel revascularization 
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(TVR) within 12-months. Secondary endpoints were death from any cause, cardiac death, MI, 
any TLR (both clinically and non-clinically indicated); any TVR, and ST.  
 
A blinded independent clinical events committee adjudicated all endpoints, and independent 
study monitors verified all case reports from data on-site.  The operators were by necessity 
aware of the assigned study stent during PCI and angiographic follow-up, but patients and 
staff involved in follow-up assessment were blinded to the allocated stent type. Angiography 
films were centrally assessed at one angiographic core laboratory (Cardialysis, Rotterdam, 
Netherlands) with assessors unaware of the allocated stent.  
 
Definitions 
Definitions of all endpoints are provided in full elsewhere.11 MI was defined using the 
electrocardiographic criteria of the Minnesota code, or by a measured level of creatinine 
kinase (CK) two times the upper limit of normal (ULN), with either a positive concentration 
of CK-myoglobin fraction, or troponin I or T. Peri-procedural MI was defined as any MI ≤48 
hours of the index procedure. Revascularisation was regarded as clinically indicated if on 
quantitative coronary angiography (QCA) the lumen DS of the treated lesion was ≥50% in the 
presence of ischaemic signs or symptoms, or ≥70% in the absence of ischaemia. TVR was 
defined as any repeat PCI or surgical bypass of any segment within the entire major coronary 
vessel proximal and distal to a target lesion, including upstream and downstream branches 
and the target lesion itself. TLR was defined as a repeat revascularisation due to a stenosis 
within the stent or within a 5mm border proximal or distal to the stent. ST was defined 
according to the Academic Research Consortium definitions.14  
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Statistical analysis: Continuous variables are expressed as mean±standard deviation; 
categorical data is presented as frequency (percentages). Patient demographic data was 
compared using the Student t-test, whilst χ2 was used for categorical data. Angiographic 
outcomes were analyzed using SAS v8 Proc Mixed for continuous, and Proc Genmod for 
binominal outcomes, taking into account the within-patient correlation structure of these data. 
Survival curves were constructed for time-to-event variables using Kaplan-Meier estimates, 
and compared by the log-rank test. The piecewise Cox proportional hazards model was used 
to compare clinical outcomes between the groups. All analyses were performed using SAS 
8.02 by a dedicated statistician. All p-values and confidence intervals were two-sided; p<0.05 
was considered statistically significant.  
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Results 
Baseline characteristics (Tables 1 and 2). 
A total of 1,707 patients were enrolled in the LEADERS study of which 29.1% (497 patients, 
534 BL) had ≥1 treated BL (Figure 1). The baseline clinical and lesion characteristics were 
well matched between those patients with BLs treated with BES (258 patients) and SES (239 
patients) as indicated in Tables 1 and 2. 
 
Procedural technique (Table 3) 
The procedural technique employed to treat the 534 BLs is summarised in Table 3. There 
were no significant differences in technique when comparing BES to SES for patients with a 
true or a partial BL. Differences in technique did exist however when comparing true BLs to 
partial BLs; those patients with a true bifurcation were significantly more likely to be treated 
with a two-stent strategy (27.5% vs. 12.3%, p<0.0001) and receive post-stenting dilatation 
(52.4% vs. 36.5%, p=0.0003).   
 
Clinical Endpoints (Table 4)  
The hierarchical and non-hierarchical clinical outcomes at 1-year follow-up are shown in 
Table 4, and the Kaplan Meier survival curves are shown in Figure 2. There was no 
significant difference in the primary end-point of MACE between BES and SES at 12-months 
follow-up  (BES 12.8% vs. SES 16.3%, p=0.31). The rate of death was equal between stents, 
whilst the rate of clinically-indicated TVR was significantly lower in those treated with BES 
(11.3% vs. 4.3%, p=0.004). MI occurred more frequently in those treated with BES (8.5% vs. 
4.6%, p=0.10), and this was driven by the significantly higher incidence of peri-procedural 
MI (MI 0-2 days: HR 2.53, 95% CI 1.1-6.0, p=0.03; MI 3-360 days: HR 0.64, 95% CI: 0.18-
2.27, p=0.49, Figure 2B).  
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The primary endpoint at 12-months was not influenced by the type of BL treated (true or 
partial), or the stenting technique used (one or two-stent strategy); however compared to SES, 
the use of BES was associated with significantly lower rates of percutaneous revascularisation 
(TLR and TVR) amongst those patients with a true BL, and those treated with one-stent 
(p<0.05 for all).  
 
Stent thrombosis (Table 5) 
The overall rates of early and late ST were similar between all patients treated with BES or 
SES, which was irrespective of the type of BL treated; or the number of stents used.  
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Discussion 
This is the first analysis comparing the management of patients with BLs using a DES with a 
biodegradable polymer to a DES with a durable polymer, and demonstrates similar overall 
clinical outcomes between both patient groups, irrespective of the type of BL treated or the 
stenting strategy used. 
 
Clinical Outcomes 
The use of DES have improved outcomes in patients with complex coronary artery disease, 
with significant reductions in restenosis, however ‘off-label’ use of DES, such as in BLs, is 
still associated with higher rates of restenosis and ST compared to ‘on-label’ use.15, 16  
Encouraging evidence from this study suggests newer DESs, such as BES, may have the 
potential to improve some of these adverse clinical outcomes. In this study the significantly 
lower rate of repeat revascularisation in those patients treated with BES was achieved despite 
any significant differences between stent groups in baseline clinical, angiographic and lesion 
characteristics, or in procedural technique. This suggests other factors such as differences in 
stent design, strut thickness, cell size and the drug polymer may have had an influential role 
on restenosis, as indicated by previous studies comparing different DESs in the patients with 
BLs treated with the same stenting technique. For example Pan et al reported a significantly 
lower rate of TLR with Cypher compared to the TAXUS (Boston Scientific, Natick, USA) 
stent (4% vs. 13%, p<0.05) in 205 patients undergoing provisional T stenting,17 whilst more 
recently, in patients undergoing culotte stenting, Adriaenssens et al reported restenosis rates 
of 18%, 29% and 35% with  Cypher, Endeavor (Medtronic, MN, USA) and TAXUS stents 
respectively (p=0.12).18 These repeated observations warrant formal assessment in dedicated 
randomised trials.  
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In contrast to this reduction in repeat revascularisation, those patients treated with BES had a 
numerically higher incidence of MI, which was irrespective of the type of BL treated or the 
stenting strategy employed. Additional analysis indicates that these events were driven by a 
significantly higher rate of peri-procedural MI with BES, which in the vast majority was 
triggered by the detection of a rise in cardiac enzymes.  
  
Although these peri-procedural MIs are a concern, their overall significance is questionable 
when considering that the rate of death amongst patients who sustained an MI was 0.0% at 
30-days. However, setting this, and the on-going discussion regarding the significance of peri-
procedural MIs aside for a moment,19 there is no disputing that these events did occur, and 
with a greater frequency in those patients treated with BES. Enzyme rises may be secondary 
to procedural factors20 however in this study amongst those patients experiencing a peri-
procedural MI there were no significant differences between stent groups in TIMI flow (MB 
or SB) either pre- or post-PCI, or plaque shift. Notably, however lesion pre-dilatation was 
significantly higher in the group of patients with peri-procedural MIs who were treated with 
BES (88% vs. 43%, p=0.03).  
 
The physical properties of the stent may also influence enzyme release. For example a smaller 
cell size can increase the chances of side branch occlusion; however bench studies indicate 
that the maximum cell circumference of a 3mm BES is 10.8mm compared to 9.5mm in a 
similarly sized SES. Another physical stent property which merits discussion is the integrity 
of the polymer coating. Basalus et al recently evaluated the biodegradable coating on BES in 
vitro using electron microscopy, and observed cracks in the polymer after high pressure 
balloon inflation,  which could potentially lead to the formation of free polymer fragments, 
capable of embolizing and causing subsequent enzyme release.21  These observations must be 
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interpreted with caution not only because these assessments were performed in vitro which 
may have affected the polymer’s stability, and without the use of vascular phantoms which 
may have stabilised the polymer, but also because of the actual lower rates of repeat 
revascularisation observed with BES in this study.  
 
Stent thrombosis 
A DES with a biodegradable polymer offers the potential to reduce the risk of late/very-late 
ST, which is pertinent in patients with BLs, as these lesions represent an independent risk 
factor for ST, and have higher rates of ST when compared with non-BLs treated with the 
same DES (p=not significant).5, 22 The cause of this increased risk of ST is likely to be multi-
factorial, but stent malapposition, and incomplete stent expansion, particularly in angulated 
bifurcation lesions, are likely to be two major contributing factors.23 Reassuringly recent 
studies have dispelled the initial concerns that rates of ST are higher with the use of complex 
as opposed to simple stenting strategies, or between different complex strategies.24-28 
Following on from this, the rates of ST in this study were similar irrespective of stent type 
(BES vs. SES), type of BL (partial vs. true) or stenting strategy used (one vs. two). 
Encouragingly provisional results from 2-year follow-up of all patients enrolled in the 
LEADERS trial does suggest a reduction in very late ST events in patients treated with a stent 
with a biodegradable polymer;29 however the current study is not powered in isolation to draw 
any definitive conclusions regarding ST.  
 
Stenting technique for bifurcation lesions 
Despite the frequent occurrence of BLs, the optimal procedural strategy remains to be 
established. In the current study a single-stent strategy was preferred for BLs, being used to 
treat over 80% of cases, with a respectable cross over rate from a one to a two stent strategy 
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of 5.3%, and comparable MACE rates of 14.0% and 16.7% for one and two stent strategies 
respectively. Historically a two stent strategy was considered the ideal method of dealing with 
a BL as this produced the best angiographic result, however data from multiple randomized 
studies3, 24, 30-33 and three recent meta-analyses indicate that a provisional stenting strategy is 
as efficacious as a two-stent strategy.25, 26, 34  The current study supports this data, and 
demonstrates that these results are achievable in an unselected population where ≥50% of 
patients were treated for ACS.   
 
Limitations 
This sub-group analysis is limited by its post-hoc nature. The initial study was not a dedicated 
bifurcation study, and therefore angiographic analysis of BLs was only available using 
conventional QCA. It is widely recognised that this is limited in its ability to accurately assess 
a BL, and as a consequence no QCA data is presented here.35 In view of the results obtained a 
more detailed assessment of BLs is warranted using dedicated bifurcation software; however 
the number of patients with BLs returning for follow-up angiography is also a potential 
limiting factor of the analysis.   
 
Conclusion 
In the treatment of BLs the use of BES lead to superior efficacy and comparable safety 
compared to SES.   
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Figure 1: Flowchart indicating the number and type of bifurcation lesions, categorized 
according to make of stent.  
 
Figure 2: Kaplan Meier survival curves for (A) Clinically indicated target vessel re 
  vascularisation, (B) Myocardial infarction, and (C) MACE. 
 
Table 1: Patient demographics and clinical presentation amongst patients with at least 
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Table 4:  Clinical outcomes at 1-year. 
 
Table 5: Rates of stent thrombosis at 30-days and 1-year. 
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Table 1. Patient demographics and clinical presentation amongst patients with ≥1 treated 
bifurcation lesion. 
Variables, n(%) unless stated BES 
N=258 
SES 
N=239 
P value† 
Patient Demographics    
Age, years 65.1±10.3 64.2±10.9 0.36 
Male 183(70.9) 178(74.5) 0.38 
Body mass index, kg/m2 27.2±4.0 27.3±4.2 0.63 
Diabetes mellitus 64(24.8) 44(18.4) 0.08 
Hypertension 187(72.5) 175(73.2) 0.85 
Hypercholesterolaemia  170(65.9) 168(70.3) 0.29 
Current Smoker 45(17.4) 57(23.8) 0.08 
Family history of CAD 98(38.0) 102(42.7) 0.29 
Previous MI 92(35.7) 93(38.9) 0.45 
Previous PCI 98(38.0) 93(38.9) 0.83 
Previous CABG 19(7.4) 28(11.7) 0.10 
Previous stroke 17(6.6) 8(3.3) 0.10 
Peripheral Vascular Disease 17(6.6) 17(7.1) 0.82 
Multi-vessel disease 98(38.0) 81(33.9) 0.34 
LVEF (%) 55.7±11.2 53.8±12.9 0.20 
Clinical presentation    
ACS  
     STEMI 
     NSTEMI 
    Unstable angina 
135(52.3) 
29(11.2) 
36(14.0) 
70(27.1) 
133(55.6) 
32(13.4) 
49(20.5) 
52(21.8) 
0.46 
0.47 
0.053 
0.16 
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Stable angina 85(32.9) 89(37.2) 0.32 
Silent ischaemia 38(14.7) 17(7.1) 0.007 
 
†All p-values: Chi-square test 
ACS, acute coronary syndrome; BES, biolimus eluting stent, CABG, coronary artery bypass 
graft surgery, CAD, coronary artery disease, MI, myocardial infarction, NSTEMI, non-ST 
elevation MI; PCI, percutaneous coronary intervention, SES, sirolimus eluting stents. 
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Table 2: Baseline lesions and procedural characteristics 
Variables, n(%) unless stated 
BES 
(n=282 lesions) 
SES 
(n=252 lesions) 
P value 
Angiographic Characteristics    
Vessels with a lesion >50% 1.25±0.55 1.19±0.61 0.22 
Lesions >50% 1.43±0.70 1.40±0.79 0.64 
Vessel territory (per lesion) 
          LAD 
          RCA 
          LCx 
          Left main stem 
          CABG 
 
222/452(49.1) 
74/452(16.4) 
138/452(30.5) 
18/452(4.0)  
0/452(0.0) 
 
208/417(49.9) 
75/417(18.0) 
123/417(29.5) 
8/417(1.9) 
3/417(0.7) 
 
0.82 
0.68 
0.78 
0.08 
n.d.* 
SYNTAX score† 16.8±8.4 
(n=198) 
16.7±8.9 
(n=182) 
0.93 
Post Procedure     
Number of stents 2.4±1.5 2.2±1.3 0.33 
Number of stented lesions 1.75±0.80 1.74±0.77 0.92 
Average stent diameter, mm 2.88±0.33 2.89±0.32 0.89 
Average stent length, mm 17.6±14.7 17.8±4.9 0.72 
Total stent length, mm 40.9±25.8 39.8±26.1 0.64 
Use of glycoprotein 2b/3a 65(25.2) 46(19.2) 0.11 
Hospital stay, days 3.2±3.1 3.2±3.1 0.88 
 
*At least one observation required in both groups 
†only calculated if both left and right angiograms were available; patients with previous 
CABG excluded.   
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CABG, SES and BES as before.  
LVEF, left ventricular ejection fraction. LAD, left anterior descending artery, RCA, right 
coronary artery; LCx, left circumflex artery,  
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Table 3. Summary of stenting technique  
 True Bifurcations Partial Bifurcation P value 
True vs. 
Partial 
Variables, n(%) BES  
(n=131) 
SES  
(n=102) 
BES  
(n=151) 
SES  
(n=150) 
Number of wires     0.76 
 One 32(24.4) 27(26.5) 30(19.8) 42(28.0)  
 Two 99(75.6) 75(73.5) 121(80.2) 108(72.0)  
      
Stenting technique     p<0.0001 
 One stent 94(71.8) 75(73.5) 129(85.4) 135(90.0)  
     1 wire 32(24.4) 27(26.5) 30(19.9) 42(28.0)  
     2 wires (Provisional T-stent) 55(42.0) 41(40.2) 57(37.7) 59(39.3)  
     2 wires (2nd wire post MB stenting) 7(5.3) 7(6.9) 42(27.8) 34(22.7)  
Two stents 37(28.2) 27(26.5) 22(14.6) 15(10.0)  
     Cross-over from 1-stent technique 7(5.3) 8(7.8) 6(4.0) 3(2.0)  
     Classic T  7(5.3) 8(7.8) 9(6.0) 7(4.7)  
     Crush 16(12.2) 7(6.9) 3(2.0) 4(2.7)  
     Culotte 7(5.3) 0(0.0) 1(0.7) 0(0.0)  
     Modified T 0(0.0) 1(1.0) 2(1.3) 0(0.0)  
     V stenting 0(0.0) 3(2.9) 1(0.7) 1(0.7)  
      
Post dilatation 73(55.7) 49(48.0) 58(38.4) 52(34.7) p=0.003 
      MB only 5(3.8) 3(2.9) 8(5.3) 14(9.3)  
      MB-SB ostium 16(12.2) 14(13.7) 19(12.6) 16(10.7)  
      Kissing balloon 52(39.7) 32(31.4) 31(20.5) 22(14.7)  
 
BES, biolimus eluting stent; SES, sirolimus eluting stent; MB, main branch; SB, side branch 
 
No significant difference in technique between BES and SES for true or partial bifurcation 
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TLR, target lesion revascularisation, TVR, target vessel revascularisation, MACE, major 
adverse cardiovascular events. 
MI, BES, SES as previously described. 
Table 4. Clinical Outcomes at 1-year follow-up. 
Outcome n(%) 
BES 
(n=258) 
SES 
(n=239) 
P Value 
Hierarchical outcomes (1-year)    
Cardiac death 7(2.7) 7(2.9) 1.00 
 MI  21(8.1) 12(5.0)  
      Q-wave 3(1.2) 2(0.8)  
      Non-Q wave 18(7.0) 10(4.2)  
Clinically justified TVR  5(1.9) 20(8.4)  
      Percutaneous 4(1.6) 18(7.5)  
      Surgical  1(0.4) 2(0.8)  
Any MACE  33(12.8) 39(16.3) 0.31 
    
Non-Hierarchical outcomes (1-year)    
Death 9(3.5) 7(2.9) 0.80 
Cardiac death 7(2.7) 7(2.9) 1.00 
MI 23(8.9) 13(5.4) 0.17 
All TLR 12(4.7) 29(12.1) 0.003 
     Percutaneous 12(4.7) 28(11.7) 0.005 
     Surgical 1(0.4) 4(1.7) 0.20 
Clinically justified TLR 9(3.5) 23(9.6) 0.006 
     Percutaneous 9(3.5) 22(9.2) 0.009 
     Surgical 1(0.4) 2(0.8) 0.61 
All TVR 16(6.2) 34(14.2) 0.004 
     Percutaneous 14(5.4) 32(13.4) 0.003 
     Surgical 3(1.2) 5(2.1) 0.49 
Clinically justified TVR 11(4.3) 27(11.3) 0.004 
     Percutaneous 11(4.3) 26(10.9) 0.006 
     Surgical 1(0.4) 3(1.3) 0.36 
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Table 4. Stent thrombosis events at 30-days and 1-year  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BES, SES as previously described 
n.d*; not done (≥1 observation required in both groups). 
 
 
BES 
(n=258) 
SES 
(n=239) 
P value 
30-days    
Stent Thrombosis 7(2.7) 7(2.9) 1.00 
       Definite  5(1.9) 6(2.5) 0.76 
       Possible  0(0.0) 0(0.0) n.d.* 
       Probable  2(0.8) 1(0.4) 1.00 
1-year    
Stent Thrombosis 11(4.3) 9(3.8) 0.82 
       Definite  5(1.9) 6(2.5) 0.77 
       Possible  4(1.6) 2(0.8) 0.69 
       Probable  2(0.8) 1(0.4) 1.00 
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Figure 1.   Flowchart indicating the number and type of bifurcation lesions categorized  
according to make of stent.  
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 No Bifurcation 599 
 Bifurcation  258        
   
 
1254 lesions 
 
 No Bifurcation lesion   972 
 Bifurcation lesions        282 
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Sirolimus 
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2467 lesions in 1707 patients 
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 No Bifurcation 611 
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 No Bifurcation lesion   961 
 Bifurcation lesion   252 
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Figure 2: Kaplan Meier survival curves 
 
 (A) Clinically justified target vessel revascularization 
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(B) Myocardial infarction 
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(C) Major adverse cardiovascular events 
 
 
p=0.31 
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Abstract
Bifurcation stenting is one of the unsolved challenges for interventional cardiologists. Patients with bifurcation lesions tend to have more
advanced disease and multiple co-morbidities. Over the last 10 years we have come to understand the importance and made progress in
bifurcation imaging for planning the procedure and for assessment of procedural success, from 3D angiography and multislice computed
tomography (MSCT) to fractional flow reserve (FFR) and optical coherence tomography (OCT). Recent clinical trials have shown improved
results with selective use of a two-stent strategy and drug-eluting stents. Rates of major adverse cardiac events (MACE) and peri-procedural
myocardial infarction (MI) for bifurcation lesions still remain high. Many challenges such as side-branch access, wire-trapping, incomplete
side-branch coverage and restenosis still remain. No single dedicated bifurcation stent design thus far has been able to solve them all. More
long-term, prospective, efficacious studies of these novel stent designs with concomitant imaging are needed for the field to progress.
Keywords
Bifurcation, drug-eluting stent, dedicated bifurcation stents, imaging
Disclosure: The authors have no conflicts of interest to declare.
Received: 17 July 2009 Accepted: 8 August 2009 
Correspondence: Willem J van der Giessen, Interventional Cardiology, Thoraxcentre Erasmus MC, ‘s-Gravendijkwal 230, 3015CE Rotterdam, The Netherlands. 
E: w.j.vandergiessen@erasmusmc.nl
Approach to the Bifurcation Patient
Historically, bifurcation lesions have been associated with lower
procedural success and a poorer clinical outcome than non-
bifurcation lesions. This may be due to the technical difficulty of the
procedure but also due to the complexity of the patients. According to
the recently presented LEADERS trial sub-study,1 patients who have
bifurcation disease are significantly more likely to have had a previous
myocardial infarction (MI) (37.2 versus 30.4%; p=0.007) and
multivessel disease (36.0 versus 17.0%; p<0.001). The latter was
reflected in a much higher Syntax score (17 versus 12; p<0.001),
indicating that next to the target bifurcation there is, on average, at
least one additional lesion. In addition, patients with bifurcation
disease tended to have smaller-diameter vessels. The rate of peri-
procedural MI in LEADERS was significantly higher in patients 
with bifurcation disease (6.6 versus 3.6%, p=0.01). Similarly, in the
ARTS-II bifurcation sub-study,2 the bifurcation group had more
extensive and complex disease (i.e. diffuse lesions, type C lesions).
The procedure itself was also more complex, with a higher number
and length of stents implanted and longer procedural time. Thus, the
first important step in planning the bifurcation procedure is to
carefully evaluate the patient and minimise his or her peri-procedural
complication risk. This may include routine use of 2β3α inhibitors or
newer antithrombotic agents on top of the usual dual antiplatelet
therapy. In addition, pre-hydration in patients with renal disease and
careful assessment of anatomy using state-of-the-art imaging
techniques is paramount. Based on this careful assessment of clinical
and procedural risk, one may even positively decide to change the
revascularisation strategy from percutaneous to surgical.1
Imaging Techniques
The treatment of bifurcation lesions requires careful assessment of the
bifurcation disease anatomy, including the size of the proximal versus
the distal vessel, the extent of the disease in the side branch, the
degree of calcification and the side-branch angle. Accurate assessment
of these bifurcation features is critical in choosing the strategy and
tools that would provide the best side-branch coverage with minimal
overlap of struts and good stent apposition, thereby minimising the
complication rates. However, angiographic 2D assessment of
bifurcations is often incomplete because of vessel overlap,
foreshortening and poor reconstruction of angles. 2D-angiography-
based Medina classification of bifurcation lesions is the most accepted,
and easiest to use, classification system.3 It divides the bifurcation into
main proximal, main distal and side-branch segments and assigns
binary (0 and 1) values to describe plaque distribution.
Angiographic assessment of bifurcation lesions was recently
summarised by Lansky et al. in 2009.4 One has to be aware of the
inherent inaccuracies in measuring QCA in bifurcation lesions. QCA
algorithms have the assumption that the vessel tapers minimally along
its course. This assumption is not true for bifurcations where Murray’s
law must be applied and standard QCA results in the underestimation
of the proximal vessel size. Dedicated bifurcation software is now
available from Medis and Pie Medical (The Netherlands). The two
software programs are described by Lansky et al.4 and Ramcharitar et
al.,5 respectively. The consensus is that bifurcation lesions should be
systematically described according to the Medina classification,3 at
least three projections are required and quantitative analysis
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performed in two views with minimal overlap and foreshortening. 2D
angulations between the proximal main branch and side branch
should be measured. This software has been developed with trial
reporting in mind. Single restenosis for the side as well as main branch
should be reported and overall restenosis for the entire bifurcation. It
is also recommended to perform a more detailed segmental analysis
of restenosis, which may give insight into its mechanism.
3D Angiography
Given the limitations of 2D angiography, we currently recommend the
use of 3D reconstruction of the bifurcation lesions with specialised
software such as Paeion Medical (Israel). This system uses two
angiographic orthogonal images to reconstruct 3D anatomy and
allows the measurement of the bifurcation angle, defined as the angle
where the centre lines of the lumen of the main and side-branch
cross (see Figure 1A). The mean 3D bifurcation angle and the systolic
and diastolic angle are then analysed. Careful assessment of
angulation not only allows one to choose the proper stenting
technique, such as T-stenting for 90º angles and other techniques for
lower angulations to avoid side-branch gap, but is also a powerful
predictor of clinical outcomes including mortality.6
Multislice Computed Tomography
For similar reasons, multislice computed tomography (MSCT) with
volume-rendered reconstructions of the coronary tree may facilitate
assessment of bifurcations, with respect not only to the angulation but
also to the distribution of plaque and calcifications. Knowledge of the
plaque distribution and calcifications allows one to better choose the
wire, navigate the calcifications and make a decision about the need
for pre-dilation, in addition to choosing the best stenting strategy.
MSCT 3D reconstruction is less user-dependent than 2D angiography
and allows for more accurate angle measurements.7 As recently
shown, steep angles >72º between the left main and left circumflex
artery are predictive of incomplete apposition and distortion of the
side-branch stent with the crush technique, which, in turn, is
associated with a higher mortality.8 Careful review of MSCT data prior
to the planned intervention is therefore highly advisable (see Figure
1B). In addition, a prior MSCT study may also decrease contrast use
during the actual procedure.
Intravascular Ultrasound
Although intravascular ultrasound (IVUS) is invasive and available 
intra-operatively, it can offer invaluable insights into the anatomy (size
and length) of the bifurcation pre- and post-stenting and guide stent
optimisation. Obtaining IVUS data is particularly important, but poor
correlation exists between angiography and IVUS measurements of
Figure 1A: 2D and 3D Angiography Assessment of
Bifurcation Angles
Figure 1B: Multislice Computed Tomography Assessment
of Lesion Complexity and Side-branch Involvement as
well as Extent of Calcification
Figure 1C: Optical Coherence Tomography 
Assessment of Carina Coverage After Stenting 
Distal stent portion (RD)
Carina
Proximal stent portion
(LAD)
CYPHER stent, optical cohertence tomography (OCT) pullback though RD.
LAD
RD
Figure 1E: Intravascular Ultrasound and Optical
Computed Tomography Imaging Post-stenting in a 
Case of LAD/D1 CTO with Left Main Disease
Figure 1D: In Vivo Optical Computed Tomography After
Bifurcation Stenting with Dedicated Nile Croco
No malapposition is seen.
From the Tryton All Comers Registry in Rotterdam with OCT Substudy.
2D-QCA vs. 3D-reconstruction
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the mean bifurcation angle.9 It can be particularly valuable in cases
where MSCT is not available or the degree of calcification obscures the
ability to assess the lesion severity. With regard to future approaches
to bifurcation treatment, pre-procedural imaging may help us to solve
two classic bifurcation problems: wire-crossing and/or twisting and 
re-cross. Importing the imaging data set onto a wire navigation system
might facilitate the engagement of even the most difficult side
branches. In our current practice, we are actively exploring the use of
both MSCT and 3D-angiography with magnet navigation and GPS-
systems (RJ van Geuns, personal communication).
Post-stenting Fractional Flow Reserve
The decision to dilate the side branch after stenting of the main
branch, and whether a side-branch stent is necessary, often cannot
be reliably made based on angiographic appearance. A shift in the
carina angle after placement of the stent often creates an illusion of
significant ‘pinching’ of the ostium. Fractional flow reserve (FFR) is a
physiological measurement of maximal myocardial flow that can be
maintained in the presence of a given stenosis. It is calculated from
the ratio of the distal coronary to proximal aortic pressure at maximal
hyperaemia. FFR <0.75 denotes significant stenosis. The seminal
paper by Koo’s group10 has shown that there was a negative
correlation between the per cent diameter of side-branch stenosis
and FFR measurement. In addition, fewer than 30% of the lesions with
angiographically significant stenosis had flow limitation shown by FFR
measurement. FFR has not been evaluated in more complex diffuse
side-branch lesions or in cases of elective two-stent strategy.
Post-stenting Optical Coherence Tomography for
Optimisation of Results
Optical coherence tomography (OCT) is emerging as the preferred
technique for post-stent assessment in terms of apposition, strut
distortion and protrusion and overlap or presence of gaps
(incomplete coverage). At 10–20μ resolution, when performed in both
limbs, OCT allows for bifurcation reconstruction at the level of detail
similar to that of the ‘Ormistogram’ model or ‘microCT’. Combined
assessment of bifurcations with IVUS-VH and OCT can identify plaque
composition as well as plaque burden and the presence of a necrotic
core with ‘thin cap’ (fibroatheroma), which is most often present in
the proximal bifurcation rim.11 At follow-up stent-strut coverage and
neo-intima thickness can be assessed with great detail. We believe
that OCT may be the technology that will give us the best insight into
the mechanisms of in-stent restenosis in bifurcation stenting and
allow for the evaluation of both two-stent techniques in conventional
stenting and dedicated stents. When the full potential of 3D OCT
reconstruction is realised, it may be used for high-resolution
hydrodynamic modelling of the stented bifurcation. We are currently
participating in first-in-man studies and registries of dedicated
bifurcation stents, using OCT extensively (see Figures 1D and 1E).
Review of Recent Trials and Evidence
Despite the complexity of bifurcation stenting and the high restenosis
rates, particularly in the side branch, several advancements such as
the introduction of drug-eluting stents and the more selective use of
two-stent strategies – as described in the MADS classification – have
reduced major adverse cardiac events. This reduction has been
reflected in recent clinical trials.
Over the last few years, Colombo et al.,12 Pan et al.,13 Steigen et al.,14
Ferenc et al.15 and Tsuchida et al.2 have shown equivalent major
adverse cardiac event (MACE) rates for one- and two-stent strategies,
ranging from 3.4 to 19% (see Table 1). The meta-analysis of these trials
including BBC-One (TCT 2008) has recently been published, and
showed that there are no differences in mortality and TLR between
one- and two-stent strategies.16 However, there is a 43% increase in
peri-procedural myocardial infarction (MI) rate with two-stent
strategy. This early difference (11.2 versus 3.6%) was particularly
apparent and drove the overall MACE rate in the BBC-One trial of
elective versus provisional T-stenting (15.2 versus 8%, hazard ratio
[HR] 2.0; p=0.0009). The Cactus trial12 showed equivalent outcomes of
crush-stenting compared with the provisional approach. One-third of
the patients in the one-stent/provisional approach arm have crossed
over to the two-stent arm due to residual stenosis in the side branch
(72% of cases), poor flow (1.9%) or significant dissection in the side
branch (39%). The Nordic 2 trial showed equivalent event rates with
culotte versus crush-stenting. In addition, Colombo and his group
have demonstrated that over the last several years as the use of
kissing-balloon inflation increased, after crush-stenting the rate of
restenosis and TLR has decreased by half.17 The rate of in-stent
restenosis in the side branch remains at 13.2% with crush-stenting,
even when kissing-balloon inflation is used. Based on these studies,
Figure 2: Design of the First Bifurcation Stents
Table 1: Summary of the Clinical Trials
Study Number of Two-stent Strategy Type of Drug- Thienopyridine Number of Duration of Clinical
Patients eluting Stent Duration (months) Centres Follow-up (months)
Pan et al. 91 Any SES 12 1 11
Colombo et al. 85 Any SES 3 5 6
NORDIC 413 Any SES 6–12 28 6
Ferenc et al. 202 T-stenting SES 6–12 1 12, 24
BBC ONE 500 Crush or culotte PES 9 20 9
CACTUS 350 Crush SES 6 12 6, 12
Total 1,641
Courtesy of Somjot S Brar, MD.
A: Jostent; B: NIR Side Royal; C: BARD.
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involving a total of 1,600 patients, the current recommendations for
the approach to bifurcation stenting are as follows:
• protect the side branch with a guidewire that facilitates access and
marks the ostium;
• perform provisional rather than elective side-branch stenting only,
with possible final kissing-inflation; and
• two-stent treatment should be limited to flow-limiting side-branch
dissection, side-branch disease extending well beyond the ostium
or an unfavourable angle after main-branch stent implantation.
We have recently shown, in the ‘all-comers’ LEADERS study, that in the
major European centres this strategy for true bifurcation treatment is
followed in the majority of patients.1 Two-thirds of the patients have
both branches wired and one-third of those are treated with a two-
stent approach. In 88% of the lesions treated with a two-stent strategy,
kissing-balloon inflation is performed. With these techniques and the
use of drug-eluting stents the MACE rate for bifurcation lesions was
16% at 12 months. Even when following these guidelines, bifurcation
stenting remains a technical challenge, the major issues being:
• difficulty in maintaining the side-branch access due to jailing of the
wire and difficulty in re-crossing through double struts, especially
in stent designs that have small cells;18
• distortion of the main-branch struts during side-branch dilatation
(seen on micro-CT in vitro and OCT in vivo), which may be one of
the reasons for in-stent restenosis and thrombosis; and
• inability to fully cover the side-branch ostium with some
angulations (e.g. shallow angles with T-stenting strategy).
Given these challenges, dedicated bifurcation stents that address
some of these problems have been developed and, hopefully, 
will not only facilitate the procedure but also improve the long-
term outcomes.
Dedicated Bifurcation Stents – What Progress
Have We Made in the Last 10 Years?
Our group was one of the first to report the acute and long-term
outcomes of the implantation of dedicated bifurcation stents such as
the Jostent, NIR Side Royal and BARD stents.19,20 Since the cells in the first
two stents were larger at the carina, the side branch had incomplete
coverage. In particular, the true bifurcation stents were bulky and
required a 9Fr guide catheter for delivery. The alignment, especially with
the ‘trapped-wire’ approach stents, was also an issue (see Figure 2). The
design of the dedicated bifurcation stents has improved and most of
them can be delivered via a 7Fr sheath for self-expanding designs and 5
or 6Fr sheath for the balloon-expandable designs. However, none of the
current designs has solved all of the challenges.
Figure 3: MADS Classification and How New Dedicated Bifurcation Stents Are Classified
1st stent
Main prox. first Distal first Side branch first
M D S
After
balloon
2 stents
3 stents
Skirt
Skirt
+ SB
Skirt
+ DM
Extended V
PM stenting
Main across side first
A
Trouser legs
and seat
MB stenting
across SB
Elective
T-stenting
Internal
crush
Culotte TAP
MB stenting
+ SB balloon
MB stenting
+ kissing
DM 
stenting
Provisional
SKS
SB ostial
stenting
SB mini-
crush
SB
crush
V-
stenting SKS
System
T-stenting
Mini-
crush Crush
DEVAX NILE Croco TRYTON
M = main proximal first, i.e. skirt ensuring access to both branches – Axxess Plus (Devax, Irvine, CA, US). A = stents for provisional side-branch stenting facilitate side-branch access after main
branch stenting – NILE CROCO (Minvasys, Genevilliers, France). S = stents for side branch first approach – Tryton (Tryton Medical, MA, US).
Table 2: Summary of the Dedicated Bifurcation Stent Studies to Date
MADS Classification Product Study Name/Type Six-month MACE Angiographic, Number of Patients
(%) Restenosis, MB/SB (%)
M Axxess Multicentre registry 7.7 3.6/4.3 302
A Nile croco Registry 10.7 N/A 75
A Frontier Registry 17.1 9/29 105
S Tryton FIM 9.9 4.3/0 30
S Capella FIM 12.5 N/A 20
Total 560
M = main proximal branch first; A = main branch (MB) across the side branch (SB); S = SB first; MACE = major adverse cardiac event; FIM = first-in-man.
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Most of the currently available bifurcation stents are non-drug-eluting
except for the Devax stent, which is coated with biolimus and
delivered from a biodegradable polymer and the new BiPax (Nile
Croco) paclitaxel-eluting stent. The bifurcation stents are meant to
facilitate the following:
• main proximal first – Skirt in the MADS classification – ensures
access to both branches and obviated the need for any re-crossing
with the wires. The best-studied stent in this category is the Axxess
Plus (Devax, Irvine, CA);
• side-branch access after main branch-stenting – these stents are
designed for provisional side-branch stenting21 (see Figure 3) – one
of the examples of main branch across the side branch is the NILE
CROCO stent (Minvasys, Genevilliers, France); and
• stents for the side-branch first approach in the MADS classification –
severely diseased large side branches may require this approach,
which mimics classic culotte-stenting; however, without layers of
overlapping struts, an example discussed here is the Tryton stent
(Tryton Medical, MA, US).
Table 2 summarises dedicated bifurcation stent studies published to
date according to the MADS classification.
Main Proximal Branch First
The best-studied example in this category of dedicated bifurcation
stents is Axxess Plus (Devax), with a 302 patient prospective
DIVERGE registry published recently in JACC.22 The stent is a 7Fr-
compatible, self-expandable, nitinol, single-wire system and elutes
biolimus from a biodegradable polymer. It has a modular design, in
that it can be tailored based on the bifurcation lesion anatomy, and
provides access to both branches but may require three stents in
total to complete coverage. DIVERGE enrolled 64% true bifurcation
medina (1,1,1) lesions and 64% of the patients had both branches
stented. In-segment late loss in the side branch was only 0.17mm
at nine-month angiographic follow-up. This translated into a 4.3%
target lesion revasularisation (TLR) rate and 7.7% MACE rate at 12
months, which compares favourably to the results of a biolimus
stent with a conventional approach to bifurcations in the LEADERS
study, where the TLR rate was 11.1% and overall MACE rate was
16%. In addition, the MI rate was 4.3%, which is considerably lower
than the 10% MI rate in the recent BBC-One trial.
Main Branch Across
Dedicated stents in this category are designed to provide easier
access to the side branch for provisional stenting. All of the stents
in this class have only been studied in small first-in-man studies or
registries. One of the examples in this category is the Nile Croco
stent, which is a 6Fr-compatible, balloon-expandable, cobalt–
chromium (73μ strut thickness) stent. It uses a double-balloon, dual
rapid-exchange system with two independent catheters that track
over two wires. It is designed for ‘provisional’ side-branch stenting
and provides partial side-branch ostium coverage/scaffolding (with
a couple of struts). The main balloon has three markers, with the
central marker indicating the position of the side-branch ostium.
After stent deployment in the main branch, a side-branch balloon is
advanced and a simultaneous kissing inflation can be performed.
While theoretically this system should obviate the need for re-
crossing, the wire twist often observed at the initial attempt of
stent delivery necessitates the withdrawal of the wire from the side
branch and re-crossing. Although there is no need to re-cross
through the struts, this is often done after initial pre-dilation in the
presence of potential dissection in the side-branch. The Nile Croco
registry of 75 patients by Lefevre et al.23 demonstrated a MACE rate
of 10.7% at six months. This included a 2.7% MI rate and a 6.7% TLR
rate. Similarly, the Spanish registry24 showed excellent procedural
success rates and a 12% MACE rate at six months. The NilePax
paclitaxel-eluting stent is now available and is undergoing clinical
testing in the Bipax study.
The Multi-link Frontier (Abbott Vascular, Santa Clara, C, US) was one of
the first stents in this category and was studied in a 105-patient
registry.25 It is a balloon-expandable 316L stainless steel stent pre-
mounted on a dedicated delivery system with two balloons (monorail
for the main branch and over-the-wire for the side branch) sharing a
single inflation port. This stent was 7Fr-compatible and difficult to
deliver in calcified vessels. While the procedural success rate was
93%, the MACE rate at six months was 17.1%, with a 44.8% overall
restenosis rate (29% for both main branch and side branch). The new-
Table 3: Summary of the Practical Approach to Bifurcation Treatment
Medina Classification Planning/ Wire(s) Technique/Device Problems Solution Post-procedure 
(2D angiography-based) Imaging Evaluation/Imaging
1.0.0 QCA with optional 1 (for angles 1-stent strategy with provisional Plaque shift and FFR OCT
IVUS and MSCT >70%, consider side-branch treatment in cases angiographic
2 wires) of dissection or slow flow appearance of a
‘pinched’ ostium
X.1.0 QCA and IVUS with 2 1-stent strategy with provisional Plaque shift and FFR OCT
optional MSCT side-branch treatment as above; re-crossing through
possibly side-branch access the struts
dedicated bifurcation stent such
as Nile croco, Stentys or Frontier
(Pathfinder)
X.X.1 QCA with mandatory 2 2-stent conventional techniques Re-crossing through Magnetic OCT
IVUS and MSCT or dedicated bifurcation stents: the multiple layers navigation
Tryton or Axxess of struts in cases and
of conventional Venture
2-stent techniques catheter
and Tryton
FFR = fractional flow rate; IVUS = intravenous ultrasound; MSCT = multislice computed tomography; OCT = optical coherence tomography; QCA = quantitative coronary angiography.
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generation Pathfinder, which incorporates the Xience V platform, is
expected to offer better results.
Side Branch First
The best example in this category is the Tryton (Tryton Medical, MA,
US), which is a 5 or 6Fr-compatible balloon-expandable cobalt–
chromium slotted-tube bare-metal stent. It uses a single balloon and
single rapid-exchange system. The stent consists of three zones:
distal side branch, transition zone at the carina and main branch
zone. The central transition zone has a specific geometry to provide
the best scaffolding and is made of three elements, which can be
independently deformed. The proximal main branch zone (the so-
called collar) has three fronds and a minimal amount of metal, and
allows for the delivery of a standard work-horse stent such as the
drug-eluting Xience V stent (most often used in our institution). This
design minimises the amount of overlapping and protruding struts
while still providing adequate coverage and scaffolding. Tryton stent
use commits users to the two-stent strategy, similar to culotte. 
The first-in-man study of 30 patients with six-month follow-up
showed excellent results, with an overall MACE rate of 11.2%. This
was composed of an MI rate of 6%, a TLR rate of 7.5% and a stent
thrombosis rate of 2.2%.26 More interestingly, the six-month
angiographic follow-up in this study showed an extremely low late
loss of 0.17mm in all three bifurcation segments, including the side
branch. This is despite the fact that the side-branch portion is
covered by a bare-metal stent only. Long-term follow-up in a larger
population will be needed to confirm the results. We have been able
to successfully use Tryton in very complex cases including left main
bifurcations and chronic total occlusions at bifurcation sites with
good procedural success and we are performing a careful OCT
evaluation of the stent post-procedure in this ‘all-comers’
population (see Figure 1E).
The Side-guard ostium protection device (Capella, MA, US) is a self-
expanding trumpet-shaped nitinol device with a low profile that
allows for T-stenting and is designed for bifurcation angles between
45 and 135º. The six-month results in the first 20 patients showed a
MACE rate of 12.5%.
As illustrated, none of the dedicated bifurcation stents has been
studied in large randomised trials with long-term follow-up. The
data are limited to small first-in-man and registry studies. While it
appears that dedicated drug-eluting bifurcation devices may halve
the MACE rate compared with historical controls (MACE of 7.7% in
DIVERGE versus 16% in LEADERS), these promising preliminary data
must be confirmed.
Summary
Bifurcation stenting is an unsolved challenge for interventional
cardiologists. Patients with bifurcation lesions tend to have more
advanced disease and multiple co-morbidities. Over the last 10 years
we have understood the importance and made progress in
bifurcation imaging for planning of procedures and in procedural
success (from 3D angiography, IVUS and MSCT to FFR and OCT).
Recent clinical trials show an improvement in results with more
selective use of a two-stent strategy and drug-eluting stents. Rates of
MACE and peri-procedural MI for bifurcation lesions still remain
higher than in non-bifurcation lesions and patients. Many challenges,
such as side-branch access, wire trapping and incomplete side-
branch coverage, still remain and have only partially been addressed
by the new dedicated bifurcation stent designs since their
development in the 1990s. More long-term prospective studies of
these novel stent designs are needed for the field to progress with
concomitant imaging. We believe that in addition to randomised trials
of the dedicated bifurcation stents, an ‘all-comers’ registry of these
devices, with long-term follow-up, would be invaluable in the
assessment of their safety and efficacy compared with conventional
approaches. Table 3 summarises our current practical approach to
bifurcation treatment. 
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ABSTRACT 
Background. Treatment of bifurcation lesions with the Tryton Sidebranch stent has been shown to 
be feasible with an acceptable clinical outcome and low side branch late loss in the first in man 
trial.  
Objective. To report acute procedural and 6 month clinical follow up after the use of the Tryton 
Sidebranch stent in an ‘all comer’ registry. 
Methods. The first 100 coronary bifurcation lesions assigned for treatment with the Tryton stent 
were included in a prospective registry. Procedural and angiographic success rates were 
determined from patient charts and pre and post procedural quantitative coronary angiography. 
Clinical follow-up was obtained by phone or mail contact. 
Results. 96 patients with 100 lesions were included in the study. 72% presented with stable angina, 
25% with unstable/NSTEMI and 3% STEMI. The bifurcation was located in the left main in 8%. 2 
lesions were chronic total occlusions. 69% were true bifurcation lesions. 1 failure of stent delivery 
occurred. Acute gain in SB was 0.76±0.64mm and 3 patients had residual stenosis of >30%. 
Angiographic success rate was 95%; procedural success rate reached 94%.  Peri-procedural MI 
occurred in 2 and there was 1 cardiac death during hospitalisation. At a median 6 months follow-
up, TLR rate was 4%, MI 3% and cardiac death 1%. The percentage MACE-free survival at 6 months 
was 94%. No cases of definite stent thrombosis occurred. 
Conclusion. In a real world the use of the Tryton Sidebranch stent is associated with good 
procedural safety and angiographic success rate and acceptable outcome at 6 months of follow-up.   
 
Keywords: Bifurcation lesions, Percutaneous Coronary Intervention, Procedural success, 6 month  
MACE  
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INTRODUCTION 
Percutaneous coronary intervention (PCI) for bifurcation lesions is considered high risk with 
increased procedural adverse events as well as inferior long term outcome when compared to non-
bifurcation intervention.  [1] Several techniques and strategies have been explored, employing one 
or two conventional tubular stents but the improvement in outcome remains limited. This is 
primarily reflected in the increased rates of sidebranch restenosis. [2] Dedicated bifurcation stents, 
specifically designed to allow minimally traumatic implantation in the main vessel and/or 
sidebranch while providing adequate scaffolding of the sidebranch ostium may offer an advantage 
over utilisation of conventional stents. [3] 
The Tryton Side-Branch Stent (Tryton Medical, Inc., Newton, MA, USA) is a dedicated bifurcation 
stent inspired by the ‘culotte’ stenting technique. [4] This Tryton Side-Branch stenting strategy 
showed acceptable clinical outcome with no sidebranch restenosis and low side-branch late loss 
(0.17±0.35mm) at six months in the First-in-Man (FIM) trial that enrolled 30 patients with stable 
coronary artery disease and de novo bifurcation lesions. Being a FIM, the study had restricted 
inclusion criteria that does not represent routine clinical practice. [5] 
The present registry analysis was conducted to evaluate the procedural success and to assess 
clinical outcome of bifurcation stenting with the Tryton Side-Branch Stent™ in conjunction with a 
standard workhorse stent in a ‘real world’, all comer population. 
METHODS 
Patient Population 
All patients with ischaemia in a myocardial segment supplied by a coronary artery with a 
bifurcation lesion with disease in both main vessel and sidebranch that were referred for PCI from 
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December 2006 at two academic tertiary hospitals in the Netherlands (Thoraxcenter, Erasmuc MC, 
Rotterdam) and Poland (University Hospital of Lord’s Transfiguration, Poznan) were eligible. 
Specifically the bifurcation could be located anywhere in the coronary circulation including grafts. 
The visually estimated reference diameter of the main vessel could be 2.5-5.0mm and that of the 
sidebranch in the range 2.0-2.75mm. These dimensions were selected to comply with the available 
sizes of the Tryton stent. However the decision to treat the bifurcation and employ a Tryton Side 
Branch Stent remained at the discretion of the treating interventional cardiologist.  The first 100 
lesions assigned for treatment with the Tryton Sidebranch Stent were included in a collaborative 
registry between the two institutions.   
 Study Device and PCI strategy 
The Tryton Side-Branch Stent is a slotted tube, balloon expandable cobalt chromium BMS with 
three zones: a distal sidebranch zone, a central transition zone and a proximal main vessel zone. 
The distal zone has standard slotted tube workhorse stent design, the central transition zone 
consists of three panels while the proximal main vessel zone is composed of three fronds that 
terminate proximally in a circumferential band. The stent is mounted either on a balloon with 
uniform diameter of 2.5mm (straight type) or on a stepped balloon with a diameter of 3.5mm 
proximally and 2.5mm distally (tapered type). The stent delivery system has 4 markers to delineate 
the proximal and distal end of the stent as well as the proximal and distal part of the transition 
zone. Further details of the stent design as well as the standard technique for implantation have 
been published [4]. In short, the procedure is typically performed via a 6Fr guiding catheter; after 
optional wiring of both main vessel and sidebranch for predilation, the Tryton stent is advanced 
over the wire into the sidebranch, and using the 2 middle markers on the delivery system, the stent 
is positioned till these markers straddle the carina. Deployment of the stent is followed by 
retraction of the guidewire from the sidebranch and repositioning it through the fronds of the 
transition zone into the distal main vessel.  A standard stent is then advanced and positioned in 
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main vessel jailing the stented sidebranch. Once the main vessel stent is deployed recrossing into 
the sidebranch allows final kissing balloon inflation. 
Procedure 
Patients were pre-treated with aspirin (75mg) and clopidogrel (300mg or 600mg) unless they were 
already taking these antiplatelet agents. Intravenous heparin was administered to maintain an 
activated clotting time of >250 seconds. Glyoprotein IIb/IIIa inhibitor use was left to the treating 
interventional cardiologist’s discretion as was the use of other additional devices such as 
thrombectomy, excimer laser, rotablator etc. Delivery failures, need for additional overlapping 
stents to cover the whole lesion, additional ballooning and procedural angiographic and clinical 
complications were noted. Aspirin was continued indefinitely and clopidogrel was continued for 12 
months after the index procedure.  
 
Cardiac enzymes and ECG 
Serial cardiac enzymes including creatinine kinase (CK)-MB mass, troponin-T, or troponin-I were 
measured after the procedure. Pre-procedure biomarkers were assessed in all patients with acute 
coronary syndrome. These patients were included the biomarker analysis only if preprocedure 
markers were normal.  A 12 lead ECG was obtained before and after procedure as part of routine 
institutional practices.    
Quantitative Coronary Angiography 
Angiographic films were analysed with a dedicated bifurcation software (CAAS 5.5, Maastricht, PIE 
Medical software, The Netherlands). [6] Reference vessel diameter, minimal luminal diameter 
(MLD) and percentage diameter stenosis were obtained for the proximal main vessel (PMV), distal 
main vessel (DMV) and sidebranch (SB) in the pre procedural angiographic film. Matched views of 
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immediate post-procedural films were then selected for determination of the same parameters. 
Acute gain was determined from the difference between MLD in each of the three segments (PMV, 
DMV, SB).  
 Follow-up   
Survival data from all patients were obtained from municipal civil registries. A health questionnaire 
was subsequently sent to all living patients with specific questions on treatment compliance, re-
admission and major adverse cardiac events. Patients who did not send the filled questionnaire 
were contacted by phone to obtain the relevant information.  Those who reported events had their 
medical records, discharge summaries and any repeat angiographic films systematically reviewed. 
Data was carefully verified and adjudicated by cardiologists according to criteria defined below. 
Definitions   
Primary device success was defined as successful deployment of the intended stent without system 
failure or device related complication. Angiographic success was defined as <30% residual stenosis 
and TIMI 3 flow in both main vessel and sidebranch after the procedure. Procedure success 
included angiographic success in the absence of in-hospital major adverse cardiac events (MACE). 
MACE was defined as a composite of cardiac or non-cardiac death, Q–wave or non-Q-wave 
myocardial infarction (MI) and ischaemia driven target lesion revascularisation (TLR). Non-Q wave 
MI was defined as clinical signs of myocardial infarction associated with a CK-MB mass or troponin 
–T/troponin-I increase to ш3 times the upper limit of normal in the absence of Q waves and not 
related to an interventional procedure. Q-wave MI occurred when there was chest pain or 
symptoms consistent with myocardial ischaemia and new pathological Q waves in 2 or more 
contiguous electrocardiograph leads. TLR was defined as any PCI of the index lesion and including 
the 5mm persistent segments in either main vessel or sidebranch. Target vessel revascularisation 
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(TVR) was defined as revascularisation of any part of the index coronary artery. Stent thrombosis 
was defined according to the Academic Research Consortium (ARC). [7]      
 
Statistical analysis 
Continuous data are expressed as mean ± SD or as median (interquartile ranges) whereas 
dichotomous data are summarized as frequencies. The Kalpan-Meier method was used to study 
the incidence of events over time relative to the number of patients at risk at each time point. 
Statistical analysis was performed using SPSS software version 17.0 (SPSS, Chicago, USA)    
 
RESULTS 
100 bifurcation lesions in 96 patients were included between December 2006 and March 2010. 
Baseline characteristics of patients included are shown in table 1. The mean age of patients was 
63.9 years and the majority were male (75%). While most patients presented for PCI with stable 
angina (72%), three patients were treated for an acute myocardial infarction.   
Lesion characteristics are described in table 2. Sixty six percent of patients had multivessel disease 
and 5 patients had two bifurcation lesions that needed revascularisation. Most bifurcations 
targeted for treatment with the Tryton Sidebranch stent were located in the left anterior 
descending/diagonal junction (72%). Eight stents were implanted in the left main coronary arteries. 
Two bifurcations involved the anastomosis of a saphenous venous graft with a native coronary 
artery; in one on the posterior descending and the other on the left anterior descending artery. A 
left anterior descending/large septal branch bifurcation was also included. 2 bifurcations were 
treated after successful crossing of a chronic total occlusion in 2 patients. Sixty nine percent of 
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lesions were true bifurcation lesions (1,0,1 or 1,1,1 or 0,1,1) with involvement of both the main 
vessel and the sidebranch.  
The mean reference diameters for the proximal main branch (PMB), distal main branch (DMB) and 
side branch (SB) were 2.91, 2.46 and 2.22mm respectively. The mean percentage diameter stenosis 
obtained by including all bifurcations, irrespective of the presence of significant disease in the three 
segments, were 49%, 41% and 40% for PMB, DMB and SB respectively.  The mean angle between 
the PMB and the SB was 152ȗ while that between the DMB and the SB was 53ȗ. These pre-
procedural quantitative coronary angiographic measurements are presented in table 3.  
Ninety nine of the 100 Tryton Sidebranch stents intended for treatment of 100 bifurcation lesions 
were successfully implanted resulting in a 99% device success rate. A case example is illustrated in 
figure 1 with corresponding optical coherence tomography images (Lightlab Imaging, Westford, 
MA) in figure 2. The tapered balloon delivery system was used in 93% of the procedures. Table 4 
lists the various types of stents used as the workhorse principal main vessel stent. Two patients 
received a bare metal stent. Procedural characteristics are shown in table 5. The mean nominal 
diameter of the main vessel stent was 3.0±0.5mm with a mean length of 24±6mm. Additional 
stents overlapping the Tryton stent in the sidebranch were deployed in 16% while in 19% of lesions 
further overlapping stents were implanted in the main vessel. Predilation was performed in 90% 
while final ‘kissing’ ballooning was done in 71%.   
Angiographic success was achieved in 95%; 1 failure of Tryton stent delivery with subsequent 
dissection in a diagonal sidebranch while 4 lesions did not meet the pre-defined angiographic 
success criterion of 30% residual stenosis. In these 4 lesions 38-47% residual stenosis on QCA was 
measured, mainly caused by a disproportionate increase in the distal sidebranch vessel diameter by 
insertion of an additional stent. Periprocedural PCI related MI occurred in the same patient who 
had unsuccessful delivery of the stent. Another patient who presented with acute myocardial 
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infarction with cardiogenic shock and who had a bifurcation treated with good angiographic result 
died within 48 hours of the procedure. Therefore the procedure success was 94%.  
The QCA parameters for the whole cohort pre and post procedure are listed in table 3. The mean 
acute gain in the sidebranch was 0.76±0.64mm. On analysis of a subgroup of bifurcations (n=76) 
with true sidebranch disease  (1,0,1 ; 1,1,1; 0,1,1 and 0,0,1), the mean acute gain was 
0.94±0.60mm.    
In-Hospital and mid-term clinical outcome 
The clinical events are summarized in table 5.  In-hospital MACE rate reached 3%. The only case of 
death was due to cardiac death in the patient treated for STEMI with cardiogenic shock as 
mentioned above. Post procedural elevations of troponins occurred in 11/33 patients treated for 
stable angina but two met criteria of a PCI related myocardial infarction. The first occurred 
secondary to dissection of the diagonal branch in which the Tryton stent could not be delivered. 
The second occurred secondary to transient slow flow in the distal main branch after placement of 
the main vessel stent. There were no cases of definite/probable stent thrombosis or target vessel 
revascularisation.   
30 day follow-up was available in all patients. There were no reported events and therefore the 
MACE is same as the in-hospital outcome.  
Patients were followed up for a median of 6 months. All a patients were compliant with their 
prescribed medications at the time of last contact.  51 patients had at least 6 months follow-up. Up 
to this time point, one patient suffered a myocardial infarction due to occlusion of a vessel other 
than that treated in the index procedure 78 days earlier. The same patient had TLR of SB at 155 
days. A second patient had a TLR so that the percentage of survival free of MACE at 6 months was 
94% as shown in the figure 3. Two other patients with longer than 6 months follow-up had 
ischaemia-driven target lesion revascularisation (194 and 292 days). Restenosis occurred in the 
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main vessel in two patients, in the side branch in the other two.  No cases of stent thrombosis were 
reported.  Thus cumulative MACE rate over a median follow-up period of 206 days (IQR: 125-386) 
at follow up reached 8% as shown in table 5.  
DISCUSSION 
In this registry in an ‘all comer’ population with implantations including 3 for acute myocardial 
infarctions, 8 left main lesions and 2 chronic total occlusions has shown that the Tryton side branch 
stent, used in conjunction with a standard workhorse stent for the treatment of complex 
bifurcation lesions has resulted in a good procedural success rate (94%) and acceptable 8% MACE 
rate at 6 months follow-up. More specifically PCI related MI was limited to 2%, the TLR rate at 
follow up was just 4% and importantly, there were no cases of stent thrombosis.   
Bifurcation intervention is historically associated with worse outcome. [1,8] Although stenting has 
improved the prognosis and DES have further improved it, restenosis and pinching of the 
sidebranch often triggers the need to intervene on the sidebranch. In a bifurcation registry study by 
Kaplan et al 80 of 288 (27.8%) bifurcation lesions treated with one stent initially  required a second 
stent due to severe impairment of the SB during the angioplasty procedure. [9] Despite technical 
improvements in the use of two stent techniques, recent randomised trials failed to show any 
advantage over use of one stent technique in terms of clinical outcome. More so, the provisional 
one stent technique is associated with lower procedural cardiac biomarker release, lower contrast 
dose used and less radiation used. [10-12] 
The culotte technique seems to be the safest, most effective, offering the best long term outcome 
of the two stent techniques.[9,13-15] Table 6 lists the studies that employed the culotte technique 
in the DES era.  A recent randomised study comparing the culotte technique (n=215) and the crush 
technique (n=209) found significant differences in biomarker release (8.8 % vs. 15.5%)  peri-
procedurally favouring the culotte technique though the incidence of major adverse cardiac events 
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including stent thrombosis at 6 months was similar between the two groups. By eliminating the 
need for crushing the side branch stent, theoretically trauma to the bifurcation vessel walls is 
reduced as may be the procedural complications. In the same study, at eight months, angiographic 
follow-up revealed a significantly higher in-stent restenosis in the ‘crush’ group (10.5% vs. 4.5%). 
This can be explained by the better scaffolding of the sidebranch ostium. Also recross into the 
sidebranch is theoretically easier in the culotte group with the guide wire having to cross less layers 
of struts so that final kissing balloon is more likely to be feasible. This last together with the fewer 
overlapping layers of metal is thought to reduce the chance of incomplete stent apposition which 
can then lead to complications such as stent thrombosis and re-stenosis. 
 In the present all comer study, we have noticed similar rates of procedural success as in the FIM 
trial reported by our group. [5] The 94% rate in the present study was slightly lower than that 
reported in a culotte versus T stenting study. [9] One explanation could be the difference in 
scaffolding and recoil properties between the transition zone part of the Tryton stent and a 
standard stent utilised in the conventional culotte technique. In fact the 3 patients with residual 
diameter stenosis (%DS) of >30% after successful Tryton stent  implantation, had their MLD located 
at the sidebranch ostium. The clinical importance of this is however uncertain as there was still a 
significant acute gain in the side branch and none of these patients had a TLR during follow-up. 
Moreover as Koo et al demonstrated, QCA is unreliable to assess the functional significance of 
sidebranch jailing when compared to fractional flow reserve. [16] Of the 4 cases of TLR, 2 occurred 
in the SB covered by the BMS. While we know that the late lumen loss in side branch at 6 months 
averaged 0.17mm in the FIM, being even better than that reported for DES (0.34-0.53mm) the TLR 
rate is less than that reported for two stent techniques.  Studies report TLR rates of 24-43% the 
when two BMS stents are employed and 5.1-28% when two DES are used.[1,9-15,17] 
 Importantly, we did not observe any stent thrombosis in our cohort at 6 months follow-up which 
compares well with previous studies that employed the culotte technique. Adriaenssens et al.  
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reports a 1.5% ST rate at 12 months follow-up in a study with 134 lesions in 132 patients.  The high 
rate of final kissing that aims to ensure adequate strut apposition may be a contributing factor.  
Although general evidence supports the use of simple, single stenting with conventional stents, the 
use of dedicated bifurcation stents especially in cases with significantly narrowed true bifurcations 
where double stenting is highly likely to be performed is probably justified. More data is therefore 
needed from the registries and randomised trials of the use of dedicated bifurcation stents in this 
high risk patient/lesion subset.    
Study Limitations 
The present study has the intrinsic limitations of a registry. Selection bias could have occurred in 
treatment of bifurcation lesions with the study stent.  No control group was used to compare the 
use of this dedicated bifurcation stent and stenting strategy with other devices and techniques. The 
registry was confined to two academic referral centres and the study lesions were limited to 100. 
Also, the patients enrolled had no angiographic or other invasive imaging follow-up. However the 
study still very likely represents the utilisation of the Tryton sidebranch stent and its performance 
in the ‘real world’ everyday practice. 
Conclusions 
In a real world, two centre registry, the use of the Tryton Sidebranch stent is associated with good 
procedural safety and angiographic success rate and acceptable outcome at 6 months of follow-up.  
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dĂďůĞϭ
ĂƐĞůŝŶĞĐůŝŶŝĐĂůĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ

ŚĂƌĂĐƚĞƌŝƐƚŝĐƐ

Eсϵϲ
DĂůĞ

ϳϮ;ϳϱйͿ
ŐĞ͕ǇĞĂƌƐ;ŵĞĂŶц^Ϳ

ϲϯ͘ϵцϴ͘ϴ
ŝĂďĞƚĞƐŵĞůůŝƚƵƐ

ϯϬ;ϯϭйͿ
,ǇƉĞƌƚĞŶƐŝŽŶ

ϱϴ;ϲϬйͿ
,ǇƉĞƌĐŚŽůĞƐƚĞƌŽůĂĞŵŝĂ

ϲϬ;ϲϯйͿ
&ĂŵŝůǇ,ŝƐƚŽƌǇŽĨĐŽƌŽŶĂƌǇĂƌƚĞƌǇĚŝƐĞĂƐĞ

ϰϲ;ϰϴйͿ
^ŵŽŬĞƌ

ϭϳ;ϭϴйͿ
WƌĞǀŝŽƵƐŵǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƚŝŽŶ

ϰϮ;ϰϰйͿ
WƌĞǀŝŽƵƐW/

ϰϬ;ϰϮйͿ
WƌĞǀŝŽƵƐ'

ϴ;ϴйͿ
^ƚĂďůĞŶŐŝŶĂ

ϲϵ;ϳϮйͿ
hŶƐƚĂďůĞŶŐŝŶĂ

Ϯϰ;ϮϱйͿ
^dĞůĞǀĂƚŝŽŶDǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƚŝŽŶ

ϯ;ϯйͿ
ĂƚĂĂƌĞƉƌĞƐĞŶƚĞĚĂƐŶƵŵďĞƌƐ;ƉĞƌĐĞŶƚĂŐĞƐͿŽƌŵĞĂŶц^ƵŶůĞƐƐƐƉĞĐŝĨŝĞĚ͘WĞƌĐĞŶƚĂŐĞƐŚĂǀĞ
ďĞĞŶƌŽƵŶĚĞĚ͘
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dĂďůĞϮ
>ĞƐŝŽŶŚĂƌĂĐƚĞƌŝƐƚŝĐƐ
ĂƚĂƌĞƉƌĞƐĞŶƚƐĂĐƚƵĂůŶƵŵďĞƌǁŚŝĐŚŝƐĞƋƵŝǀĂůĞŶƚƚŽƚŚĞƉĞƌĐĞŶƚĂŐĞƐŝŶĐĞƚŚĞŶƵŵďĞƌŽĨůĞƐŝŽŶƐŝƐϭϬϬƵŶůĞƐƐƐƉĞĐŝĨŝĞĚ͘
ΎϲϮƉĂƚŝĞŶƚƐŽƵƚŽĨϵϲŚĂĚĚŝƐĞĂƐĞŝŶĂǀĞƐƐĞůŽƚŚĞƌƚŚĂŶƚŚĞŽŶĞǁŝƚŚƚŚĞŝŶĚĞǆďŝĨƵƌĐĂƚŝŽŶ
>ĞƐŝŽŶƐ EсϭϬϬ
ŝĨƵƌĐĂƚŝŽŶůŽĐĂƚŝŽŶ

>ĞĨƚDĂŝŶ
>ĞĨƚŶƚĞƌŝŽƌĞƐĐĞŶĚŝŶŐͬŝĂŐŽŶĂů
>ĞĨƚŝƌĐƵŵĨůĞǆͬKďƚƵƐĞDĂƌŐŝŶĂů
WŽƐƚĞƌŽůĂƚĞƌĂůͬWŽƐƚĞƌŝŽƌĞƐĐĞŶĚŝŶŐ
^ĂƉŚĞŶŽƵƐsĞŝŶ'ƌĂĨƚͬEĂƚŝǀĞsĞƐƐĞů
KƚŚĞƌ



ϴ
ϳϮ
ϭϭ
ϱ
Ϯ
Ϯ
DĞĚŝŶĂůĂƐƐŝĨŝĐĂƚŝŽŶ

ϭ͕Ϭ͕Ϭ
ϭ͕ϭ͕Ϭ
Ϭ͕ϭ͕Ϭ
Ϭ͕Ϭ͕ϭ
ϭ͕Ϭ͕ϭ
Ϭ͕ϭ͕ϭ
ϭ͕ϭ͕ϭ



ϭϬ
ϭϭ
ϯ
ϲ
ϭϯ
ϯ
ϱϰ
ĐůĂƐƐŝĨŝĐĂƚŝŽŶ

ϭ
Ϯ



Ϭ
Ϯϴ
ϯϵ
ϯϯ
DƵůƚŝǀĞƐƐĞůĚŝƐĞĂƐĞΎ

ϲϮ;ϲϲйͿ
ŚƌŽŶŝĐƚŽƚĂůŽĐĐůƵƐŝŽŶ

Ϯ
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dĂďůĞϯ
YƵĂŶƚŝƚĂƚŝǀĞĂŶŐŝŽŐƌĂƉŚŝĐƉĂƌĂŵĞƚĞƌƐƉƌĞĂŶĚƉŽƐƚƉƌŽĐĞĚƵƌĂů;ŶсϭϬϬͿ

WĂƌĂŵĞƚĞƌ

WƌĞƉƌŽĐĞĚƵƌĞ WŽƐƚƉƌŽĐĞĚƵƌĞ
WƌŽǆŝŵĂůDĂŝŶƌĂŶĐŚ

D>;ŵŵͿ
ZĞĨĞƌĞŶĐĞĚŝĂŵĞƚĞƌ;ŵŵͿ
йŝĂŵĞƚĞƌƐƚĞŶŽƐŝƐ
ĐƵƚĞŐĂŝŶ;ŵŵͿ


ϭ͘ϰϵцϬ͘ϳϲ
Ϯ͘ϵϭцϬ͘ϲϮ
ϰϵцϮϰ


ϯ͘ϬϵцϬ͘ϰϴ
ϯ͘ϯϮцϬ͘ϱϲ
ϴцϴ
ϭ͘ϲϮцϬ͘ϳϰ
ŝƐƚĂůDĂŝŶƌĂŶĐŚ

D>;ŵŵͿ
ZĞĨĞƌĞŶĐĞĚŝĂŵĞƚĞƌ;ŵŵͿ
йŝĂŵĞƚĞƌƐƚĞŶŽƐŝƐ
ĐƵƚĞŐĂŝŶ;ŵŵͿ


ϭ͘ϰϯцϬ͘ϳϰ
Ϯ͘ϰϲцϬ͘ϱϮ
ϰϭцϮϵ


Ϯ͘ϱϰцϬ͘ϰϰ
Ϯ͘ϳϳцϬ͘ϰϰ
ϴцϴ
ϭ͘ϭϮцϬ͘ϳϳ
^ŝĚĞďƌĂŶĐŚ

D>;ŵŵͿ
ZĞĨĞƌĞŶĐĞĚŝĂŵĞƚĞƌ;ŵŵͿ
йŝĂŵĞƚĞƌƐƚĞŶŽƐŝƐ
ĐƵƚĞŐĂŝŶ;ŵŵͿ


ϭ͘ϯϬцϬ͘ϱϲ
Ϯ͘ϮϮцϬ͘ϰϬ
ϰϬцϮϲ


Ϯ͘ϬϰцϬ͘ϯϲ
Ϯ͘ϯϭцϬ͘ϯϱ
ϭϮцϭϭ
Ϭ͘ϳϲцϬ͘ϲϰ
ŝĨƵƌĐĂƚŝŽŶĂŶŐůĞƐŝŶĚĞŐƌĞĞƐ

WDĂŶĚ^
DĂŶĚ^



ϭϱϭ͘ϲцϭ͘ϱ
ϱϮ͘ϱцϬ͘ϱ


ĂƚĂŝƐĞǆƉƌĞƐƐĞĚŝŶŵĞĂŶц^͘D>сŵŝŶŝŵĂůůƵŵŝŶĂůĚŝĂŵĞƚĞƌ͖WDсƉƌŽǆŝŵĂůŵĂŝŶďƌĂŶĐŚ͖
DсĚŝƐƚĂůŵĂŝŶďƌĂŶĐŚ͖^сƐŝĚĞďƌĂŶĐŚ
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dĂďůĞϰ͗DĂŝŶǀĞƐƐĞůƐƚĞŶƚƐŝŵƉůĂŶƚĞĚ
^ƚĞŶƚŶĂŵĞ DĂŶƵĨĂĐƚƵƌĞƌ ƌƵŐĞůƵƚĞĚ &ƌĞƋƵĞŶĐǇ
yŝĞŶĐĞs ďďŽƚƚsĂƐĐƵůĂƌ͕^ĂŶƚĂůĂƌĂ͕ĂůŝĨ ǀĞƌŽůŝŵƵƐ ϰϳ
yŝĞŶĐĞWƌŝŵĞ ďďŽƚƚsĂƐĐƵůĂƌ͕^ĂŶƚĂůĂƌĂ͕ĂůŝĨ ǀĞƌŽůŝŵƵƐ ϭϳ
dĂǆƵƐ>ŝďĞƌƚĠ ŽƐƚŽŶ^ĐŝĞŶƚŝĨŝĐ͕EĂƚŝĐŬ͕DĂƐƐ WĂĐůŝƚĂǆĞů ϭϯ
EsKZƌĞƐŽůƵƚĞ DĞĚƚƌŽŶŝĐsĂƐĐƵůĂƌ͕^ĂŶƚĂZŽƐĂ͕ĂůŝĨ ŽƚĂƌŽůŝŵƵƐ ϳ
ǇƉŚĞƌ^ĞůĞĐƚ ŽƌĚŝƐŽƌƉ͕tĂƌƌĞŶ͕E: ^ŝƌŽůŝŵƵƐ ϲ
WƌŽŵƵƐ ŽƐƚŽŶ^ĐŝĞŶƚŝĨŝĐ͕EĂƚŝĐŬ͕DĂƐƐ ǀĞƌŽůŝŵƵƐ ϯ
ŝŽŵĂƚƌŝǆ ŝŽƐĞŶƐŽƌƐ/ŶƚĞƌŶĂƚŝŽŶĂů͕^ŝŶŐĂƉŽƌĞ ŝŽůŝŵƵƐϵ ϭ
ŽƌŽĨůĞǆWůĞĂƐĞ ͘ƌĂƵŶ͕DĞůƐƵŶŐĞŶ͕'ĞƌŵĂŶǇ WĂĐůŝƚĂǆĞů ϭ
>ƵĐͲŚŽƉŝŶ ĂůƚŽŶ͕tĂƌƐĂǁ͕WŽůĂŶĚ WĂĐůŝƚĂǆĞů ϭ
^ŬǇůŽƌ /ŶǀĂƚĞĐ͕ƌĞƐĐŝĂ͕/ƚĂůǇ EŽŶĞ ϭ
sŝƐŝŽŶ ďďŽƚƚsĂƐĐƵůĂƌ͕^ĂŶƚĂůĂƌĂ͕ĂůŝĨ EŽŶĞ ϭ

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dĂďůĞϱ͘WƌŽĐĞĚƵƌĂůĂŶĚůŝŶŝĐĂůŽƵƚĐŽŵĞ;ůĞƐŝŽŶŶсϵϵͿ
WƌĞĚŝůĂƚŝŽŶ
^ŝĚĞƌĂŶĐŚ
DĂŝŶsĞƐƐĞů
^ĞƉĂƌĂƚĞWŽƐƚĚŝůĂƚŝŽŶ
&ŝŶĂů<ŝƐƐŝŶŐ
ĚĚŝƚŝŽŶĂůŽǀĞƌůĂƉƉŝŶŐƐƚĞŶƚŝŵƉůĂŶƚĂƚŝŽŶΎ
^ŝĚĞƌĂŶĐŚ
DĂŝŶsĞƐƐĞů
dŽƚĂůƐƚĞŶƚƐŝŵƉůĂŶƚĞĚ
^ƚĞŶƚƐƉĞƌďŝĨƵƌĐĂƚŝŽŶ
^ƚĞŶƚƐƉĞƌƉĂƚŝĞŶƚ
DƵůƚŝǀĞƐƐĞůƐƚĞŶƚŝŶŐŝŶŝŶĚĞǆƉƌŽĐĞĚƵƌĞ


ϲϵ;ϳϬйͿ
ϴϯ;ϴϰйͿ
ϳϭ;ϳϮйͿ
ϳϬ;ϳϭйͿ

ϭϱ;ϭϲйͿ
ϭϵ;ϮϬйͿ
Ϯϳϱ
Ϯ͘ϰцϬ͘ϳ
Ϯ͘ϵцϭ͘ϯ
Ϯϲ;ϮϲйͿ
ĐƵƚĞƉƌŽĐĞĚƵƌĂůŽƵƚĐŽŵĞ

ĞǀŝĐĞƐƵĐĐĞƐƐ
ŶŐŝŽŐƌĂƉŚŝĐƐƵĐĐĞƐƐ
W/ƌĞůĂƚĞĚďŝŽŵĂƌŬĞƌĞůĞǀĂƚŝŽŶ
W/ƌĞůĂƚĞĚD/
WƌŽĐĞĚƵƌĂůƐƵĐĐĞƐƐ

EсϭϬϬ

ϵϵ
ϵϱ
ϭϭͬϯϯ;ϯϯйͿ
Ϯ
ϵϰ

/ŶͲŚŽƐƉŝƚĂůŽƵƚĐŽŵĞΒ

ĂƌĚŝĂĐĞĂƚŚ
DǇŽĐĂƌĚŝĂů/ŶĨĂƌĐƚŝŽŶ
'
dĂƌŐĞƚ>ĞƐŝŽŶZĞǀĂƐĐƵůĂƌŝƐĂƚŝŽŶ
dĂƌŐĞƚsĞƐƐĞůZĞǀĂƐĐƵůĂƌŝƐĂƚŝŽŶ
ĞĨŝŶŝƚĞͬWƌŽďĂďůĞƐƚĞŶƚƚŚƌŽŵďŽƐŝƐ
ĂƌĚŝĂĐĚĞĂƚŚŽƌD/
D;ĐĂƌĚŝĂĐĚĞĂƚŚ͕D/͕'Žƌd>ZͿ

Eсϵϲ

ϭ
Ϯ
Ϭ
Ϭ
Ϭ
Ϭ
Ϯ
Ϯ

DĞĚŝĂŶϲŵŽŶƚŚŽƵƚĐŽŵĞ;ĐƵŵƵůĂƚŝǀĞͿΒ

ĂƌĚŝĂĐĞĂƚŚ
DǇŽĐĂƌĚŝĂů/ŶĨĂƌĐƚŝŽŶ
'
dĂƌŐĞƚ>ĞƐŝŽŶZĞǀĂƐĐƵůĂƌŝƐĂƚŝŽŶ
dĂƌŐĞƚsĞƐƐĞůZĞǀĂƐĐƵůĂƌŝƐĂƚŝŽŶ
ĞĨŝŶŝƚĞͬWƌŽďĂďůĞƐƚĞŶƚƚŚƌŽŵďŽƐŝƐ
ĂƌĚŝĂĐĚĞĂƚŚŽƌD/
D;ĐĂƌĚŝĂĐĚĞĂƚŚ͕D/͕'Žƌd>ZͿ
ĞǀŝĐĞͬW/ƐƚƌĂƚĞŐǇͲƌĞůĂƚĞĚDΑ

Eсϵϲ

ϭ
ϯ
Ϭ
ϰ
ϰ
Ϭ
ϯ
ϴ
ϴ

ĂƚĂĂƌĞĞǆƉƌĞƐƐĞĚŝŶŶƵŵďĞƌƐĂŶĚƉĞƌĐĞŶƚĂŐĞƐ͘D/сŵǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƚŝŽŶ͖'сĐŽƌŽŶĂƌǇĂƌƚĞƌǇďǇƉĂƐƐŐƌĂĨƚŝŶŐ͖d>Zс
ƚĂƌŐĞƚůĞƐŝŽŶƌĞǀĂƐĐƵůĂƌŝƐĂƚŝŽŶ͘ΎZĞĨĞƌƐƚŽŶƵŵďĞƌŽĨůĞƐŝŽŶƐƌĞƋƵŝƌŝŶŐĞǆƚƌĂƐƚĞŶƚĂƉĂƌƚĨƌŽŵƚŚĞdƌǇƚŽŶƐƚĞŶƚĂŶĚƚŚĞ
ŵĂŝŶǀĞƐƐĞůƐƚĞŶƚ͘ΒĂƚĂĞǆƉƌĞƐƐĞĚŝŶĂĐƚƵĂůŶƵŵďĞƌƐǁŚŝĐŚŝƐĂůƐŽĞƋƵŝǀĂůĞŶƚƚŽƉĞƌĐĞŶƚĂŐĞƐ͘ΑǆĐůƵĚĞƐŽŶĞƉĂƚŝĞŶƚǁŝƚŚ
ĂD/ĂƚĨŽůůŽǁƵƉŝŶĂƚĞƌƌŝƚŽƌǇŽƚŚĞƌƚŚĂŶƚŚĂƚƐƵƉƉůŝĞĚďǇƚƌĞĂƚĞĚǀĞƐƐĞůĂŶĚĂŶŽƚŚĞƌǁŚŽĚŝĞĚŽĨĐĂƌĚŝŽŐĞŶŝĐƐŚŽĐŬƚŚĂƚ
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Case example of Tryton Side Branch Stent insertion in the left main (LM) coronary 
bifurcation. (A) Diagnostic angiogram of a patient with previous left internal mammary graft to the 
left anterior descending artery, and persistent ischaemia, showing significant disease at the LM 
bifurcation. (B) Positioning of the Tryton stent in the smaller calibre left anterior descending artery, 
in this case considered the Side Branch. Note the straddling of the carina with the middle two 
markers. (C) Deployment of Tryton by inflation of the stepped balloon. Guide wire retraction and 
redirection into the dominant larger left circumflex artery (main vessel) was followed by deployment 
of a standard drug eluting stent with proximal part in 
LM and distal part in left circumflex (D). Wire re-cross into side branch and fenestration with 
small balloon allowed final kissing balloon inflation (E). Angiographic result at the end of 
procedure (F,G).  
40x30mm (600 x 600 DPI)  
Ch
ap
te
r 1
1
232
 
 
Optical coherence tomography performed after treatment of the left main coronary artery 
bifurcation described in figure 1. Pullback from the left anterior descending artery shows good 
apposition of the Tryton stent (right upper panel). Pullback from the left circumflex artery also 
shows good standard stent apposition in left circumflex (right lower panel). Left main coronary 
imaging shows minimal strut overlap (left upper panel). Imaging at the bifurcation also reveals 
satisfactory strut apposition (right lower panel).  
40x30mm (600 x 600 DPI)  
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Abstract: 
Objectives: This study compared the 5-year clinical outcomes of diabetic patients with 
multivessel disease who were treated with bare metal stents (BMS), sirolimus eluting stents 
(SES),  and coronary artery bypass surgery (CABG) and enrolled in the Arterial 
Revascularization Therapies Studies (ARTS) Part I and II. 
Background: Diabetes is an established risk factor for major adverse cardiac events after 
revascularization. Recent trials, however, suggest that up to two years revascularization with 
drug eluting stents has equivalent safety to by-pass surgery up to two-years. 
Methods and Results: The ARTS I and II included 367 diabetic patients (BMS: 112, SES: 159 
and CABG: 96) and 1445 non-diabetic patients (BMS: 509, SES 448 and CABG 488). The 
rate of major adverse cardiovascular and cerebrovascular events (MACCE), a composite of 
death, myocardial infarction, stroke and repeat revascularization was significantly higher in 
diabetic patients treated with BMS (BMS 53.6% vs. SES 40.5% vs. CABG 23.4%; Log rank 
p<0.01for SES vs. BMS and SES vs. CABG). Overall there were no significant differences in 
either mortality (BMS 13.6%, SES 9.0%, CABG 8.6%, p=0.23 for SES vs. BMS and p=0.91 
for SES vs. CABG) or MI (BMS 11.0%, SES 4.8% and CABG 5.2%, p=0.04 for SES vs. 
BMS and p=0.76 for SES vs. CABG) amongst all three treatment groups. The rate of repeat 
revascularization was significantly lower in patients treated with CABG compared to patients 
treated with SES (SES 33.2% vs. CABG 10.7%, p<0.001). The superior outcomes with 
CABG persisted even after adjustment of confounding factors. Revascularization rate of 
patients treated with SES at 5 years approached that of patients treated with BMS (43.7%), 
although it remained significantly lower. This “catch-up” phenomenon was not apparent in 
the non-diabetic population.   
Conclusion: In our diabetic population with multivessel disease, the 5-year mortality was 
comparable between BMS, SES and CABG, while CABG showed superior efficacy in terms 
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of reducing repeat revascularization compared to BMS and SES. MI rate was twofold higher 
in diabetic patients treated with BMS than in patients treated with either SES or CABG. 
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Introduction: 
Diabetes mellitus is an established risk factor for development and progression of coronary 
atherosclerosis, and is associated with an increased incidence of major adverse cardiac events 
(MACE) after revascularization.(1, -2) The difference in MACE between diabetic and non-
diabetic patients treated with percutaneous revascularization has consistently been driven by 
the higher rates of repeat revascularization in diabetic patients.(3, -4) Similarly, among 
diabetic patients with multivessel (MVD) disease randomized to treatment with percutaneous 
coronary intervention (PCI) or coronary artery bypass surgery (CABG), a correspondingly 
higher rate of repeat revascularization has been seen in those treated with PCI. With respect to 
mortality, other than the BARI trial which reported a lower mortality with CABG compared 
to balloon angioplasty,(5) more contemporary studies report equivalent mortality amongst 
diabetic patients with MVD treated with CABG or PCI with either bare metal or drug eluting 
stents (DES).(4, 6-10)  
 
At present there are limited data on the long-term follow-up of patients with diabetes and 
MVD treated with DES. The Arterial Revascularization Therapies Part I (ARTS-I) and Part II 
(ARTS-II) studies both recruited patients with MVD using the same inclusion criteria.(11, -
12) In the ARTS-I study patients were randomized to treatment with a bare metal stent (BMS) 
or CABG, while in the single arm ARTS-II study all patients received a sirolimus eluting 
stent (SES). The 3-year outcomes of 367 patients with diabetes from the ARTS-I and ARTS-
II study have been published previously.(3) The aim of this report was to describe the 5-year 
outcomes of this important sub-group of patients, which consequently represents the longest 
reported follow-up of diabetic patients with MVD treated with DES. (3, -4) 
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Methods: 
ARTS-II study design: 
The ARTS-I and ARTS-II studies has been published previously.(11, -12)  In brief, the ARTS-
II study was a multicenter non-randomized open label trial designed to assess the safety and 
efficacy of SES in patients with native MVD, and to compare the results with historical 
controls enrolled in the ARTS-I study.(3,13-14) 
3, 14 
The inclusion and exclusion criteria for both studies were the same. Patients with stable or 
unstable angina, or silent ischemia who had 2 coronary lesions, located in different major 
epicardial vessels and/or their side-branches (not including the left main stem) that were 
potentially amenable to stent implantation were eligible for inclusion. All patients were 
required to have a lesion with a diameter stenosis>50% in the LAD, and 1 other major 
epicardial coronary artery.  Stents with a diameter of 2.5 to 3.5mm and length up to 33mm 
were used. The goal was to achieve complete anatomic revascularization. There was no 
restriction on the total implanted stent length. Decisions to place stents in lesions with 
bifurcations, fresh thrombus, calcification, diffuse disease, complex anatomy or stenting of 
side branches were left to the discretion of the operators.  
 
Patients with any prior coronary intervention, left main coronary disease, overt congestive 
heart failure or a left ventricular ejection fraction of less than 30% were excluded. Additional 
exclusion criteria included: history of a cerebrovascular accident, transmural myocardial 
infarction in the preceding week, severe hepatic or renal disease, neutropenia or 
thrombocytopenia, intolerance or contraindication to acetylsalicylic acid or thienopyridines, 
need for concomitant major surgery, and life-limiting major non-cardiac diseases. The study 
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was approved by the ethical committees of each participation institution. All patients signed 
informed consent prior to study entry. 
 
Patient population: 
In total 367 diabetic patients (20.4% of the overall ARTS I and II population) were studied in 
this analysis comprising of the 218 diabetic patients enrolled in the ARTS-I trial who were 
treated with BMS (n=112) or CABG (n=96), and the 159 diabetic patients enrolled in ARTS-
II treated with SES. In addition, comparison is made with the non-diabetic patient cohort. 
 
Study objectives and Endpoints: 
The primary objectives of the present analysis were to assess the long-term safety and 
efficacy of the SES compared to BMS and CABG in patients with diabetes and MVD. 
Comparison with the non-diabetic population is also provided. 
 
The primary endpoint of this study was 5-year MACCE, a composite of death, stroke, 
myocardial infarction (MI), and repeat revascularization. Other secondary endpoints included: 
death, stroke, MI, repeat revascularization, and stent thrombosis at 5-year follow-up. 
 
Endpoints and definitions: 
Deaths from all causes were reported.  Cerebrovascular events (CVA) included: stroke, 
transient ischemic attacks, and reversible ischemic neurologic deficits.  Within 7 days after 
the intervention, a diagnosis of myocardial infarction was made if new abnormal Q-waves 
(according to the Minnesota code) and either a ratio of serum creatine kinase MB (CK-MB) 
isoenzyme to total cardiac enzyme that was greater than 0.1 or a CK-MB value that was 5 
times the upper limit of normal were present. Serum creatine kinase levels were measured 6 
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and 12 hours after the intervention and before discharge. Beginning 8 days after the 
intervention, either abnormal Q-waves or enzymatic changes were sufficient for a diagnosis of 
myocardial infarction. This two-part method of defining myocardial infarction was developed 
for ARTS I to address the difficulty of diagnosing a myocardial infarction after surgery. A 
myocardial infarction was confirmed only after the relevant electrocardiograms had been an-
alyzed by the electrocardiographic core laboratory. All repeat revascularization procedures 
were recorded.  Events were counted from the time of the start of the initial procedure. All 
clinical events were adjudicated by the clinical events committee. Five year clinical follow-up 
was required in all patients and was obtained via a telephone interview with the patient, and 
when needed also the patient’s physician. The incidence of stent thrombosis according to the 
Academic Research Consortium definitions was only available for patients in ARTS-II.(15) 
Renal impairment was classified by estimated creatinine clearance (Ccr) calculated by use of 
the Cockcroft–Gault formula(16): Ccr (mL/min) = [(140 - age) x weight (kg)] / [serum 
creatinine (mg/dL) x 72]. The formula was multiplied by a factor of 0.85 for female patients. 
Patients who had Ccr < 60 mL/min was regarded as renal impairment. Amongst 1205 patients 
in the ARTS I, 1062 patients (88%) had their Ccr level before the revascularization, while in 
the ARTS II, 580 patients (96%) had CCR level pre-procedure amongst 607 patients.  
 
 
Statistical analysis: 
Baseline characteristics were compared for diabetic patients in both ARTS-I and ARTS-II 
trial. Continuous variables are reported as mean + standard deviation. Binary variable are 
reported as percentages with 95% confidence intervals. Two group t-test and Fisher tests were 
used for continuous and discrete variables respectively. Time-to-event variables are presented 
as Kaplan-Meier curves generated using log-rank test. To compensate for differences in 
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baseline and procedural characteristics between patients enrolled in ARTS-I and ARTS-II 
outcomes were adjusted using a Cox regression analysis with adjustments made for the 
potential confounding factors (listed in table 3). Unadjusted hazard ratios are also reported in 
table 2. Post hoc Bonferroni correction was performed for ANOVA analysis. All analyses 
were performed using SPSS. 
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Results: 
Baseline characteristics of diabetic patients:  
Baseline and procedural characteristics of the 367 diabetic patients enrolled in the ARTS-I 
and ARTS-II trials are summarized in Table 1 and 2. Patients treated with SES were 
significantly more likely to be hypertensive, have hypercholesterolemia, and complex 
coronary artery disease (type C lesions) compared to historical controls from the ARTS-I trial. 
Consequently, a greater number of stents and an overall longer total length was implanted in 
the ARTS-II cohort. In addition, reported completeness of revascularization was lower for 
patients treated with SES versus BMS (68.6% for BMS versus 59.9% for SES treated patients 
and 77.4% for CABG treated patients with diabetes; p=0.017). 
 
Five-year clinical outcomes: 
Overall MACCE, death, MI, CVA and repeat revascularization rates at 5 years are reported in 
Kaplan-Meier curves (Figure 1 A-F). The event rates were higher than those reported for the 
overall ARTS-I and ARTS-II populations (17). MACCE rate was the highest in patients 
treated with BMS (BMS 53.8% versus SES 40.5% versus CABG 23.4%; log rank p-values 
for SES vs. BMS and SES vs. CABG p<0.001). Cumulative incidence of all-cause mortality 
was 13.6%, 9.0% and 8.6%  for patients treated with BMS, SES and CABG, respectively (log 
rank for SES vs. BMS p=0.23; SES vs. CABG p=0.91). The rate of myocardial infarction was 
highest (11.0%) for BMS, versus 4.8% for SES-treated patients and 5.2% for CABG patients 
(log rank SES vs. BMS p=0.04; SES vs. CABG p=0.76); with a statistically significant 
difference between SES and BMS. There were no differences in the rates of cerebrovascular 
events between treatment groups at 5 years. Rates of repeat revascularization were the highest 
in the BMS revascularization group at 43.7% versus 33.2% in the SES treated group and 
10.7% in the CABG group (logrank SES vs. BMS p=0.02; SES vs. CABG p<0.01).  
Ch
ap
te
r 1
2
244
In SES group, clopidogrel use at 5 years was 13.2% in diabetic patients and 23.2% in non-
diabetic patients (p=0.008). Aspirin use was 68.6% in the diabetic patients and 77.7% in the 
non-diabetic patients (p=0.03). 
 
Cox regression analysis: The hazard ratios (adjusted for baseline characteristics) for CABG 
versus SES and BMS versus SES are shown in Table 3. Treatment with BMS conferred 
significantly higher risk of MACCE, death, MI and repeat revascularization than treatment 
with SES. CABG offered no advantage over treatment with SES in terms of mortality or risk 
of myocardial infarction. There was a reduced risk of repeat revascularization and overall 
(revascularization driven) MACCE with CABG compared to treatment with SES in diabetic 
patients. Similar analysis in the non-diabetic population (Table 3) showed equivalent hazard 
ratios for MACCE and MI between CABG and SES and higher mortality for CABG. 
Revascularization rates remained higher in the SES group when compared to CABG, although 
the HR was 0.54 in the non-diabetic population versus 0.31 in the diabetic population. The 
interaction, however, between treatment type and diabetic status was non-significant for all 
clinical end-points.  
 
Stent thrombosis: In diabetic patients treated with SES there were a total of 17 stent 
thrombosis events (10.7%) with 6 definite, 6 probable  and 5 possible stent thrombosis events. 
This is higher than the overall stent thrombosis rate reported for the ARTS-II population of 
9.4% and 8.7% for the non-diabetic subgroup. The rate of definite stent thrombosis in both the 
diabetic and non-diabetic patient population was 3.8%. Two late and two very late stent 
thrombosis cases occurred in the diabetic patient population. Two patients with diabetes 
receiving SES (1.3% of 159) and 12 patients without diabetes receiving SES suffered from 
very late stent thrombosis (2.7% of 448). 
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Discussion 
In this analysis we present a 5 years outcome of PCI with the SES in diabetic patients with 
multivessel disease. At three years follow-up of the ARTS-II trial, patients treated with SES 
had lower MACCE rates that patients treated with BMS PCI and CABG in ARTS-I, although 
the differences did not reach statistical significance.(3) In contrast, at 5 years follow-up 
MACCE rates were lowest for diabetic patients treated with CABG in ARTS-I. Patients 
treated with SES had a MACCE rate lower than that of patients treated with BMS PCI in 
ARTS-I but considerably higher than that of patients treated with CABG. As illustrated by the 
Kaplan-Meier curves for MACCE (Figure 1 A), while the event rate for patients treated with 
BMS and CABG reach an asymptotic value at 1 year, events continue to accumulate for 
patients treated with SES in ARTS-II. After two years this increase in events is partly 
explained by an increase in myocardial infarction rates (Figure 1 B). This “catch-up” 
phenomenon is much more apparent in the diabetic population compared to non-diabetic 
patients (Table 3). The rate of repeat revascularizations also continues to accumulate 
approaching closer to that of the BMS treated patients at 5 years (Figure 1 F). Cox regression 
model hazard ratios suggest  an advantage of CABG over SES in reducing repeat 
revascularization procedures but equivalence of the two procedures in terms of mortality and 
myocardial infarction risk after adjusting for baseline covariates in patients with diabetes 
(Table 3). SES clearly reduced the risk of myocardial infarction, repeat revascularization and 
overall MACCE but had only a non-significant effect on mortality compared to treatment with 
BMS. Overall stent thrombosis rate in the diabetic population treated with DES is 10.7% at 5 
years, which is somewhat higher than that observed in the overall ARTS-II population (9.4%). 
The rates of definite stent thrombosis in diabetic and non-diabetic patients are the same at 
3.8% with two thirds of the cases classified as late or very late stent thrombosis. 
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Our analysis at 5 years follow-up is in agreement with other recent trials such as CARDIA 
and SYNTAX which also demonstrate equivalent mortality of PCI with drug eluting stents 
and CABG in patients with diabetes at one year follow-up.(4, 9, -10) Both of these studies also 
demonstrate consistently higher revascularization rates in the PCI arms versus CABG arm. 
The SYNTAX diabetic subgroup analysis may have, however, been underpowered to detect 
differences in mortality at 1 and 2 years. Our results are also consistent with the BARI-2D 
trial findings where survival rates were similar between PCI treated and CABG treated groups 
(86.4% for CABG vs. 89.2% for PCI) at 5 years. The differences in the MACE-free survival 
rate in patients with multivessel disease randomized to CABG versus medical therapy were 
statistically significant but no such difference was appreciated in patients randomized to PCI 
versus medical therapy. Effectiveness of PCI over medical therapy versus CABG will be 
assessed in the FREEDOM trial, the first properly powered prospective trial of 
revascularization strategies in diabetic patients. 
Limitations: 
This study is a sub-analysis of the main ARTS-I and ARTS-II trials and hence suffers from 
inherent limitations, such as the lack of sufficient power because of the limited number of 
patients in the subgroups to provide definite answers. While the protocol required that the 
lesions in ARTS-II be potentially treatable by CABG, the absence of dialogue with the 
surgeons prior to the intervention may have caused a selection bias. Another potential bias of 
this study is that a five-year time difference exists between the groups that were being 
compared, and technology and medical practice have improved with time, as have surgical 
mortality rates. The study is non-randomized and consequently statistical adjustment is 
required to correct for the differences between the current study population and the historical 
ARTS-I population.   
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However, the results of the study after adjustment for differences in risk factors did not 
substantially differ from the unadjusted outcome, since the patients enrolled in ARTS-II were 
in fact more complex in terms of demographics and lesion characteristics than those included 
in ARTS-I. In addition, some of the factors such as stent length used or operator’s willingness 
to treat more complex lesions with drug eluting stents or use of dual anti-platelet agents could 
not be adjusted for and can be a confounding factor in the analysis. Given low numbers of 
events in some of the subgroups the multivariate model may have been over-fitted. 
 
Conclusions: 
When compared to the outcome of the diabetic patients with multivessel disease treated with 
either PCI or CABG, the overall MACCE-free survival rate at 5 years in patients treated with 
SES  is higher than in patients treated with CABG and, while still more favorable than in 
patients treated with BMS, it appears to approach the rate of events in the BMS treated group. 
The MACCE rate in diabetic patients treated with SES is predominantly driven by the rate of 
repeat revascularization. The mortality in the SES treated  population is similar to that of 
CABG patients at 5 years. Myocardial infarction rate was two-fold higher in diabetic patients 
treated with BMS than in patients treated with either SES or CABG. At five years follow-up 
CABG appears to have better outcomes than PCI in a diabetic patient population by virtue of 
reducing repeat revascularization rates making CABG the preferred treatment for this 
subgroup of patients with multivessel disease. 
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Table 1. Baseline clinical and angiographic characteristics 
 
 Diabetic patients  Non-Diabetic patients  
  BMS   (N=112) SES        (N=159) CABG   (N=96) P-value BMS   (N=509) SES        (N=448) CABG     (N=488) P-value 
Age in years, mean  63 65 63 0.12 60 62 61 0.01 
Ejection Fraction, % 61 60 60 0.81 61 60 60 0.66 
Male % 73 67 69 0.53 78 80 77 0.56 
Diabetes insulin-treated % 21 18 17 0.78     
Hypertension % 64 80 56 <0.01 40 63 43 <0.01 
Hypercholesterolemia % 55 74 49 <0.01 59 74 59 <0.01 
Renal impairment, %* 15 5 15 <0.01 13 4 14 <0.01 
Previous MI % 41 30 49 <0.01 41 36 41 0.02 
Previous PCI % 2 0 2 0.17 1 1 2 0.1 
Current Smoking, % 21 12 17 0.15 30 22 28 0.02 
Unstable Angina % 38 32 33 0.64 38 38 38 1
Stable Angina % 59 54 63 0.35 56 53 57 0.45 
Silent Ischaemia % 4 15 4 <0.01 7 9 5 0.04 
2 Vessel Disease, % 65 49 64 0.01 69 45 67 <0.01 
3 Vessel Disease, % 31 50 35 <0.01 27 55 29 <0.01 
Total Number of 
implanted stent, mean±SD 3.0±1.5 3.6±1.5  <0.01 2.7±1.2 3.7±1.5  <0.01 
Total Stented Length in 
mm, mean±SD 52.7±25.6 73.9±31.9  <0.01 46.4±20.6 72.0±32.1  <0.01 
Max. Stent Pressure in 
atm, mean±SD 14.9±2.9 16.2±2.7   <0.01 14.6±2.8 16.4±2.9   <0.01 
 
*Patients who had Ccr < 60 mL/min (calculated by Cockcroft-Gault formula) was regarded as renal impairment. 
MI = myocardial infarction, PCI = percutaneous coronary intervention, SD = standard deviation, CABG = coronary artery bypass graft, SES = 
sirolimus-eluting stent, BMS = bare-metal stent 
Table 2. Unadjusted Non-hierarchical event rates up to 1800 days and hazard ratios  
 
 
 Diabetic patients Non-Diabetic patients 
 BMS  SES  CABG  
HR            
CABG vs. 
SES  p-value
HR            
BMS vs. SES p-value BMS  SES  CABG  
HR           
CABG vs. 
SES  p-value  
HR            
BMS vs. SES p-value  
MACCE  
60 
(53.6%)  
63    
(39.6%)  
22 
(22.9%)  
0.54        
(0.34-0.88) 0.014 
1.65      
(1.16-2.35) 0.006 
187 
(38.3%) 
102  
(22.8%)  
103 
(20.5%) 
0.93        
(0.70-1.22) 0.575 
1.94        
(1.53-2.47) <0.001
Death  
15 
(13.4%)  
14   
(8.8%)  
8 
(8.3%)  
0.95        
(0.40-2.27) 0.911 
1.56     
(0.76-3.24) 0.229 
32 
(6.6%)  
19   
(4.2%)  
35 
(7.0%)  
1.70        
(0.97-2.97) 0.063 
1.57        
(0.89-2.78) 0.118 
CVA  
7    
(6.3%)  
9 
(5.7%)  
6 
(6.3%)  
1.24        
(0.42-3.65) 0.7 
1.33     
(0.49-3.59) 0.58 
16 
(3.3%)  
13  
(2.9%)  
14 
(2.8%)  
0.99        
(0.45-2.18) 0.99 
1.34        
(0.81-2.23) 0.25 
MI  
12 
(10.7%)  
7 
(4.4%)  
5 
(5.2%)  
1.20        
(0.38-3.78) 0.754 
2.65     
(1.01-6.51) 0.048 
37 
(7.6%)  
28   
(6.3%)  
29 
(5.8%)  
0.96        
(0.57-1.61) 0.866 
1.25        
(0.76-2.04) 0.379 
Revasc. 
47 
(42.0%)  
50 
(31.4%)  
10 
(10.4%)  
0.29        
(0.15-0.57) <0.001
1.58     
(1.06-2.35) 0.025 
134 
(27.5%) 
73 
(16.3%) 
42     
(8.4%)  
0.51        
(0.35-0.74) <0.001
1.88        
(1.41-2.50) <0.001
 
MACCE = Major adverse cardiac and cerebrovascular events (a composite of all-cause mortality, myocardial infarction, cardiovascular accident, 
or revascularization), CVA = cardiovascular accident, MI = myocardial infarction, Revasc. = Revascularization, CABG = coronary artery bypass 
graft, SES = sirolimus-eluting stent, BMS = bare-metal stent 
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Table 3. Adjusted hazard ratios 
 
 Diabetic patients Non-diabetic patients
 HR             
CABG vs. SES  p-value 
HR            
BMS vs. SES p-value 
HR           
CABG vs. SES   p-value  
HR          
BMS vs. SES p-value  
Death 1.11          (0.47-2.66) 0.812 
1.77         
(0.85-3.67) 0.127 
1.99         
(1.12-3.53)  0.02 
1.88        
(1.05-3.38) 0.04 
CVA 1.24         (0.42-3.65) 0.7 
1.33          
(0.49-3.59) 0.58 
0.99         
(0.45-2.18)  0.99 
1.15        
(0.53-2.50) 0.72 
MI 1.19          (0.38-3.76) 0.763 
2.55         
(1.00-6.47) 0.049 
1.01          
(0.60-1.73)  0.96 
1.34        
(0.81-2.23) 0.25 
Death/CVA/MI 1.33          (0.70-2.50) 0.38 
2.09          
(1.21-3.62) <0.01 
1.26          
(0.83-1.72)  0.33 
1.49        
(1.05-2.11) 0.03 
Any Revasc. 0.31         (0.16-0.62) 0.001 
1.61         
(1.08-2.41) 0.02 
0.54         
(0.37-0.80)  <0.01  
2.01        
(1.49-2.71) <0.01  
MACCE 0.58         (0.36-0.95) 0.03 
1.80         
(1.25-2.57) 0.001 
0.97          
(0.75-1.32)  0.97 
2.10        
(1.64-2.70) <0.01  
Hazard ratios are presented with 95% confindence interval in brackets. The cox regression models are constructed to adjust the following 
variables: age, gender, previous myocardial infarction, history of revascularization, CABG, insuline dependence (only for diabetic patients), 
current smoking, dyslipidemia and hypertension. 
HR = hazard ratio, CVA = cerebrovascular accident, MI = myocardial infarction, Revasc. = Revascularization, MACCE= Major adverse cardiac 
and cerebrovascular events (a composite of all-cause mortality, myocardial infarction, cardiovascular accident, or revascularization), CABG = 
coronary artery bypass graft, SES = sirolimus-eluting stent, BMS = bare-metal stent 
Figure legend 
 
Figures 1 present cumulative Kaplan-Meier incidence estimates up to 5 years in diabetics and 
in non-diabetics, i) for MACCE (major adverse cardiac and cerebrovascular events [a 
composite of all-cause mortality, myocardial infarction, cardiovascular accident, or 
revascularization]) (A), ii) for all-cause mortality (B), iii) for myocardial infarction (C), iv) 
cerebrovascular accidents (D), v) for a composite endpoints of death, cerebrovascular 
accidents, or myocardial infarction (E), and vi) for any revascularization (F).  
 
BMS = Bare-metal stents, SES = Sirolimus-eluting stents, CABG = Coronary artery bypass 
graft 
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Figure 1 A. Cumulative incidence of 
MACCE up to 5 years
Diabetics Non-Diabetics
60 60 BMS
%%
SESvs BMSLogrankp<0 01
50 50
CABG
SESBMS 53.8%
SES 40 5% SESvs CABG Logrank p=0 57
. .
SESvs. CABG Logrankp<0.01
SESvs. BMSLogrankp<0.01
40
30
40
30
 .
BMS 38.7%
.   .
20 20
CABG 23.4%
CABG 20 7%
SES 22.9%
10
0
10
0
 .
0 1 2 3 4 5 0 1 2 3 4 5
Time (Years) Time (Years)
Figure 1 B. Cumulative incidence of all-
cause mortality up to 5 years
Diabetics Non-Diabetics
60 60BMS BMS
%%
50 50
CABG
SES
CABG
SES
SES vs. BMSLogrank p=0.23 SES vs. BMS Logrank p=0.11
40
30
40
30
SES vs. CABG Logrank p=0.91 SES vs. CABG Logrankp=0.06
20 20BMS 13.6%
SES 9 0%
10
0
10
0
 .
CABG 8.6%
BMS 6.7%
SES 4 3%
CABG 7.1%
0 1 2 3 4 5 0 1 2 3 4 5
Time (Years) Time (Years)
  .
Diabetic patients in ARTS-II (5 year data) 253
Figure 1 C. Cumulative incidence of 
Myocardial Infarction up to 5 years
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Figure 1 D. Cumulative incidence of 
CVA up to 5 years
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Figure 1 E. Cumulative incidence of 
Death/CVA/MI up to 5 years
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Figure 1 F. Cumulative incidence of 
Any revascularization up to 5 years
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ABSTRACT:
Objectives: The current study reports clinical outcomes at three year follow-up of the LEADERS 
clinical trial which was the fi rst all-comers trial comparing a new generation biodegradable 
polymer biolimus drug eluting stent (BES) with the fi rst generation permanent polymer siroli-
mus eluting stent (SES).
Methods and results: 1,707 patients were randomized to unrestricted use of BES (n=857) 
or SES (n=850) in an all-comers population. Three year follow up was available in 95% of the 
patients, 812 treated with BES and 809 treated with SES. At three years BES remains non-inferior 
to SES for the primary endpoint of major adverse cardiac events (composite of cardiac death, 
myocardial infarction (MI), or clinically-indicated target vessel revascularization (CI-TVR) (BES 
15.7% versus SES 19%; HR 0.82 CI 0.65-1.03; p=0.09). The MACE Kaplan Meier event curves 
increasingly diverge with the diff erence in events increasing from 1.4% to 2.4% and 3.3% at 
1, 2 and 3 years, respectively in favor of BES. The rate of cardiac death was non-signifi cantly 
lower 4.2% versus 5.2% (HR=0.81 CI 0.52-1.26; p=0.34) and the rate of myocardial infarction was 
equivalent 7.2% versus 7.1% (HR 1.01 CI 0.70-1.44; p=0.97) for BES versus SES, respectively. Thus 
BES was non-inferior to SES in all the safety end-points. Clinically-indicated TVR occurred in 
9.4% of BES treated patients versus 11.1% of SES treated patients (HR 0.84 CI 0.62-1.13; p=0.25). 
Rates of defi nite stent thrombosis were 2.2% for BES and 2.9% for SES (HR 0.78 CI 0.43-1.43; 
p=0.43), with the event rate increase of 0.2% from 1 to 3 years for BES and 0.9% for SES. For 
patients presenting with ST elevation myocardial infarction.BES was superior to SES in reducing 
MACE.
Conclusions: The fi ndings of the three year follow-up support the claim that biodegradable 
polymer biolimus eluting stent has equivalent safety and effi  cacy to permanent polymer 
sirolimus eluting stent in an all-comers patient population. Its performance is superior in some 
subpopulations such as ST elevation MI patients and event rates for BES are overall lower that 
for SES with a trend toward increasing divergence of outcomes over three years.
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INTRODUCTION:
Drug eluting stents (DES) dubbed the third revolution in interventional cardiology (after bal-
loon angioplasty and bare metal stents being fi rst and second) have to a large degree solved 
the problem of in-stent restenosis.1 However, the fi rst generation devices such as sirolimus 
eluting and paclitaxel eluting stents with permanent polymer have relatively high rates of stent 
thrombosis, including very late stent thrombosis of up to 6% at 5 years in an all-comers unre-
stricted population (Bern-Rotterdam).2 The reason for this high event rate is multifactorial but 
one of the prominent causes may be a hypersensitivity reaction and endothelial dysfunction 
caused by the permanent polymer from which the drug is eluted in the fi rst generation DES. 3, 4
For this reason with reduction of stent thrombosis in mind Biomatrix Flex biolimus eluting 
stent (BES) (Biosensors, Morges, Switzerland) was designed to elute biolimus from a polylactide 
(PLA) biodegradable polymer applied to the stent’s abluminal surface.5 The polymer is fully 
metabolized to water and carbon dioxide within six to nine months from implantation leaving 
only the bare metal stainless steel platform behind. Biolimus is a semi-synthetic highly lipo-
philic inhibitor of the mammalian target of rapamycin, ten times as potent as sirolimus. BES has 
been shown to be non-inferior to the sirolimus eluting permanent polymer stent at 9 and 12 
months in terms of major adverse cardiac events in the all-comers LEADERS clinical trial.6 The 
current study is a report of three year outcomes of the fi rst all-comers trial in an unrestricted 
population of BES versus SES with focus on special patient populations and very late defi nite 
stent thrombosis risk, especially in patients who have interrupted DAPT therapy.
METHODS:
Study population:
LEADERS was a multicenter European non-inferiority trial comparing the safety and effi  cacy 
of the BioMatrix™ Flex biolimus eluting stent with a biodegradable polymer (BES) (Biosensors, 
Morges, Switzerland) to the Cypher® SelectTM sirolimus eluting stent with a durable polymer 
(SES) (Cordis, NJ, USA) in 1,707 ‘all-comers’ patients. Detailed study protocol can be found in the 
main publication.6 Briefl y, patients included had chronic stable coronary artery disease or acute 
coronary syndromes including ST elevation myocardial infarction, one of more lesions of >50% 
and a reference vessel diameter 2.25-3.5 mm. The only exclusion criteria were: known allergy to 
acetylsalicylic acid, clopidogrel, heparin, stainless steel, sirolimus, biolimus or contrast that can-
not be premedicated, planned surgery within 6 months of PCI unless DAPT could be continued 
through surgery, pregnancy or participation in another trial before reaching its primary end-
point. The study complied with the Declaration of Helsinki and was approved by all institutional 
ethics committees. All patients provided written, informed consent for participation in the trial.
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Randomization and Procedures:
Randomization was done centrally after diagnostic cardiac catheterization and before per-
cutaneous coronary intervention (PCI) by use of a telephone allocation service (Limburgia 
telefonische Antwoord Service BV, 3068 NP Rotterdam, Netherlands). The allocation sequence 
was computer generated, stratifi ed according to center, and blocked with block sizes of 8 and 
16, which varied randomly. We randomly allocated patients on a1:1 basis to treatment with a 
BES (Biomatrix Flex, Biosensors Inc., Newport Beach, CA, USA) or a SES (Cypher SELECT, Cordis, 
Miami Lakes, FL, USA) and to active angiographic follow-up at 9 months or clinical follow-up 
only on a 1:3 basis, with a factorial design.
BES were available in diameters of 2.25-3.5 mm and in lengths of 8- 28 mm. SES were avail-
able in diameters of 2.25- 3.5 mm and in lengths of 8-33 mm. We performed balloon angioplasty 
and stent implantation according to standard technique and direct stenting was allowed. No 
mixture of drug eluting stents was permitted within a given patient, unless the operator was 
unable to insert the study stent, in which case crossover to another device of the operator’s 
choice was possible. Before or at the time of the procedure, patients were given at least 75 mg 
of acetylsalicylic acid, 300-600 mg loading dose of clopidogrel, and unfractionated heparin at 
a dose at least 5,000 I or 70-100 IU/kg. After the procedure, all patients were advised to take 
aspirin indefi nitely and clopidogrel for at least 12 months. In case of intercurrent revasculariza-
tion procedures requiring stent implantation, treating cardiologists were encouraged to use 
the study stent. For other details we refer to the primary endpoint publication.6 
Study endpoints:
Defi nitions of all endpoints are provided elsewhere.6 The primary endpoint of this sub-study 
was MACE, defi ned as the composite of cardiac death, MI, and clinically-indicated target vessel 
revascularization (TVR) within 9-months. Secondary endpoints were any target lesion revas-
cularization (TLR) (both clinically and non-clinically indicated), any TVR, cardiac death, death 
from any cause, myocardial infarction, stent thrombosis (defi ned according to the Academic 
Research Council)7, 8, device success, and lesion success.
Statistics:
 The trial was powered for non-inferiority on the primary clinical endpoint. Continuous variables 
are expressed as mean+standard deviation and compared with student t-test. Categorical vari-
ables are presented as frequency (percentages) and compared using chi-square test. Survival 
curves were constructed using Kaplan-Meier estimates, and compared by the log-rank test. The 
Mantel-Cox model was used for the rate ratios of clinical outcome. All analyses were performed 
using SAS 8.02 by a dedicated statistician. All p-values and confi dence intervals were two-sided 
and p<0.05 was considered signifi cant.
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RESULTS:
Follow-up rate at three years:
Figure 1 fl ow chart summarizes the follow-up rates at 1, 2 and 3 years. Follow-up was available in 
1,621 patients i.e. 95%. In the BES treated group 17 patients were lost to follow-up whereas 20 were 
lost to follow-up in the SES treated group. 11 patients in each treatment arm withdrew consent.
Patient demographics and lesion characteristics:
The baseline clinical and angiographic characteristics are summarized in Table 1, respectively. 
There were no signifi cant diff erences between the two stent groups.
Clinical outcomes at 36 months (3 years):
At three years BES remained non-inferior to SES for the primary endpoint of major adverse 
cardiac events (composite of cardiac death, myocardial infarction (MI), or clinically-indicated 
target vessel revascularization (TVR)) (BES 15.7% versus SES 19%; HR 0.82 CI 0.65-1.03; p=0.09). 
The MACE Kaplan Meier event curves tend to increasingly diverge with the diff erence in events 
increasing from 1.4% to 2.4% and 3.3% at 1, 2 and 3 years, respectively in favor of BES (Figure 2A). 
The rate of cardiac death was non-signifi cantly lower 4.2% versus 5.2% (HR=0.81 CI 0.52-1.26; 
p=0.34; Figure 2B) and the rate of myocardial infarction was equivalent 7.2% versus 7.1% (HR 
1.01 CI 0.70-1.44; p=0.97; Figure 2C) for BES versus SES, respectively. Thus BES was non-inferior 
to SES in all the safety end-points at three years (Figure 3A). Clinically-indicated TVR occurred in 
9.4% of BES treated patients versus 11.1% of SES treated patients (HR 0.84 CI 0.62-1.13; p=0.25; 
Figure 2D). BES was non-inferior to SES in effi  cacy end-points at three years (Figure 3B). 
Randomized
(N=1,707)
BES (N=857) SES (N=850)
1-year follow-up
(N=1 666; 97 6%),  .
BES (N=837) SES (N=829)
2-year follow-up
(N=1,655; 97.0%)
BES (N=832) SES (N=823)  
3-year follow-up
(N=1,621; 95.0%)
Lost to F/U = 17
Patient withdrawal = 11
20 = Lost to F/U
11 = Patient withdrawal
BES (N=812) SES (N=809)
Other = 17 10 = Other
Figure 1. Flow chart showing completeness of follow-up at 1, 2 and 3 years
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Table 1: Baseline demographic and angiographic patient datag p
BES SES
857 Patients 850 Patients
Age in years 65 r 11 65 r 11    
Male gender 75% 75%
Arterial hypertension 74% 73%
Diabetes mellitus 26% 23%
- insulin-dependent 10% 9%
Hypercholesterolemia 65% 68%
Family history 40% 44%
Smoking 24% 25%
Previous MI 32% 33%
Previous PCI 36% 37%
- with drug-eluting stent 12% 14%
Previous CABG 11% 13%
Chronic stable angina 45% 44%  
Figure 2A. Kaplan Meier curve for MACE (cardiac death, myocardial infarction and target vessel 
revascularization) rate at 3 years and Hazard Ratios for superiority: BES (blue) versus SES (yellow). 2B. 
Kaplan Meier curve for Cardiac Death at 3 years. 2C. Kaplan Meier curve for all myocardial infarctions at 3 
years. 2D. Kaplan Meier curve for Target Vessel Revascularization at 3 years.
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P=0.25* P=0.77* P=0.12* P=0.27*P=1.00*P=0.36*
% values calculated on total randomized population
%
*P values for superiority (Fisher Exact Test) 
P=0.38* P=0.21*P=0.29*P=0.33*
% values calculated on total randomized population
%
*P values for superiority (Fisher Exact Test) 
Figure 3A. Three year safety endpoints for BES versus SES showing equivalent safety (death, cardiac 
death, myocardial infarction, non-Q wave myocardial infarction, Q-wave myocardial infarction and 
combined cardiac death or myocardial infarction.
Figure 3B. Three year effi  cacy end-point for BES versus SES showing equivalent effi  cacy with a trend to 
lower TVR for BES (clinically indicated TLR, any TLR, clinically indicated TVR and any TVR)
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Subpopulations (pre-specifi ed and post-hoc): 
The fi ndings of the primary end-point (MACE) were consistent across the pre-specifi ed analyses 
for diabetes, acute coronary syndromes, de novo lesions, left anterior descending lesions, off -
label use, small vessels and long-lesions except a signifi cant interaction was observed between 
estimated HR and presence or absence of ST-elevation myocardial infarction at baseline (HR 
0.43; CI 0.22-0.83; p=0.01) (Figure 4). In addition, there was a trend to reduction in event rates 
with the use of BES in patients with multivessel disease (HR 0.65; CI 0.41-1.03; p=0.06). Post-hoc 
analysis of the highest SYNTAX score tertile patients (defi ned as SYNTAX score > 16) showed 
signifi cantly lower cardiac death for patients treated with BES (4.7% versus 10.5%; HR 0.43; CI 
0.21-0.89; p=0.02). (Figure 5)
g y
P P
Overall 132/857 157/850 0.80 (0.63 to 1.03) ns
Diabetes mellitus ns
Yes 53/223 45/191 1.02 (0.68 to  1.52) 0.92
BES SES
 
ValueRisk Ratio (95% CI)  Int
No 79/634 112/659 0.72 (0.54 to 0.96) 0.02
Acute coronary ns
Yes 68/470 87/473 0.77 (0.56 to  1.06) 0.11
No 64/387 70/377 0.88 (0.63 to 1.25) 0.48
ST-elevation MI 0.03
Yes 13/135 29/140 0.43 (0.22 to 0.83) 0.01
No 119/722 128/710 0.91 (0.71 to 1.18) 0.48
Left anterior ns
Yes 59/407 71/417 0.84 (0.59 to 1.17) 0.32
No 73/449 86/431 0.81 (0.59 to 1.11) 0.18   
Multivessel disease ns
Yes 33/209 42/176 0.65 (0.41 to 1.03) 0.06
No 99/648 115/674 0.89 (0.68 to 1.16) 0.39
Off-label use ns
Yes 116/696 135/665 0 81 (0 63 to 1 04) 0 09.  .   . .
No 16/160 22/183 0.83 (0.44 to 1.59) 0.58
De-novo lesions ns
Yes 114/788 136/774 0.82 (0.64 to 1.05) 0.11
No 18/68 21/74 0.92 (0.49 to 1.73) 0.79
Small essel disease ns-v  
Yes 96/585 104/568 0.89 (0.68 to 1.18) 0.43
No 36/271 53/280 0.68 (0.45 to 1.04) 0.08
Long lesions ns
Yes 46/262 52/225 0.74 (0.50 to 1.10) 0.14
No 86/594 105/623 0.85 (0.64 to 1.13) 0.27
.25 .5 1 2 4
Figure 4. MACE rate for patients treated with BES versus SES stratifi ed by pre-specifi ed subgroups: 
diabetic patients, acute coronary syndrome at presentation, ST elevation myocardial infarction at 
presentation, left anterior descending artery disease, multivessel disease, off -label use, de-novo lesions, 
small vessels and long lesions. BES performs superiorly to DES in patients presenting with ST elevation 
myocardial infarction.
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20 BESSES
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MonthsNumber at risk
BES 239 238 228 226 224 220 213
*P values for superiority
SES 222 221 205 204 201 193 180
Figure 5. Cardiac death for patients in the highest tertile of the SYNTAX score is lower for patients treated 
with BES versus SES at three years (HR 0.43; p=0.02).
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SES
2-year HR
0.90 [0.48 to 1.67 
P = 0.73*
1-year HR
0.99 [0.51 to 1.94]
P = 0.98*
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0.78 [0.43 to 1.43]
P = 0.43*4.0
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ǻ 0 0%
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 .
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 .
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0
0 6 12 18 24 3630
MonthsNumber at risk
BES 857 846 808 797 787 774 732
12 18 30 36
*P values for superiority
SES 850 841 801 792 779 758 715
Figure 6. Defi nite stent thrombosis rate at three years for patients treated with BES versus SES showing 
greater increases in very late events for SES.
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Stent thrombosis and DAPT treatment: 
Rates of defi nite stent thrombosis were 2.2% for BES and 2.9% for SES (HR 0.78 CI 0.43-1.43; 
p=0.43), with the event rate increase of 0.2% from 1 to 3 years for BES and 1.2% for SES (Figure 
6). Table 2 summarizes the rates of anti-platelet agent utilization at 9, 12, 24 and 36 months 
which were non-diff erent in the BES and SES group (aspirin use of 94% and clopidogrel use of 
20%). Among patients who discontinued DAPT before 12 months, defi nite stent thrombosis 
occurred in 4 patients treated with SES and none treated with BES. Among patients who dis-
continued clopidogrel after 12 months, defi nite stent thrombosis occurred in 2 patients treated 
with SES and none treated with BES. (Figure 7)
Table 2. Anti-platelet agent utilization at 9, 12, 24 and 36 months for patients treated with BES and SES.p g
BES  SES P value
Aspirin
- At 9 months
- At 12 months
96.6% (n=818) 97.4%(n=798) 0.39
97 0% (n=810) 96 1% (n=801) 0 34  .  . .
- At 24 months 94.9% (n=789) 94.2% (n=778) 0.58
- At 36 months 94.3% (n=757) 94.8% (n=746) 0.73
Clopidrogel/Thienopyridine
- At 9 months 95.6% (n=818) 95.2%(n=798) 0.81
- At 12 months 68.1% (n=810) 66.5%(n=801) 0.52
- At 24 months 23.4% (n=789) 24.3%(n=778) 0.72
At 36 months 19 6% (n=757) 20 4% (n=747) 0 75-   .  .  .
P=0.38* P=0.21*P=0.29*P=0.33*
% values calculated on total randomized population
*P values for superiority (Fisher Exact Test) 
Figure 7. The eff ect of DAPT discontinuation before 12 months and after 12 months post-procedure on 
stent thrombosis events in patients treated with BES (no events) versus SES.
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DISCUSSION:
This study confi rms that biodegradable polymer biolimus eluting stent (BES) is non-inferior to 
the permanent polymer sirolimus eluting stent (SES) at three year follow-up in the context of 
an unrestricted use in a randomized “all-comers” trial. The primary clinical end point of MACE 
(combined cardiac death, myocardial infarction and clinically indicated target vessel revascu-
larization) continues to show lower event rate for patients treated with BES with incremental 
benefi t to the use of BES over SES and trend towards statistical signifi cance. In addition, the 
subgroup analysis confi rms that high risk patients such as patients presenting with acute ST-
elevation myocardial infarction have better outcomes with BES treatment. Patients with high 
SYNTAX score have a lower cardiac death rate when treated with BES when compared to SES.9
The major strength of this trial is that it tested the performance of the new generation drug 
elution stent with biodegradable polymer in a patient population that has close to 80% off -label 
use and increased risk of adverse events. It refl ects the real clinical practice and therefore tests 
the device in the real-world setting.10 Thus in both treatment groups the event rates are overall 
higher than the ones reported from the initial DES trials and some of the more recent random-
ized trials such as ENDEAVOR IV and SPIRIT III in which simple de novo lesions were treated. 11-14 
In addition, while ENDEAVOR and SPIRIT used angiographically-driven outcomes (lesion-based 
and device-based analysis), LEADERS focused on patient-based clinical outcomes: all cardiac 
death, all MI and all clinically-driven TVR.
The use of the fi rst generation drug eluting stents has been associated with an increased risk 
of stent thrombosis, an issue that was of particular importance in off -label indication cases.15 
We show in this study that biodegradable polymer BES has lower stent thrombosis rates than 
the permanent polymer stent of the fi rst generation. The diff erences do not reach statistical 
signifi cance as the trial has not been powered to detect them and registry data with larger 
patient numbers or longer follow-up will be needed to confi rm whether biodegradable poly-
mer DES can reduce stent thrombosis rates. Bern-Rotterdam registry shows that event rates 
steadily increase for sirolimus eluting stents at 0.6% per year.2, 16 Similarly in ARTS-II overall stent 
thrombosis rate reaches 9.4% at 5 years for sirolimus stent treated patients.17 One can project 
when the diff erences in stent thrombosis for BES versus SES may reach statistical signifi cance if 
average very late defi nite stent thrombosis rate is 0.1% for BES and 0.6% for SES. OCT analysis 
at 9 months seems to suggest that biodegradable polymer biolimus eluting stent has better 
strut coverage than the permanent polymer sirolimus eluting stent.18 In addition, patients who 
stopped DAPT do not appear to have any additional events at three years in the BES arm while 
these events do accrue in the SES arm.
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LIMITATIONS
The study was performed in tertiary care center with high volume operators throughout Europe 
and thus the results might not be generalizable to low volume peripheral centers.
CONCLUSIONS
The fi ndings of the three year follow-up support the claim that biodegradable polymer biolimus 
eluting stent has equivalent safety and effi  cacy to permanent polymer sirolimus eluting stent 
in an all-comers patient population. Its performance is superior in some subpopulations such 
as ST elevation MI patients and event rates for BES are overall lower that for SES with increasing 
divergence of Kaplan Meier curves.
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Objectives: IBIS-1 was a pilot study undertaken to correlate coronary imaging with circulating biomarker
expression in patients with stable angina, unstable angina and acute myocardial infarction. We hypothesized
that patients at high risk of future events could be identified in the future by a combination of high risk
plaque features by plaque echogenicity and palpography and a set of circulating blood biomarkers.
Results and methods:Weassessed the expressionof conventional biomarkers andnovelmarker proteinmicroarray
(170 analytes) over 6 months. There were no strong correlations observed between conventional biomarkers and
coronary imaging in non-culprit artery. Proteomic microarray was performed in 66 patients. Seventy eight (45%)
analytes showed dynamic changes over time. Using hierarchical clustering and principal component analysis two
subsets of biomarkers were identified: initial up-regulation and decrease over time (D-dimer, hepatocyte growth
factor, CXCL9/MIG, platelet factor 4/CXCL4, CTACK, C-6Kine, follistatin, andFGF-7) and theopposite increase (PAI-1-
anti-apoptotic protein and I-309— chemokine induced on the human endothelium by Lp(a)).
Conclusions: Proteomic analysis identifies dynamic patterns in circulating biomarkers in a wide range of patients
with coronary artery disease. Further large natural history studies are needed to better define multibiomarker sets
for identification of patients at risk of future CV events.
© 2009 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Inflammation is an established component of the pathogenesis of
coronary artery disease and some of the biomarkers of systemic
inflammation and macrophage activation such as hs-CRP, sCD40L and
sICAM or myeloperoxidase expression have been shown to correlate
with increased risk of coronary events [1,2]. Given that coronary
artery disease often presents for the first time as sudden cardiac death
or acute myocardial infarction, it is important to define non-invasive
methods of screening for patients at high risk of such events. Lesions
that are responsible for causing these events in 60% of cases are not
obstructive on invasive angiography [3].
IBIS-1 studywas a single center prospective pilot study to assess both
invasive and non-invasive methods of identifying coronary lesions with
high risk features based on intravascular ultrasound imaging [4],
palpography [5], and multislice CT scanning [6] and to correlate this to
systemic biomarker expression [7]. We hypothesized that patients at
high risk of future events could be identified prospectively by a
combination of high risk plaque features by plaque echogenicity and
palpography and a set of circulating blood biomarkers.
The results of multimodality coronary imaging in IBIS-1 were
previously published. Plasma biomarkers were measured during initial
presentation, at three and six months thus providing the opportunity to
investigate patterns in various classes of circulating analytes. The results
of this pilot study indicate dynamic changes in circulating biomarkers
(down regulation and up-regulation) as a result of natural history of
coronaryheart diseaseor concomitant therapy. Thesedynamic changes in
the clusters of biomarkers rather than static values in individual analytes
may offer prospect of better multibiomarker approach for the identifica-
tion of patients at risk of cardiovascular events and their response to
therapy, alongwith imaging biomarker. In addition, while imaging of the
plaque may reflect local features of high risk plaque, pro-inflammatory
and pro-coagulability systemic blood markers may reflect, so-called
“blood vulnerability”, and it is the combination of these two that creates a
“vulnerable patient” at risk of events.
2. Methods
2.1. Study patients
We studied 89 consecutive patients with coronary artery disease and either stable
angina or acute coronary syndromes (including 21 non-ST elevation MI and 14 ST elevation
⁎ Corresponding author. Interventional Cardiology, Thoraxcentrum, Erasmus MC, 's
Gravendijkwal 230 Ba 583, 3015 CE Rotterdam, Netherlands.
E-mail address: p.w.j.c.serruys@erasmusmc.nl (P.W. Serruys).
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MI patients) enrolled in the IBIS-1 study in 2003 at the Thoraxcentrum, Erasmus MC. The
studywas approved by the Ethics Committee of the ErasmusMedical Center. The basic study
designandprotocol is described elsewhere [7]. Bloodplasma sampleswere collected from66
of patients at index cardiac catheterization procedure, 3 and 6 months follow up. Patients
enrolled in the study were receiving the standard of care medical treatment that included
aspirine (91%), clopidogrel (94%), statins (99% of patients), ACE inhibitors (51%) and beta-
blockers (75%), at the discretion of their physician.
2.2. Sample collection
Testing was performed in duplicates. Serum plasma was separated from other blood
components and the samples were stored at−70 °C. Biomarker analysis was performed
with anMSI amplifiedmicroarray to look at 170 analytes and their differential expression
between time points.
Classical biomarker quantificationwas also performedonhs-CRP, IL-6 and lipoprotein-
associated phospholipase A2 andNT-proBNP, TNF-alpha and sCD40Lwere also assessed by
well-established methods. Briefly, blood for biomarker analysis was centrifuged within
30 min and stored at−70 °C. SerumC-reactive protein (Diagnostic Systems Laboratories),
plasma interleukin 6 and tumor necrosis factor-α (R&D Systems), were measured in the
Human Biomarker Center (GlaxoSmithKline, PA)with the use of protocols provided by the
manufacturer. Lipoprotein-associated phospholipase A2 activity (Lp-PLA2) assay measures
theproportional release of aqueous 3H acetate resulting fromtheenzymatic cleavage of the
3H acetyl-platelet activating factor 8 substrate (100∝M). N-terminal pro brain natriuretic
peptidewasmeasuredwith theuse of a two site electrochemiluminescent assay. The limits
of quantification were 0.0048 mg/L for C-reactive protein, 0.057 pg/mL for interleukin-6,
3.92 nmol/min/mL for Lp-PLA2, 10 pg/ml for N-terminal pro brain natriuretic peptide, and
0.88 pg/mL for tumor necrosis factor-α.
2.3. Protein expression assessment
Microarray was manufactured by Molecular Staging Inc. by printing with a Perkin-
Elmer SpotArray Enterprise non-contact arrayer. Antibodies were applied at a concentra-
tion of 0.5 mg/ml. Chips were validated using normal human plasma and a mixture of
purified recombinant cytokines representing all analytes in the array. Titration curves
were generated for every analyte. Rolling circle amplification (RCA) immunoassay was
performed according to the standard operating procedures detailed [8].
2.4. Microarray data analysis
Data were logarithm transformed to stabilize variance and improve normality of
the data. Only analytes with two-fold higher changes in specific features than in non-
specific controls were chosen for further analysis. Ninety four of the 170 analytes were
Fig. 1. Change in classical biomarker levels at time of presentation. Data are presented as box-whisker plots, with 25th and 75th percentiles (box) and 10th and 90th percentiles (I).
There were significant differences among patient groups with acute myocardial infarction (black), unstable angina (red), and stable angina (green) for systemic values of high
sensitivity C-reactive protein (hs-CRP mg/L: P=0.0003), interleukin-6 (IL-6 pg/mL: P=0.001), lipoprotein-associated phospholipase A2 activity (Lp-PLA2 nmol/min/mL:
P=0.035), and N-terminal pro brain natriuretic peptide (NT-proBNP pg/ml: P=0.0012). Plasma levels of tumor necrosis factor α (TNF-α pg/mL) did not differ significantly among
groups. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 1
Change in classical biomarker levels over time stratified by angina status. CRP and IL-6 decreased in acute coronary syndrome patients only while LpPLA2 decreased in all patients
over time. There was no significant change in sCD40L levels.
Biomarker (mean change±STD) STEMI (n=14) Unstable angina (N=20) Stable angina (N=31) All patients (N=65)
CRP (mg/L) −7.59±7.73
P=0.004
−19.21±31.22
P=0.0038
0.17±7.45
P=0.91
−7.58±20.08
P=0.0014
IL-6 (pg/mL) −9.82±23.04
P=0.0017
−2.96±5.39
P=0.0062
−3.94±21.27
P=0.59
−4.92±18.26
P=0.0001
LpPLA2 (nmol/min/mL) −43.2±26.87
P<0.0001
−29.95±30.72
P=0.0003
−29.23±27.12
P<0.0001
−32.51±28.37
P<0.0001
NT-proBNP (pg/mL) −624±1343
P=0.36
−262±384
P=0.0009
−47±329
P=0.58
−236±719
P=0.0022
TNF-alpha (pg/mL) 1.51±8.29
P=0.64
0.14±1.38
P=0.65
2.06±4.08
P=0.0085
1.29±4.85
P=0.16
sCD40L (ng/mL) 2.45±2.01
P=0.0124
−0.46±3.05
P=0.78
−0.93±3.41
P=0.62
−0.28±3.27
P=0.75
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chosen for further analysis whose change in expression over time within the patient
was larger than the platform imprecision. Paired t-test was used to assess for
statistically significant changes in analyte levels between baseline index event and
three and six months time points, as well as at steady state between 3 and 6 months
time points. Repeat mixed model analysis of variance was performed to identify
significant changes in expression with time. In addition, a piecewise linear regression
was performed to obtain slopes for the change in expression level between time points
(baseline to 3 month=slope 1 and 3 months to 6 months=slope 2). Plots with
predicted and measured values were compared to verify the correctness of the model.
Hierarchical clustering was performed with analytes demonstrating significant
difference in expression observed between patient baseline levels and levels detected
after 3 or 6 months. Euclidian distance matrix was calculated between every pair of
proteins and patients included in the analysis. Ward linkage was used to form clusters
in two dimensions. There were two approximately equal groups of patients: one group
with predominantly up-regulation in expression, and the other with predominantly
down-regulated expression.
In addition principal component analysis (PCA) was performed to simplify and
highlight the differences and similarities between data sets in this complex and
multidimensional data set without losing information. Briefly, PCA involves a mathemat-
ical procedure that transforms a number of correlated variables into a smaller number of
uncorrelated variables calledprincipal components. Thefirst principal component accounts
for as much of the variability in the data as possible, and each succeeding component
accounts for as much of the remaining variability as possible.
2.5. IVUS-based imaging protocol
The reader is referred to the study design manuscript and the main manuscript for
details [7,9].
2.6. Other statistical analysis
Finally data obtained on the biomarkers with differential expression between
patient groups in time was represented as box plots with whiskers and t-tests were
performed to obtained P-values for the difference in biomarker expression.
3. Results
3.1. Conventional biomarkers
Baseline levels of conventional biomarkers are shown in Fig. 1. There
were significant differences among patient groups with acute myocar-
dial infarction, unstable angina, and stable angina for systemic values of
high sensitivity C-reactive protein (hs-CRP mg/L: P=0.0003), interleu-
kin-6 (IL-6 pg/mL: P=0.001), lipoprotein-associated phospholipase A2
Table 2
Correlation between classical biomarkers and imaging parameters. Levels of CRP, IL-6, Lp-PLA2, proBNP and TNF-alpha are correlated with angiographic percent diameter stenosis
(QCA), mean plaque area, vessel area, percent plaque obstruction and hypoechogenicity on IVUS-gray scale as well as strain on palpography. CRP and IL-6 levels are only weakly
correlated with plaque hypoechogenicity in the non-culprit vessel.
Angiography
percent stenosis
Ultrasonography mean
plaque area (mm2)
Ultrasonography mean
vessel area (mm2)
Ultrasonography percent
plaque area obstruction
Tissue characterization percent
hypoechogenic plaque
Palpography grade 3/4
spots per 10 mm
CRP −0.16 −0.03 0.12 −0.16 0.32* 0.01
IL−6 0.04 0.08 0.14 −0.02 0.27† 0.13
Lp-PLA2 −0.01 −0.16 0.08 −0.31* 0.18 0.18
NT-proBNP 0.04 −0.09 0.04 −0.14 0.16 −0.02
TNF-α −0.05 −0.10 −0.16 0.03 −0.05 −0.03
*P=0.005, †P=0.015.
•The values in the table are the Pearson correlation coefficients.
•CRP: C-reactive protein, IL-6: interleukin 6, Lp-PLA2; lipoprotein-associated phospholipase A2, NT-proBNP: N-terminal pro brain natriuretic peptide, and TNF-α: tumor necrosis
factor alpha.
Fig. 2. Hierarchical clustering: lack of correlation between initial angina status and differential biomarker expression.
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activity (Lp-PLA2 nmol/min/mL: P=0.035), and N-terminal pro brain
natriuretic peptide (NT-proBNP pg/ml: P=0.0012). Plasma levels of
tumor necrosis factor α (TNF-α pg/mL) did not differ significantly
among groups. In addition we investigated changes in classical
biomarker levels over time (Table 1). Not surprisingly some inflamma-
tory biomarkers (CRP, IL-6 and Lp-PLA2) tended to decrease over time
mainly in patients with myocardial infarction and unstable angina.
There was no difference in TNF-alpha or sCD40L levels. Table 2 shows
correlations between these biomarkers and the results ofmultimodality
coronary imaging involving non-culprit artery. Of note, there were no
apparent correlations with the measurements of plaque size or lumen
narrowing, whereas CRP (r=0.31; P=0.005) and IL-6 (r=0.27;
P=0.015) weakly correlated with plaque hypoechogenicity. Lp-PLA2
levels negatively correlated with the percent area obstruction on IVUS
Fig. 3. Principal component analysis — summary. Fig. 3 (continued).
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and angiography, underlying the fact that non-obstructive lesions are
often positively remodeled and contain large lipid cores that are at risk
of rupture. More detailed analysis of remodeling index correlation with
baseline biomarker levels and change in biomarker levels showed no
significant correlations (see Supplemental table).
3.2. Proteomic microarray analysis (novel biomarkers)
Among 170 biomarkers, 78 analytes (46%) showed significant
differences in expression between baseline and either 3 or 6 months
(paired t-test). While the expression of these analytes was different
over time in two patient subsets, there was no correlation of
expressionwith anginal status at presentation (stable versus unstable,
non-ST elevation MI or ST elevation MI) (Fig. 2).
This complex data set was further compressed using hierarchical
clustering and principal component analysis. This yielded two subsets
of proteins demonstrating statistically robust differences in abun-
dance between patient groups (Figs. 3 and 4; Table 3). The first subset
displayed initial up-regulation of expression and decreased over time
in one patient subgroup (D-dimer, hepatocyte growth factor, CXC L9/
MIG, platelet factor 4/CXC L4, CTACK, C-6 Kine, follistatin, and FGF-7).
The second subset increased over time in the same patient subgroup
(PAI-1- anti-apoptotic protein and I-309— chemokine that is induced
Fig. 3 (continued).
Fig. 4. Plots of novel marker levels with up-regulated expression at baseline and decreasing levels over time identified by principal component analysis.
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on the human endothelium by Lp(a)). Similarly to the classical
biomarkers, multianalyte cluster analysis did not reveal any clustering
of analytes that correlated with the baseline angina status (Fig. 4).
4. Discussion
In this pilot exploratory study we examined correlation between
classical biomarker expression and the imaging phenotype of the
plaque. We tried to identify novel biomarkers that could better define
the inflammatory and pro-coagulable (“vulnerable blood”)milieu of the
high risk patients. Several novel biomarkers were up-regulated
differentially in a subset of patients with angina or acute coronary
syndromes. D-dimer, HGF, PF-4, chemokines, CCL27 (CTACK), 6-C Kine,
MIG and follistatin were all up-regulated at baseline and decreased at 3
and 6 months in a subgroup of patients (group 1). They all appear to
denote increased pro-coagulability, endothelial activation or injury or
macrophage/monocyte trafficking into the plaque. All these mechan-
isms are at the root of pathogenesis of vulnerable plaque.
D-dimer has been previously shown to be elevated in patients with
unstable angina and acute MI, as a marker of increased pro-
coagulability. Although no direct pathogenic role of d-dimer in
atherosclerosis progression or plaque instability has been described,
fibrin degradation products correlate with platelet activation and
other acute phase proteins, as well as plaque burden [10]. Similarly,
Platelet factor 4 which belongs to the CXC containing chemokine
subfamily, is up-regulated and plays an important role in response to
endothelial injury and inflammation, the only confounder being that
PF4 release is induced by heparin administration. PF4 can interact
with platelet-derived RANTES to up-regulate adhesion molecule
expression on the endothelium and thereby is capable of amplifying
RANTES-induced monocyte/macrophage trafficking into the plaque
and further plaque instability [11]. Platelet-derived RANTES is
involved in monocyte trafficking. Similarly HGF is a marker of
increased prothrombotic state [12]. However, more importantly,
recently together with its c-met receptor it has been implicated in
neovessel formation within the plaque or so-called plaque neovascu-
larization [13], which may contribute to plaque instability. On the
other hand, HGF can also allow for endothelial progenitor cell and
pericyte trafficking to the ischemic myocardium and thus allow for
vascular regeneration [14]. CTACK and C-6 Kine are also chemokines
that allow for T-cell and macrophage trafficking into the plaque [15].
Lastly, follistatin and activin A are both up-regulated in unstable
coronary syndromes [16] and increased follistatin expression has
been recently found in the aortic wall endothelium exposed to
turbulent flow together with bone morphogenic protein-4 [17]. This
later associationmay possibly provide a link between high stress/stain
areas of the coronary arteries and the proclivity of plaques in those
areas to rupture.
Two additional markers that became up-regulated at 3 months
PAI-10 and I-309 are anti-apoptotic protein and a chemokine involved
in Lp(a) induced endothelial activation and macrophage trafficking
[18] but also to increasematrixmetalloproteinase 2 production [19]. It
is possible that this increase may be induced by medications such as
statins, which are known to increase Lp(a) expression and its related
proteins [20].
Although these novel biomarkers correlated poorly with the initial
angina status of the patient, this can be easily explained by
heterogeneity of the patient population enrolled and small sample
size. The correlation with imaging plaque characteristics of vulnerable
plaque was also only weak. The technology used for plaque imaging,
however, wasmostly limited to gray scale IVUS, which has poor ability
to discriminate fibrous from fatty/necrotic core plaque based on
echogenicity alone. In addition, only one out of the three coronary
arteries was sampled, which may have caused us to miss some high
risk plaques in other vessels. Plasma biomarker levels reflect an
overall diffuse nature of coronary and other vascular disease, as well
as overall inflammatory and metabolic state of an individual patient.
This global biomarker milieu might not necessarily correlate with
activity at one local site of vascular injury.
While this study was exploratory in nature, it lays a foundation for
further large scale natural history studies of vulnerable patients,
which are underway in our andmany other institutions. We hope that
with larger patient populations such as in AtheroRemo and Biomarcs
studies we will be able to further characterize the molecular/
proteomic footprint of high risk patients and correlate these finding
with state of the art imaging technologies, such as IVUS-virtual
histology, near-infrared spectroscopy, optical coherence tomography
and Raman spectroscopy. These novel technologies may allow us to
more accurately investigate the interplay between vulnerable/high
risk plaque and vulnerable blood.
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ABSTRACT:
Background and objectives: In several landmark angiographic studies it has been demon-
strated that 60-70% of myocardial infarctions occur at the site of non-obstructive lesions and 
that they tend to occur preferentially in the proximal one third of each of the coronary vessels. 
In prior small IVUS studies, the distance from the vessel ostium has been an independent pre-
dictor of the necrotic core rich plaque. In this sub-study of the PROSPECT trial we attempted to 
validate whether there is a plaque burden and necrotic core content gradient along the vessel 
from proximal to distal in the three coronary vessels.
Methods and results: Of the 697 patients with acute coronary syndrome who underwent 
successful PCI for the index lesion, 673 underwent IVUS greyscale examination of the proximal 
6-8 cm of the coronary vessels. Virtual histology recordings were available for analysis in 623 
patients. The percent plaque volume although greater in the proximal 60 mm of the vessel than 
the very distal portion was not diff erent in the fi rst and mid 30 mm of the vessel (50% vs 50% 
vs 47.8%; p=0.0033). The numbers of plaque ruptures decreased from proximal to distal but 
the diff erence did not reach statistically signifi cant level (7% vs 5.8% vs 3.8%; p=0.2379). Total 
necrotic core volume was also the highest in the proximal 30 mm of the vessel (19.7 mm3 vs 
14.4 mm3 vs 9.3 mm3; p<0.001), however, the percentage necrotic core volume was no diff erent 
from proximal to distal vessel (21.5% vs 21.5% vs 22%; p=0.4093). The distance from the ostium 
was not a statistically signifi cant predictor of the presence of TCFA or necrotic core rich lesions.
Conclusions: We have found that the distance from the ostium is not a signifi cant predictor 
of the necrotic core content or presence of TCFAs. It appears that the clustering of plaque 
ruptures in the proximal vessel segments observed in the epidemiological studies cannot be 
simply mechanistically linked to percent necrotic core or presence of the IVUS-VH derived TCFA. 
There is likely a more complex interplay between this vessel wall substrate and other local and 
hemodynamic factors that leads to plaque rupture and consequent acute vessel occlusion and 
myocardial infarction. 
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INTRODUCTION: 
The majority of acute coronary syndromes are caused by coronary plaque rupture at the site of 
thin cap fi broatheroma with subsequent local thrombosis.1, 2 In several landmark angiographic 
studies it has been demonstrated that 60-70% of myocardial infarctions occur at the site of non-
obstructive lesions 3-5 and furthermore that they tend to occur preferentially in the proximal 
one third of each of the coronary vessels 6. It has been previously demonstrated in a pilot single 
center study of 51 patients that the percentage of necrotic core content was increased in the 
fi rst 10 mm of the vessel relative to the distal segment (fi rst 10 mm segment versus third and 
fourth 10 mm segment)7. In addition, the distance from the ostium appeared to be an indepen-
dent predictor of relative necrotic core content, together with parameters such as age, unstable 
angina, lack of statin use and diabetes mellitus. This could potentially suggest a mechanism 
for the above mentioned proclivity of myocardial infarctions to occur at the proximal portion 
of the coronary artery and thus imply that one should direct therapies to stabilize “vulnerable” 
high risk plaques at the proximal portion of the coronary tree. 
PROSPECT trial was the fi rst natural history multicenter trial to examine plaque distribution 
and plaque composition in non-culprit vessels with intravascular ultrasound (IVUS) and virtual 
histology (VH) in patients presenting with acute coronary syndromes, and to relate the features 
of the coronary disease to major adverse cardiac events at three years (Stone G. et al, 2010 
NEJM). In this sub-study of the PROSPECT trial (623 patients in whom VH analysis was available) 
we attempted to validate whether there is a plaque burden and necrotic core content gradient 
along the vessel from proximal to distal in the three coronary vessels. 
METHODS:
Patient population:
The enrollment criteria and the methodology of the PROSPECT study have been previously 
described in detail elsewhere (Stone G et al., 2010). In brief, of the 697 patients with acute 
coronary syndrome who underwent successful PCI for the index lesion, 673 underwent IVUS 
grayscale examination of the proximal 6-8 cm of the coronary vessels. Virtual histology record-
ings were available for analysis in 623 patients.
Imaging acquisition and analysis:
Imaging with grayscale IVUS was performed using a phased-array, 20 MHz, 3.2 Fr catheter 
(Eagle Eye, Volcano Corporation, Rancho Cordova, CA). During a motorized catheter pullback 
at 0.5 mm/s, grayscale IVUS was recorded and raw frequency data were captured gated to the 
R-wave (In-Vision Gold, Volcano). In contrast to conventional grayscale IVUS, radiofrequency 
IVUS uses spectral analysis in addition to the amplitude analysis. This radiofrequency spectral 
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analysis has been correlated to histological samples and validated for its high specifi city and 
sensitivity to defi ne tissue subtypes (calcifi ed, fi brotic, fi brofatty and necrotic core).8 
Angiographic qualitative and quantitative measures (QCA) of the entire length of the 
coronary tree were made as previously described9, 10, including each major epicardial coronary 
artery and every sidebranch ≥1.5 mm in diameter, using a proprietary methodology modifi ed 
from standard Medis CMS software (Version 7.0, Lieden, the Netherlands). This 3-vessel angio-
graphic analysis served as a roadmap to identify each lesion based on longitudinal axis location 
(mm). For each 1.5mm of vessel, the interpolated reference and the minimal lumen diameter 
(MLD) were recorded and used to derive the percent diameter stenosis [(1-MLD/ reference)
x100]. Angiographic lesion, coronary segment and vessel level parameters were also assessed. 
All IVUS images were analyzed at independent core laboratories. Off -line grayscale and 
radiofrequency-IVUS analysis were performed using (1) QCU-CMS (Medis) for contouring; (2) 
pcVH 2.1 software (Volcano) for contouring and data output; and (3) proprietary qVH software 
(Cardiovascular Research Foundation) for segmental qualitative assessment and quantitative 
data output. External elastic membrane (EEM) and lumen borders were contoured for all 
recorded frames (each ~0.5mm in length). Quantitative IVUS measurements included EEM 
cross-sectional area (CSA), lumen CSA, plaque and media (P&M; EEM minus lumen) CSA, plaque 
burden (P&M divided by EEM CSA), and minimal lumen area (MLA). Radiofrequency-IVUS 
plaque components were color-coded as dense calcium (white), necrotic core (red), fi brofatty 
(light green), and fi brotic tissue (dark green), and reported as CSA and percentages of total 
plaque area.8 Volumetric data was calculated using Simpson’s rule. A lesion was defi ned as a 
segment with ≥3 consecutive frames with ≥40% plaque burden, and classifi ed as (1) thin-cap 
fi broatheroma (TCFA); (2) thick cap fi broatheroma; (3) pathological intimal thickening; (4) 
fi brotic plaque; and (5) fi brocalcifi c plaque.11 (Garcia-Garcia HM et al., 2009; Supplemental 
Figure 1) Each grayscale and radiofrequency-IVUS frame was co-registered to the angiographic 
roadmap using fi duciary branch points to align the imaging modality outputs. Corresponding 
IVUS lesions were thereby assigned angiographic landmarks and measures.
The vessels examined were divided into30 mm segments from the ostium to the distal 
vessel for the purpose of establishing the longitudinal diff erences in the plaque burden and 
necrotic core content.
Statistical analysis:
Categorical variables are presented using frequencies and percentages, continuous variables 
with mean and standard deviations or median and quartiles as indicated. Comparisons 
between vessel segments proximal to distal with respect to variables such as plaque burden 
and necrotic core content and percentage were performed using a linear mixed model with a 
compound symmetry correlation structure and the intercept as only random eff ect. The values 
for the IVUS and IVUS-VH variables were compared between segments using chi-square test 
for trend for categorical data and Jonckheere-Terpstra test for continuous data. In order to 
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establish determinants of necrotic core content and evaluate the distance from the ostium as 
an independent predictor of relative necrotic core content, a univariate and multivariate linear 
mixed models were applied. The following patient level variables were used in the analysis: age, 
gender, diabetes, smoking, insulin dependent diabetes, history of angina, body mass index, 
congestive heart failure, hypertension, hypercholesterolemia, prior myocardial infarction, HDL, 
chronic kidney disease, number of culprit vessels, history of cardiac interventions and aspirin 
use in the last 7 days. For lesion level data, a model with generalized estimating equations (GEE) 
approach was used to compensate for any potential cluster eff ect of multiple lesions in the 
same patient. All statistical analyses were performed using SAS version 9.1.3, Cary, NC.
RESULTS:
Baseline characteristics of the 697 patients enrolled in the study have been reported else-
where (Supplemental Table 1; Stone G. et al., 2010). Briefl y, Median age of the patients was 58.1 
years, 24% were women and 17.2% had diabetes. 
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Figure 1. Distribution of necrotic core rich lesions from proximal to distal in the LAD, RCX and RCA in 10 
mm segments.
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Plaque burden and necrotic core content of lesions in the proximal 30 mm of the vessels 
versus 30-60 mm segment versus >60 mm distance from the ostium (Table 1 and 2): 
TCFA lesions in the proximal 30 mm of the vessels were longer (20.6 mm vs 17.1 mm vs 16 
mm; p=0.0122) and had greater plaque volume (171 mm3 vs 130 mm3 vs 98 mm3; p<0.001). 
The percent plaque volume although also greater in the proximal 60 mm of the vessel than 
Table 1. Grayscale IVUS plaque longitudinal distribution from the ostium in all three coronary vessels 
excluding left main. 
Ostium to Max 
NC
<30mm
Ostium to 
Max NC
30-60mm
Ostium to Max 
NC
≥60mm
Combined
P-Value1
All 
Groups
Lesion Length & 
Volumetric Data
Lesion Length (mm)
 median [IQR]
20.61 (12.34, 
32.44)
17.13 (10.07, 
32.98)
15.98 (7.05, 
28.60)
18.95 (10.47, 
31.75)
0.0122
Total EEM Volume (mm3)
 median [IQR]
347.54 (191.93, 
545.43)
260.38 (123.99, 
558.20)
197.23 (78.58, 
408.51)
302.27 (146.57, 
528.64)
<.0001
Total Lumen Volume (mm3)
 median [IQR]
176.04 (97.53, 
262.30)
130.80 (59.05, 
268.98)
105.96 (43.05, 
214.11)
152.25 (75.43, 
258.52)
<.0001
Total Plaque & Media 
Volume (mm3)
 median [IQR]
170.93 (93.47, 
294.29)
130.44 (60.48, 
281.68)
97.54 (37.29, 
201.06)
145.66 (70.69, 
272.90)
<.0001
% Plaque Volume (%)
 median [IQR]
49.88 (45.48, 
54.31)
49.78 (45.12, 
53.02)
47.80 (42.37, 
51.07)
49.44 (44.99, 
53.48)
0.0033
Average EEM CSA (mm3/
mm)
 median [IQR]
16.97 (14.00, 
20.24)
15.25 (11.27, 
18.66)
13.52 (10.09, 
17.71)
15.91 (12.39, 
19.39)
<.0001
Average Lumen CSA (mm3/
mm)
 median [IQR] 8.37 (6.73, 10.39)
7.50 (5.60, 
9.72)
6.87 (5.18, 9.19) 7.81 (6.15, 9.96) <.0001
Average Plaque + Media 
CSA (mm3/mm)
 median [IQR] 8.44 (6.81, 10.41)
7.24 (5.55, 
9.53)
6.38 (4.55, 8.50) 7.73 (5.96, 9.80) <.0001
Morphology Data
Plaque Rupture 7.0% (22/314) 5.8% (11/191) 3.8% (4/104) 6.1% (37/609) 0.2379
Remodeling Index
 median [IQR] 0.88 (0.77, 0.98)
0.93 (0.84, 
0.98)
0.95 (0.87, 1.01) 0.90 (0.81, 0.99) <.0001
1 P-Value calculated using chi-square test for trend for categorical data and Jonckheere-Terpstra test for 
continuous data
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Table 2: IVUS-VH longitudinal TCFA distribution from the ostium in all three coronary vessels (excluding 
left main).
Ostium to Max 
NC
<30mm
Ostium to Max 
NC
30-60mm
Ostium to 
Max NC
≥60mm
Combined
P-Value1
All 
Groups
Lesion Phenotype
TCFA
100.0% 
(314/314)
100.0% (191/191)
100.0% 
(104/104)
100.0% 
(609/609)
N/A
Volumetric Data
Total Necrotic Core Volume 
(mm3)
 median [IQR]
19.70 (9.46, 
34.28)
14.42 (5.69, 
30.50)
9.29 (3.41, 
20.53)
16.05 (6.56, 
31.54)
<.0001
Total Dense Calcium 
Volume (mm3)
 median [IQR]
7.15 (3.04, 
15.08)
4.97 (1.94, 12.70)
3.21 (1.52, 
7.50)
5.80 (2.23, 
12.70)
<.0001
Total Fibrous Tissue Volume 
(mm3)
 median [IQR]
55.27 (27.95, 
92.69)
34.66 (14.66, 
93.85)
24.94 (8.70, 
65.78)
43.79 (19.05, 
87.14)
<.0001
Total Fibrofatty Volume 
(mm3)
 median [IQR]
11.20 (5.09, 
22.61)
5.71 (2.09, 19.53)
4.51 (1.12, 
16.44)
8.87 (2.76, 
20.49)
<.0001
Total Media Volume (mm3)
 median [IQR]
73.60 (40.75, 
114.21)
59.64 (30.65, 
114.17)
49.24 (22.49, 
91.22)
65.16 (34.15, 
109.93)
0.0004
Average Necrotic Core CSA 
(mm3/mm)
 median [IQR] 0.96 (0.67, 1.35) 0.79 (0.49, 1.20)
0.64 (0.37, 
0.86)
0.85 (0.53, 
1.25)
<.0001
Average Dense Calcium 
CSA (mm3/mm)
 median [IQR] 0.33 (0.21, 0.56) 0.31 (0.16, 0.48)
0.23 (0.14, 
0.36)
0.31 (0.17, 
0.52)
<.0001
Average Fibrous Tissue CSA 
(mm3/mm)
 median [IQR] 2.67 (1.86, 3.65) 2.17 (1.33, 3.40)
1.71 (0.96, 
2.65)
2.40 (1.51, 
3.46)
<.0001
Average Fibrofatty CSA 
(mm3/mm)
 median [IQR] 0.57 (0.33, 0.98) 0.39 (0.16, 0.82)
0.29 (0.13, 
0.69)
0.49 (0.21, 
0.86)
<.0001
Average Media CSA (mm3/
mm)
 median [IQR] 3.62 (3.19, 3.97) 3.45 (2.98, 3.81)
3.21 (2.79, 
3.67)
3.50 (3.05, 
3.88)
<.0001
% Necrotic Core Volume
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the very distal portion was not diff erent in the fi rst and mid 30 mm of the vessel (50% vs 50% 
vs 47.8%; p=0.0033). The numbers of plaque ruptures decreased from proximal to distal but 
the diff erence did not reach statistically signifi cant level (7% vs 5.8% vs 3.8%; p=0.2379). Total 
necrotic core volume was also the highest in the proximal 30 mm of the vessel (19.7 mm3 vs 
14.4 mm3 vs 9.3 mm3; p<0.001), however similar diff erence in volumes of dense calcium, fi brous 
tissue and fi brofatty volume were observed and the percentage necrotic core volume was no 
diff erent from proximal to distal vessel (21.5% vs 21.5% vs 22%; p=0.4093).
Tables 3 summarizes the plaque burden and necrotic core content diff erences along the 
proximal, mid and distal segments of LAD, Circumfl ex (RCX) and RCA respectively. Notably, the 
number of plaque ruptures in the proximal LAD 5.1% is statistically signifi cantly diff erent than 
in the mid and distal LAD (1.8% and 0%; p=0.0018; data not shown). The pattern of plaque 
volume and necrotic core content distribution is similar to that shown in the pooled analysis of 
all vessels. The percent necrotic core was 13.5% vs 13.8% vs 13.8% (p=0.1158). The percentage 
of lesions classifi ed as thin cap fi broatheromas (high risk lesions) did not diff er between the 
proximal and distal LAD (24.4% vs 22.2% vs 24.2%; p=0.7167). Thin cap fi broatheromas were in 
fact more frequent in the mid and distal rather than in the proximal circumfl ex vessel (18.2% vs 
28% vs 30.4%; p=0.0022) and percent necrotic core volume was higher in the most distal seg-
ment (10.4% vs 12.9% vs 13.5%; p=0.0002). In the right coronary artery there was no diff erence 
from proximal to distal in the number of plaque ruptures (5.2% vs 5.7% vs 3.4%; p=0.3316), 
there was no statistically signifi cant diff erence in the proportion of thin cap fi broatheromas 
from proximal to distal and percentage of the necrotic core was highest in the distal segment 
(9.8% vs 9.1% vs 11.1%; p=0.0357). Figure 1 illustrates the distribution of the necrotic core rich 
lesions along the three main coronary arteries every 10 mm. While the necrotic core lesions are 
almost equally distributed in the proximal, mid and distal 30 mm of the vessel, there is clearly 
lower number of necrotic core lesions in the most distal vessel (>90 mm distance from the 
Ostium to Max 
NC
<30mm
Ostium to Max 
NC
30-60mm
Ostium to 
Max NC
≥60mm
Combined
P-Value1
All 
Groups
 median [IQR]
21.48 (16.02, 
26.76)
21.50 (15.86, 
28.36)
21.97 (16.17, 
27.17)
21.67 (15.91, 
27.17)
0.4093
% Dense Calcium Volume
 median [IQR]
7.77 (4.70, 
12.51)
7.88 (5.01, 13.13)
7.49 (4.99, 
12.65)
7.77 (4.94, 
12.81)
0.7036
% Fibrous Tissue Volume
 median [IQR]
56.91 (51.10, 
61.67)
57.60 (51.88, 
62.58)
58.63 (51.47, 
62.63)
57.43 (51.24, 
62.12)
0.1587
% Fibrofatty Volume
 median [IQR]
12.09 (8.33, 
17.69)
10.65 (6.41, 
15.84)
10.04 (6.74, 
15.27)
11.33 (7.25, 
16.61)
0.0012
1 P-Value calculated using chi-square test for trend for categorical data and Jonckheere-Terpstra test for 
continuous data
Table 2: Continued
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ostium) with skewing of the distribution to the right. The skewing is most prominent in the LAD 
followed by RCX and least prominent in the RCA. Figure 2 shows similar distribution for thin 
cap fi broatheroma lesions (TCFAs).
Comparison between thin cap fi broatheromas (TCFA) and other tissue types (non-TCFA) 
(Table 4): 
TCFA lesions were longer than non-TCFA lesions (18.7 mm vs 9.9 mm; p<0.0001), had larger 
plaque volume (144 vs 70 mm3; p<0.0001) and slightly higher percentage plaque volume 
(49% vs 47%; p<0.0001). Plaque ruptures were present in 6.2% of TCFAs vs 2.9% of non-TCFAs 
Table 3. Distribution of IVUS-VH plaques in the three coronary vessels
Ostium to 
Max NC
<30mm
Ostium to 
Max NC
30-60mm
Ostium to 
Max NC
≥60mm
Combined
P-Value1
All Groups
LAD
TCFA
24.4% 
(138/566)
22.2% 
(61/275)
24.2% (24/99)
23.7% 
(223/940)
0.7167
ThCFA
49.5% 
(280/566)
39.6% 
(109/275)
29.3% (29/99)
44.5% 
(418/940)
<.0001
PIT
22.4% 
(127/566)
32.7% 
(90/275)
40.4% (40/99)
27.3% 
(257/940)
<.0001
Fibrotic 2.3% (13/566) 3.6% (10/275) 5.1% (5/99) 3.0% (28/940) 0.0947
Fibrocalcifi c 1.4% (8/566) 1.8% (5/275) 1.0% (1/99) 1.5% (14/940) 0.9859
Any FA (TCFA or ThCFA)
73.9% 
(418/566)
61.8% 
(170/275)
53.5% (53/99)
68.2% 
(641/940)
<.0001
LCX
TCFA
18.2% 
(87/477)
28.0% 
(56/200)
30.4% (14/46)
21.7% 
(157/723)
0.0022
ThCFA
36.3% 
(173/477)
27.5% 
(55/200)
21.7% (10/46)
32.9% 
(238/723)
0.0059
PIT
41.7% 
(199/477)
41.0% 
(82/200)
47.8% (22/46)
41.9% 
(303/723)
0.6523
Fibrotic 2.5% (12/477) 3.5% (7/200) 0.0% (0/46) 2.6% (19/723) 0.7963
Fibrocalcifi c 1.3% (6/477) 0.0% (0/200) 0.0% (0/46) 0.8% (6/723) 0.1015
Any FA (TCFA or ThCFA)
54.5% 
(260/477)
55.5% 
(111/200)
52.2% (24/46)
54.6% 
(395/723)
0.9480
RCA
TCFA
21.2% 
(89/420)
24.8% 
(74/298)
25.0% 
(66/264)
23.3% 
(229/982)
0.2179
ThCFA
36.0% 
(151/420)
32.2% 
(96/298)
35.2% 
(93/264)
34.6% 
(340/982)
0.7441
PIT
39.5% 
(166/420)
39.3% 
(117/298)
36.4% 
(96/264)
38.6% 
(379/982)
0.4334
Fibrotic 2.1% (9/420) 2.3% (7/298) 2.7% (7/264) 2.3% (23/982) 0.6702
Fibrocalcifi c 1.2% (5/420) 1.3% (4/298) 0.8% (2/264) 1.1% (11/982) 0.6430
Any FA (TCFA or ThCFA)
57.1% 
(240/420)
57.0% 
(170/298)
60.2% 
(159/264)
57.9% 
(569/982)
0.4587
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(p<0.0001). Median distance from the ostium to a maximal necrotic core lesion was 28.8 mm 
for a TCFA lesion and 24 mm for non-TCFA lesion (p=0.0002). Median volume of necrotic core in 
the TCFA lesion was 15.9 mm3 versus 3 mm3 in a non-TCFA (p<0.0001). Median percent necrotic 
core volume was 21.8 percent for TCFA versus 9.2 percent for non-TCFA (p<0.0001).
Multivariate logistic model:
In order to determine whether the distance from the ostium was an independent predictor of 
necrotic core rich plaque a multivariate logistic regression was performed. Of all the clinical 
characteristics used as co-variates the following were used in the fi nal model: history of cardiac 
interventions, lesion length measured by IVUS, percent plaque volume, remodeling index, 
age, history of angina, use of aspirin in the last 7 days and hypercholesterolemia. There was no 
multicollinearity in the model and the model was adjusted for clustering. The distance from the 
ostium was not a statistically signifi cant predictor of the presence of TCFA or necrotic core rich 
lesions (Table 5 and 6).
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Figure 2. Distribution of thin cap fi broatheroma lesions from proximal to distal in the LAD, RCX and RCA 
in 10 mm segments.
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Table 4. Comparison of the TCFA and non-TCFA lesions with respect to their IVUS grayscale and VH 
characteristics and distance from the vessel ostium. 
  TCFA Non TCFA Combined P-value
Geometrical Data
Lesion Length (mm)
 median [IQR]
18.73 
[10.07,31.32]
9.85 [5.15,18.31] 11.52 [5.73, 21.64] <0.0001
Total EEM Volume (mm3)
 median [IQR]
301.13 
[145.88,525.98]
147.92 
[74.15,291.28]
171.72 [82.41, 
352.05]
<0.0001
Total Lumen Volume (mm3)
 median [IQR]
151.60 
[74.21,255.43]
77.23 
[39.24,148.85]
88.45 [43.62, 
176.04]
<0.0001
Total Plaque & Media Volume 
(mm3)
 median [IQR]
143.81 
[69.69,271.82]
70.23 
[33.92,142.57]
82.09 [37.78, 
172.06]
<0.0001
% Plaque Volume (%)
 median [IQR] 49.3 [44.9,53.5] 47.2 [43.7,51.2] 47.6 [43.9, 51.7] <0.0001
Average EEM CSA (mm3/mm)
 median [IQR]
16.06 
[12.52,19.80]
15.50 
[11.81,19.98]
15.63 [11.97, 
19.94]
0.08
Average Lumen CSA (mm3/mm)
 median [IQR] 7.94 [6.22,10.21] 7.90 [6.04,10.40] 7.90 [6.07, 10.34] 0.97
Average Plaque + Media CSA 
(mm3/mm)
 median [IQR] 7.89 [6.02,9.85] 7.32 [5.55,9.63] 7.46 [5.60, 9.68] 0.002
Compositional data
Total Necrotic Core Volume 
(mm3)
 median [IQR]
15.91 
[6.53,31.66]
3.02 [1.04,8.18] 4.39 [1.43, 12.62] <0.0001
Total Dense Calcium Volume 
(mm3)
 median [IQR] 5.76 [2.18,12.89] 1.15 [0.32,3.81] 1.77 [0.45, 5.75] <0.0001
Total Fibrous Tissue Volume 
(mm3)
 median [IQR]
42.17 
[18.89,87.14]
21.39 [9.33,49.28]
25.32 [10.35, 
56.38]
<0.0001
Total Fibrofatty Volume (mm3)
 median [IQR] 8.85 [2.67,19.88] 7.83 [2.93,18.26] 8.04 [2.89, 18.94] 0.72
Total Media Volume (mm3)
 median [IQR]
64.29 
[33.48,108.91]
33.02 
[17.16,62.89]
38.60 [19.09, 
75.19]
<0.0001
Average Necrotic Core CSA 
(mm3/mm)
 median [IQR] 0.87 [0.54,1.28] 0.31 [0.16,0.57] 0.40 [0.20, 0.76] <0.0001
Average Dense Calcium CSA 
(mm3/mm)
 median [IQR] 0.31 [0.17,0.53] 0.12 [0.05,0.29] 0.16 [0.06, 0.36] <0.0001
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DISCUSSION
The main fi nding of this substudy of the PROSPECT trial aimed at examining the longitudinal 
distribution of necrotic core rich high risk plaque and IVUS-VH derived thin cap fi broatheromas 
(TCFAs) are the following: 1. The distance from the vessel ostium is not a signifi cant predictor 
overall of TCFA or necrotic core rich plaque location., 2. Plaque ruptures appear to be more 
frequent in the proximal 30 mm of the LAD but not in the LCX or the RCA., 3. Plaque ruptures 
are in fact more frequent in the mid and distal vessel for the RCX and distal segment in the RCA., 
4. Percent necrotic core volume is non-diff erent in the fi rst, second and third 30 mm segment 
of the vessel.
While histopathologic data from the post-mortem specimens12 and epidemiological 
data from the acute myocardial infarction patients3, 5 gathered over the decades appeared 
  TCFA Non TCFA Combined P-value
Average Fibrous Tissue CSA 
(mm3/mm)
 median [IQR] 2.42 [1.54,3.52] 2.28 [1.47,3.45] 2.33 [1.47, 3.45] 0.34
Average Fibrofatty CSA (mm3/
mm)
 median [IQR] 0.49 [0.21,0.88] 0.83 [0.42,1.47] 0.74 [0.36, 1.34] <0.0001
Average Media CSA (mm3/mm)
 median [IQR] 3.53 [3.07,3.91] 3.49 [2.99,3.93] 3.50 [3.02, 3.92] 0.45
% Necrotic Core Volume
 median [IQR] 21.8 [15.9,27.2] 9.2 [4.9,14.7] 11.5 [5.9, 18.3] <0.0001
% Dense Calcium Volume
 median [IQR] 7.8 [4.9,12.9] 3.4 [1.4,7.4] 4.4 [1.8, 8.8] <0.0001
% Fibrous Tissue Volume
 median [IQR] 57.2 [51.2,62.1] 61.4 [54.9,66.9] 60.2 [54.0, 65.8] <0.0001
% Fibrofatty Volume
 median [IQR] 11.3 [7.2,16.6] 21.8 [14.8,30.7] 18.9 [12.2, 27.9] <0.0001
IVUS Distances
Distance from Ostium to MLA
 median [IQR]
32.16 
[16.41,50.68]
26.06 [9.71,47.25]
27.40 [11.15, 
47.83]
<0.0001
Distance from Ostium to Distal 
Edge
 median [IQR]
40.95 
[23.73,59.72]
32.15 
[14.66,53.41]
34.71 [16.53, 
55.22]
<0.0001
Distance from Ostium to 
Proximal Edge
 median [IQR]
16.45 
[2.38,38.27]
15.92 [2.30,38.02] 16.02 [2.33, 38.10] 0.80
Distance from Ostium to Max NC
 median [IQR]
28.78 
[13.32,46.73]
23.95 [9.25,45.09]
24.97 [10.18, 
45.63]
0.0002
Table 4: Continued
Longitudinal distribution of necrotic core lesions in PROSPECT 291
to suggest that the proximal one third of each major coronary vessel tends to be the site of 
plaque ruptures6, up until recently the characteristics of these plaque rupture-prone lesions 
could not be examined in vivo due to lack of appropriate intravascular imaging tools. With the 
availability of IVUS and Virtual histology we have gained the ability to examine vessel walls 
and the plaque characteristics including its necrotic core content 8, (Garcia-Garcia HM et al; 
2009). Small single center pilot studies appeared to suggest that using this new methodology 
we could indeed see that necrotic core rich lesions and IVUS-VH derived TCFAs tended to be 
Table 5. Multivariate GEE model. The distance from the ostium is not a signifi cant independent predictor 
of TCFA distribution.
# 
Subjects
Multivariate Predictors* Coeffi  cient
Standard 
Error
p value
Odds Ratio 
[95% C.I.]
2550
Distance from Ostium to Max NC (10mm 
increase)
0.0288 0.0182 0.1126
1.03 [ 0.99, 
1.07]
 
History of cardiac intervention prior to the 
current ACS
-0.5990 0.2578 0.0202
0.55 [ 0.33, 
0.91]
 IVUS lesion length (1mm increase) 0.0370 0.0038 <0.0001
1.04 [ 1.03, 
1.05]
 % Plaque Volume (10 mm3 unit increase) 0.1797 0.1026 0.0800
1.20 [ 0.98, 
1.46]
 Remodeling index (1 unit increase) -0.6383 0.3603 0.0765
0.53 [ 0.26, 
1.07]
 Age (10 year increase) -0.1911 0.0648 0.0032
0.83 [ 0.73, 
0.94]
 History of Angina -0.4246 0.1763 0.0160
0.65 [ 0.46, 
0.92]
 Use of aspirin in the last 7 days 0.1751 0.1508 0.2456
1.19 [ 0.89, 
1.60]
 Hypercholesterolemia Requiring Medication 0.1515
 
0.1453
0.2973
1.16 [ 0.88, 
1.55]
Table 6. Multivariate GEE model. The distance from the ostium is not a signifi cant independent predictor 
of necrotic rich lesion distribution.
# 
Subjects
Multivariate Predictors* Coeffi  cient Standard 
Error
p value
2094 Intercept 16.5342 1.9940 <0.0001
Distance from Ostium to max NC 0.0061 0.0062 0.3262
History of cardiac intervention prior to the 
current ACS
0.9028 1.0637 0.3960
Gender: Male -1.3185 0.6936 0.0573
History of angina -1.3689 0.6585 0.0376
Use of aspirin in the last 7 days 0.6063 0.6459 0.3479
Hypercholesterolemia requring medication 0.8516 0.6115 0.1638
Tobacco use within last month -0.8712 0.5702 0.1266
% Plaque Volume 0.0539 0.0319 0.0910
MLA -0.5217 0.0741 <0.0001
Remodeling index -2.2607 0.8556 0.0082
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more proximally distributed and the distance from the ostium was a predictor of higher lipid 
content.7 This fi nding opened an attractive option of targeting therapy to the proximal one 
third of the major coronary vessels to prevent progression of atherosclerosis or even restore 
the normal architecture of the vessel by scaff olding the rupture-prone plaque (13; Serruys et al., 
personal communication; Wykrzykowska et al., TCT 2009). 
In this large multicenter natural history study of patients with acute coronary syndromes we 
failed to replicate the preliminary fi ndings of the single center trial with respect to clustering 
of the necrotic rich core lesions in the proximal one third of the vessel. One of the obvious 
diff erences between the methodologies used in the Valgimigli study7 is that it imaged a small 
number of patients and focused on the most proximal 40 m of the vessel, breaking it up into 
10 mm segments to examine the gradient of necrotic core distribution. Only one vessel was 
imaged. With such small number of highly selected patients there may have been a chance 
eff ect occurring in the multivariate model which established the distance from the ostium as 
a signifi cant predictor of necrotic core rich plaque content. It is also possible that in our study, 
patients who had plaque ruptures in the proximal vessel were treated as an index lesion and 
that segment was subsequently excluded from analysis biasing the results. In addition while the 
necrotic core content of the plaque may be similar in all three 30 mm segments of the vessels, 
we have noted that in the LAD plaque ruptures were more frequently observed in the proximal 
30 mm segment. This may have to do with local conditions such as low shear stress which is 
known to up-regulate pro-infl ammatory markers on the endothelium14 and presence of bifur-
cations. The latter factor may explain potentially why plaque ruptures would be more frequent 
in the distal RCA bed as the major bifurcation in that vessel into RPL and RDP is indeed located 
in its distal portion. In the LAD, on the other hand bifurcation with diagonal vessels occurs more 
proximally. We have recently demonstrated in fact that proximal rim of the bifurcations tends 
to be rich in necrotic core plaque.15 In addition, in the pilot study recently performed in our 
institution which randomized patients with IVUS-VD derived TCFAs to medical therapy versus 
scaff olding with a nitinol vShield device, the TCFAs were located in an equal distribution in the 
proximal or mid vessels. (Wykrzykowska et al., submitted).
Lastly, while the absolute plaque burden and necrotic core volume do decrease gradually 
from proximal to distal vessel (Figure 1), the percentage plaque burden and percentage necrotic 
core remain the same. This may relate to the conservation of mass and fl ow at the bifurcations 
previously shown by Murray, Hess and Kassab.16, 17 Just as the branching of the coronary arteries 
and the relationship of parent and daughter vessels on quantitative angiography is based on the 
principle of minimizing the cost function and according to Murray’s law the cube of the radius 
of a parent vessel equals the sum of the cubes of the radii of the daughter vessels, similar phe-
nomenon may apply to the plaque burden and necrotic core volume. When the pullback is done 
in the segment 6 of the LAD before the bifurcation with the D1 (fi rst 30 mm) and subsequently 
into segment 7 after the branch point (second 30 mm), plaque burden and necrotic core volume 
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decrease as the proportion of the volume is distributed into the daughter diagonal vessel and 
more distal LAD vessel. The percentages of plaque and necrotic core, however, stay the same.
LIMITATIONS
Although this was a large multicenter study which performed three-vessel intravascular IVUS 
and IVUS-VH examination there are several limitations that may have aff ected the results 
reported here: 1. The IVUS and IVUS-VH examination was performed after successful PCI 
treatment of the culprit lesion which was then excluded from examination. Thus the primary 
necrotic core rich plaque was treated and only secondary more quiescent TCFAs/necrotic core 
rich lesions were included in the study., and 2. In most patients 6-8 cm of the proximal vessels 
were examined and the most distal segment of the coronary tree was often excluded from 
analysis due to small diameter and risk of dissection with IVUS catheter.
CONCLUSION
In summary, we have found that the distance from the ostium is not a signifi cant predictor 
of the necrotic core content or presence of TCFAs. It appears that the clustering of plaque 
ruptures in the proximal vessel segments observed in the epidemiological studies cannot be 
simply mechanistically linked to percent necrotic core or presence of the IVUS-VH derived TCFA. 
There is likely a more complex interplay between this vessel wall substrate and other local and 
hemodynamic factors that leads to plaque rupture and consequent acute vessel occlusion and 
myocardial infarction.
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Table 1S. Baseline characteristics
Age (years, median [IQR]) 58.1 [50.5, 66.6]
Sex (female) 167/697 (24.0%)
Diabetes mellitus 119/694 (17.2%)
 - Insulin requiring 21/694 (3.0%)
Metabolic syndrome 327/673 (48.6%)
Current cigarette use 328/687 (47.7%)
Hypertension 320/691 (46.3%)
Hyperlipidemia 279/632 (44.1%)
Prior myocardial infarction 73/693 (10.5%)
Family history of coronary artery disease 276/616 (44.8%)
Framingham risk score 7.0 [5.0, 9.0]
Prior percutaneous coronary intervention 77/696 (11.1%)
Clinical presentation
 - ST-segment elevation myocardial infarction 211/697 (30.3%)
 - Non ST-segment elevation myocardial infarction 457/697 (65.6%)
 - Unstable angina with ECG changes 29/697 (4.2%)
Body mass index (kg/m2, median [IQR]) 27.9 [25.1, 31.2]
Total cholesterol (mg/dl, median [IQR]) 170.0 [149.0, 198.0]
LDL cholesterol (mg/dl, median [IQR]) 93.6 [62.6, 121.4]
HDL cholesterol (mg/dl, median [IQR]) 38.6 [33.0, 45.0]
Triglycerides (mg/dl, median [IQR]) 124.0 [88.6, 177.1]
Hemoglobin A1C (median [IQR]) 5.8 [5.3, 6.2]
Estimated creatinine clearance (ml/min, median [IQR]) 97.8 [76.4, 123.6]
High sensitivity C-reactive protein (mg/dl, median [IQR]) 7.2 [2.5, 18.9]
Number of diseased epicardial coronary arteries (core laboratory)*
 - One 149/697 (21.4%)
 - Two 283/697 (40.6%)
 - Three 265/697 (38.0%)
One vessel PCI performed 507/697 (72.7%)
Two vessel PCI performed 190/697 (27.3%)
FA
FT
Ca FA
TCFAPIT
CaTCFA
FCAIT
Adaptative intimal
thickening
Fibrocalcific Calcified FA
Calcified TCFA
Pathological 
intimal thickening
Fibrotic Fibroatheroma Thin cap 
fibroatheroma
Figure 1S. Classifi cation of plaque types based on IVUS-VH derived composition (Garcia-Garcia, HM et al., 
2009)
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Abstract Antiplatelet therapy with clopidogrel has been
shown to reduce major adverse cardiac events in acute
coronary syndromes and after percutaneous interventions.
This effect is not only due to its anti-platelet effect but
also possibly due to an anti-inflammatory effect. The
effect of clopidogrel cessation after one year of therapy
on markers of inflammation has been investigated in
diabetics and showed an increase in platelet aggregation
as well as hsCRP and surface P-selectin levels. This was
an exploratory multicenter prospective open-label single
arm study of 98 non-diabetic patients who had received
one or more drug eluting stents and were coming to the
end of their 12 months course of clopidogrel therapy.
The effect of clopidogrel cessation on expression of
biomarkers: sCD40L, soluble P-selectin and hsCRP was
measured right before clopidogrel cessation (day 0), and
subsequently at 1, 2, 3 and 4 weeks after drug with-
drawal. A median increase in sCD40L expression from
224 to 324.5 pg/ml was observed between baseline and
4 weeks after clopidogrel cessation, which corresponded
to a 39% mean percent change based on an ANCOVA
model (P\ 0.001). Over the 4 weeks observation period
the change in sCD40L expression correlated weakly
with soluble P-selectin levels (at 4 weeks Spearman’s
correlation coefficient = 0.32; P = 0.0024). Increase in
P-selectin expression from baseline was statistically sig-
nificant at week 1 and 2. Conversely, hsCRP level
decreased by 21% at 1 week (P = 0.008) and was still
reduced by 18% by 4 weeks (P = 0.062). The change in
sCD40L expression appeared to vary with the type of
drug eluting stent. Patients treated with drug eluting
stents at 1 year after implantation display significant
increase in sCD40L and decrease in hsCRP after clopi-
dogrel cessation. Further studies should elucidate if this
increase in sCD40L levels reflects solely the removal of
the inhibitory effects of clopidogrel on platelet activity
or rather an increase in pro-inflammatory state. The latter
hypothesis may be less likely given decrease in hsCRP
levels. Randomized studies are urgently needed to
establish potential link of clopidogrel discontinuation and
vascular outcomes.
Keywords Clopidogrel cessation  Platelet inhibition 
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Introduction
Addition of clopidogrel to aspirin results in reduction in
platelet reactivity [1]. This effect is particularly important
in patients that have been treated with percutaneous coro-
nary angioplasty and stenting [2]. Those who are non-
responders to clopidogrel may be at higher risk of adverse
events. Similarly, patients who interrupt their clopidogrel
therapy may be at risk of major adverse cardiovascular
event, among them stent thrombosis. Late stent thrombosis
has been shown to occur after drug eluting stent implan-
tation at a rate of 0.6% per year for up to 4 years [3]. While
the pathogenesis of stent thrombosis is likely multifacto-
rial, from stent malapposition (initial and acquired), geo-
graphic miss [4], through polymer-induced inflammation
and incomplete tissue coverage [5], it has also been sug-
gested that discontinuation of dual anti-platelet therapy
plays a role in a large proportion of cases [6, 7]. Increased
pro-coagulability after withdrawal of platelet inhibition is
likely a major factor, as incomplete platelet inhibition has
emerged as a significant risk factor for major adverse
cardiac events [8–11]. What has also emerged as a possible
mechanism is a potential increase in inflammation after
clopidogrel cessation. The role of clopidogrel, as well as
GP IIb/IIIa inhibitors, in modulating inflammation has been
documented in multiple studies in the context of acute
coronary syndrome and percutaneous coronary intervention
[12–17]. The effect of clopidogrel cessation on inflamma-
tory marker expression has not been investigated to date,
other than in a small cohort of 54 diabetic patients [8]. In
this study, platelet aggregation as well as hsCRP levels and
surface platelet P-selectin levels increased significantly at
4 weeks after cessation of clopidogrel. It is not known
whether cessation of treatment in non-diabetic patients also
leads to pro-inflammatory marker upregulation and, if so,
whether this could cause an increase in late stent throm-
bosis in a proportion of patients. In this exploratory study,
we set out to describe the changes in the levels inflam-
matory markers sCD40L, P-selectin and hsCRP within
4 weeks of clopidogrel withdrawal in a 100 non-diabetic
patients treated with stable doses of aspirin and statin.
Methods
Study design
The Discontinuation Effect of Clopidogrel After Drug
Eluting Stent (DECADES) trial was an exploratory, mul-
ticenter, open-label, single-arm study to determine the
effects of withdrawing clopidogrel therapy 12 months after
implantation of DES on markers of inflammation and
platelet activation in a non-diabetic population. The trial
took place between 31 October 2007 and 30 June 2008 and
was conducted at 6 sites in 4 European countries. The trial
was approved by the institutional review board/indepen-
dent ethics committee at every study centre. Written
informed consent for trial participation was obtained from
each patient. The trial was conducted in line with the
guidelines of the current amendment to the Declaration of
Helsinki, in accordance with the International Conference
on Harmonization of Good Clinical Practice and applicable
regulatory requirements.
Study population
Patients older than 18,who had receivedC1DESof any type,
were receiving statin and low-dose aspirin therapy, and were
coming to the end of 12 months of therapy with clopidogrel
75 mg/day, were eligible to participate in the trial. Current
medication doses (including aspirin and statins) must have
been stable for 3 months. Patients were excluded from the
study if they had a clinical history of diabetes mellitus, had
uncontrolled hypertension (systolic blood pressure[
180 mmHg or diastolic BP[ 100 mmHg), were intolerant
of (or had contraindications to) aspirin or statins. The fol-
lowing patients were also excluded: those who had used
within the previous 3 months or were currently using oral
anticoagulants, dipyridamole or oral glucocorticoids; or
were taking another investigational study medication or had
taken an investigational study medication within the previ-
ous 30 days of the enrolment visit. Use of antiplatelet agents,
other than stable doses of low-dose aspirin, was prohibited
during the study.
Study protocol
After obtaining written informed consent, eligible patients
were enrolled in the study. At this time, therapy with clopi-
dogrel 75 mg/day was stopped, and stable dosages of statins
and low-dose aspirin continued. The aim of the study was to
evaluate the discontinuation effect of clopidogrel on bio-
markers by taking blood samples prior to or on the day of
Day 0 – 12 months visit 
after index PCI and  
baseline biomarker
Day 0 - Decision 
to  stop 
measurement
clopidogrel
Biomarker measurements 
after clopidogrel cessation:
Week 1
Week 2
Week 3
Week 4
Fig. 1 Study flow chart
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discontinuation of clopidogrel (baseline), and then at follow-
up visits at the end of weeks 1, 2, 3 and 4 (Fig. 1).
Safety was evaluated during the entire study period by
reporting any adverse events and serious adverse events. At
each follow-up visit patients were asked if they had
experienced any symptoms since clopidogrel withdrawal.
Biomarker assessments
Blood samples were obtained by direct venipuncture by an
experienced phlebotomist. The primary endpoint was the
mean change from baseline to week 4 in levels of sCD40L.
Secondary endpoints included changes from baseline in
plasma soluble P-selectin and hsCRP levels. All blood
samples were frozen and sent for analysis to a central
laboratory (Quintiles Limited, Livingston, UK). sCD40L,
soluble P-selectin and hsCRP levels were analysed.
Inflammation markers
The blood samples collected for immunoassays were cen-
trifuged at 1400 g for 10 min. Measurements of hsCRP,
CD40L and P-selectin were performed in duplicate by
enzyme-linked immunosorbent assay using commercially
available kits from R&D Systems (Minneapolis, MN) for
sCD40L and P-selectin and DPC Immulite for hsCRP
(Block Scientific, Holbrok, NJ).
Statistical methods
This was an exploratory study and therefore data on the
effect of withdrawing clopidogrel on sCD40L were not
available for this study population. The sample size was
not based on power considerations. Analyses were per-
formed in the clopidogrel cessation population. All patients
signed informed consent. The primary and secondary
endpoint variables were evaluated using an ANCOVA
model with baseline as covariate and investigative site as
the main effect. As all three biomarkers showed a log-
normal distribution at week 4, all ANCOVA analyses were
performed on log-transformed values (using the natural
logarithm transformation). The least-square mean was
computed using a weighting scheme based on the actual
sample sizes at each site. Data in the pre-specified analysis
are presented as mean change from baseline, with 95%
confidence intervals (CI). For all changes from baseline
analyses, only subjects with at least a baseline and one
post-clopidogrel withdrawal measurement were included.
No imputation technique was used to attempt to account for
missing data. Demographic and baseline characteristics, as
well as safety data, were summarized using descriptive
statistics, medians and interquartile ranges. Analyses were
performed using the SAS 8.2 statistical package.
As post-hoc analysis, correlation between P-selectin
levels and sCD40L was performed. In addition, the effect
of the type of DES on the change from baseline in levels of
sCD40L was assessed using an ANCOVA model with
baseline as covariate and type of DES as the main effect.
Results
Study population
A total of 103 patients were enrolled in the study and 98
patients completed the protocol. Two patients failed to have
baseline biomarker measurements. Two patients withdrew
their consent and one patient no longer met the criteria for
enrolment after baseline evaluation. Baseline characteristics
are summarized in Table 1A. They were predominantly
male with high proportion of patients having risk factors of
hypertension, hypercholesterolemia and a prior history of
myocardial infarction (63%) and none of the patients were
diabetic by trial design. Mean total duration of clopidogrel
use was 386 ± 62 days. All patients were also on stable
aspirin and statin regimens (Table 1B). The type of stent
implanted in the last procedure is listed in Table 2.
Adverse clinical events
There were no deaths, myocardial infarctions or stent
thrombosis in this patient cohort after clopidogrel cessa-
tion. Two patients represented with symptoms, one with
non-cardiac chest pain and another with angina symptoms,
which did not require catheterization.
Biomarker assessments
Changes in inflammatory markers such as sCD40L, soluble
P-selectin and hsCRP over 4 weeks after withdrawal of
clopidogrel are shown in Table 3 (medians and interquar-
tile ranges) and as mean percentage changes from baseline
levels obtained at 12 months after clopidogrel administra-
tion. CD40L levels increased from a median of 224 to
324.5 pg/ml by week four after clopidogrel cessation
(Table 3A).
P-selectin levels, on the other hand, appeared to increase
slightly two weeks after clopidogrel cessation (from 44 to
50 ng/ml; P\ 0.001) and then decreased to the baseline
levels (45 ng/ml; P = 0.488) after 4 weeks (Table 3B).
Changes in soluble P-selectin levels correlated only weakly
with changes in sCD40L levels (correlation coefficient
reached 0.32 at 4 weeks with P = 0.024; Fig. 2).
hsCRP levels decreased by 21% at 1 week (P = 0.008)
and was still reduced by 18% by 4 weeks (P = 0.062)
(Table 3C).
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sCD40L and stent type
Increase in CD40L varied with drug eluting stent used.
Patients who were treated with zotarolimus stents appeared
to have the greatest upregulation of sCD40L after clopi-
dogrel discontinuation compared to the patients treated
with paclitaxel, sirolimus eluting stents or bare metal stents
(Fig. 3). The degree of sCD40L upregulation was depen-
dent on baseline levels. There was no difference in total
stent length between stent types implanted to confound the
results.
Discussion
To our knowledge this is the first study to evaluate the
effect of clopidogrel cessation at 1 year after initial stent-
ing with drug eluting stents on inflammatory markers and
markers of platelet activation in non-diabetic patients. This
study was exploratory in nature, but nevertheless demon-
strated a significant increase in CD40L expression after
clopidogrel cessation indicative of possible enhanced
platelet activation. Although not statistically significant at
4 weeks, P-selectin level increase seemed to parallel the
CD40L changes, at least for the first 2 weeks, and corre-
lated only weakly. P-selectin levels returned to baseline by
4 weeks suggesting that the stimulus causing this transient
increase has disappeared. P-selectin is expressed upon
platelet activation and binds the P-selectin glycoprotein
ligand-1 on leukocytes [18]. P-selectin expression ulti-
mately results in tissue factor expression by the monocytes
and other inflammatory cytokines [12, 19]. More general
marker of inflammation hsCRP decreased by 21% at
1 week. This opposite effect suggests that the increase in
sCD40L levels reflects solely the removal of the inhibitory
effects of clopidogrel on platelet activity rather than an
increase in pro-inflammatory state. The interpretation of
this result is greatly limited by lack of measure of platelet
inhibition or overall thrombogenicity assay (such as
thromboelastography) [20–22].
While considerable data are now available on inflam-
matory markers and their modification with anti-platelet
therapy in the context of acute coronary syndromes and
percutaneous intervention [23, 24] it is not clear what
impact cessation of an anti-platelet agent in a stable patient
1 year post-procedure has on inflammation and pro-
coagulability. Even more difficult to interpret are con-
founding effects of drug eluting stent type. There may be a
significant interaction between endothelial dysfunction due
to local inflammation from the drug eluting stent polymer
and platelet activation. Based on the animal data from
Nakazawa et al. [25], the zotarolimus stent should have the
greatest late loss and restenosis rate but also the best
Table 1 (A) Demographic baseline patient characteristics; (B) length
of clopidogrel, aspirin and statin treatment
Variable Total (N = 98)
(A) Baseline characteristics
Age (years)
Mean 63.3
SD 8.5
Median (min, max) 63 (44, 81)
Gender, N (%)
Male/female 78/20 (79.6/20.4)
Race, N (%)
Caucasian 93 (94.9)
Asian oriental 5 (5.1)
Risk factors/comorbidities, N (%)
History of hypertension 53 (54.1)
Hypercholesterolemia 80 (81.6)
Congestive heart failure 2 (2.0)
Prior myocardial infarction 62 (63.3)
Atrial fibrillation 3 (3.1)
Stroke 4 (4.1)
Transient ischemic attack 5 (5.1)
Peripheral arterial disease 8 (8.2)
CABG 6 (6.1)
Peripheral angioplasty or bypass surgery 1 (1.0)
Current smoker 16 (16.3)
Extent of exposure to clopidogrel
and ASA and statins
Total (N = 98)
Mean; SD
(B) Time elapsed from initial clopidogrel administration
Clopidogrel use prior to withdrawal
Duration (days) 385.8; 62.4
Last dose (mg/day) 75.0; 0.0
ASA use prior to clopidogrel withdrawal
Duration (days) 763.5; 1041
Last dose (mg/day) 101.2; 27.2
Statin use prior to clopidogrel withdrawal
Duration (days) 887.3; 1394
Last dose (mg/day) 43.1; 20.5
Table 2 Type of stent implanted at index procedure
Type of DES Total (N = 98)
Implanted in most recent year, N (%)
Paclitaxel eluting stent 45 (45.9)
Sirolimus eluting stent 33 (33.7)
Zotarolimus eluting stent 18 (18.4)
Everolimus eluting stent 2 (2.0)
Other type of stent 6 (6.1)
No stent implanted in most recent year 4 (4.1)
Type of stent implanted missing 2 (2.0)
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endothelialization and the least local inflammation com-
pared to sirolimus and paclitaxel stents. These results in
animal models were ascribed to better biocompatibility of
phosphotylcholine polymer used in zotarolimus-eluting
stents than polyethelyne co-vinyl acetate and poly-n-butyl
methacrylate (sirolimus eluting stents) and polystyrene-b-
isobutyle-b-styrene (paclitaxel eluting stents). The latter
two polymers have been shown to cause inflammation,
local upregulation of tissue factor and macrophage acti-
vation [26]. We observed, however, the greatest sCD40L
upregulation after clopidogrel discontinuation in patients
treated with zotarolimus-eluting stents compared to siroli-
mus and paclitaxel drug eluting stents. This observation
needs to be explored further in future studies and may
Table 3 Change in the levels of (A) sCD40L, (B) P-selectin and (C) hsCRP over 4 weeks presented as medians and interquartile ranges as well
as mean percentage change
Baseline Week 1 Week 2 Week 3 Week 4
(A) sCD40L levels over 4 weeks after clopidogrel cessation
CD40L
Median 224 298 285.5 292 324.5
Max 1450 2483 2559 2871 2474
Min 10 36 23 42 18
Q3 364.5 478 569.5 509 541
Q1 129.5 161 160.75 155 199.5
Upper limit of normal 0 pg/ml
Lower limit of normal 5000 pg/nl
Average 310.2 434.9 469.1 412.9 446.1
Std 282.3 453.8 483.7 431.3 409.5
Mean percent change from baseline ? SE 35% ? 10% 39% ? 11% 33% ? 10% 39% ? 11%
P\ 0.001 P\ 0.001 P\ 0.001 P\ 0.001
(B) P-selectin levels over 4 weeks after clopidogrel cessation
P-selectin
Median 44 49 50 45.5 45
Max 104 114 138 147 150
Min 20 22 9 17 23
Q3 58 60.25 60.25 59 55.25
Q1 37 40 39 35 35
Upper limit of normal 51 ng/ml
Lower limit of normal 113 ng/ml
Mean 47.2 51.3 51.7 49.2 48.1
Std 16.2 17.2 18.7 20.1 20.3
Mean percent change from baseline ? SE 9% ? 2% 11% ? 2% 4% ? 3% 2% ? 3%
P\ 0.001 P\ 0.001 P = 0.173 P = 0.488
(C) Levels of CRP over 4 weeks after clopidogrel cessation
hsCRP (mg/L)
Median 1.59 1.25 1.1 1.11 1.22
Min 0.1 0.1 0.2 0.2 0.1
Max 57.9 27.7 15.6 62.9 19.5
Q3 3.70 2.61 3.46 3.29 2.83
Q1 0.74 0.72 0.66 0.62 0.61
Average 3.92 2.39 2.33 2.87 2.76
Std 7.73 3.60 2.63 6.70 3.96
Lower limit of normal 0 mg/L
Upper limit of normal 11 mg/L
Mean percent change from baseline ? SE -21% ? 7% -23% ? 7% -19.% ? 8% -18% ? 8%
P = 0.008 P = 0.004 P = 0.038 P = 0.062
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reflect a complex interaction between systemic pro-
inflammatory state, platelet activation and local peri-stent
polymer-induced inflammation.
Our results in this cohort of patients with stable coronary
disease are in agreement with Azar et al. [27], who found
only a modest decrease in sCD40L after starting clopidogrel
in stable patients (17% decrease after 8 weeks of therapy).
It appears, however, that even at 12 months post-stenting
clopidogrel still has an effect on inflammatory biomarkers
and these effects are detectable in patients treated with
stable doses of aspirin and statins. The poor correlation
between sCD40L and P-selectin while somewhat perplex-
ing, seem to echo the findings from the ELAPSE study on
proinflammatory marker levels at 12 months after com-
mencement of therapy [9]. Similarly, no correlation
between more systemic hsCRP and more-platelet/athero-
sclerosis specific sCD40L/P-selectin was found in that
study.
Lastly, a source of variability and the lack of strong
correlations between different markers in our data set could
be due to different doses of statins and potencies used in
the study. Although a given patient had to be on a stable
statin dose as the inclusion criteria, using variable doses
with different down-modulation of the pro-inflammatory
state (as reflected by hsCRP) could have made the patients
on lower statin doses more likely to upregulate inflamma-
tory markers after clopidogrel withdrawal. Ideally, when a
larger study is performed all patients should be on a single
statin such as rosuvastatin with LDL and hsCRP suppres-
sion goals optimized [28].
Limitations
Our study was limited by lack of biomarker level mea-
surements before starting clopidogrel treatment as well as
lack of concomitant data on platelet inhibition levels. The
sample size was small and the study was exploratory in
nature, and therefore not powered to detect clinical
outcomes.
Conclusions
Patients treated with drug eluting stents at 1 year after
implantation display significant increase in sCD40L and
decrease in hsCRP after clopidogrel cessation. Further
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studies should elucidate if this increase in sCD40L levels
reflects solely the removal of the inhibitory effects of
clopidogrel on platelet activity or rather an increase in pro-
inflammatory state. The latter hypothesis may be less likely
given decrease in hsCRP levels. Zotarolimus stent
implantation appears to be associated with the highest
sCD40L upregulation after stopping clopidogrel but the
clinical significance of this observation is uncertain.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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EU grant Proposal full title: Late stent thrombosis prevention using novel stent technolo-
gies assessed by combining frequency domain optical coherence tomography (OFDI) 
imaging with investigation of platelet biology.
Proposal acronym: LAST PROPHET
LAte Stent Thrombosis prediction and PRevention based on frequency domain OPtical 
coHErence Tomography.
Coordinator: Prof. Dr. P.W.J.C. Serruys, EMC, The Netherlands
Synopsis:
Prevalence of late stent thrombosis has increased as the use of drug eluting stents spread to larger
patient population with more complex coronary artery disease. Despite improvements in stent design
and anti‐platelet regimen patients with complex disease have a 9.4% incidence of defi nite and probable
stent thrombosis at 5 years with 45% mortality. Acute coronary syndrome is one of the major risk factors
for stent thrombosis.
The aim of the project will be:
1. To integrate basic, translational science and clinical trial results in order to gain insights into
mechanisms of late stent thrombosis
2. To solve within 5 years important issues related to late stent thrombosis and develop a systematic
approach aimed at prediction and prevention of late stent thrombosis strategies.
3. To deliver to the EU commission a detailed strategy to eliminate late stent thrombosis
This research project will be carried out by 12 Partners collaborating intensively in 11 work packages
Permanent endovascular metallic stent prosthesis and coronary vessel caging, as well as lack of stent
strut coverage, strut malapposition and intraluminal defects have been proposed as possible imaging
correlates of stent thrombosis risk.
LAST PROPHET aims to use novel molecular (metabolomic, proteomic, genomic) and imaging (Optical
Frequency Domain Imaging) strategies to characterize the patients at risk for late stent thrombosis and
stent platforms that minimize this risk.
The main driving hypothesis of the project is that:
1. biocompatible durable polymer;
2. biodegradable polymer and ;
3. polymer free platforms will reduce the risk of late stent thrombosis due to decreased
infl ammation; and that the
4. fully biodegradable stent platform will provide the ultimate solution to the late stent thrombosis
problem. The latter technology uses a polylactic acid polymer (with fully biological catabolic
products). In addition it elutes the drug everolimus drug which promotes autophagy of
macrophages and thereby further reduces infl ammation.
The LAST PROPHET project will enroll 400 patients with acute coronary syndromes randomized to 4
diff erent stent platforms. All patients will be treated with aspirin and ticagrelor (novel P2Y12 inhibitor)
and the lesion will be examined with IVUS VH for the presence of necrotic core.
Optical Frequency Domain Imaging (OFDI) will be performed after stent placement for optimization of
result. Patients will be investigated after discontinuation of their ticagrelor at 1 year with OFDI for
Neointimal Healing Index, endothelium‐dependent vasomotion and shear stress measurement. These
parameters will allow to diff erentiate which of the stent technologies allows for the best restoration of
normal endothelial function and structure, thereby reducing the risk of late stent thrombosis.
Patients will undergo characterization of their pro‐thrombotic phenotype and genotype. Patients will be
clinically followed for 3 years for MACE and stent thrombosis events.
Pre‐clinical studies in LAST PROPHET will correlate the imaging (OFDI) fi ndings with its Neointimal
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Healing Index to the histological and pathological fi ndings.
This interdisciplinary medium scale project, based on translational approaches will demonstrate that the
transient bioabsorbable scaff old could eff ectively replace the permanent metallic prosthesis in the
treatment of atherosclerotic coronary stenosis while restoring normal vascular structure and function,
thereby preventing the phenomenon of late stent thrombosis.
(Full proposal is available electronically on demand)
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First case of stenting of a vulnerable plaque  
in the SECRITT I trial—the dawn of a new era?
Steve Ramcharitar, Nieves Gonzalo, Robert Jan van Geuns, Hector M. Garcia-Garcia,  
Joanna J. Wykrzykowska, Jurgen M. R. Ligthart, Evelyn Regar and Patrick W. Serruys
Background. A 63-year-old man presented with class II anginal symptoms.
Investigations. Cardiac catheterization, intravascular ultrasound (IVUS) virtual histology, optical coherence 
tomography and off-line palpography.
Diagnosis. The patient was diagnosed as having a culprit lesion in the left circumflex artery and a vulnerable 
plaque in the left anterior descending artery.
Management. The culprit lesion was treated with two overlapping drug-eluting stents. The vulnerable plaque 
was then treated with a self-expanding stent tailored to shield vulnerable plaques (vProtect® Luminal Shield). 
After dilatation of the stent with a low-pressure balloon, IVUS and optical coherence tomography showed 
excellent apposition of the stent to the vessel wall, with no signs of tissue prolapse or edge dissections. 
At the 6-month follow-up appointment, the stent showed complete tissue coverage without signs of in-stent 
restenosis.
Conclusions. Six months of follow-up has demonstrated that a patient with an IVUS-derived, thin capped 
fibroatheroma was successfully treated with a stent tailored to shield vulnerable plaques.
Ramcharitar, S. et al. Nat. Rev. Cardiol. 6, 374–378 (2009); doi:10.1038/nrcardio.2009.34
The case
A 63-year-old man complained of chest pains during 
exercise. He was a retired public servant who exer-
cised regularly in the gym. Risk factors for coronary 
artery disease included being an ex-smoker (he stopped 
smoking 18 months before his presentation but had 
smoked for 30 years previously), diabetes (oral hypo-
glycemics), hypertension, hypercholesterolemia and 
a strong family history of ischemic heart disease. On 
admission the patient had a pulse rate of 70 bpm and a 
blood pressure of 140/70 mmHg. Electrocardiography 
showed sinus rhythm (75 bpm) with good R wave pro-
gression and no apparent signs of cardiac ischemia. 
Transthoracic echocardio graphy demonstrated good 
left ventricular function with no significant valvular 
abnormalities. A significant lesion in the left circum-
flex coronary artery together with a non-flow-limiting 
lesion in the left anterior descending artery was noted 
on coronary angio graphy performed at the referring 
hospital. The right coronary artery was dominant 
and nondiseased.
The patient gave written informed consent to be 
enrolled in a prospective, randomized study investi gating 
the proactive shielding of an intravascular ultrasound 
(IVUS)-derived, thin-capped fibroatheroma (IDTCFA).1 
The SECRITT I (Santorini Criteria2 for Investigating and 
Treating Thin Capped Fibroatheroma) trial (Figure 1) 
required treatment of the culprit lesions with a drug-
eluting stent, followed by treatment of the IDTCFA 
with a self-expanding stent tailored to treat vulner-
able plaques—the vProtect® Luminal Shield (Prescient 
Medical, Inc., Doylestown, PA).3
The culprit lesion in the left circumflex coronary 
artery was crossed with a magnetically enabled Titan™ 
3 mm wire (Stereotaxis, St Louis, MO) and stented 
with over lapping Xience V® stents, 2.5 × 12.0 mm and 
2.5 × 28.0 mm (Abbott Vascular, Santa Clara, CA).
Quantitative coronary angiography of the lesion in 
the left anterior descending artery revealed a minimal 
luminal diameter of 1.76 mm, a proximal reference dia-
meter of 2.94 mm, 40% diameter stenosis, and a lesion 
length of 11 mm (Figure 2a). Brightwire™ II Pressure 
Guide Wire (Volcano, Rancho Cordova, CA) demon-
strated a fractional flow reserve of 0.84 with infused 
adenosine. IVUS virtual histology (IVUS-VH) per-
formed using a 20 MHz Eagle Eye® catheter (Volcano, 
Rancho Cordova, CA) revealed a plaque with calcified 
IDTCFA morphology (Figure 3a, parts 1 and 2). The 
plaque had a minimal luminal area of 4.2 mm2 and 
a plaque burden of 71%. The tissue composition of the 
plaque was 23% necrotic core (15.9 mm3), 22% calcified 
tissue (14.9 mm3), 8% fibrofatty tissue (5.8 mm3) and 47% 
fibrotic tissue (31.9 mm3). More than 10% of the conflu-
ent necrotic core was in direct contact with the vessel 
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lumen on three consecutive frames. Use of optical coher-
ence tomography (OCT; ImageWire™, LightLab Imaging 
Inc., Westford, MA) confirmed the presence of a thin 
fibrous cap (60 μm) encasing the necrotic core (Figure 3a, 
part 3).4 A palpogram acquired simultaneously during an 
IVUS pullback (0.5 mm per second) with the Eagle Eye® 
catheter recorded a maximum Rotterdam classifi cation 
(ROC) score of II (Figure 4a).5
The IDTCFA was treated with a 4.0 × 15 mm vProtect® 
Luminal Shield stent. Withdrawal of the distal outer 
sheath that houses the vProtect® Luminal Shield within 
the retractable delivery system deployed the self-
 expanding Nitinol stent. After low-pressure (6 atm) 
balloon dilatation (Voyager™ 4.0 × 12 mm, Abbott 
Vascular, Santa Clara CA) of the stent, quantitative 
coronary angiography showed a minimal luminal dia-
meter of 3.05 mm and 0% diameter stenosis (Figure 2b). 
Post-stent IVUS-VH analysis (Figure 3b, parts 1 and 2) 
showed complete lesion coverage with good stent expan-
sion and apposition. OCT (Figure 3b, part 3) revealed the 
stent struts fully apposed and superficially embedded in 
the underlying fibrous cap without evidence of fracture 
of the cap, prolapse of atherosed material between the 
vProtect® Luminal Shield scaffolding struts or edge dissec-
tions. The maximum ROC score after stent implantation 
was II (Figure 4b).
The patient was observed overnight and discharged 
home following a normal cardiac biochemical profile 
(creatine kinase = 125 ng/ml, creatine kinase–MB 
isoenzyme = 0.5 ng/ml and troponins <0.05 ng/ml). 
Medications on discharge were metformin 1 g twice daily, 
and aspirin 75 mg, atorvastatin 40 mg and felodipine 
5 mg, once daily. The patient was also told to continue 
with clopidogrel 75 mg daily for 6 months.
At the 6-month follow-up, angiography showed no 
signs of stent restenosis (Figure 2c). On IVUS-VH the 
stent struts were well apposed and had an appearance 
similar to dense calcium (Figure 3c, parts 1 and 2). 
OCT examination showed complete tissue coverage of 
the stent, and there was no demonstrable increase in 
strain pattern on palpography (Figure 3c, part 3 and 
Figure 4).
Discussion of diagnosis
Sudden cardiac death and acute coronary syndromes 
caused by acute thrombotic occlusion of the coronary 
lumen are common initial manifestations of coro-
nary atherosclerosis.6 Pathological examinations have 
demonstrated that intraluminal thrombi usually arise 
from plaque rupture, and thin-capped fibroatheroma 
(TCFA) has been identified as the plaque type most 
prone to rupture.7 Such lesions are characterized by a 
large necrotic core (tissue with lipid-rich necrotic areas 
containing remnants of foam cells, lymphocytes, chol-
esterol clefts and microcalcification) covered by a thin 
fibrous cap (usually less than 65 μm thick) with outward 
remodeling, paucity of smooth muscle cells and intense 
macrophage infiltration.8 Several biological factors (for 
example, focal inflammation and intraplaque hemor-
rhage) and mechanical factors might contribute to the 
weakening and final rupture of the fibrous cap that 
exposes the underlying thrombogenic material to the 
blood stream.9
The majority of TCFAs occur in the proximal portion 
of the three major epicardial coronary arteries, and more 
than 80% have luminal narrowing of less than 75% of 
the cross-sectional area (that is, less than 50% diameter 
stenosis).10,11 Indeed, postmortem findings have suggested 
that most myocardial infarctions result from non-flow-
limiting lesions rather than a critical blockage.12 Similarly, 
coronary angiography in the months preceding an acute 
infarction often show that the culprit lesion had less 
than 50% diameter stenosis;13 only approxi mately 15% 
of culprit lesions arise from lesions that had greater than 
60% stenoses.14 These findings tell us that even though 
coronary flow is not obstructed (because of outward 
[positive] remodeling), a critical plaque volume exists for 
determination of lesion vulnerability. The data suggest 
that the long-term prognosis of a patient might depend 
on far more detailed plaque assessment than angio-
graphy, and on adequate treatment of plaques at risk of 
rupture. The rationale for IVUS-VH analysis in plaque 
characterization has been supported by autopsy findings, 
particularly for TCFA identification.15 Studies from our 
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Figure 1 | Trial profile of the SECRITT I (Santorini Criteria for Investigating and 
Treating Thin Capped Fibroatheroma) trial. Abbreviations: DES, drug-eluting stent; 
FFR, fractional flow reserve; IVUS-VH, intravascular ultrasound virtual histology; 
OCT, optical coherence tomography; QCA, quantitative coronary angiography.
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institution on IVUS-VH assessment of three vessels,11,16 as 
well as the PROSPECT trial,17 suggest that the frequency 
of IDTCFA correlates with postmortem pathological 
specimens from patients who had a myo cardial infarc-
tion and IVUS-documented plaque ruptures (mean 2.08 
per patient; range 0–6).
Identification of a ruptured plaque within the culprit 
lesion was first reported in 2002 in 24 patients referred 
for percutaneous coronary intervention after first 
acute coronary syndrome with troponin I elevation.10 
Interestingly, plaque rupture in the culprit lesion was 
found in only nine patients (37%). In 19 patients (79%), 
at least 1 plaque rupture was found somewhere other 
than the culprit lesion, such as in a different artery (in 
70%) and in two other arteries (in 12.5% of the patients). 
Increasing evidence supports the notion that patients 
referred for coronary percutaneous interventions can 
often have non-flow-limiting plaques with high-risk 
morphology remotely located from the culprit lesion 
that cause the presenting symptoms. The identification 
and treatment of these prone-to-rupture or ‘vulnerable’ 
plaques could potentially prevent the occurrence of 
future coronary events. The limited number of TCFAs 
in each patient suggests that the pathology could be 
treated by focal approach. However, no large, published 
studies linking the presence of TCFA—detected in vivo 
by invasive techniques—to their imminent rupture and 
their associated clinical events exist to date.
Treatment and management
Currently, there are two strategies for managing patients 
after the identification of a TCFA. The conservative 
approach is based on the premise that as long as the posi-
tive and negative predictive value of these imaging tech-
niques (OCT,18 IVUS-VH19) in predicting the eminence 
of a clinical event has not been established, no local treat-
ment is warranted. In the more liberal approach, a limited 
number of focal pathologies are randomly allocated 
to treatment or no treatment to allow the clinical and 
physio logic effect of TCFA shielding to be determined.
SECRITT I is a randomized, controlled pilot study 
(n = 30) conceived to evaluate the safety and feasibility 
of stenting a vulnerable plaque with a dedicated stent 
(the vProtect® Luminal Shield) compared with a medi-
cally treated, non-stented (control) group (Figure 1). In 
the study, intermediate lesions (quantitative coronary 
angiography 40–50%) remote from the culprit lesion 
are evaluated by fractional flow reserve measurements. 
Lesions with fractional flow reserve greater than 0.75 are 
then analyzed by IVUS-VH to identify IDTCFA before 
randomization to therapy. Lesions with a fractional flow 
reserve less than 0.75 are managed as the culprit lesions. 
Palpographic assessment, of the change in strain pattern 
of the IDTCFA, and OCT are used together in the evalu-
ation of cap thickness and the effect of vProtect® Luminal 
Shield implantation on the morphology of the fibrous 
cap. These imaging modalities are normally not suffi-
ciently accurate to detect TCFA when used alone, but 
are thought to offer an increased precision when used 
in combination. Change in strain pattern was used as a 
primary outcome in the SECRITT I trial because in the 
ABSORB trial palpography in 12 patients demonstrated 
that the mean number of frames with ROC III–IV per 
centimeter decreased from 1.22 ± 1.91 before stenting to 
0.12 ± 0.31 after the procedure (P = 0.0781).20 Similarly, 
the mean cumulative strain values (that is, all frames 
with ROC I–IV scores) changed from 0.50 ± 0.27% 
to 0.20 ± 0.10% (P = 0.0034).20 Investigators involved 
in the ABSORB trial hypothesized that reductions in 
high strain values immediately after stenting might be 
because of a decrease in deformability of the stented 
vessel wall.20
The vProtect® Luminal Shield is uniquely designed 
so that it has mechanical properties that include self-
expandable scaffoldings and an austenitic finish, and is 
precision engineered for stabilizing nonobstructive and 
relatively soft lesions. Standard workhorse drug-eluting 
stents are not ideally suited in this setting as the required 
high deployment pressure can critically deform the cap 
and result in rupture.21 Animal studies, involving rabbit 
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Figure 2 | Quantitative coronary angiography analysis of the intravascular-ultrasound-derived, thin-capped fibroatheroma. 
Analysis was performed a | before stenting b | immediately after treatment with the vProtect® Luminal Shield and c | at the 
6-month follow-up appointment. Abbreviations: CF, calibration factor; MLD, minimal luminal diameter.
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Figure 3 | Morphology of the patient’s plaque with IVUS-derived, thin-capped fibroatheroma. Matched grayscale IVUS (1), 
IVUS-VH (2) and OCT (3) images of the IVUS-derived, thin-capped fibroatheroma a | before stenting with the vProtect® 
Luminal Shield, b | immediately after treatment with the vProtect® Luminal Shield and c | at the 6-month follow-up 
appointment. The arrow in panel a part 2 indicates the necrotic core in contact with the lumen. The arrow in panel a part 3 
indicates the thin fibrous cap, and the asterisk indicates a guidewire artifact. In the IVUS-VH images (parts 2): red, necrotic 
core; dark green, fibrotic tissue; light green, fibrofatty tissue; and white, dense calcium. Abbreviations: IVUS, intravascular 
ultrasound; IVUS-VH, intravascular ultrasound virtual histology; OCT, optical coherence tomography.
iliac artery injury models, demonstrated that the vPro-
tect® Luminal Shield can promote vascular healing to 
achieve complete endothelialization of the stented vessel 
segment in 7 days.3
Although atherosclerosis is a systemic disease, and 
aggressive management of cardiac risk factors is war-
ranted,22,23 many patients are on appropriate medical 
therapy, including statins and antihypertensives, 
when they present with an acute coronary syndrome. 
Mechanical modification of the plaque might be con-
sidered crude, but stent technology has radically 
changed over the years. New generation stents, such as 
the vProtect® Luminal Shield, push the frontier of stent-
ing techno logy in a different direction and allow us to 
address the issue of the vulnerable plaque. However, 
as with conventional stenting approaches, procedural 
related acute complications, such as restenosis and 
thrombotic events, might occur. No long-term data on 
the vProtect® Luminal Shield exist to date, so the follow-
up of this and other patients in the SECRITT I study will 
ultimately determine the success of mechanical shielding 
of a vulnerable plaque.
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Conclusions
The patient is enrolled in a prospective pilot trial 
(SECRITT I) aimed at evaluating the acute stabilization 
and long-term consequences of proactively stenting a vul-
nerable plaque. A patient with an IDTCFA was treated 
with a stent tailored for vulnerable plaques; data from 
the patient’s 6-month follow-up appointment were very 
encouraging. Further follow-up of this and other patients 
will help determine if mechanical shielding of a vulnerable 
plaque is a feasible and safe treatment option.
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Figure 4 | Palpography of the intravascular-ultrasound-derived, thin-capped fibroatheroma. Palpography was performed  
a | before stenting with the vProtect® Luminal Shield, b | immediately after treatment with the vProtect® Luminal Shield,  
and c | at the 6-month follow-up appointment. The blue circle around the lumen indicates the absence of high strain areas.
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ABSTRACT
Background: The acute impact in vivo from a self-expanding stent on the vessel wall has not 
been suffi  ciently evaluated.
Objectives: We sought to compare acute in vivo injury on the vessel wall and clinical impact 
between a self-expanding coronary stent and conventional balloon-expandable stents imme-
diately after stent implantation.
Methods: We included forty patients (45 vessels) with stable or unstable angina who were 
assigned to either the self-expanding stent (vProtect® Luminal Shield) group (n = 9; group 
1) or the conventional balloon-expandable stent group (n = 36; group 2). Optical coherence 
tomography (OCT) was performed after stent deployment as were qualitative and quantitative 
assessments of tissue prolapse, intra-stent dissection, edge dissection, and incomplete stent 
apposition.
Results: Tissue prolapse was visible in all vessels in both groups. The corrected tissue prolapse 
area by stent length was larger in group 2 than group 1 (0.06 ± 0.06 vs. 0.02 ± 0.01 mm², p 
<0.001). Intra-stent dissection was more frequently seen in group 2 (33/36 vs. 4/9 vessels, p = 
0.004) and the mean length of the dissection fl ap was greater in group 2 than in group 1 (277.6 
± 110.0 vs. 76.9 ± 103.7 μm, p<0.001). Although edge dissection was not detected in group 1, 
it was visible in 19/36 vessels (52.8%) in group 2. The frequency of incomplete stent apposition 
was not signifi cantly diff erent between group 2 and group 1 (23/36 vs. 7/9 vessels, p = 0.7) but 
the mean depth of incomplete stent apposition was greater in group 2 than in group 1(268.2 ± 
72.1 vs. 178.2 ± 156.7 μm, p = 0.03).
Conclusions: A self-expanding stent was associated with less intra-stent dissection and edge 
dissection than conventional balloon-expandable stents with OCT.
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INTRODUCTION
Although balloon-expandable stenting techniques with high pressure have proved to be use-
ful for optimal stent implantation to reduce the risks of restenosis and subacute thrombosis, 
this stent deployment strategy may also increase the risk of creating vessel damage in the 
stented segment or at its edges 1. As a stent is expanded with high pressure, immediate injury 
occurs deep in the vessel wall within the stented segment as well as in the unscaff olded peri-
stent margins 2. Importantly, several stent trials have drawn our attention to the problem of 
accelerated lumen loss at stent margins, which accounts for up to one-third of target-vessel 
revascularization in patients treated with balloon-expandable stents 3-5. On the other hand, 
a self-expanding stent allows deployment at lower pressures resulting in less intimal trauma. 
Late loss was signifi cantly smaller at the peristent margins in the self-expanding stent than it 
was in the balloon-expandable stent 2.
Optical coherence tomography (OCT) is a high-resolution technique that allows very 
detailed assessment of the relationship between the stent and the vessel wall.
The objective of the present study was to qualitatively and quantitatively compare with 
OCT stent implantation-associated vessel wall injury between a self-expanding stent (vProtect® 
Luminal Shield) and conventional balloon-expandable stents, and to compare their clinical 
impacts during the hospitalization period.
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METHODS
Study population
This study was conducted in single center of the Netherlands (Thoraxcenter, Erasmus MC). 
All consecutive 89 patients were performed OCT after stent implantation in native coronary 
arteries between May 2007 and March 2009 were included. Acute myocardial infarction and 
long lesion that needed over 50 mm of stent length (n = 33) were excluded. We also excluded 
16 patients due to poor OCT images. Finally forty patients (45 vessels) with stable angina or 
unstable angina were included in the study. During the same period of time, nine patients 
enrolled in the SECRITT trial were included for evaluation of vProtect® Luminal Shield 6. All 
patients gave informed consent.
OCT acquisition
OCT acquisition was performed using a commercially available system for intracoronary imag-
ing (LightLab Imaging Inc, Westford, MA, USA). In 5 cases, the occlusive technique was used 
in which a proximal, low-pressure (0.4 atm) occlusion balloon (Helios, Goodman Inc, Nagoya, 
Japan) was infl ated with simultaneous distal fl ush delivery (lactated ringer; fl ow rate 0.8mL/
sec) to remove blood from the vessel lumen. Images were acquired during a pullback rate 
of 1.0 mm/sec. In 40 cases, OCT was acquired with the non-occlusive technique. In this case, 
the Image Wire was positioned distal to the region of interest using a double-lumen catheter 
(Twin Pass catheter, Vascular Solutions Inc) that had been previously placed in the artery over 
a conventional guide wire. The automated pullback was performed at 3 mm/s (n = 39) or 20 
mm/sec (n = 1,C7XR: LightLab Imaging Inc, Westford, MA, USA) while blood was removed by 
the continuous injection of iso-osmolar contrast (Iodixanol 370, Visipaque™, GE Health Care, 
Ireland) at 37° Celsius through the guiding catheter. Data were stored on CD for offl  ine analysis. 
Defi nitions of the acute impacts of stent implantation in OCT (Figure1)
Tissue prolapse was defi ned as protrusion of tissue between the stent struts without disrup-
tion of the continuity of the vessel luminal surface 7. Protrusion of tissue between struts was 
considered tissue prolapse only if the distance from the arc connecting adjacent stent struts to 
the greatest extent of protrusion was >50 μm 8. Intra-stent dissection was defi ned as disruption 
of the vessel luminal surface in the stent segment with a visible dissection fl ap 8.
Edge dissection was defi ned as disruption of the vessel luminal surface in the stent edge 
within the 5 mm proximal and distal segments. Incomplete stent apposition (ISA) was defi ned 
as at least one stent strut with detachment from the wall >1 thickness of the strut for the 
respective stent and unrelated with a side branch 9. Thrombus was defi ned as an irregular mass 
protruding into the lumen or an intraluminal mass unconnected from the surface of the vessel 
wall that had single-free shadowing in the OCT image 10. 
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Quantitative OCT analysis of the acute impacts of stent implantation 8
The analyzed region comprised the stented segment and the 5 mm proximal and distal peri-
stent segments. The lumen and stent areas were measured at 1 mm intervals. In the case of 
tissue prolapse, the number of sites with tissue prolapse and the area were measured. Tissue 
Figure 1. Various OCT images of acute impacts after stent implantation. (A) Tissue prolapse & intra-
stent dissection; the white empty arrow points to an example of tissue prolapse with visible dissection 
fl ap (white arrow). (B) Edge dissection; a disruption of the vessel luminal surface in the edge regions 
within 5-mm proximal and distal to the stented region (white arrows). (C) Incomplete stent apposition; 
3 stent struts are malapposed (white arrows). (D) Thrombus; an irregular mass protruding in the lumen 
accompanied by a shadow (white arrow).
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prolapse length was defi ned as the distance from the arc connecting adjacent stent struts to 
the greatest extent of protrusion. The area of tissue protruding between the stent struts was 
also measured. When there were signs of intra-stent dissection, the number of dissection fl aps 
was counted and the length of the fl ap from its tip to the joint point with the vessel wall was 
measured. When edge dissection was present, the length of the dissection fl ap was measured 
in a similar way as described for the intra-stent dissection fl ap. At sites of ISA, maximum depth 
in single cut was measured and the average length is reported. The presence of thrombus 
was qualitatively assessed and maximum length of thrombus was measured. To account for 
diff erences in stent length, the number and total area of tissue prolapse and the number of 
dissection fl aps were corrected according to the stent length and expressed on a per mm basis. 
Image analysts were blinded to the clinical and procedural characteristics.
Clinical follow-up
The presence of events (death, myocardial infarction, target lesion revascularization, target ves-
sel revascularization and stent thrombosis) during the hospitalization period following stent 
implantation was registered in both groups. Myocardial infarction (MI) defi ned as chest pain 
together with ST-elevation or new left bundle branch block and an increase in cardiac enzymes 
(i.e. creatine kinase-MB fraction of 3 times the upper limit of normal) 8.
Statistical analysis
Continuous variables are expressed as mean± standard deviation. Categorical variables are 
expressed as percentages. Comparisons between groups were performed with the χ2 test for 
categorical variables. Continuous variables were compared with Student t test when they had a 
normal distribution and with nonparametric test (Mann-Whitney) when their distribution was 
not normal. A p value <0.05 was considered statistically signifi cant.
RESULTS
Table 1 shows clinical and procedural characteristics. There were no signifi cant diff erences 
between both groups. Group 2 had diff erent stent types, 6 balloon-expandable bare-metal 
stents, 1 Paclitaxel-eluting stent, 3 Zotarolimus-eluting stents and 26 Everolimus-eluting stents. 
The frequency of ACC/AHA type B2 or C lesions was not signifi cantly diff erent, and the frequen-
cies of pre-dilation and post-dilation did not diff er signifi cantly. However, stent length was sig-
nifi cantly larger in group 2 than in group 1 (26.2 ± 8.8 and 17.1 ± 5.2 mm, respectively, p = 0.001).
Acute impacts of stent implantation assessed by OCT (Figure 2)
After stenting, the lumen area was 7.9 ± 2.3 mm² in group 1 and 7.3 ± 1.7 mm² in group 2 
(p = 0.3). The mean and minimum stent areas were 8.0 ± 2.3 and 6.3 ± 2.3 mm² in group 1 
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and 7.6 ± 1.9 and 6.0 ± 1.7 mm² in group 2, respectively. Although all vessels in both groups 
showed tissue prolapse, the corrected number of tissue prolapse and corrected area by stent 
length were larger in group 2 than in group 1 (Table 2). The vProtect® Luminal Shield had less 
intra-stent dissection than balloon-expandable stents and the corrected number of dissections 
and average length of intra-stent dissection fl ap were all lower (Table 2). In addition, there was 
no edge dissection in group 1, while in group 2 the distal and proximal edges presented edge 
dissection in 14/36 (38.9%) and 10/36 (27.8%) vessels, respectively. Among patients in group 2, 
fi ve vessels (14%) showed both proximal and distal edge dissection. The average length of the 
dissection fl ap was 515 ± 403 μm. Regarding ISA, seven out of 9 vessels in group 1 and 23 out of 
36 vessels in group 2, respectively, showed at least one malapposed stent strut; the maximum 
depth of ISA was 178 ± 156 μm in group 1 and 267 ± 72 μm in group 2 (p = 0.03). Images 
suggestive of thrombus were visible in 2 vessels in group 1 and 16 in group 2. Maximum length 
of visible thrombus was 131 ± 30 μm and 298 ± 122 μm, respectively.
Table 1. Clinical and pçrocedural characteristics of the self-expanding stent (vProtect® Luminal Shield; 
group 1) vs. the balloon-expandable stent (group 2).
Group 1 (n = 9) Group 2 (n = 36) p
Demographics
Age 68.4 ± 9.9 62.9 ± 10.0 0.15
Male 5 (55.6) 28 (77.8) 0.22
Hypertension 8 (88.9) 23 (63.9) 0.24
Diabetes Mellitus 0 7 (19.4) 0.32
Dyslipidemia 8 (88.9) 26 (72.2) 0.42
Smoker 2 (22.2) 9 (25.0) 1.0
Cardiac history 
Previous MI 5 (55.6) 16 (44.4) 0.71
Previous CABG 0 2 (5.6) 1.0
Previous PCI 4 (44.4) 16 (44.4) 1.0
Vessel 0.53
LAD 3 (33.3) 19 (52.8)
LCX 1 (11.1) 5 (13.9)
RCA 5 (55.6) 12 (33.3)
Stent type <0.001
BMS 9 (100) 6 (16.7)
Paclitaxel-eluting stent 0 1 (2.8 )
Zotarolimus-eluting stent 0 3 (8.3)
Everolimus-eluting stent 0 26 (72.2)
Lesion type B2 or C 2 (22.2) 17 (47.2) 0.26
Stent length (mm) 17.1 ± 5.2 26.2 ± 8.8 0.006
Implantation pressure (atm) 0 16.3 ± 3.7 <0.001
Predilatation 2 (22.2) 18 (50.0) 0.25
Postdilatation 5 (55.6) 14 (38.9) 0.62
Values are presented as n (%) or mean ± SD. BMS: bare-metal stent
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In-hospital events
There were no events (death, MI, target-lesion revascularization, target-vessel revascularization 
or stent thrombosis) during the hospitalization period in both groups.
Figure 2. A and B show a case of balloon-expandable stent; tissue prolapse (A, white empty arrow) with 
intra-stent dissection (A, white arrow) and incomplete stent apposition (ISA) (B, two white arrows). C and 
D show a case of a self-expanding stent (vProtect® Luminal Shield); there are no tissue prolapse, intra-
stent dissection and ISA.
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DISCUSSION
The present study is the fi rst report comparing by OCT the acute impacts on the vessel wall 
between a self-expanding stent and balloon-expandable stents. The main fi ndings are: 1) All 
stented segments showed tissue prolapse and a very high proportion of patients intra-stent 
dissection visible by OCT after stent implantation in both groups. Although the frequency of 
visible tissue prolapse was not signifi cantly diff erent between groups, average and corrected 
prolapsed area by stent length was larger in the balloon-expandable stent group. 2) Intra-stent 
and edge dissection was more frequently seen in balloon-expandable stents than in the self-
expanding stent. 3) The frequency of ISA was not diff erent in both groups but the maximum 
depth of ISA was greater in the balloon-expandable stent group. 4) The diff erence of acute 
impacts after stenting between two kinds of stent was not associated with clinical events dur-
ing hospitalization.
According to OCT resolution, this technique has opened new possibilities for the evalu-
ation of stents allowing a very detailed assessment of strut apposition 11, 12. Furthermore, 
Table 2. Acute impacts of stent implantation on the vessel wall in the self-expanding stent (vProtect® 
Luminal Shield; group 1) vs. the balloon-expandable stent (group 2).
Group 1 (n = 9) Group 2 (n = 36) p
Post-stenting measurement (mm²)
Lumen area 7.9 ± 2.3 7.3 ± 1.7 0.3
Stent area 8.0 ± 2.3 7.6 ± 1.9 0.6
Minimum stent area 6.3 ± 2.3 6.0 ± 1.7 0.7
Tissue prolapse 
Number of vessels with tissue prolapse 9 (100) 36 (100) 1.0
Number of tissue prolapse per mm 0.34 ± 0.34 0.64 ± 0.56 0.03
Average area (mm²) 0.06 ± 0.03 0.13 ± 0.08 <0.001
Total area per mm (mm²) 0.02 ± 0.01 0.06 ± 0.06 0.001
Intrastent dissection
Number of vessel with intra-stent dissection 4 (44.4) 33 (91.7) 0,004
Number of dissected fl aps per mm 0.06 ± 0.08 0.21 ± 0.18 0,003
Average length (μm) 79.6 ± 103.7 277.6 ± 110.0 <0.001
Edge dissection 
Proximal 0 10 (27.8) 0.17
Distal 0 14 (38.9) 0.04
Average length (μm) 0 515.2 ± 403.4 <0.001
Incomplete stent apposition
Number of vessels 7 (77.8) 23 (63.9) 0.7
Maximum depth (μm) 178.2 ± 156.7 267.2 ± 72.1 0.03
Thrombus
Number of vessels 2 (22.2) 16 (44.4) 0.28
Maximum length (μm) 131.4 ± 30.3 297.6 ± 121.5 0.08
Values are presented as n (%) or mean ± SD.
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OCT allows not only qualitative but also quantitative evaluation of the acute in vivo injury after 
stenting. In a previously published pathological study, plaque compression by stent struts was 
observed in 94% patients and 91% arterial sections after stent implantation 13; while IVUS 
studies have reported plaque-prolapse frequencies ranging only from 18 to 35% 14. Our group 
has published the frequency of tissue prolapse by OCT, the tissue prolapse within the stented 
segment was visible in 97.5% of the cases 8. Similarly in the present study, even though the 
stent types were diff erent, tissue prolapse was visible in all patients. However, in this study, 
no clinical events during hospitalization occurred even though the balloon-expandable stent 
group had visibly larger corrected number of tissue prolapse sites and area by OCT.
IVUS has inherent limitations to distinguish between intra-stent dissections and plaque 
prolapse, OCT can clearly diff erentiate those 2 entities 8. In our series, despite a high frequency 
of OCT-visible intra-stent dissections and edge dissections in the balloon-expandable stent 
group, no intra-hospital events were registered. In the literature, the relationship between 
these variables and clinical events at longer follow-up continues to be a matter of debate. On 
one hand, in a study of drug-eluting stents, 30% of proximal edge restenosis was developed 
after 6 months because of local injury outside the stent 15. But on the other hand, non-fl ow-
limiting edge dissections detected by IVUS have not been associated with an increase in the 
rates of acute or long-term events or the development of restenosis 16-18. However, the long-
term impact of the presence of intra-stent dissection on the incidence of restenosis or stent 
thrombosis is unknown.
As an alternative to balloon-expandable stents, self-expanding stents off er the potential 
advantages of less barotrauma to the vessel wall, diff erential expansion, and increased fl ex-
ibility. Compared with balloon-expandable stents, self-expanding stainless steel stents, nitinol 
stents such as the vProtect® Luminal Shield stent may off er more accurate stent deployment 
through its use of thermal memory as the expansion mechanism. In native coronary arteries, 
studies have shown less vessel-wall injury and less edge dissection nitinol self-expanding 
stents 19, 20, which is in keeping with our present fi ndings with OCT. Subgroup analysis in the 
SCORES trial revealed that lesions requiring higher pressure balloon infl ation for implantation 
had higher rates of restenosis necessitating target lesion revascularization (TLR) than lesions 
requiring lower pressure balloon infl ation 20. Another recent prospective randomized trial 
demonstrated that the incidence of procedural complications, such as slow fl ow, side branch 
occlusion, and edge dissection were signifi cantly lower in the self-expanding stent group than 
in the balloon-expandable stent group and the occurrence of myocardial infarction tended to 
be lower in self-expanding stent group than in balloon-expandable stent group 12. In addition, 
the use of self-expanding stents with low-pressure dilatation instead of balloon-expandable 
stents could lead to lower incidences of periprocedural non Q-wave myocardial infarction. A 
high infl ation pressure during PCI increases risk for periprocedural non-ST-segment elevation, 
myocardial infarctions, and increased systemic infl ammatory state due to microembolization 
Self-expanding versus ballon expandable stent: OCT study 329
21. This strategy of self-expanding stents could reduce directly the procedural risk by limiting 
the infl ation pressure. 
Limitations
This study has several limitations. 1) It is a non-randomised study, and a relatively small popula-
tion was included in the self-expanding stent group. 2) The two study groups were not matched 
for lesion severity. Because target lesions were relatively simple in the self-expanding stent 
group and acute vessel injury might increase in the conventional balloon-expandable stent 
group, a large prospective study is needed to confi rm our observations on the acute impact of 
self-expanding and balloon-expandable stents. 
Conclusions
Although a very high proportion of patients showed tissue prolapse or intra-stent dissection 
visible by OCT after stent implantation in both groups, the self-expanding vProtect® Luminal 
Shield stent appears to be less frequently associated with intra-stent and edge dissection than 
conventional balloon-expandable stents. However, the latter vessel-wall injuries were not asso-
ciated with in-hospital clinical events. OCT-detectable acute vessel-wall injury after stenting 
might therefore not be associated with early untoward early clinical safety events.
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ABSTRACT
Background: High risk plaque (thin cap fi broatheroma, TCFA) is defi ned as a large lipid pool 
(within large plaque burden), thin cap (less than 65 μm) and macrophage dense infl ammation, 
as well as positive remodeling. The majority of these plaques occur in the primal portion of the 
three major epicardial coronary arteries. Currently there are two strategies to manage patients 
with TCFA: medical therapy or mechanical plaque sealing.
Objective: The aim of the pilot SECRITT trial was to evaluate the safety and feasibility of seal-
ing the high risk IVUS and OCT-derived TCFAs with a dedicated nitinol self-expanding vShield 
device. 
Methods and results: After screening with angiography, FFR, IVUS-VH and OCT 23 patients 
met enrollment criteria (presence of non-obstructive VH-derived TCFA lesion with thin cap on 
OCT) and were randomized to vShield (n=13) versus medical therapy (n=10). Baseline percent 
diameter stenosis was 33%+14%,FFR was 0.93+0.06, baseline plaque burden was 61%+9%, 
percent necrotic core in contact with the lumen was 35%+6% and average MLA was 6.8+2.4 
mm2. At 6 months follow-up in shielded patients percent diameter stenosis further decreased 
to 19%+17% and FFR remained the same 0.93+0.05. Average late loss was 0.24 mm.. Average 
baseline fi brous cap thickness was 48+12 μm. After shield placement at 6 months follow-up 
neo-cap formation was observed with average cap thickness of 201+168 μm. There were no 
dissections after shield placement and no plaque ruptures. In addition, mean stent area of 8.67 
mm2 increased to 9.44 mm2, that is by 8.9% at 6 months follow-up. Number of malapposed 
struts decreased from 10.7% to 7.6% and the number of uncovered struts at 6 months was 
8.1%. There were no device-related MACE events at 6 months follow-up.
Conclusion: High risk plaque passivation and sealing with v-Shield self expanding nitinol 
device appears feasible and safe. Long-term larger randomized study with streamlined screen-
ing criteria is needed to evaluate the effi  cacy of this approach over medical therapy.
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INTRODUCTION
Our current understanding of the pathogenesis of acute coronary syndrome, the progression 
of coronary artery disease and sudden death is that patients with atherosclerosis and fatal myo-
cardial infarction 70% of the time incur plaque rupture of the so-called thin cap fi broatheroma 
and in the rest of the cases pathology reveals plaque erosion or calcifi ed nodule.(1-3) Many 
of these plaques have gone undetected by conventional coronary angiography because the 
underlying lesion was non-obstructive (<50% diameter stenosis) due to the so-called Glagov 
eff ect (positive remodeling at the site of large plaque burden). High risk plaque is defi ned as 
a large lipid pool (within large plaque burden), thin cap (less than 65 μm) and macrophage 
dense infl ammation, as well as positive remodeling.(2, 4-6) The majority of these plaques occur 
in the primal portion of the three major epicardial coronary arteries(7, 8). It is also becoming 
clear that obstructive plaques (with minimal luminal area < 4mm2) can also be high risk and 
identify a patient at risk of future events. In fact these plaques have been shown to result in the 
highest number of events in the PROSPECT trial, (9) the fi rst prospective natural history study 
of atherosclerosis using multimodality imaging. Currently there are two strategies to manage 
patients with thin cap fi broatheromas: 1) conservative medical therapy based on the premise 
that none of the imaging modalities to-date have been able to identify reliable features of the 
plaque that render it prone to major adverse cardiac events, and 2) focal treatment to seal and 
passivate the plaque. The latter approach has been recently demonstrated in the VELETI trial to 
prevent progression of disease in vein grafts with non-obstructive lesions.(10) The SECRITT trial 
is a randomized, controlled pilot study that evaluates the safety and feasibility of sealing the 
high risk IVUS and OCT-derived TCFAs with a dedicated nitinol self-expanding vShield device. 
As such it is the fi rst such trial in native coronary arteries of a dedicated device for treatment of 
“vulnerable plaque”. 
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METHODS
Device description: 
The vProtect™ luminal shield system consists of the self expanding (Nitinol) vascular shield 
(Figure 1A) and a rapid exchange delivery system. The delivery system is compatible with .014” 
guidewires and 6 Fr Guiding catheters. The delivery system consists of a distal outer sheath 
that houses the luminal shield and an inner body with radiopaque markers at the distal and 
proximal ends of the Shield. The luminal shield is constructed from a nickel-titanium alloy 
with an austenetic fi nish. The shield has a wall thickness that is less than 70 μm and has been 
designed with the objective to match the elastic properties of the TCFA. The shield is available 
in 3.5 mm, 4.0 mm and 4.5 mm diameter with length of 15 mm for all the diameters. This allows 
vessels 2.75 mm to 4.0 mm to be treated. The distinctive feature of the shield is the hysteresis 
between the inward radial resistive force and the outward force exerted on the vessel wall. The 
latter is very low not exceeding 100 mm Hg (Figure 1B) thereby minimizing the trauma to the 
vessel wall and potential for plaque rupture during the deployment.
Study design and patient population:
SECRITT is a clinical prospective pilot, open, single center randomized study assessing the safety 
and feasibility of shielding the non-obstructive IVUS-derived TCFAs, and the eff ects on the 
prevention of plaque progression at 6 months follow-up. Patients over the age of 18 admitted 
with stable or unstable coronary syndromes (including Non-ST elevation myocardial infarction) 
and an angiogram demonstrating the need for PCI in one or more lesion, and concomitant 
presence of angiographically and hemodynamically non-obstructive IVUS-derived TCFA were 
eligible for the study. After obtaining informed consent and successful treatment of the culprit 
lesion (Flow chart 1) patients were randomized 1:1 to treatment with the shield device or 
medical therapy. Exclusion criteria were as follows: acute myocardial infarction, prior CABG, sig-
nifi cant left main disease, cardiogenic shock, renal insuffi  ciency (cr > 1.5 mg/dL), resuscitation 
or intubation, cerebrovascular event within the last 30 days, major bleeding event within the 
last 30 days, severe hypertension refractory to medical therapy, history of signifi cant trauma or 
surgery within the last 6 weeks, know nickel allergy, allergy to aspirin or clopidogrel that can-
not be treated, pregnancy, coexisting condition with life expectancy < 12 months and vessel 
diameter on angiography or < 2.5 or > 4.0 mm. All patients in the study were on aspirin therapy 
and received clopidogrel loading dose (600 mg) or were on maintenance clopidogrel dose. 
Anticoagulation during the procedure was achieved with heparin (with goal ACT > 300 msec). 
After the procedure all patients received aspirine and clopidogrel. All patients were treated 
with anti-cholesterol medications with the goal low-density lipoprotein < 70 mg/dL. The study 
protocol was approved by the institutional ethics committee and all patients provided signed 
informed consent.
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Figure 1 A. Device design and structure highlighting the ultra-thin struts and tantalum markers to allow 
for positioning. 1B. Hysteresis curve between radial resistive force and chronic outward force (COF) 
exerted by the device on the vessel wall. In the case of the V-shield COF is around 100 mmHg minimizing 
vessel trauma and allowing for gentle continued expansion over time (9% at 6 months).
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Study lesion defi nition: 
Lesions qualifi ed as study lesions if (1) they were angiographically intermediate with 40-50% 
diameter stenosis and (2) had an FFR of more than 0.75 (Pathway B in the fl ow chart) and (3) 
fulfi lled the criteria for IVUS-derived TCFA. Cap thickness and presence of the lipid pool was also 
documented by OCT.
Quantitative angiography: 
The target coronary segment was be fi lmed in 2 orthogonal planes that have been prescribed 
after viewing of the preceding angiogram. QCA was performed following administration of 
100-200 micrograms of Nitroglycerin to assess the proper length and diameter of the vessel. A 
fi nal angiogram was made under the same rotation and skew angles following intracoronary 
Nitroglycerine administration. A QCA off -line using CMS-Medis quantitative angiography 
(Medis, Leiden, Netherlands) was made to quantify the fi nal result. The following measures 
were obtained for each lesion: minimal luminal diameter, reference vessel diameter and per-
cent diameter stenosis. Late loss was calculated from the diff erence between minimal luminal 
diameter immediately post shielding and at 6 months follow-up. Restenosis was defi ned as the 
presence of in-lesion > 50% diameter stenosis at follow-up. 
Fractional fl ow reserve assessment:
Fractional fl ow reserve was measured with a sensor-tipped 0.014” angioplasty guidewire 
(WaveWire/WaveMap, Volcano Therapeutics, Inc, Rancho Cordova, CA or PressureWire, Radi 
Medical Systems, Uppsala, Sweden). After crossing the target lesion with the wire, hyperemia 
was induced with intravenous infusion of 140 μg/kg/min of adenosine (Adrecar, Sanofi , Munich, 
Germany) for a total of 2 minutes. The maximum pressure gradient used to calculate FFR was 
defi ned as the ratio of the mean post-stenotic pressure to the mean aortic pressure, measured 
by the guiding catheter, during maximal hyperemia. FFR of ≥0.75, was considered functionally 
not signifi cant and constituted the enrollment criterion. Exact FFR measurement at baseline 
and at 6 months follow up was recorded.
IVUS-VH acquisition and analysis:
Details regarding the validation of the technique, have previously been reported.(11, 12) 
Briefl y, IVUS-VH uses spectral analysis of IVUS radiofrequency data to construct tissue maps 
that are correlated with a specifi c spectrum of the radiofrequency signal and assigned color 
codes [fi brous (labeled green), fi brolipidic (labeled greenish-yellow), necrotic core (labeled red) 
and calcium (labeled white)]. 
IVUS-VH data was acquired using either the In-Vision Gold console (in the same pullback 
as palpography) or the S5 imaging system, and a 20 MHz eagle Eye Gold catheter (Rancho 
Cordova, CA, USA). The IVUS-VH sampling rate during pullback is gated to peak R-wave and is 
therefore dependent on heart rate.   
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IVUS B-mode images were reconstructed from the RF data by customized software (IVUS Lab 
Version 4.4, Volcano Therapeutics, Rancho Cordova, CA). Semi-automated contour detection of 
both lumen and the media-adventitia interface was performed and the RF data was normalized 
using a technique known as “Blind Deconvolution”, an iterative algorithm that deconvolves the 
catheter transfer function from the backscatter, thus accounting for catheter-to-catheter vari-
ability. Compositional data obtained for every slice was expressed as mean percent for each 
component. 
Pullback of 40 mm was performed after administration of 100-200 micrograms of intra-
coronary nitroglycerine and incorporated the segment at least 5 mm proximal and distal to the 
region of interest. Pullback speed was 0.5 mm/sec. 
Online analysis was performed to look for ID-TCFA (enrollment criterion). The analysis was 
subsequently repeated off -line by two independent observers blinded to patient clinical data 
and randomization to verify the presence of ID-TCFA. After tracing the lumen and external elas-
tic membrane diameters, plaque, lumen and total vessel area and volumes were computed for 
the segment of interest. The three consecutive cross-sections with >40% plaque burden, >10% 
necrotic core in contact with the lumen were identifi ed and their quantitative characteristics 
and measurements were recorded. In addition, minimal luminal area (MLA) was measured.
IVUS-Palpography acquisition and analysis:
Intravascular ultrasound palpography is a technique that allows the assessment of local 
mechanical tissue properties. At a defi ned pressure diff erence, soft tissue (e.g., lipid-rich) 
components will deform more than hard tissue components (e.g., fi brous-calcifi ed).(13-15) 
In coronary arteries, the tissue of interest is the vessel wall, while the blood pressure with its 
physiologic changes during the heart cycle is used as the excitation force. Radiofrequency data 
obtained at diff erent pressure levels are compared to determine the local tissue deformation.
Each palpogram represents the strain information for a certain cross section over the full 
cardiac cycle. Palpograms will be acquired using a 20-MHz phased-array IVUS catheter (Eagle-
EyeTM Volcano Therapeutics, Rancho Cordova, USA). Cine runs, before and during contrast 
injection were performed to defi ne the position of the IVUS catheter. Digital radiofrequency 
data was acquired using a custom-designed workstation. 
During the recordings, data was continuously acquired at a pullback speed of 0.5 mm/s using 
an automated pullback device (Track Back II, Volcano Therapeutics, Rancho Cordova, USA) with 
simultaneous recording of the ECG and the aortic pressure. The data was stored on a DVD and 
sent to the imaging core lab for offl  ine analysis (Cardialysis BV, Rotterdam, The Netherlands). 
The local strain was then calculated from the gated radiofrequency traces using cross-
correlation analysis and displayed color-coded, from blue (for 0% strain) via red through to 
yellow (for 2% strain). This color-coded information was superimposed on the lumen vessel 
boundary of the cross-sectional IVUS image.
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Using previously described methodology, plaque strain values were assigned a Rotterdam 
Classifi cation (ROC) score ranging from 1 to 4 (ROC I = 0-0.5 %; ROC II = 0.6- <0.9 %; ROC III 
= 0.9- 1.2 %; ROC IV = > 1.2 %). A CSA was defi ned as a high-strain when it had a high strain 
region (ROC III-IV) that spanned an arc of at least 12° at the surface of a plaque (identifi ed on the 
IVUS recording) adjacent to low-strain regions (<0.5 %). The highest value of strain in the cross 
section is taken as the strain level of the CSA.
Highest strain value pre and post-shielding and was recorded and colocalization with the 
IVUS-VH derived TCFA performed using time stamps.
TD and OFDI-OCT acquisition and analysis:
The OCT M3 (TD-OCT) and C7 (OFDI-OCT) systems used in this study (LightLab Imaging Inc., 
Westford, MA, US) have been described previously (16-21). Briefl y, a TD or an OFDI-OCT catheter 
was advanced distal to the stented lesion over a conventional coronary guide wire in the case of 
C7 system or, in the case of M3 system, OCT imaging wire (ImageWire™) was directly advanced 
past the lesion. The OCT catheter was then withdrawn proximal to the stented segment and the 
lesion visualized using an automated pullback system at 20 mm/sec in the case of C7 system 
and 3.0mm/sec in the case of M3 system. During image acquisition, coronary blood fl ow is 
replaced by continuous fl ushing of contrast at 3.0-4.0 ml/sec using a power injector (Mark V 
ProVis, Medrad, Inc. Indianola, PA, US) at 300 psi. Cross sectional images are acquired at 100 
frames/sec for C7 and 20 frames/sec for M3. During the baseline study documentary OCT was 
performed to measure and record the thickness of the fi brous cap overlying the lipid pool 
corresponding to the area of the ID-TCFA. The thinnest cap measurement was recorded. The 
assessment of the shield with OCT post implantation was used to assess procedure related 
trauma to the vessel wall (plaque prolapse, presence of fi lling defects, proximal and distal edge 
dissection), and at 6 months follow-up to assess shield strut apposition and tissue coverage 
and to measure the thickness of neo-cap. The thickness of the cap was measured every 1 mm 
within the shielded segment (15 frames per shield) using 360 degree analysis off -line software. 
In addition, shield areas were measured immediately post-shielding and at 6 months follow up 
to assess the degree of continued shield expansion with OCT.
Measurements were repeated off -line by two independent observers using Lightlabs imag-
ing software. 
Follow-up and study endpoints:
The primary end-point of the study was the acute change in lesion strain pattern immediately 
after shielding and acute device and angiographic success. Secondary end-points of the study 
included: 1) change in the fi brous cap thickness from baseline to 6 months post-shielding, 2) 
change in the stent area, 3) percent diameter stenosis at baseline and at follow-up, late loss and 
binary re-stenosis rate, and 4) cumulative incidence of major adverse cardiac events (death, MI 
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and revascularization) at 6 months follow-up. Stent thrombosis occurrence was defi ned and 
classifi ed according to the ARC criteria.(22) 
Sample size calculation and statistical analysis:
The study population was statistically based on the change in study lesion strain patterns 
immediately post-stenting as noted in the ABSORB trial.(23) In this trial the mean of the maximal 
strain/crossection /patient decreased from 0.44 ± 0.25 to 0.00 ± 0.01. Based on the assumptions 
for these the sample size was calculated as detailed below. 
Assumptions for the sample size calculation using a paired t-test:
- mean diff erence between pre and post equal to zero;
- alpha = 0.05;
- mean pre = 0.4;
- mean post = 0.0;
- SD of diff erence pre-post = 0.3;
- 90% power.
To assess the change in strain observed on palpography post-treatment, paired (pre-and post-) 
data of 9 patients would have been needed. However, in order to account for the patient loss to 
follow-up, we aimed to enrol a total of 15 patients in each arm of the trial. 
Discreet variables are presented as counts and percentages. Continuous variables are 
expressed as means + standard deviation.
RESULTS
Patient enrollment : From June 2008 through February 2010 over 100 patients were approached 
for participation in the trial, 48 signed informed consent but only 23 patients met inclusion 
and enrollment criteria (including presence of ID-TCFA) and were enrolled in the trial. Thirteen 
patients were randomized to shield device and 10 randomized to medical therapy but with one 
patient crossing over to the shield arm. Baseline clinical characteristics of the patients enrolled 
are summarized in Table 1. Notably 24% of the patients were diabetic and 65% had multivessel 
disease. Of the 13 shielded patients 11 completed full angiographic and imaging follow-up. Of 
the 10 control patients only 5 completed full angiographic and imaging follow-up.
Angiographic and FFR analysis: In 24% of the case proximal or mid LAD was the site of the 
TCFA treated, in 24% LCX and in 52% cases the RCA. Baseline percent diameter stenosis was 
33%+14% with MLD of 2.01+0.39 mm and lesion length of 14 mm (Table 2). Baseline FFR was 
0.93+0.06. Post-stenting percent diameter stenosis decreased to 21%+11% in the shielded 
patients and MLD increased to 2.43+0.44 mm. At 6 months follow-up in shielded patients 
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percent diameter stenosis further decreased to 19%+17% with MLD of 2.19+0.33 mm and FFR 
remained the same 0.93+0.05. Average late loss was 0.24 mm.
IVUS-VH analysis and palpography: At the site of the TCFA lesion baseline plaque burden 
was 61%+9%, percent necrotic core in contact with the lumen was 35%+6% averaged over 
three consecutive frames. Average MLA was 6.8+2.4 mm2 (Table 3 and Figure 2). At follow up 
the the 5 control patients no increase in plaque burden (66%) or necrotic core (33% down to 
26% with some patients showing a decrease and some an increase) was observed over time 
and no MLA decrease (6.2 mm2 at both baseline and follow-up) (data not shown). 
Table 3. IVUS VH and palpography baseline and acute data summary
Parameter (n=23)
MLA mm2 6.8 + 2.4
% plaque burden 60.6 + 8.8
%Necrotic core 34.7 + 6.3
Strain pre-shield 0.71%+0.53%
Strain post-shield 0.1%+0.09%
Table 1. Baseline clinical characteristics for the overall population
Characteristic N=23
Age 67 (range 50-82)
Gender (male) 76%
Current smoking 18%
Hypertension 71%
Hypercholesterolemia 76%
Diabetes melitus 24%
Prior MI 41%
Prior PCI 58%
Angina type:
Stable
Unstable
76%
24%
Multivessel disease 65%
Non-culprit vessel (TCFA vessel)
LAD
LCX
RCA
24%
24%
52%
Table 2. Angiographic and FFR assessment
Parameter Pre-stenting
(n=11)
Post-stenting
(n=11)
6 months follow-up
(n=11)
MLD (mm)
RVD (mm)
2.01+0.39
2.95+0.39
2.43+0.44 2.19+0.33
% Diameter Stenosis 33.2+13.5% 21.0+10.7% 18.7+16.9%
FFR 0.93+0.06 0.93+0.05
Late loss (mm) 0.24
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Average strain before shield placement was 0.71%+0.53% (ROC score of II on average). This 
decreased acutely post-shield placement to 0.1%+0.09% (ROC score of I).
OCT analysis and data: As previously reported by our group,(24) deployment of the self-
expanding shield resulted in minimal trauma to the vessel wall, particularly when compared 
to the balloon-expandable devices. There were no proximal or distal edge dissections and no 
fi lling defects. Length of intrastent dissections was also minimal.
Average baseline fi brous cap thickness was 48+12 μm with a range of 30-70 μm. After shield 
placement at 6 months follow-up neo-cap formation was observed with average cap thickness 
of 201+168 μm (range 50-608 μm) (Table 4). The patient with 608 μm of neo-cap formation at 
baseline had adjacent calcifi cations which required high pressure (16 atms) post-dilation of the 
shield with resultant barotrauma and more exuberant healing response.
In addition, mean stent area of 8.67 mm2 increased to 9.44 mm2, that is by 9% at 6 months 
follow-up (Table 4 and Figure 3). Number of malapposed struts decreased from 10.7% to 7.6% 
and the number of uncovered struts at 6 months was 8.1%. 
 
Figure 2. Example of baseline imaging for one of the enrolled patients. A. In the upper left, Palpogram 
showing stain value of 1.4% (ROC III-IV), B. In the upper right corresponding matched TCFA on IVUS VH 
analysis with plaque burden of 56% and necrotic core of 34% in three consecutive frames, and C. In lower 
left corner, matched OCT frame showing cap thickness of 40 μm.
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Detailed per strut analysis: Total of 11 stents were evaluated at baseline. Total length of 
stents evaluated at baseline was 127.15 mm. Mean lumen area was 9.03+2.29 mm2 and mean 
stent area was 8.67+2.16 mm2. In two patients there was high degree of malaposition due 
to undersizing of the device. Mean ISA area was 0.36+0.47 mm2. Mean prolapse area was 
0.009+0.17 mm2. Of the 1,721 stent struts counted at baseline 1,521 were well apposed, 185 
(10.7%) were malapposed and 15 were in front of side branches. There were no dissections 
seen. Mean thrombus area was 0.015 mm2. 
At 6 month follow up 12 stents were evaluated with a total length of 142.95 mm. Mean 
lumen area was 8.36+2.87 mm2 (decreased by 7.4%), with late loss of 0.13 mm. There were 
no binary restenosis events. Mean stent area increased to 9.45+2.30 mm2 (by 8.9%), imply-
ing continued stent expansion. Mean ISA area was 0.88+0.85 mm2. Of the total of 2072 struts 
evaluated, 1910 were well apposed, 159 were malapposed (7.6%; decrease from baseline), and 
3 were in front of a side-branch. 8.1% of all struts were non-covered. Of the well-apposed struts 
93.2% were covered, while of the malapposed struts 78% were covered. 
Clinical events: There were no device-related MACE events (Table 5). One of the control 
(non-shielded) patients returned within two weeks of the procedure with an unstable coronary 
syndrome and crossed over to the shield arm. There were no stent thrombosis events. Lastly, 
non-invasive assessment of shield patency with MSCT appears feasible owing to its thin nitinol 
struts (Figure 4).
Table 4. Optical coherence tomography at baseline, post-shield and at 6 months follow-up
Pre-shield/acute post-shield 6 months follow-up
Cap thickness (μm) 48 + 12
(range 30-70)
201 + 168
(range 50-608)
Presence of lipid pool 100%
Mean lumen area mm2 9.03 8.36
Mean stent area mm2 8.76 9.44 (9% increase)
Minimum lumen area mm2 7.23 6.12
Malapposed struts 10.7% 7.6%
Uncovered struts 8.1%
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DISCUSSION
In this First in Man experience with shielding of vulnerable plaque (thin cap fi broatheroma) 
using self-expanding nitinol shield, we demonstrate the feasibility and preliminary effi  cacy 
of the approach. The device delivery was successful in all 13 patients who were randomized 
to the shield and there were no MACE events related to the shield device treatment at 6 
months of follow up. The treatment strategy employed in this protocol is based on the fact 
that most myocardial infarctions (MI) result, not from a critical blockage, but from lesions that 
are non-fl ow limiting.(25-30) In individuals that have undergone angiography in the months 
preceding myocardial infarct the culprit lesions most often show <50% diameter stenosis.
(27) Moreover, only approximately 15% of acute MIs arise from lesions of <60% stenosis on a 
Figure 3. Example of per-strut OCT analysis and appearance of V-shield at 6 months follow-up with 
uniform strut coverage of around 200 μm and no malapposition.
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Table 5. Cummulative incidence of MACE rate at 6 months follow up
Shield arm
(n=13)
Medical therapy arm
(n=10)
MACE 0 1
Death 0 0
MI 0 0
Clinicaly driven Revascularization 0 1 (cross-over to shield)
Revascularization related to the 
target lesion/shielded vessel
0 0
Figure 4. MSCT image of V-shield at 6 months. There is no beam-hardening artifact from nitinol struts 
(except for tantalum markers at the edges) allowing for good non-invasive evaluation of patentcy.
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previous angiogram (11). These lesions, however, have a substantial plaque volume/percent 
plaque burden. The coronary fl ow is not obstructed because of outward (positive) remodelling. 
Longer term prognosis of a patient might depend on far more detailed plaque assessment than 
angiography and on adequate treatment of plaques at risk to rupture. 
The use of IVUS-VH to identify vulnerable plaques (IDTFCA) is well documented and is com-
parative to what has been demonstrated from documented plaque ruptures. IDTCFA is currently 
defi ned as a lesion fulfi lling the following criteria in at least 3 consecutive cross-sectional areas 
(CSA): 1) necrotic core ≥10% without evident overlying fi brous tissue, 2) lumen obstruction ≥ 40 
%. In addition, the IDTCFA must also demonstrate positive remodeling by having a remodeling 
index (RI) > 1.05. In a study population of 21 patients Garcia-Garcia (12) found in 13 patients 42 
IDTCFA that fulfi ll the IVUS-VH criteria. This meant that on average there are approximately 3 
IDTCFA per patient. Documented plaque ruptures were reported by Rioufol(31) in 2002 in 24 
patients referred for PCI after a fi rst ACS with a troponin I elevation. He found that there were 
50 plaque ruptures corresponding to 2.08 vulnerable plaques per patients presenting with an 
ACS which is in accordance with Garcia-Garcia’s IVUS-VH fi ndings. Interestingly plaque rupture 
on the culprit lesion was found only in 9 patients (37%). In 19 patients (79%) at least 1 plaque 
rupture was found somewhere other than the culprit lesion, in a diff erent artery in 70% and in 
both other arteries in 12.5% of the patients. This reinforces the importance of identifying and 
treating vulnerable plaques and the fact that they can be remotely associated from the culprit 
lesion causing the presenting symptom. This also constitutes the rationale for the treatment 
of intermediate non-fl ow limiting lesions with signs of vulnerability. Accuracy of thin cap ath-
eroma detection can be further increased by combining IVUS-VH imaging with OCT imaging of 
the lesion which due to its micron resolution can allow to measure the thickness of the fi brous 
cap. Sawada and Garcia-Garcia(32) have shown that out of 126 lesions examined with two 
modalities only 28 (22%) fulfi ll thin cap fi broatheroma criteria by both IVUS-VH and OCT with 
thin cap defi ned as < 65 micron. For these reasons, we have chosen in this study to perform very 
detailed multimodality examination of plaque before enrolling the patient in the study. The 
examination that each patient underwent were 1. Angiography, 2. FFR, 3. Palpography (off -line), 
4. IVUS-VH and 5. OCT online at baseline. This was followed by post-shielding assessment with 
1. Angiography, 2. Palpography and 3. OCT. At 6 months follow-up the assessment included: 
1. Angiography, 2. FFR, 3. Palpography/IVUS and 4. OCT. With such extensive examination and 
procedure times which was challenging for both patients, personel and operators enrollment 
in the study was rather slow (23 patients in under 2 years), and several patients (particularly 
in the control arm) were unwilling to participate in the follow-up catherization. While using 
stringent criteria for enrollment was justifi ed in this pilot study, the protocol may have been 
more successful had we used a simple combination of non-invasive coronary MSCT assessment 
(for positive remodeling, plaque burden, 3D strain and fl ow) combined with intraprocedural 
OCT (to measure cap thickness and show presence of a lipid pool). In the future, angiography, 
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FFR and IVUS/palpography assessment should be replaced by MSCT examination which can 
provide equivalent information before the start of the invasive procedure. (33-35)
We have been able to demonstrate here that the self-expanding device is ideally suited for 
treatment of thin-cap fi broatheromas. Self-expanding nature of the device causes minimal 
trauma to the vessel wall minimizing the risk of thin cap rupture and necrotic core emboli-
zation. We had no per-procedural MIs in this patient cohort. Furthermore, the device is well 
apposed and continues to expand gently by 9% over 6 months minimizing the risk of having 
malapposed and uncovered struts. While there is no drug coating and the device is bare metal, 
the combination of thin nitinol struts and lack of traumatic balloon expansion, result in minimal 
neo-intimal formation. 8% of the struts were still uncovered at 6 months with average neo-cap 
of 201 μm and late loss of 0.13 mm which is comparable to some of the state of the art drug 
eluting stents. There were no stent thrombosis events. The continued gentle expansion of the 
device is similar to that observed by Granada et al. in the First in Human trial of the vShield 
device in moderate stable lesions completed recently(36) and also comparable to the results 
achieved with the Stentys stent in the Apposition study.(37)
The number of patients enrolled and lack of events made it impossible to determine whether 
placement of the shield and plaque passivation demonstrated by OCT off ered an advantage 
over standard medical therapy with aspirin, clopidogrel and statins. Such ability to prevent 
plaque growth and disease progression to a signifi cant lesion was demonstrated recently in 
the VELETI trial of paclitaxel eluting stent treatment versus medical therapy in graft disease.(10) 
Limitations: This is an exploratory analysis with all its inherent limitations. The greatest 
limitation was failure to complete the full projected study enrollment and lack of angiographic/
imaging follow-up in a large proportion of non-shielded control arm patients.
Conclusion: Passivation of the thin cap fi broatheroma with self-expanding nitinol vShield 
device appears to be safe and feasible. Larger cohort study with long-term follow-up will be 
needed to evaluate this device as a treatment for necrotic core rich lesions.
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ABSTRACT
Background: The mechanics of expansion of balloon-expandable stents are complex and 
usually result in under-deployment and malapossition. An emerging new generation of self-
expanding coronary stents promises to improve some of the limitations of balloon-based 
technologies. This fi rst-in-human study aimed to evaluate the safety and feasibility of a new 
generation low pressure self-expanding luminal Shield (LS; vProtect™, Prescient Medical, 
Doylestown, PA) for the treatment of intermediate coronary lesions. 
Methods and Results: A total of 29 patients with evidence of myocardial ischemia and inter-
mediate de novo coronary lesions were included in the study. All target lesions were pre-dilated 
under low dilatation pressures. Following LS deployment, post-dilatation was allowed if the 
residual angiographic %DS was ≥30%. Angiographic and IVUS follow-up were performed at 9 
months following LS implantation. In all patients %DS <30% was achieved and device success 
was 100%. No patient required bailout stenting. The mean lumen area was 6.11 ± 1.23 mm² 
following LS implantation and post-dilatation and 7.00 ± 1.41 mm² at 9 months follow up. The 
cumulative MACE event rate at 9 months was 10.3% and was related to target lesion revascular-
izations. There were no cases of deat h, myocardial infarction or stent thrombosis. Angiographic 
follow up showed an in-stent lumen loss of 0.50±0.30 mm and a binary restenosis rate of 10.3%. 
Conclusions: In patients undergoing intervention of intermediate de novo coronary lesions 
the implantation of the LS was safe, feasible and displayed a low restenosis rate. IVUS analysis 
showed favorable mechanical properties of the LS as compared to previous generation self-
expanding stents.
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Balloon-expandable stent (BES) technologies are the standard of care for the interventional 
therapy of obstructive atherosclerotic coronary lesions (1). Due to its mechanism of expansion, 
BES typically exerts an unpredictable pattern of mechanical stress to the vessel wall leading to 
variable degrees of vascular injury and restenosis (2). In addition, due to the fact that BES relies 
on the plastic deformation of its structure via balloon dilatation, these devices are frequently 
associated to acute under-deployment and late malapossition, especially in situations in which 
the vessel lumen can not be accurately determined (i.e., STEMI) (3). 
A new generation of self-expanding coronary stents displaying more stable biomechanics 
(lower chronic expansive forces) are under development (4). It has been hypothesized that 
these devices may improve clinical outcomes by providing suitable outward forces enabling 
proper vessel wall apposition and controlled luminal gain yet reducing the amount of vascular 
injury and resulting neointimal formation (5). In this fi rst-in-human study, we aimed to evalu-
ate the safety and feasibility of implantation of a new generation low pressure self-expanding 
luminal shield device (vProtect™, Prescient Medical Inc., Doylestown, PA, USA) among patients 
with de novo intermediate coronary lesions. 
METHODS
Device Description
The vProtect™ luminal shield is a self expanding Nitinol-based device originally designed to 
achieve the mechanical stabilization of non-obstructive, thin-cap fi bro-atheromas in the coro-
nary territory. The biomechanical behavior of the device shows lower chronic outward forces 
compared to previously designed self-expanding stents while maintaining a stable radial force 
(crush-resistant), thus avoiding collapse following implantation. The device consists of self 
expanding luminal shield and a rapid exchange delivery system. This system is compatible with 
0.014” guidewires and 6 Fr Guiding catheters. The shield has a strut thickness of ~57 microns 
and has a vessel surface area coverage from 13% to 15% in 2.5 to 3.0mm vessels (4).
Study Design 
The current study was designed as a non-randomized, single-arm, single center (Corbic 
Research Institute, Corbic Institute, Envigado, Colombia) prospective trial to evaluate the safety 
and feasibility of implantation of the luminal shield among patients with evidence of myocar-
dial ischemia and intermediate de novo coronary lesions. The study was approved by the Insti-
tutional Ethics Committee. All patients provided written informed consent for participation in 
the trial. The study case reports were verifi ed by independent study monitors (Clinlogix, North 
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Wales, PA). All potential adverse events were independently adjudicated by an independent 
clinical event committee and reported to the ethics committee.
Inclusion and Exclusion Criteria
Patients aged 18 years or older presenting symptoms of coronary artery disease were eligible if 
they had single, non-calcifi ed target lesion by angiography of ≤ 15 mm in length with a diam-
eter stenosis of ≥50% (by visual assessment) that was suitable for stent implantation in a vessel 
with a reference diameter ranging from 2.75 to 3.5mm in diameter. Baseline IVUS examination 
was mandatory in order to exclude lesions with a calcium arc greater than 90 degrees. Only one 
luminal shield was permitted to be implanted per lesion in every single patient. Other lesions 
could be treated with other clinically approved devices. 
The principal exclusion criteria were known allergy or sensitivity to Nitinol or its components; 
known hypersensitivity or contraindications to anticoagulant or antiplatelet therapies; history of 
bleeding or known coagulopathy; major surgery within the past 30 days; lesions that were severely 
calcifi ed based on IVUS imaging defi ned as a ring of calcium occupying more than 90 degrees of 
the visual fi eld; left main coronary disease; previous stent placement or angioplasty in the target 
vessel; ST segment elevation myocardial infarction; lesions involving a side branch of ≥ 2.0mm in 
diameter or side branches < 2.0mm with the presence of occlusive ostial disease or plaque shift-
ing following balloon dilatation of the main vessel lesion; unsuitable coronary anatomy; females 
who were pregnant; participation in another investigational device or drug trial.
Procedural Description
All patients received 600mg of Clopidogrel and 300mg of Aspirin (or 100mg if they were 
already taking daily chronic dose) at least 2 hours before the angioplasty procedure. Following 
the procedure Clopidogrel was maintained at a dose of 75mg for at least 4 weeks and Aspirin 
was admin istered in a dose of 300mg for at least 1 month. Aspirin was continued indefi nitely 
at a dose of at least 100mg daily. Intravenous unfractionated heparin was administered dur-
ing the procedure in doses suffi  cient to achieve and maintain an Activated Coagulation Time 
(ACT) between 250 to 350 seconds. The use of glycoprotein IIb/IIIa antagonists was left at the 
discretion of the operator. Percutaneous coronary intervention was performed using standard 
techniques. After angiography images were obtained intravascular ultrasound (IVUS) imag-
ing was performed to determine the presence or absence of calcifi ed lesions according to 
the inclusion criteria. A description of the procedural methodology is shown in Figure 1. All 
target lesions were pre-dilated with a 2.5mm balloon that was infl ated at 1-ATM increment 
(“stepwise fashion”) until complete balloon dilatation was achieved. Then, the target diameter 
of the luminal shield was selected based on the QCA measurements. The luminal shield was 
available in diameters of 2.75 to 4.0 mm and in a single length of 15 mm. Size selection was 
performed by selecting half a size above the vessel reference diameter (3.0 diameter for a ~2.5 
mm vessel reference diameter). The luminal shield was deployed aiming to cover the borders 
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of the previously dilated lesion. Post-dilatation, using a non-compliant balloon usually shorter 
than the total length of the luminal shield was allowed when the residual on-line angiographic 
%DS was ≥30%. The procedure was terminated if the angiographic %DS was <30% and if a 
fi nal TIMI III fl ow was reached. In the case two consecutive balloon infl ations failed to reduce 
the angiographic %DS to ≤ 30% or the presence of altered coronary fl ow or dissections were 
noted, bailout stenting was indicated. At the end of the procedure, fi nal IVUS imaging was 
performed. A 12-lead electrocardiograph was obtained before the procedure, within 24 h after 
and in case of suspected acute ischemia. Cardiac enzymes were monitored through the entire 
hospitalization. 
Study End-Points
Angiographic follow-up was performed in all patients at 9 months following the procedure. 
Clinical follow-up was performed immediately after the procedure, prior to hospital discharge, 
at 30 days and at 6, and 9 months post procedure. The primary endpoints of the study were 
defi ned as post-procedural angiographic %DS ≤ 30%, IVUS mean lumen area ≥ 4mm2 and 
in-hospital and 30 days major adverse cardiac event (MACE) rate defi ned as cardiac death, 
myocardial infarction (MI) and target lesion revascularization (TLR). Secondary endpoints 
Figure 1.  Flow chart of study design.
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included 6 month MACE and 9 month angiographic restenosis rate, TLR, target vessel revas-
cularization (TVR), target vessel failure (TVF) and MACE. TLR was defi ned as revascularization 
(any percutaneous intervention or bypass surgery) performed on the target lesion due to a 
stenosis including 5mm margins (proximal and distal to the stent) at any time after the index 
procedure; TVR was defi ned as revascularization performed on the target vessel at any time 
after the index procedure; TVF was defi ned as TVR, myocardial infarction, or death that could 
not be clearly attributed to a vessel other than the target vessel. A revascularization procedure 
was adjudicated as “clinically indicated” if the stenosis of the treated lesion was at least 50% of 
the lumen diameter on the basis of QCA in the presence of ischemic signs or symptoms, or if the 
diameter stenosis was at least 70% irrespective of the presence or absence of ischemic signs or 
symptoms. Device success was defi ned as attainment of ≤ 30 % residual stenosis immediately 
following the procedure of the target lesion using only the assigned device. Procedural suc-
cess was defi ned as attainment of a ≤ 30% residual diameter stenosis of the target lesion and 
freedom from in-hospital MACE.
Imaging Analysis
Angiographic and IVUS data were analyzed by an independent core laboratory (Cardialysis, 
Rotterdam, Netherlands). The QCA analysis was performed with the CAAS II analysis system 
(Pie Medical BV, Maastricht, the Netherlands). All angiographic measurements were obtained 
within the stented segment (in-stent) and over the entire segment consisting of the stent and 
its 5mm proximal and distal margins (in-segment). Acute gain was calculated as a diff erence 
between minimal lumen diameter (MLD) after the procedure and MLD at baseline. Late lumen 
loss (LL) was a diff erence between MLD after the procedure and MLD at follow-up. Percent 
diameter stenosis (%DS) was defi ned as ([reference vessel diameter – minimal lumen diameter] 
/ reference vessel diameter) x 100%. The case was classifi ed as a binary restenosis when per-
centage diameter stenosis was equal or greater than 50% in the target lesion. The CURAD QCU 
Analysis Software (Curad B.V., Wijk bij Duurstede, the Netherlands) was used to analyze the IVUS 
images obtained immediatelly after stents implantation and at 9-month follow-up. Analysis 
was performed at the target segment (stent ± 5mm) to measure and calculate the lumen, ves-
sel, plaque and stent volumes. In addition, mean stent symmetry, in-stent obstruction volume 
(%) and number of patients with mean lumen area ≥ 4.0mm2 were analyzed. 
RESULTS
Study Population
A total of 33 patients were screened and 4 were not fi nally included in the study population 
due to procedurally-related exclusion criteria. The baseline clinical variables are shown in Table 
1. The mean age of all 29 included patients was 60 years of whom almost 59% were male. 
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Demographic features were similar to other published stent studies except for a slightly higher 
number of diabetic patients (41%, 10.3% requiring insulin therapy). Almost one third of all 
patients had a history of prior myocardial infarction, 21% had previous percutaneous revascu-
larization and more than 50% presented two or three coronary vessel disease. 
In-Hospital Outcomes
Procedural characteristics including baseline lesion characteristics and distribution as well as 
procedural data are presented in the Tables 2 and 3. The mean baseline vessel diameter was 
2.94 ± 0.34 mm and % DS was 53.97 ± 11.11 % which decreased to 35.9 % ± 8.2% immediately 
following pre-dilatation and luminal shield implantation and further decreased to 16.71% ± 
6.53% after fi nal balloon post-dilatation. Post-dilatation was performed in 93% of patients 
achieving an average in-stent acute gain of 1.09 mm. In all patients %DS <30% was achieved and 
device success was 100%. No patient required bailout stenting. There were no peri-procedural 
complications and no incidents of MACE, repeat revascularization or stent thrombosis during 
hospitalization period.
IVUS Analysis of Luminal Shield Mechanics
IVUS analysis revealed that the average minimal lumen area before intervention was 2.75 ± 
0.74 mm2. Immediately following low pressure balloon-dilatation and luminal shield implan-
tation the average minimal lumen area increased to 4.49 ± 1.20 mm2 (63.3 % increase from 
baseline). Following fi nal balloon post-dilatation of the luminal shield, all patients reached a 
Table 1. Baseline demographic characteristic
n=29
Age (years) 60.2 (7.6)
Male sex 17 (58.6%)
Diabetes 12 (41.4%)
 Insulin-requiring 3 (10.3%)
Hypertension 18 (62.1%)
Hyperlipidemia 19 (65.5%)
Current smoker 7 (24.1%)
Renal insuffi  ciency 0 (0%)
Family history of CAD 3 (10.3%)
Prior myocardial infarction 10 (34.5%)
Prior percutaneous coronary intervention 6 (20.7%)
Prior coronary-artery bypass grafting 0 (0%)
Stable angina pectoris 9 (31%)
Unstable angina pectoris 20 (69%)
Coronary artery disease
 1 - vessel
 2 - vessel
 3 - vessel
11 (38%)
14 (48%)
5 (17%)
Baseline ejection fraction (%) 57.6 (±8.4%)
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post-procedural mean shield lumen area ≥ 4.0 mm2 (mean shield area post procedure = 6.11 
± 1.23 mm2) and all had mean shield symmetry index ≥ 0.7 (0.87 ± 0.04). However, commonly 
the lumen area tended to be slightly lower in the center of the device where the plaque burden 
was the highest (Figure 3). Overall, the net acute volumetric luminal gain at the end of the 
procedure was 15% (Figure 4). 
Long-Term Outcomes
Clinical, angiographic and IVUS follow up was completed in all enrolled patients. During 9 
month follow-up no case of death, myocardial infarction or stent thrombosis occurred. In total, 
there were 3 cases of MACE, all caused by TLR. Two patients with TLR presented with symptoms 
of unstable angina 2 and 7 months following luminal shield implantation. In all these patients 
there was angiographic evidence of in stent re-stenosis and all the patients were successfully 
treated with drug eluting stent (DES) implantation. These two cases were qualifi ed as a clinically-
driven TLR. The third patient with TLR underwent successful PCI with DES implantation after 
Table 2. Angiographic characteristics of the target lesions.
n=29
Target lesion coronary artery
 Left anterior descending 8 (27.6%)
 Left circumfl ex 8 (27.6%)
 Right 12 (41.4%)
 Ramus intermediate 1 (3.4%)
Lesion length (mm) 11.20 (±3.89)
Reference vessel diameter (mm) 2.94 (±0.34)
Minimum lumen diameter (mm) 1.35 (±0.31)
% Diameter stenosis 53.97 (±11.11)
Baseline TIMI fl ow = 3 29 (100%)
Table 3. Procedural characteristics.
Mean stent diameter (mm) 3.88 ±0.29
Stent length (mm) 15.0
Predilatation 29 (100%)
 Balloon diameter (mm) 2.5
 Mean pressure (atm.) 7.66 ±2.21
Post dilatation 27 (93.1%)
 Balloon diameter (mm) 3.28 ±0.25
 Mean pressure (atm.) 10.3 ±3.8
 Number of patients requiring post-dilatation 27 (93%)
Patients requiring bailout procedure 0
Device success 29 (100%)
Procedural success 29 (100%)
Geographic miss 1 (3.4%)
No of patients with post-procedural %DS < 30% 29 (100%)
Final TIMI fl ow = 3 29 (100%)
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the planned 9-month control angiography revealed signifi cant in-stent restenosis. The average 
in-stent LL at 9 month follow-up was 0.50 mm, mean in-stent % DS was 28.3% and the total 
binary restenosis rate was 10.3%. 
IVUS Analysis of Vascular Remodeling
At 9 months, IVUS volumetric analysis displayed an additional 13% increase in the total shield 
volume compared to the post-implantation values (total increase in shield volume over time 
of 28%). The mean shield area at 9 months was 7.00 ± 1.41 mm2 (additional 14.6 % increase). 
In addition, the volumetric analysis showed that there was a slight increase (5%) in total vessel 
volume over time (fi gure 4). The resulting in-stent obstruction volume was 19.8% and the mean 
stent symmetry index was 0.89. 
Figure 2. vProtect luminal shield placement in the left circumfl ex (LCX) artery (LAO 0, CAU 20) of a patient 
undergoing PCI. (1). Baseline angiography presenting lesion in a mid LCX (%DS = 68%); (1a). IVUS cross 
sectional view. (2). Eff ect after balloon pre-dilatation (balloon 2.5 x 9mm; max. pressure: 12 atm); (2a). 
vProtect Luminal Shield (4.0 x 15mm) positioning. (3). Final eff ect after vProtect placement and balloon 
post-dilatation (balloon 3.5 x 8mm; max. pressure: 12 atm); (3a). IVUS cross sectional view of the fi nal 
eff ect. (4). Angiographic results at 9-months follow-up; (4a). IVUS cross sectional view at 9 month follow-
up. Image courtesy of Corbic Research Institute, Envigado, Colombia. 
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DISCUSSION
Clinically available coronary stent technologies base their mechanism of expansion on the 
plastic deformation of its metallic structure via balloon infl ation (6, 7). This mechanism of stent 
delivery elicits an unpredictable degree of mechanical injury to the vessel wall typically result-
ing in an injury-dependent pattern of vascular healing and restenosis (5). Similarly, due to its 
limited capability of expansion, stent malapossition is a common phenomenon seen following 
BES deployment especially in clinical circumstances in which the lumen of the vessel can not be 
accurately determined (i.e., STEMI) (3). Due to their intrinsic mechanical properties and material 
composition, self-expanding stent technologies have the potential to improve some of these 
limitations (6). Specifi cally, self-expanding stent platforms have the ideal mechanical character-
istics for the treatment of coronary lesions in which either high-radial expansive forces are not 
required (i.e., non-calcifi c), stent-wall apposition is highly desirable (i.e., STEMI) or the potential 
for distal embolization during PCI is likely (i.e., large necrotic cores) (2). 
Figure 3. IVUS analysis of vessel remodeling at proximal, mid and distal segments of shield at diff erent 
time points. Immediately following shield implantation the average lumen area was slightly lower in 
the center of the device where the plaque burden was the highest. During the next 9 months the shield 
continued to enlarge resulting in a fi nal lumen area comparable to what has been reported in BES studies 
with optimal device symmetry.
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In this study, we evaluated the safety and effi  cacy of implantation a new self-expanding (SE) 
luminal shield (vProtect™ Luminal Shield, Prescient Medical, Doylestown, PA) for the therapy of 
intermediate lesions in patients scheduled for PCI with evidence of myocardial ischemia. The 
device utilized in this study is structurally and mechanically diff erent to previous generations of 
SE stent technologies. The luminal shield is characterized by maintaining lower and more stable 
chronic outward expanding forces over time thus resulting in lower degree of vascular injury (4, 
8). Previous biomechanical testing has shown that the luminal shield posses 50% less chronic 
outward forces than the previously clinically tested Radius™ stent (Boston Scientifi c, Natick, 
MA), however, maintaining a similar radial resistance force at the same dilation diameters (2). 
Preliminary animal data demonstrated proper vascular healing and no evidence of chronic 
over-expansion over 180 days in normal porcine coronary arteries (9). 
In this study, we used a very specifi c pre-dilatation technique aiming to facilitate the analy-
sis of the biomechanical behavior of the luminal shield. Following shield implantation, IVUS 
analysis showed that the fi nal mean lumen area achieved (6.11 ± 1.23 mm²) was slightly lower 
than the average mean lumen areas reported in clinical trials of contemporaneous BES tech-
nologies (range from 6.5 to 9.3mm) (3, 10, 11) and fi rst generation SES (7.7 ± 2.1 mm², Radius 
Figure 4. Mechanical behavior of the vProtect™ luminal shield and its infl uence on vessel and lumen 
remodeling based on IVUS calculations. (A). Acute gain (calculated as a diff erence between shield volume 
post-procedure minus lumen volume measured at baseline); (B). Stent volume change (diff erence 
between stent volume post-procedure and stent volume at 9 month follow-up); (C). Lumen volume 
change (diff erence between lumen volume post-procedure and lumen volume at 9 month follow-up); (D). 
Vessel volume change (diff erence between vessel volume post-procedure and vessel volume at 9 month 
follow-up).
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stent, Boston Scientifi c, Natick, MA) (11). These changes are refl ected on the ~16% residual 
angiographic diameter of stenosis typically not seen in BES trials following immediate stent 
implantation. IVUS analysis showed that the device was always apposed to the vessel wall and 
Table 4. Clinical outcomes.
In-hospital and through 30 days post-procedural events N (%)
MACE (all) 0
Cardiac death 0
Myocardial infarction (Q-wave and non-Q-wave) 0
TLR 0
Events at 6 months
MACE (all) 1 (3.4%)
Cardiac death 0
Myocardial infarction (Q-wave and non-Q-wave) 0
TLR 1 (3.4%)
Events at 9 months
MACE (all) 3 (10.3%)
Death (cardiac and non-cardiac) 0
Myocardial infarction (Q-wave and non-Q-wave) 0
Clinically-indicated TLR 2 (6.9%)
Any TLR 3 (10.3%)
Clinically-indicated TVR 2 (6.9%)
Any TVR 3 (10.3%)
Any TVF 3 (10.3%)
Stent thrombosis 0
Table 5. Procedural and 9 months angiographic analysis.
Mean (n=29)
Post procedure
Acute gain in-stent (mm) 1.09 (±0.33)
Acute gain in-segment (mm) 0.93 (±0.36)
Reference vessel diameter (mm) 2.85 (±0.35)
Minimum lumen diameter in-stent (mm) 2.44 (±0.24)
Minimum lumen diameter in-segment (mm) 2.28 (±0.30)
% Diameter stenosis in-stent (mm) 16.71 (±6.53)
% Diameter stenosis in-segment (mm) 19.79 (±7.05)
9 months follow-up
In-stent % diameter stenosis 28.34 (±12.13)
In-segment % diameter stenosis 28.38 (±12.31)
In-stent minimum lumen diameter (mm) 1.95 (±0.41)
In-segment minimum lumen diameter (mm) 1.91 (±0.40)
Reference vessel diameter (mm) 2.66 (±0.36)
In-stent lumen loss (mm) 0.50 (±0.30)
In-segment lumen loss (mm) 0.38 (±0.31)
Binary restenosis (all) 3 (±10.3%)
 Clinically driven 2 (±6.9%)
 Angiographic 1 (±3.4%)
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conformed to the diff erent degrees of plaque burden, displaying lower luminal areas at places 
in which the plaque burden was the highest. In addition, the shield had a good post-procedure 
symmetry index, demonstrating a homogeneous distribution of the radial force and no local-
ized stent recoil. 
The acute deployment of the shield and resulting mechanical behavior was not associated 
to any in-hospital or short-term clinical adverse events. The primary endpoint of this study, 
a combination of a post-procedural %DS ≤ 30%, an IVUS mean lumen area ≥ 4mm2 and in-
hospital through 30 days major adverse cardiac event (MACE) rate showed that the use of the 
shield was safe and feasible. At 9 months of clinical follow-up, there was no incidence of death, 
myocardial infarction or stent thrombosis. The total incidence of MACE was 10.3% (3 patients) 
and was related to target lesion revascularizations. Two of these patients classifi ed as undergo-
ing a clinically-indicated PCI as they presented symptoms of unstable angina at 2 and 7 months 
of follow-up respectively. In all cases, follow up angiography revealed in-stent restenosis which 
were successfully treated with DES implantatiThe long term IVUS analysis displayed very inter-
esting fi ndings in regards to the biomechanics of the device and its impact on vascular remod-
eling. In contrast to what has been previously published with previous generations of SE stent 
platforms (11), the luminal shield did not “over expand” over time. Instead, following device 
implantation, the shield starts off  with a lumen area lower than previously reported, then the 
device continues to enlarge and fi nally achieves an additional 13% of area gain over 9 months 
Table 6. Intravascular Ultrasound (IVUS) analysis.
Mean (n=29)
Post procedure
Luminal volume (mm3) 90.39 (±18.76)
Vessel volume (mm3) 188.3 (±41.10)
Stent volume (mm3) 90.53 (±18.79)
Total Plaque Volume (mm3) 97.93 (±26.64)
In-stent plaque volume (mm3) 0.15 (±0.33)
Plaque behind stent volume (mm3) 97.78 (±26.71)
In-Stent obstruction volume (%) 0.17 (±0.36)
Mean stent symmetry 0.87 (±0.04)
No of patients with stent symmetry index ≥ 0.7 29 (100%)
No of patients with mean lumen area ≥4.0mm2 29 (100%)
9 months follow-up
Luminal volume (mm3) 83.99 (±22 .49)
Vessel volume (mm3) 197.8 (±42.67)
Stent volume (mm3) 104.2 (±21.70)
Total Plaque Volume (mm3) 113.8 (±26.05)
In-stent plaque volume (mm3) 20.30 (±8.02)
Plaque behind stent volume (mm3) 93.54 (±26.21)
In-Stent obstruction volume (%) 19.81 (±8.29)
Mean Stent symmetry 0.89 (±0.02)
No of patients with stent symmetry index ≥ 0.7 29 (100%)
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resulting in a fi nal area comparable to what has been reported in BES studies (mean 7.55 mm; 
range: 6.5 – 9.4) (10-12). Interes tingly, this increase in shield areas was not related to an increase 
in the total vessel dimensions (~5% increase of vessel volume; fi gure 4). Instead, the remodeling 
eff ect appeared to be related to plaque remodeling occurring over time throughout the length 
of the device. Conversely, previous data suggests that the Radius stent achieved stent areas 
comparable to BES almost immediately following stent implantation and then over-expansion 
occurred (20% to 40% in stent areas) over time (11, 13, 14). This relatively high increase of the 
Radius stent volume over time may have been responsible for additional injury to the vessel 
wall resulting in a higher restenosis rate (24%) and late lumen loss (0.82 – 0.98mm) at 6 month 
follow-up compared to our study (13-15). In the present study, although the lower restenosis 
rate may have been related to the mechanical properties of the device itself, it is possible that 
the technique employed for plaque and device dilatation (“gentle balloon dilatation”) may have 
played a role in the lower restenosis rate found in this study. It is important to highlight that one 
case of restenosis found in the present study was most probably related to stent misplacement 
(“geographical miss”) leading to edge restenosis rather than to a “classic” biological response of 
the vessel wall to a stent. Also, the control angiography and IVUS imaging were performed at 
9 month follow-up as opposed to most previously published clinical trials evaluating the fi rst 
generation SES at 6 month follow-up which further underline the value of our results.
The main limitation of the present study is the sample size and the highly selected popula-
tion that was included in the study. Secondly, although the target lesions were defi ned as non-
calcifi ed we did not specify the type and morphology of underlying plaques which potentially 
may infl uence the results. Is summary, our study demonstrated that the implantation of an 
innovative luminal shield for the treatment of intermediate coronary lesions is safe and feasible. 
The device maintains its mechanical integrity following implantation and is capable to resists 
plaque compression forces. It induces progressive but well controlled vascular remodeling 
overtime, which is far less than originally reported with fi rst generation self expanding stents. 
Due to its intrinsic mechanical properties, this device may improve the outcomes of PCI by 
inducing less injury at the time of implantation. Thus, this device could be indicated in specifi c 
patient subsets such as acute coronary syndromes if long-term data in a larger population 
subset is obtained.
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SUMMARY AND CONCLUSIONS.
While we are fully aware that the drug eluting stents still face challenges in complex patient 
populations, the fi rst two “all-comers” studies comparing the fi rst generation permanent poly-
mer and new generation biodegradable polymer drug stent (LEADERS) and two new drug elut-
ing permanent polymer stents (RESOLUTE) could only demonstrate non-inferiority but failed to 
demonstrate superiority of one device over the other, despite the fact that they had enrolled 
close to 80% of off -label indication cases. However, when the LEADERS patient population was 
further analyzed in sub-studies focusing on subgroups known to be particularly challenging to 
interventional cardiologists advantage of the new generation biodegradable polymer device 
over the fi rst generation permanent polymer device could be demonstrated (Chapters 5, 7, 8, 9).
First and foremost, we have demonstrated for the fi rst time that risk stratifi cation scores 
such as SYNTAX score and ACEF score can be applied to the “all comers” PCI patient popula-
tion and allow for meaningful risk assessment not only in patients with multivessel disease 
(Chapter 2 and 3). Further we showed that in the highest tertile of the SYNTAX score within 
this “all-comers” group, the two devices and their performance can be separated, with the new 
generation biodegradable polymer device being superior in primary clinical endpoints such 
as cardiac mortality (Chapter 5). Other challenging subgroups in which a distinction could be 
made between the devices are also studied in this thesis: small vessels (Chapter 7), long lesions 
(Chapter 8) and bifurcation lesions (Chapter 9, 10, 11). Furthermore, a demonstration was made 
that while superiority end-points are not reached at short term follow-up of 9 months, sepa-
ration of clinical outcomes occurs at longer term follow-up of 3 years (Chapter 13). Whether 
the superior performance of the biodegradable polymer device has to do with its better strut 
coverage as demonstrated at 1 and 2 year follow-up by optical coherence tomography or other 
factors such as better profi le of the device has still not been directly proven but the former 
is suggested by the results from our group. This issue of stent strut coverage also raises the 
question of the ability to stop the dual antiplatelet therapy sooner without increasing the pro-
infl ammatory markers as occurs in the case of many fi rst generation devices (Chapter 16) and 
exposing the patient to higher risk of stent thrombosis. We have shown that patients within the 
highest tertile SYNTAX score treated with the biodegradable polymer device have lower stent 
thrombosis rates than patients treated with the permanent polymer fi rst generation devices 
(Chapter 5).
The ultimate solution to the greatest remaining challenge of metallic devices, namely stent 
thrombosis, may potentially be the fully biodegradable scaff olding device (Chapter 17). This 
has been heralded as the 4th revolution in interventional cardiology, balloon angioplasty being 
the1st, metallic bare metal stent being the 2nd and metallic drug eluting stents being the 3rd. 
Again, performance of these devices in the most challenging lesion subsets and patient popu-
lations will determine if these devices/scaff olds will be the future of our clinical practice. We 
have started to formulate the plan to further explore the issues of prediction and prevention of 
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stent thrombosis in the synopsis of the European Union grant proposal (Chapter 17; full grant 
text available electronically on demand).
Lesions at high risk of causing an acute coronary syndrome such as non-obstructive thin cap 
fi broatheromas (Chapter 15) may also benefi t from a dedicated device such as a gentle outward 
force self-expanding rather than balloon-expandable device. The former would reduce the 
trauma to the vessel wall but passivate the plaque and induce protective fi brous cap forma-
tion as is suggested by the pilot SECRITT trial and its companion vPROTECT fi rst in man study 
(Chapter 18-21). The ultimate challenge of treating these high risk lesions at risk of rupture, 
however, remains their appropriate diagnosis of the patient and identifi cation of the lesion 
whether with biomarkers and/or intravascular imaging methods (Chapter 14 and 15). As we 
have shown in IBIS-1 proteomic analysis and in a substudy of the PROSPECT trial aiming at 
establishing whether thin cap fi broatheroma lesions tend to be more proximally distributed 
and therefore more easily accessible to focal treatment, diagnosis of truly “vulnerable patient 
and plaque” still remains elusive.
Last but not least in this thesis we explored the performance of bare metal stents, drug 
eluting stents versus coronary artery bypass surgery in diabetic patients at 5 years follow up 
within the ARTS studies population showing that while the safety of the drug eluting stents at 
fi ve years at long term follow-up is equivalent to CABG, the effi  cacy remains better for CABG 
(Chapter 1 and 12). Bare metal stent treatment in patients with diabetes is unsafe. We have 
summarized the state of the art knowledge of multivessel disease treatment in a book chapter 
that serves as an introduction to this thesis (Chapter 1).
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SAMENVATTING EN CONCLUSIE.
Het gebruik van drug eluting stents in complexe patiëntenpopulaties staat nog steeds voor 
grote uitdagingen. De eerste twee “all-comers” studies LEADERS, waarbij de eerste generatie 
duurzame polymere stents werden vergeleken met nieuwe generatie stents met oplosbaar 
polymeer, de zogenaamde biodegradables, en RESOLUTE, waarbij twee verschillende nieuwe 
drug eluting met duurzaam polymeer vergeleken werden, toonden beide studies non-inferio-
riteit aan, maar slaagden ze er niet in om superioriteit van de ene stent boven een andere aan 
te tonen, waarbij aangetekend dat er bijna 80% van de patiënten waren geïncludeerd met een 
off -label indicatie. Wanneer de LEADERS patiëntenpopulatie echter in bepaalde subgroepen, 
die als moeilijk behandelbaar te boek staan, werd onderverdeeld bleek er wel degelijk voordeel 
te kunnen worden aangetoond van de nieuwe generatie biodegradable stents ten opzichte 
van de eerste generatie duurzame polymere stents (hoofdstukken 5, 7,8 en 9). 
Wat we vooral en als eerste hebben aangetoond is dat het gebruik van risico stratifi catie 
scores zoals de SYNTAX of de ACEF scores toepasbaar zijn op alle patiënten die percutane coro-
naire interventie ondergaan en dus niet alleen bij patiënten met meervatslijden (Hoofdstuk2). 
Daarbij toonden we aan dat in het hoogste tertiel van de SYNTAX score van deze all-comers 
groep een verschil is tussen de twee soorten stents en hun prestaties, waarbij de nieuwe 
biodegradable stent superieur was in primaire klinische eindpunten zoals cardiale mortaliteit 
(Hoofdstuk 5). Andere moeilijk behandelbare subgroepen waarbij eventuele verschillen tussen 
de verschillende stents zou kunnen worden aangetoond zijn ook onderzocht in dit proefschrift, 
zoals kleine vaten (Hoofdstuk 7), lange laesies (Hoofdstuk 8) en bifurcatie laesies (Hoofdstukken 
9, 10 en 11). Bovendien werd aangetoond dat de uitkomsten, hoewel nog niet verschillend na 
korte follow-up van 9 maanden, na een langere follow-up van 3 jaar wel verschillend werden 
tussen de verschillende stents (hoofdstuk 13). Of het superieure resultaat van de biodegradable 
stent te verklaren valt uit een betere bedekking van de struts van de stent zoals aangetoond 
werd met behulp van optical coherence tomography na 1 en 2 jaar follow-up of verklaard kan 
worden door andere factoren zoals een beter profi el van de stent is nog niet direct bewezen, 
maar de resultaten van onze onderzoeksgroep ondersteunen de eerste verklaring. Betere strut 
bedekking zou eventueel ook de mogelijkheid scheppen om de dubbele antiplaatjes thera-
pie eerder te stoppen zonder dat de pro-infl ammatoire markers stijgen zoals bij veel eerste 
generatie stents het geval is (Hoofdstuk 16) en waarbij de patiënt aan een hoger risico van 
stent trombose wordt blootgesteld. We hebben laten zien dat patiënten binnen het hoogste 
tertiel van de SYNTAX score die behandeld zijn met biodegradables een lagere stent trombose 
hebben dan patiënten die met een eerste generatie duurzame polymere stent behandeld is 
(Hoofdstuk 5).
De ultieme oplossing voor de grootste overgebleven uitdaging van metalen stents, namelijk 
stent trombose, zou potentieel de volledig oplosbare devices, oftewel de fully biodegradable 
scaff olding devices, kunnen zijn (Hoofdstuk 17). Dit wordt binnen de interventiecardiologie, 
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na de introductie van ballonangioplastiek, bare metal stents en de drug eluting stents aan-
gekondigd als de vierde revolutie. De uitkomsten van het gebruik van deze nieuwe devices 
in moeilijk behandelbare laesies en patiëntenpopulaties zullen bepalen of deze devices in de 
toekomst in de kliniek gebruikt zullen gaan worden. In de samenvatting van de aanvraag voor 
de Europese Unie beurs hebben we een plan geformuleerd om voorspelling en preventie van 
stent trombose nader te onderzoeken. (Hoofdstuk 17; volledige tekst van de beursaanvraag is 
op aanvraag elektronisch verkrijgbaar).
Laesies met hoog risico voor het veroorzaken van een acuut coronair syndroom zoals een 
niet obstructieve fi broatheroom met dunne kap (Hoofdstuk 15) zouden ook kunnen profi teren 
van speciaal voor het type laesie ontworpen stents, zoals een zichzelf ontvouwende stent in 
plaats van een stent die zich ontvouwd met hulp van een ballon. De eerste zou schade van 
de vaatwand laten afnemen, terwijl de plaque bedekt wordt en de formatie van een bescher-
mende kap wordt geïnduceerd zoals gesuggereerd wordt in de pilot SECRITT trial en de 
gerelateerde vPROTECT fi rst in man study (Hoofdstukken 18-21). De ultieme uitdaging van de 
behandeling van laesies met verhoogde kans op rupturatie blijft echter het herkennen van 
dergelijke laesies met behulp van biomarkers en/of intravasculaire beeldvormende methodes 
(Hoofdtukken 14 en 15). Zoals we in de IBIS-1 proteomic analyse en in een substudie van de 
PROSPECT trial, waarbij werd beoogd om aan te tonen of fi broatherome laesies met dunne 
kap meer geneigd zijn om meer proximaal gelegen te zijn en zodoende makkelijker bereikbaar 
voor focale behandeling, hebben aangetoond blijft de diagnose van de “kwetsbare patient en 
plaque” ongrijpbaar.
Tot slot hebben we de resultaten onderzocht van bare metal stents versus drug eluting 
stents versus coronaire arteriële bypass chirurgie (CABG) in patiënten met diabetes na 5 
jaar follow-up in de patiëntenpopulatie van de ARTS studies. Daarbij werd aangetoond dat, 
hoewel de veiligheid gelijk was, CABG betere uitkomsten liet zien ten opzichte van de drug 
eluting stents (Hoofdstukken 1 en 12). Bovendien bleek behandeling met bare metal stenst in 
patiënten met diabetes bleek niet veilig. Ten slotte hebben we de state-of-the-art kennis over 
behandeling van meervatslijden in een hoofdstuk voor een boek samengevat dat tevens dient 
als een introductie van dit proefschrift (Hoofdstuk 1).
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